URL,HCVR,LCVR,HC_Description,LC_Description,Source
https://patents.google.com/patent/CN112285348B/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Tyr Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Ser Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Asn Asp Tyr Asp Glu Gly Glu Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(1/2)  the heavy chain and light chain amino acid sequences of the antibody 1 are respectively shown as seq id no:1 and seq id no:2
https://patents.google.com/patent/CN112285348B/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Pro Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met Gly Leu Ile Tyr Thr Asp Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Val Arg Gly Glu Asn Trp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Arg Val Thr Met Thr Cys Thr Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys His Gln Tyr His Arg Ser Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(3/4)  the heavy chain and light chain amino acid sequences of the antibody 2 are respectively shown as seq id no:3 and seq id no:4
https://patents.google.com/patent/CN111303280B/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Met Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Thr Ala Val Ala Gly Thr Pro Asp Leu Phe Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln Ala Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens,  Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/WO2021252878A1/en,,,,,(105/168) s309-11 comprises the wild-type vh sequence (seq id no:105) and wild-type vl sequence (seq id no:168) of s309
https://patents.google.com/patent/WO2021252878A1/en,,,,,"(119/168) in certain embodiments, an antibody or an antigen-binding fragment of the present disclosure comprises a vh comprising or consisting of the sequence according to seq id no:119 and a vl comprising or consisting of the sequence according to seq id no:168 and binds to sars-cov-2 s protein rbd with an ec50 of about 8 to about 22 ng/ml"
https://patents.google.com/patent/WO2021252878A1/en,,,,,"(79/83) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:79 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:83. "
https://patents.google.com/patent/WO2021252878A1/en,,,,,(113/168) s309-12 comprises an n55q vh variant sequence (seq id no:113) and the wild-type vl sequence (seq id no:168) of s309
https://patents.google.com/patent/WO2021252878A1/en,,,,,"(129/168) in certain embodiments, an antibody or an antigen-binding fragment of the present disclosure comprises a vh comprising or consisting of the amino acid sequence according to seq id no:129 and a vl comprising or consistingof the amino acid sequence according to seq id no:168 and binds to sars-cov-2 s protein rbd with an ec50 of about 8 to about 22 ng/ml"
https://patents.google.com/patent/US20110159001A1/en,,,,,(94/96) antibody s227.14 consists of a heavy chain having the amino acid sequence recited in seq id no:94 and a light chain having the amino acid sequence recited in seq id no:96
https://patents.google.com/patent/US20110159001A1/en,,,,,(98/101) antibody s109.8 consists of a heavy chain having the amino acid sequence recited in seq id no:98 and a light chain having the amino acid sequence recited in seq id no:101.
https://patents.google.com/patent/US20110159001A1/en,,,,,(90/92) antibody s230.15 consists of a heavy chain having the amino acid sequence recited in seq id no:90 and a light chain having the amino acid sequence recited in seq id no:92
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Glu Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser His Tyr Phe Trp Ser Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No.48 HC variable region , No.48 LC variable region ,(1836/1835)  a) the light chain variable region set forth in seq id no:1835; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1836; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , No.66 HC variable region , No.66 LC variable region ,(1872/1871)  a) the light chain variable region set forth in seq id no:1871; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1872; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.213 HC variable region , No.213 LC variable region ,(2166/2165)  a) the light chain variable region set forth in seq id no:2165; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2166; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.206 HC variable region , No.206 LC variable region ,(2152/2151)  a) the light chain variable region set forth in seq id no:2151; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2152; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.208 HC variable region , No.208 LC variable region ,(2156/2155)  a) the light chain variable region set forth in seq id no:2155; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2156; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Arg Asp Ser Ser Ser Asp His Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.266 HC variable region , No.266 LC variable region ,(2272/2271)  a) the light chain variable region set forth in seq id no:2271; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2272; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr Gly Gly Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Ala Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.53 HC variable region , No.53 LC variable region ,(1846/1845)  a) the light chain variable region set forth in seq id no:1845; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1846; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ile Ala Pro Tyr Thr Arg Gly Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Pro Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.279 HC variable region , No.279 LC variable region ,(2298/2297)  a) the light chain variable region set forth in seq id no:2297; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2298; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.221 HC variable region , No.221 LC variable region ,(2182/2181)  a) the light chain variable region set forth in seq id no:2181; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2182; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Ala Ala Pro Lys Leu Leu Ile Tyr Ser Asn Ser Gln Arg Pro Ser Gly Val Pro Asp Arg Val Ser Ala Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Gly Asp Tyr Tyr Cys Ala Gly Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.219 HC variable region , No.219 LC variable region ,(2178/2177)  a) the light chain variable region set forth in seq id no:2177; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2178; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Arg Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.93 HC variable region , No.93 LC variable region ,(1926/1925)  a) the light chain variable region set forth in seq id no:1925; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1926; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ala Gln Thr Leu Arg Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Phe Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.91 HC variable region , No.91 LC variable region ,(1922/1921)  a) the light chain variable region set forth in seq id no:1921; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1922; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Arg Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ala Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.207 HC variable region , No.207 LC variable region ,(2154/2153)  a) the light chain variable region set forth in seq id no:2153; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2154; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Asn Phe Thr Arg Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Gly Ile Ala Val Ala Gly Thr Pro Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Gly Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asp Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.195 HC variable region , No.195 LC variable region ,(2130/2129)  a) the light chain variable region set forth in seq id no:2129; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2130; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Pro Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.72 HC variable region , No.72 LC variable region ,(1884/1883)  a) the light chain variable region set forth in seq id no:1883; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1884; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.204 HC variable region , No.204 LC variable region ,(2148/2147)  a) the light chain variable region set forth in seq id no:2147; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2148; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Arg Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gly Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.31 HC variable region , No.31 LC variable region ,(1802/1801)  a) the light chain variable region set forth in seq id no:1801; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1802; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro Gly Arg Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No.56 HC variable region , No.56 LC variable region ,(1852/1851)  a) the light chain variable region set forth in seq id no:1851; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1852; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Pro Gly Thr Lys Leu Thr Val Leu , No.246 HC variable region , No.246 LC variable region ,(2232/2231)  a) the light chain variable region set forth in seq id no:2231; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2232; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Arg Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Glu Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.212 HC variable region , No.212 LC variable region ,(2164/2163)  a) the light chain variable region set forth in seq id no:2163; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2164; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Ser Ala Thr Leu Ala Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro Gly Arg Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No.65 HC variable region , No.65 LC variable region ,(1870/1869)  a) the light chain variable region set forth in seq id no:1869; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1870; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Pro Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.254 HC variable region , No.254 LC variable region ,(2248/2247)  a) the light chain variable region set forth in seq id no:2247; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2248; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ser Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Asn Leu Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.129 HC variable region , No.129 LC variable region ,(1998/1997)  a) the light chain variable region set forth in seq id no:1997; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1998; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Pro Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Thr Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , No.44 HC variable region , No.44 LC variable region ,(1828/1827)  a) the light chain variable region set forth in seq id no:1827; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1828; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asp Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.4 HC variable region , No.4 LC variable region ,(1748/1747)  a) the light chain variable region set forth in seq id no:1747; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1748; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.152 HC variable region , No.152 LC variable region ,(2044/2043)  a) the light chain variable region set forth in seq id no:2043; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2044; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Asp Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Ser Asp Ser Gly Leu Thr Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.268 HC variable region , No.268 LC variable region ,(2276/2275)  a) the light chain variable region set forth in seq id no:2275; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2276; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.118 HC variable region , No.118 LC variable region ,(1976/1975)  a) the light chain variable region set forth in seq id no:1975; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1976; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.252 HC variable region , No.252 LC variable region ,(2244/2243)  a) the light chain variable region set forth in seq id no:2243; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2244; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.6 HC variable region , No.6 LC variable region ,(1752/1751)  a) the light chain variable region set forth in seq id no:1751; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1752; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.242 HC variable region , No.242 LC variable region ,(2224/2223)  a) the light chain variable region set forth in seq id no:2223; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2224; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.245 HC variable region , No.245 LC variable region ,(2230/2229)  a) the light chain variable region set forth in seq id no:2229; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2230; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Pro Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Phe Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.220 HC variable region , No.220 LC variable region ,(2180/2179)  a) the light chain variable region set forth in seq id no:2179; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2180; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Gly Val Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , No.283 HC variable region , No.283 LC variable region ,(2306/2305)  a) the light chain variable region set forth in seq id no:2305; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2306; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ile Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.281 HC variable region , No.281 LC variable region ,(2302/2301)  a) the light chain variable region set forth in seq id no:2301; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2302; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.95 HC variable region , No.95 LC variable region ,(1930/1929)  a) the light chain variable region set forth in seq id no:1929; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1930; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.55 HC variable region , No.55 LC variable region ,(1850/1849)  a) the light chain variable region set forth in seq id no:1849; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1850; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.261 HC variable region , No.261 LC variable region ,(2262/2261)  a) the light chain variable region set forth in seq id no:2261; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2262; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.203 HC variable region , No.203 LC variable region ,(2146/2145)  a) the light chain variable region set forth in seq id no:2145; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2146; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Glu Ala Thr Thr Gly Ile Asn Thr Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.287 HC variable region , No.287 LC variable region ,(2314/2313)  a) the light chain variable region set forth in seq id no:2313; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2314; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Ile Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Thr Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.260 HC variable region , No.260 LC variable region ,(2260/2259)  a) the light chain variable region set forth in seq id no:2259; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2260; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.70 HC variable region , No.70 LC variable region ,(1880/1879)  a) the light chain variable region set forth in seq id no:1879; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1880; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ile Ala Pro Tyr Thr Arg Gly Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Gly Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala His Ser Phe Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No.278 HC variable region , No.278 LC variable region ,(2296/2295)  a) the light chain variable region set forth in seq id no:2295; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2296; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.108 HC variable region , No.108 LC variable region ,(1956/1955)  a) the light chain variable region set forth in seq id no:1955; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1956; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.290 HC variable region , No.290 LC variable region ,(2320/2319)  a) the light chain variable region set forth in seq id no:2319; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2320. 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly His Val Asp Ile Pro Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.284 HC variable region , No.284 LC variable region ,(2308/2307)  a) the light chain variable region set forth in seq id no:2307; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2308; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Pro Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Met Leu Thr Gln Pro His Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Thr Leu Asp Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.214 HC variable region , No.214 LC variable region ,(2168/2167)  a) the light chain variable region set forth in seq id no:2167; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2168; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No.235 HC variable region , No.235 LC variable region ,(2210/2209)  a) the light chain variable region set forth in seq id no:2209; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2210; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Pro Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.7 HC variable region , No.7 LC variable region ,(1754/1753)  a) the light chain variable region set forth in seq id no:1753; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1754; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Lys Gly Tyr Ser Gly Ser Gly Ser Val Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.285 HC variable region , No.285 LC variable region ,(2310/2309)  a) a light chain variable region set forth in seq id no:2309; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2310; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.243 HC variable region , No.243 LC variable region ,(2226/2225)  a) the light chain variable region set forth in seq id no:2225; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2226; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Ala Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Ser Asp Val Gly Trp Tyr Gln His Leu Pro Gly Met Ala Pro Arg Leu Leu Ile Tyr Lys Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Ala Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Gly Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Arg Leu Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.276 HC variable region , No.276 LC variable region ,(2292/2291)  a) the light chain variable region set forth in seq id no:2291; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2292; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Arg Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.89 HC variable region , No.89 LC variable region ,(1918/1917)  a) the light chain variable region set forth in seq id no:1917; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1918; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,(2018/2017)  a) the light chain variable region set forth in seq id no:2017; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2018; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Glu Ala Thr Thr Gly Ile Asn Thr Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.250 HC variable region , No.250 LC variable region ,(2240/2239)  a) the light chain variable region set forth in seq id no:2239; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2240; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.216 HC variable region , No.216 LC variable region ,(2172/2171)  a) the light chain variable region set forth in seq id no:2171; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2172; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Phe Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.230 HC variable region , No.230 LC variable region ,(2200/2199)  a) the light chain variable region set forth in seq id no:2199; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2200; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No.270 HC variable region , No.270 LC variable region ,(2280/2279)  a) the light chain variable region set forth in seq id no:2279; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2280; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn Phe Val Ser Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.128 HC variable region , No.128 LC variable region ,(1996/1995)  a) the light chain variable region set forth in seq id no:1995; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1996; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.8 HC variable region , No.8 LC variable region ,(1756/1755)  a) the light chain variable region set forth in seq id no:1755; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1756; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Gly Asp Cys Gly Gly Asp Cys Tyr Ser Phe Leu Leu Gly Glu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Thr Tyr Leu Asn Trp Tyr Gln Gln Lys Val Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Arg Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ile Pro His Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No.2 HC variable region , No.2 LC variable region ,(1744/1743)  a) the light chain variable region set forth in seq id no:1743; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1744; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Ala Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.209 HC variable region , No.209 LC variable region ,(2158/2157)  a) the light chain variable region set forth in seq id no:2157; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2158; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ile Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Thr Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.280 HC variable region , No.280 LC variable region ,(2300/2299)  a) the light chain variable region set forth in seq id no:2299; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2300; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Met Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.239 HC variable region , No.239 LC variable region ,(2218/2217)  a) the light chain variable region set forth in seq id no:2217; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2218; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No.244 HC variable region , No.244 LC variable region ,(2228/2227)  a) the light chain variable region set forth in seq id no:2227; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2228; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No.81 HC variable region , No.81 LC variable region ,(1902/1901)  a) the light chain variable region set forth in seq id no:1901; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1902; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.259 HC variable region , No.259 LC variable region ,(2258/2257)  a) the light chain variable region set forth in seq id no:2257; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2258; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.215 HC variable region , No.215 LC variable region ,(2170/2169)  a) the light chain variable region set forth in seq id no:2169; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2170; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Pro Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No.263 HC variable region , No.263 LC variable region ,(2266/2265)  a) the light chain variable region set forth in seq id no:2265; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2266; 
https://patents.google.com/patent/KR102205028B1/en, Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Leu Ser His Gly Val Val Gly Ala Gln Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Gly Ser Ser Asp His Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No.249 HC variable region , No.249 LC variable region ,(2238/2237)  a) the light chain variable region set forth in seq id no:2237; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2238; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No.83 HC variable region , No.83 LC variable region ,(1906/1905)  a) the light chain variable region set forth in seq id no:1905; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1906; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asn Leu Gly Tyr Cys Thr Asn Gly Val Cys Ala Pro Ser Gly Gly Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn His Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.288 HC variable region , No.288 LC variable region ,(2316/2315)  a) the light chain variable region set forth in seq id no:2315; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2316; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Arg Ala Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No.86 HC variable region , No.86 LC variable region ,(1912/1911)  a) the light chain variable region set forth in seq id no:1911; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1912; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.265 HC variable region , No.265 LC variable region ,(2270/2269)  a) the light chain variable region set forth in seq id no:2269; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2270; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.79 HC variable region , No.79 LC variable region ,(1898/1897)  a) the light chain variable region set forth in seq id no:1897; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1898; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.247 HC variable region , No.247 LC variable region ,(2234/2233)  a) the light chain variable region set forth in seq id no:2233; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2234; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Ser Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Tyr Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.13 HC variable region , No.13 LC variable region ,(1766/1765)  a) the light chain variable region set forth in seq id no:1765; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1766; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Phe Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No.47 HC variable region , No.47 LC variable region ,(1834/1833)  a) the light chain variable region set forth in seq id no:1833; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1834; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.3 HC variable region , No.3 LC variable region ,(1746/1745)  a) the light chain variable region set forth in seq id no:1745; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1746; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.275 HC variable region , No.275 LC variable region ,(2290/2289)  a) the light chain variable region set forth in seq id no:2289; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2290; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asn Leu Arg Tyr Phe Asp Trp Leu Leu Gly Asp Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Gly Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.289 HC variable region , No.289 LC variable region ,(2318/2317)  a) the light chain variable region set forth in seq id no:2317; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2318; and 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.256 HC variable region , No.256 LC variable region ,(2252/2251)  a) the light chain variable region set forth in seq id no:2251; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2252; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No.46 HC variable region , No.46 LC variable region ,(1832/1831)  a) the light chain variable region set forth in seq id no:1831; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1832; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.88 HC variable region , No.88 LC variable region ,(1916/1915)  a) the light chain variable region set forth in seq id no:1915; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1916; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.103 HC variable region , No.103 LC variable region ,(1946/1945)  a) the light chain variable region set forth in seq id no:1945; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1946; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Arg Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Asn Ser Glu Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.236 HC variable region , No.236 LC variable region ,(2212/2211)  a) the light chain variable region set forth in seq id no:2211; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2212; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Asn Asn Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.271 HC variable region , No.271 LC variable region ,(2282/2281)  a) the light chain variable region set forth in seq id no:2281; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2282; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.49 HC variable region , No.49 LC variable region ,(1838/1837)  a) the light chain variable region set forth in seq id no:1837; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1838; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Glu Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.197 HC variable region , No.197 LC variable region ,(2134/2133)  a) the light chain variable region set forth in seq id no:2133; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2134; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile His Ala Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Val Glu Pro Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Asp Ser Leu Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No.69 HC variable region , No.69 LC variable region ,(1878/1877)  a) the light chain variable region set forth in seq id no:1877; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1878; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Val Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.217 HC variable region , No.217 LC variable region ,(2174/2173)  a) the light chain variable region set forth in seq id no:2173; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2174; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.14 HC variable region , No.14 LC variable region ,(1768/1767)  a) a light chain variable region set forth in seq id no:1767; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1768; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.201 HC variable region , No.201 LC variable region ,(2142/2141)  a) the light chain variable region set forth in seq id no:2141; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2142; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.232 HC variable region , No.232 LC variable region ,(2204/2203)  a) the light chain variable region set forth in seq id no:2203; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2204; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.274 HC variable region , No.274 LC variable region ,(2288/2287)  a) the light chain variable region set forth in seq id no:2287; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2288; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No.196 HC variable region , No.196 LC variable region ,(2132/2131)  a) the light chain variable region set forth in seq id no:2131; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2132; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Gly Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No.71 HC variable region , No.71 LC variable region ,(1882/1881)  a) the light chain variable region set forth in seq id no:1881; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1882; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ile Asn Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Leu Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No.241 HC variable region , No.241 LC variable region ,(2222/2221)  a) the light chain variable region set forth in seq id no:2221; and b) an antibody comprising a heavy chain variable region set forth in seq id no:2222; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No.224 HC variable region , No.224 LC variable region ,(2188/2187)  a) the light chain variable region set forth in seq id no:2187; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2188; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ala Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.205 HC variable region , No.205 LC variable region ,(2150/2149)  a) the light chain variable region set forth in seq id no:2149; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2150; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Ile Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.113 HC variable region , No.113 LC variable region ,(1966/1965)  a) the light chain variable region set forth in seq id no:1965; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1966; 
https://patents.google.com/patent/KR102205028B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Ser Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn Pro Val Asn Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asn Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.218 HC variable region , No.218 LC variable region ,(2176/2175)  a) the light chain variable region set forth in seq id no:2175; and b) an antibody comprising the heavy chain variable region set forth in seq id no:2176; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Gly Asp Cys Gly Gly Asp Cys Tyr Ser Phe Leu Leu Gly Glu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No.1 HC variable region , No.1 LC variable region ,(1742/1741)  a) the light chain variable region set forth in seq id no:1741; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1742; 
https://patents.google.com/patent/KR102205028B1/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No.9 HC variable region , No.9 LC variable region ,(1758/1757)  a) the light chain variable region set forth in seq id no:1757; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1758; 
https://patents.google.com/patent/KR102205028B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.90 HC variable region , No.90 LC variable region ,(1920/1919)  a) the light chain variable region set forth in seq id no:1919; and b) an antibody comprising the heavy chain variable region set forth in seq id no:1920; 
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(200/223) [0092] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:223"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(205/228) [0097] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:205 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:228"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(194/217) [0086] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:194 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:217"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(196/219) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:196 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:219"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(204/227) [0096] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:204 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:227"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(199/222) [0091] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:199 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:222"
https://patents.google.com/patent/WO2021194965A1/en,,,,,(195/218) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:195 and a vl having an amino acid sequence of seq id no:218
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(213/236) [0107] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:213 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(207/230) [0100] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:207 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:230"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(206/229) [0099] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:206 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229"
https://patents.google.com/patent/WO2021194965A1/en,,,,,(209/232) the antibody or the antigen binding fragment can comprise a vh having an amino acid sequence of seq id no:209 and a vl having an amino acid sequence of seq id no:232
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(192/215) [0084] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:192 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:215"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(210/233) [0104] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:233"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(193/216) [0085] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:193 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:216"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(211/234) [0105] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:211 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:234"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(212/235) [0106] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:212 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:235"
https://patents.google.com/patent/WO2021194965A1/en,,,,,(208/231) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:208 and a vl having an amino acid sequence of seq id no:231
https://patents.google.com/patent/WO2021194965A1/en,,,,,(198/221) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:198 and a vl having an amino acid sequence of seq id no:221
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(203/226)  [0095] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:203 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:226. (covid19 p11 d"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(197/220) [0089] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:197 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:220"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(214/237) [0110] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:214 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:237"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(201/224) [0093] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:201 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:224"
https://patents.google.com/patent/WO2021194965A1/en,,,,,"(202/225) [0094] in one instance, an antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:225"
https://patents.google.com/patent/WO2021226249A1/en,,,,,(6/7) in some embodiments an antigen binding protein as provided herein is or comprises an igg antibody having the heavy chain variable region of seq id no:6 and the light chain variable region of seq id no:7
https://patents.google.com/patent/CN113004396B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Pro Ser Gly Gly Trp Tyr Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Arg Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8)  wherein, the amino acid sequence of vh is shown as seq id no:4, and the amino acid sequence of vl is shown as seq id no:8."
https://patents.google.com/patent/CN113004396B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(12/16)  wherein the amino acid sequence of vh is shown as seq id no:12, and the amino acid sequence of vl is shown as seq id no:16."
https://patents.google.com/patent/CN113461812A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Tyr Ile Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asn Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Ile Phe Ile Thr Thr Val Ile Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu, Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Ser Gly Thr Thr Leu Met Gln Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Val Ala Met Tyr Phe Cys His Gln Ser Arg Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Val Thr Val Ser Ala , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(8/7) the amino acid sequences of the light and heavy chain variable regions of antibody ncov-00d are shown in seq id no:7 and 8, respectively."
https://patents.google.com/patent/CN113461812A/en, Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr Tyr Ile Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asn Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Ile Phe Ile Thr Thr Val Ile Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Ser Gly Thr Thr Leu Met Gln Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Val Ala Met Tyr Phe Cys His Gln Ser Arg Glu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(12/11) in one embodiment of the present invention, the amino acid sequences of the light and heavy chains of a whole antibody igg are shown in seq id no:11 and 12, respectively, and the nucleotide sequences encoding the light and heavy chains are shown in seq id no:13-14, respectively."
https://patents.google.com/patent/US11021532B1/en,,,,,"(353/377) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:353 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:377."
https://patents.google.com/patent/US11021532B1/en,,,,,"(355/379) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:355 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:379."
https://patents.google.com/patent/US11021532B1/en,,,,,"(361/385) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:361 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:385."
https://patents.google.com/patent/US11021532B1/en,,,,,"(356/380) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:356 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:380."
https://patents.google.com/patent/US11021532B1/en,,,,,"(436/437) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:436 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:437."
https://patents.google.com/patent/US11021532B1/en,,,,,"(347/371) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:347 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:371."
https://patents.google.com/patent/US11021532B1/en,,,,,"(345/369) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:345 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:369."
https://patents.google.com/patent/US11021532B1/en,,,,,"(346/370) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:346 and an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:370."
https://patents.google.com/patent/US11021532B1/en,,,,,"(354/378) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:354 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:378."
https://patents.google.com/patent/US11021532B1/en,,,,,"(348/372) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:348 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:372."
https://patents.google.com/patent/US11021532B1/en,,,,,"(358/382) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh having an amino acid sequence of seq id no:358 and a vl having an amino acid sequence of seq id no:382."
https://patents.google.com/patent/US11021532B1/en,,,,,"(344/368) further provided herein is an sh antibody or antigen-binding fragment that comprises a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to seq id no:344 and a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to seq id no:368"
https://patents.google.com/patent/US11021532B1/en,,,,,"(349/373) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:349 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:373."
https://patents.google.com/patent/US11021532B1/en,,,,,"(342/366) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:342 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:366."
https://patents.google.com/patent/US11021532B1/en,,,,,"(362/386) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:362 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:386."
https://patents.google.com/patent/US11021532B1/en,,,,,"(363/387) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:363 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:387."
https://patents.google.com/patent/US11021532B1/en,,,,,"(360/384) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:360 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:384."
https://patents.google.com/patent/US11021532B1/en,,,,,"(343/367) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:343 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:367."
https://patents.google.com/patent/US11021532B1/en,,,,,"(359/383) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:359 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:383."
https://patents.google.com/patent/US11021532B1/en,,,,,"(357/381) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:357 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:381."
https://patents.google.com/patent/US11021532B1/en,,,,,"(351/375) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:351 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:375."
https://patents.google.com/patent/US11021532B1/en,,,,,"(341/365) further provided herein is an sh antibody or antigen-binding fragment that comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:365-388 and 437, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:341-364 and 436"
https://patents.google.com/patent/US11021532B1/en,,,,,"(352/376) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:352 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:376."
https://patents.google.com/patent/US11021532B1/en,,,,,"(364/388) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:364 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:388."
https://patents.google.com/patent/US11021532B1/en,,,,,"(350/374) in one instance, a sh antibody or antigen-binding fragment, herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:350 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:374."
https://patents.google.com/patent/CN113834933A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Ile Val Ser Arg Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Val Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Glu Ser Gln Asn Thr Leu Tyr Leu Gln Met Asn Arg Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Arg Asp Leu Gly Pro Arg Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(1/2)  the heavy chain and light chain amino acid sequences of the neutralizing antibody are respectively shown as seq id no:1 and 2.
https://patents.google.com/patent/EP3919126A1/en,,,,,(406/408)  and/or a heavy chain variable region of the amino acid sequence in seq id no:406 and a light chain variable region of the amino acid sequence in seq id no:408
https://patents.google.com/patent/EP3919126A1/en,,,,,(1066/1068)  a heavy chain variable region of the amino acid sequence in seq id no:1066 and a light chain variable region of the amino acid sequence in seq id no:1068
https://patents.google.com/patent/EP3919126A1/en,,,,,(366/368)  a heavy chain variable region of the amino acid sequence in seq id no:366 and a light chain variable region of the amino acid sequence in seq id no:368
https://patents.google.com/patent/EP3919126A1/en,,,,,(1305/1309)  a heavy chain variable region of the amino acid sequence in seq id no:1305 and a light chain variable region of the amino acid sequence in seq id no:1309
https://patents.google.com/patent/EP3919126A1/en,,,,,(1166/1168)  a heavy chain variable region of the amino acid sequence in seq id no:1166 and a light chain variable region of the amino acid sequence in seq id no:1168
https://patents.google.com/patent/EP3919126A1/en,,,,,(926/928)  a heavy chain variable region of the amino acid sequence in seq id no:926 and a light chain variable region of the amino acid sequence in seq id no:928
https://patents.google.com/patent/CN112898415B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Gly Pro Leu Met Val Arg Gly Val Ile Ile Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Asn Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region has the amino acid sequence set forth in seq id no:4; the amino acid sequence of the light chain variable region is shown in seq id no:8."
https://patents.google.com/patent/CN112898415B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN103864924A/en,,,,,"(1/2) a middle east respiration syndrome coronavirus antibody, is characterized in that, is mouse resource monoclonal neutralizing antibody, and the aminoacid sequence of its heavy chain, light chain is respectively as shown in seq id no:1, seq id no:2."
https://patents.google.com/patent/CN103864924A/en,,,,,"(3/4) the heavy chain of described humanization mers-cov mouse resource monoclonal neutralizing antibody, the aminoacid sequence of light chain are respectively as shown in seq id no:3, seq id no:4."
https://patents.google.com/patent/CN111560070B/en, caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc tcctgcaagg cttctggagg caccttcagc agctatgcta tcagctgggt gcgacaggcc cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggaggt tgggtgattt gtagtagtac cagctgctac actaagtact cctactacgg tatggacgtc tggggccaag ggaccacggt caccgtctcc tca , cagagcgtgc tcacgcagcc gccctcagtg tctgcggccc caggacagaa ggtcaccatc tcctgctctg gaagcagctc caacattggg aataattatg tatcctggta ccagcagctc ccaggaacag cccccaaact cctcatttat gacaataata agcgaccctc agggattcct gaccgattct ctggctccaa gtctggcacg tcagccaccc tgggcatcac cggactccag actggggacg aggccgatta ttactgcgga acgtgggata gcagcctgat tgcccggttg ttcggcggag ggaccaagct gaccgtccta , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(17/18) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:18, and the variable region of the antibody heavy chain is seq id no:17."
https://patents.google.com/patent/CN111560070B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Val Ile Cys Ser Ser Thr Ser Cys Tyr Thr Lys Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ile Ala Arg Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody of claim 1, wherein the first variable region is an antibody light chain variable region as set forth in seq id no:8; the second variable region is an antibody heavy chain variable region which is represented by seq id no:4."
https://patents.google.com/patent/CN111560070B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16)  wherein the heavy chain variable region comprises seq id no:12 and the light chain variable region comprises the amino acid sequence shown in seq id no:16.
https://patents.google.com/patent/CN112175073A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Trp Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asn Thr Ala Val Tyr Tyr Cys Ala Arg Glu Pro Leu Tyr Cys Ser Ser Thr Ser Cys Tyr Val Ala Ser Gly Leu Glu Asp Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(29/30) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:29, and the light chain amino acid sequence is shown as seq id no:30"
https://patents.google.com/patent/CN112175073A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Ser Lys Ala Tyr Gly Gly Thr Thr Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Asp Arg Tyr Ala Arg Tyr Asp Ile Leu Thr Gly Leu Ser Pro Ala Gly Ala Asp Tyr Phe Tyr Tyr Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Gln Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(39/40) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:39, and the light chain amino acid sequence is shown as seq id no:40."
https://patents.google.com/patent/CN112175073A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Thr Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys His His Gln Ile Ala Val Ala Gly Asp Ala Glu Asp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Arg Ser Asp Arg Val Val Phe Gly Gly Gly Thr Lys Leu Thr Ala Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(9/10) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:9, and the light chain amino acid sequence is shown as seq id no:10"
https://patents.google.com/patent/CN112175073A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Thr Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Ser Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Tyr Tyr Asp Ser Ser Gly Tyr Ser Tyr Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Gly Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Asn Phe Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(19/20) in a preferred embodiment of the invention, the heavy chain amino acid sequence of the antibody or antigen binding fragment thereof is set forth in seq id no:19, and the light chain amino acid sequence is set forth in seq id no:20"
https://patents.google.com/patent/WO2019039891A1/en,,,,,"(1/6) for example, the complementarity determining region may comprise a heavy chain variable region consisting of an amino acid sequence represented by seq id no:1, 3, 5, 7, 9, 11, 13, 15, 17, which may be a monoclonal antibody that specifically binds to a middle respiratory syndrome coronavirus spike protein comprising a light chain variable region comprising an amino acid sequence as set forth in seq id no:6, 8, 10, 12, 14, 16, 18, 20 or 22 ."
https://patents.google.com/patent/CN113388028A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Phe Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Val Leu Gly Ile Ala Asn Tyr Ala Gln Glu Val Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Phe Cys Thr Thr Asp Arg Phe Val Glu Pro Ala Thr Gly Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Asn Trp Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(9/11) the human antibody or fragment thereof of claim 3, wherein the heavy chain variable region of the antibody having the same binding site as ace2 on sars-cov-2s1 protein is selected from seq id no:9, 13 and the light chain variable region is selected from seq id no:11, 15."
https://patents.google.com/patent/CN113388028A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Glu Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Ile Thr Gly Thr Thr Phe Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Ala Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(17/19) the human antibody or fragment thereof of claim 3, wherein the antibody heavy chain variable region that inhibits binding of ace2 to sars-cov-2s1 by steric hindrance effect is seq id no:17 and the light chain variable region is seq id no:19."
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(6/8)  and b) a vl comprising seq id no:8. [00123] in some embodiments, a polypeptide disclosed herein comprises: a) a vh comprising seq id no:6"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(40/49)  and  b) the vl comprises seq id no:49. [00134] in some embodiments, a polypeptide disclosed herein comprises: a) the vh comprises seq id no:40"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(34/44) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:34; and b) the vl comprises seq id no:44"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(36/46)  and b) the vl comprises seq id no:46. [00130] in some embodiments, a polypeptide disclosed herein comprises: a) the vh comprises seq id no:36"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(34/43)  and b) a vl comprising seq id no:43. [00126] in some embodiments, a polypeptide disclosed herein comprises: a) a vh comprising seq id no:34"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(35/45)  and b) a vl comprising seq id no:45. [00128] in some embodiments, a polypeptide disclosed herein comprises a vh and vl that contain human framework regions. [00129] in some embodiments, a polypeptide disclosed herein comprises: a) the vh comprises seq id no:35"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(6/10) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:6; and b) the vl comprises seq id no:10"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(37/48) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:37; and b) the vl comprises seq id no:48"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(33/43) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:33; and  b) the vl comprises seq id no:43"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(33/45) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:33; and b) the vl comprises seq id no:45"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(39/50) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:39; and b) the vl comprises seq id no:50"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(40/51) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:40; and b) the vl comprises seq id no:51"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(27/10)  and b) a vl comprising seq id no:10. [00124] in some embodiments, a polypeptide disclosed herein comprises: a) a vh comprising seq id no:27"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(3/8) in some embodiments, the reference antibody comprises a vh sequence of seq id no:3 and a vl sequence of seq id no:8"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(38/49) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:38; and b) the vl comprises seq id no:49"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(4/9) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:4; and b) the vl comprises seq id no:9"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(35/46) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:35; and b) the vl comprises seq id no:46"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(33/28)  and b) a vl comprising seq id no:28. [00125] in some embodiments, a polypeptide disclosed herein comprises: a) a vh comprising seq id no:33"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(5/9)  and b) a vl comprising seq id no:9. [00122] in some embodiments, a polypeptide disclosed herein comprises: a) a vh comprising seq id no:5"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(17/19) [0058] in another aspect, the invention provides a polypeptide that specifically binds a sars-cov-2 spike protein, wherein the polypeptide comprises: a) an immunoglobulin heavy chain variable region (vh) comprising an amino acid sequence that is at least 55% (e.g., at least 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) identical to seq id no:3; b) an immunoglobulin light chain variable region (vl) comprising an amino acid sequence that is at least 55% (e.g., at least 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) identical to seq id no:8; or c) both a) and b), wherein the polypeptide does not comprise all three of seq id no:12, seq id no:17 and seq id no:19"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(36/47) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:36; and b) the vl comprises seq id no:47"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(37/47)  and b) the vl comprises seq id no:47. [00131] in some embodiments, a polypeptide disclosed herein comprises: a) the vh comprises seq id no:37"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(38/48)  and b) the vl comprises seq id no:48. [00132] in some embodiments, a polypeptide disclosed herein comprises: a) the vh comprises seq id no:38"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(5/8) the polypeptide of any one of claims 2-28, wherein: a) the vh comprises seq id no:5; and b) the vl comprises seq id no:8"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(19/17) [0057] in some embodiments, the polypeptide that binds to a sars-cov-2 spike protein (e.g., seq id no:1, seq id no:59) and comprises an immunoglobulin light chain variable region, an immunoglobulin heavy chain variable region, or an immunoglobulin light chain variable region and an immunoglobulin heavy chain variable region, wherein the polypeptide does not comprise all three of seq id no:12, seq id no:17 and seq id no:19"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(27/28) [00124] in some embodiments, a polypeptide disclosed herein comprises: a) a vh comprising seq id no:27; and b) a vl comprising seq id no:28"
https://patents.google.com/patent/WO2022010921A1/en,,,,,"(33/44)  and b) a vl comprising seq id no:44. [00127] in some embodiments, a polypeptide disclosed herein comprises: a) a vh comprising seq id no:33"
https://patents.google.com/patent/CN111978398A/en,,,,,"(19/5) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: comprises the amino acid sequence shown in seq id no:5 in the light chain variable region; and a polypeptide comprising seq id no:19 in a heavy chain variable region of the amino acid sequence of seq id no."
https://patents.google.com/patent/CN111978398A/en,,,,,"(1/18) in particular, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of seq id no:1-17 (see table 1) and a light chain variable region comprising an amino acid sequence selected from seq id no:18-26 (see table 2)"
https://patents.google.com/patent/CN111978398A/en,,,,,"(18/1) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: a light chain variable region comprising a sequence selected from seq id no:1-4; and a heavy chain variable region comprising seq id no:18."
https://patents.google.com/patent/CN111978398A/en,,,,,"(78/80)  and seq id no:78, and a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the heavy chain set forth in seq id no:80, or a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto."
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Leu Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Gly Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Asn Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Asn Val Leu Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Asn Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(120/145) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:120, and the amino acid sequence of the light chain variable region is shown as seq id no:145"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Arg Ile Arg Ser Lys Ser Asp Asn Tyr Ala Ala Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Ala Asp Gly Tyr Ser Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Val Val Met Thr Gln Ile Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr Leu His Trp Phe Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(118/143) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:118, and the amino acid sequence of the light chain variable region is shown as seq id no:143"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Pro Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ala Gly Gly Asn Thr Asn Tyr Asn Ser Ala Leu Met Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Leu Asn Ser Leu Gln Val Asp Asp Thr Ala Met Tyr Tyr Cys Ala Tyr Tyr Arg Tyr Asp Ala Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met Phe Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr His Cys Gln His Ser Arg Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(115/140) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:115, and the amino acid sequence of the light chain variable region is shown as seq id no:140"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv2, PR300928VLhuv1,"(177/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:182"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Met Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Thr Tyr Trp Met Thr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Gly Tyr Asp Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Val Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Thr Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Thr Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Gly Pro Trp Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys , Synthetic, Synthetic,"(117/142) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:117, and the amino acid sequence of the light chain variable region is shown as seq id no:142"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Arg Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(130/154) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:130, and the amino acid sequence of the light chain variable region is shown as seq id no:154"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Phe Ser Asn Tyr Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Tyr Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asp Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(131/155) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:131, and the amino acid sequence of the light chain variable region is shown as seq id no:155"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv3, PR300928VLhuv2,"(176/181) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:176, and the amino acid sequence of the light chain variable region is shown in seq id no:181"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Val Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Leu Gly Met Ile His Pro Ser Asp Ser Glu Ser Arg Leu Asn Gln Lys Phe Met Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Asn Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Val Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Ser Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(114/139) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:114, and the amino acid sequence of the light chain variable region is shown as seq id no:139"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv2, PR300961Vlhuv2,"(172/168) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:168"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Ile Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(121/146) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:121, and the amino acid sequence of the light chain variable region is shown as seq id no:146"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Ser Cys Ala Arg Glu Thr Ser Tyr Ser Gly Tyr Asp Trp Gly Tyr Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Thr Leu Gln Thr Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys, Synthetic, Synthetic,"(137/97) or the amino acid sequence of the heavy chain variable region is shown as seq id no:137, and the amino acid sequence of the light chain variable region is shown as seq id no:97"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv2, PR300928VLhuv3,"(177/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:180"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv1, PR300961Vlhuv1,"(173/169) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:169"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv1, PR300961Vlhuv2,"(173/168) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:168"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv1, PR300928VLhuv2,"(178/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:181"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Thr Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv3, PR300961Vlhuv3,"(171/167) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:167"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv4, PR300928VLhuv3,"(175/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:180."
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Leu Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asn Ser Ile Tyr His Pro Asn Phe Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Ala Ala Val Tyr Tyr Cys Ala Ser Pro Tyr Gly Phe Ile Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Met Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(126/150) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:126, and the amino acid sequence of the light chain variable region is shown in seq id no:150"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Thr Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv3, PR300961Vlhuv2,"(171/168) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:168"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Tyr Gln Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Phe Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Phe Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Synthetic, Synthetic,"(136/91) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:136, and the amino acid sequence of the light chain variable region is shown as seq id no:91"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv4, PR300928VLhuv2,"(175/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:181"
https://patents.google.com/patent/CN113480644A/en, Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Ser Leu Glu Trp Val Ala Tyr Ile Ser Asn Gly Gly Ala Asn Thr Tyr Tyr Pro Asp Thr Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg His Arg Asp Trp Asp Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Thr Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(116/141) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:116, and the amino acid sequence of the light chain variable region is shown as seq id no:141"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv3, PR300928VLhuv1,"(176/182) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:176, and the amino acid sequence of the light chain variable region is shown in seq id no:182"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv4, PR300928VLhuv1,"(175/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:175, and the amino acid sequence of the light chain variable region is shown as seq id no:182"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asp Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(135/155) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:135, and the amino acid sequence of the light chain variable region is shown in seq id no:155"
https://patents.google.com/patent/CN113480644A/en, Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Tyr Ile Ser Asn Gly Gly Val Asn Thr Tyr Tyr Pro Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg His Arg Asp Trp Asp Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Thr Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(124/148) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:124, and the amino acid sequence of the light chain variable region is shown in seq id no:148"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Met Lys Ser Ser Gly Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Arg Ser Ser Asn Trp Trp Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Phe Gln Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Asp Tyr Tyr Gly Ser Gly Ser Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Arg Gly Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(128/152) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:128, and the amino acid sequence of the light chain variable region is shown as seq id no:152"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv1, PR300928VLhuv1,"(178/182) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:182"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Thr Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Phe Phe Cys Ala Arg Glu Asp Gly Asn Tyr Val Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Ser Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys His Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Synthetic, Synthetic,"(125/149) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:125, and the amino acid sequence of the light chain variable region is shown in seq id no:149"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv2, PR300961Vlhuv3,"(172/167) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:167"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Phe Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr Met Asp Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(119/144) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:119, and the amino acid sequence of the light chain variable region is shown as seq id no:144"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv1, PR300961Vlhuv3,"(173/167) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:173, and the amino acid sequence of the light chain variable region is shown as seq id no:167"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Arg Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Gly Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(133/154) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:133, and the amino acid sequence of the light chain variable region is shown as seq id no:154"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv1, PR300928VLhuv3,"(178/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:178, and the amino acid sequence of the light chain variable region is shown as seq id no:180"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ala Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Gly Trp Asp Val Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(132/156) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:132, and the amino acid sequence of the light chain variable region is shown in seq id no:156"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Gln Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv3, PR300928VLhuv3,"(176/180) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:176, and the amino acid sequence of the light chain variable region is shown as seq id no:180"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asn Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser His Ser Gly Tyr Tyr Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Thr Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(127/151) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:127, and the amino acid sequence of the light chain variable region is shown as seq id no:151"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ala Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Gly Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro Glu Asp Leu Ala Thr Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhuv2, PR300928VLhuv2,"(177/181) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:177, and the amino acid sequence of the light chain variable region is shown as seq id no:181"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Phe Tyr Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asn Tyr Tyr Gly Ser Gly Ile Tyr Leu Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Phe Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(129/153) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:129, and the amino acid sequence of the light chain variable region is shown as seq id no:153"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Val Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Ser Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(123/139) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:123, and the amino acid sequence of the light chain variable region is shown in seq id no:139"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Ser Tyr Tyr Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Pro Gly Leu Arg Phe Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Gln Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic, Synthetic,"(134/157) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:134, and the amino acid sequence of the light chain variable region is shown as seq id no:157"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv2, PR300961Vlhuv1,"(172/169) or, the amino acid sequence of the heavy chain variable region is shown as seq id no:172, and the amino acid sequence of the light chain variable region is shown as seq id no:169"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Phe Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Leu Asn Pro Asn Asn Asp Asp Thr Thr Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Thr Arg Glu Asp Gly Asn Tyr Val Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Gly Ala Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ile Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Synthetic, Synthetic,"(113/138) in a specific embodiment of the present invention, the amino acid sequence of the heavy chain variable region is represented by seq id no:113, and the amino acid sequence of the light chain variable region is represented by seq id no:138"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Gly Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Ser Cys Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Tyr Pro Tyr Met Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , PR300961VHhu, Synthetic,"(174/150) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:174, and the amino acid sequence of the light chain variable region is shown in seq id no:150"
https://patents.google.com/patent/CN113480644A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Asn Thr Tyr Asn Gln Lys Leu Lys Gly Lys Ala Thr Leu Thr Val His Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile Tyr Ser Ala Ser Ser Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Asn Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Synthetic, Synthetic,"(122/147) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:122, and the amino acid sequence of the light chain variable region is shown in seq id no:147"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Pro Tyr Tyr Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Asn Val Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile Tyr Ser Ala Ser His Arg Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Thr Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300928VHhu, PR300928VLhu,"(179/183) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:179, and the amino acid sequence of the light chain variable region is shown in seq id no:183"
https://patents.google.com/patent/CN113480644A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Val Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Thr Tyr Glu Trp Tyr Phe Asp Val Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Pro Gly Gln Arg Ala Thr Ile Thr Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asn Asp Val Ala Asn Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , PR300961VHhuv3, PR300961Vlhuv1,"(171/169) or, the amino acid sequence of the heavy chain variable region is shown in seq id no:171, and the amino acid sequence of the light chain variable region is shown in seq id no:169"
https://patents.google.com/patent/CN113817050A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Met Glu Val Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Tyr Asn Ser Ala Pro Phe Ala Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/CN111732654B/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Ser Asp Phe Asp Trp Leu Tyr Arg Ser His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gln Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/US20210388065A1/en,,,,,"(37/39) the antibody or antigen-binding fragment thereof of claim 1, wherein the hcvr/lcvr amino acid sequence pairs are combined with heavy and light chain constant regions comprised of seq id no:37 and 39, respectively."
https://patents.google.com/patent/US20210388065A1/en,,,,,"(28/10)  sequences selected from the group consisting of seq id no:28-36, wherein the antibody or antigen-binding fragment comprises a hcvr/lcvr amino acid sequence pair selected from the group consisting of seq id no:10/28, 11/29, 12/30, 13/31, 14/32, 15/33, 16/34, 17/35, 18/36. "
https://patents.google.com/patent/US20210388065A1/en,,,,,"(10/28)  contained within any one of the light chain variable region (lcvr) sequences selected from the group consisting of seq id no:28-36, wherein the antibody or antigen-binding fragment comprises a hcvr/lcvr amino acid sequence pair selected from the group consisting of seq id no:10/28, 11/29, 12/30, 13/31, 14/32, 15/33, 16/34, 17/35, 18/36. "
https://patents.google.com/patent/CN113150129A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Thr Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Thr Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Thr Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Gly Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Glu Arg Trp Leu Gln Leu His Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ala Pro Arg Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr His Asn Asp Leu Leu Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Arg Leu Asn Gly Arg Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , Artificial Synthesis, Artificial Synthesis,"(4/8) in certain preferred embodiments, the heavy chain variable region of the scfv-27 sequence of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:8"
https://patents.google.com/patent/CN113150129A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Arg Ser Leu Asn Asn Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr Asn Gly Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Asn Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Ala Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Synthesis, Artificial Synthesis,"(12/16) the heavy chain variable region of the scfv-32 sequence comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:12, and the light chain variable region of the scfv-32 sequence comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:16."
https://patents.google.com/patent/WO2021216876A2/en,,,,,"(245/246) the isolated monoclonal antibody or an antigen-binding fragment thereof of claim 1, wherein the vh and vl comprise the amino acid sequences seq id no:245 and seq id no:246, respectively"
https://patents.google.com/patent/CN112521496A/en, caggtccaac tgcagcagcc tggggctgag ctggtgaggc ctggaccttc agtgaagctg tcctgcaagg cttctggcta ttccttcacc agctactgga tgaactgggt gaagcagagg cctggacaag gccttgagtg gattggcatg attcatcctt ccgatagtga aactaggtta aatcagaagt tcaaggacaa ggccacattg actgtagaca aatcctccag cacagcctac atgcaactca gcagcccgac atctgaggac tctgcggtct attactgtgc aagatcggac ggctactatt ggtacttcga tgtctggggc gcagggacca cggtcaccgt ctcctcagcc , attgtgttga cccaatctcc agcttctttg gcggtgtctc tagggcagag ggccaccata tcctgcagag ccagtgaaag tgttgatagt tatggcaata gttttatgca ctggtaccag cagaaaccag gacagccacc caaactcctc atctatcttg catccaacct agaatctggg gtccctgcca ggttcagtgg cagtgggtct aggacagact tcaccctcac cattgatcct gtggaggctg ctgatgctgc aacctattac tgtcagcaag ataatgagga tccgtggacg ttcggtggag gcaccaagct ggaaatcaaa , Artificial Synthesis, Artificial Synthesis,"(6/5) the gene of the encoding monoclonal antibody, the gene sequence of the variable region of the light chain of the encoding sars-cov-2 spike rbd/2e10 is shown in seq id no:5; the gene sequence of the heavy chain variable region of coding sars-cov-2 spike rbd/2e10 is shown in seq id no:6."
https://patents.google.com/patent/CN112521496A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Pro Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Asp Gly Tyr Tyr Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala , Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asp Asn Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Synthesis, Artificial Synthesis,"(2/1)  the amino acid sequence of the light chain variable region of the sars-cov-2 spike rbd/2e10 is shown in seq id no:1, and the amino acid sequence of the heavy chain variable region of the sars-cov-2 spike rbd/2e10 is shown in seq id no:2."
https://patents.google.com/patent/CN112521496A/en, Met Ala Val Val Thr Gly Val Asn Ser Glu Val Gln Val Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Thr Asn Asp Asp Ile Lys Tyr Asp Pro Lys Phe Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Val Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Phe Tyr Cys Ala Ser Arg Tyr Asp Tyr Val Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Pro Val Tyr Pro Leu Ala Pro Gly Ser Leu Gly Ile Ser Arg Gly Ser Pro Gly Thr Glu Leu Glu Phe Val Ile Met Val Ile Ala Val Ser Cys Val Lys Leu Leu Ser Ala His Asn Ser Thr Gln His Thr Ser Arg Lys His Lys Val , Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile Arg Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp Lys , Artificial Synthesis, Artificial Synthesis,"(4/3) the amino acid sequence of the light chain variable region of the sars-cov-2 spike rbd/6e2 is shown in seq id no:3, and the amino acid sequence of the heavy chain variable region of the sars-cov-2 spike rbd/6e2 is shown in seq id no:4"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(176/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:176 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p13 g "
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(173/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:173 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p13 b "
https://patents.google.com/patent/WO2021194951A1/en,,,,,(171/201) the antibody or the antigen-binding fragment can comprise a vh chain having an amino acid sequence of seq id no:171 and a vl chain having an amino acid sequence of seq id no:201
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(169/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:169 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p02 c"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(183/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:183 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p14 d"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(154/194) [0091] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:154 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:194 (covid 19 p02 h"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(155/195)  . [0092] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:155 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 (covid 19_p 13 c"
https://patents.google.com/patent/WO2021194951A1/en,,,,,(165/203) [0009] the antibody or the antigen-binding fragment can comprise a vh chain having an amino acid sequence of seq id no:165 and a vl chain having an amino acid sequence of seq id no:203
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(178/200) the antibody or the antigen-binding fragment of claim 1 or 4, that comprises a vh chain having an amino acid sequence of seq id no:178 and a vl chain having an amino acid sequence of seq id no:200"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(180/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:180 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p14 b"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(188/213) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:188 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:213 (covid 19_p 14 f"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(168/206) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:168 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:206 (covid 19 p02 a "
https://patents.google.com/patent/WO2021194951A1/en,,,,,(153/193) the antibody or the antigen-binding fragment can comprise a vh chain having an amino acid sequence of seq id no:153 and a vl chain having an amino acid sequence of seq id no:193
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(189/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:189 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p14 h "
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(175/208) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:175 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:208 (covid 19 p13 d "
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(161/195) [0098] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:161 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 (covid 19 p01 c"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(171/211) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:171 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:211 (covid 19 p14 e"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(185/212) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:185 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:212 (covid 19_p 14 f"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(151/191) [0088] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:151 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:191 (covid 19 p01 e"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(150/190) [0087] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:150 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:190 (covid 19 p01 e"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(157/197) [0094] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:157 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:197 (covid 19 p14 d "
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(167/205) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:167 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:205 (covid 19 p02 a"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(177/209) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:177 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:209 (covid 19_p 13 h"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(182/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:182 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p14 c"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(174/207) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:174 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:207 (covid 19 p13 d"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(170/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:170 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p02 d "
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(160/200) [0097] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:160 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19 p01 b"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(172/195) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:172 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 (covid 19 p13 b"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(163/202) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:163 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 (covid 19_p01 g"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(184/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:184 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19_p 14_e01 "
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(166/204) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:166 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:204 (covid 19 p01 h"
https://patents.google.com/patent/WO2021194951A1/en,,,,,(152/192) the antibody or the antigen binding fragment can comprise a vh chain having an amino acid sequence of seq id no:152 and a vl chain having an amino acid sequence of seq id no:192
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(164/190) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:164 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:190 (covid 19 p01 h"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(162/201) [0099] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:162 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:201 (covid 19 p01 e"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(181/200) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:181 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 (covid 19_p 14 b"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(186/202) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:186 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 (covid 19 p14 f"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(187/210) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:187 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 (covid 19 p14 f"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(159/199) [0096] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:159 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:199 (covid 19 p01 b"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(158/198) [0095] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:158 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:198 (covid 19 p14 g"
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(156/196) [0093] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars- cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:156 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:196 (covid 19 p14 c "
https://patents.google.com/patent/WO2021194951A1/en,,,,,"(179/210) sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:179 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 (covid 19_p 14 b"
https://patents.google.com/patent/CN111909262A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 067). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111909262A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 070). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111909262A/en,,,,,(29/28)  the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 079). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111909262A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (monoclonal antibody 7-cqts 072). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111909262A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (monoclonal antibody 3-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(37/36)  the light chain amino acid sequence can also be shown as seq id no:36 (monoclonal antibody 18-cqts 083). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111909262A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence may also be shown as seq id no:40 (mab 20-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(13/12)  the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 071). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111909262A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence can also be shown as seq id no:36 (monoclonal antibody 18-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence can also be shown as seq id no:38 (mab 19-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 074). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111909262A/en,,,,,(39/38)  the light chain amino acid sequence can also be shown as seq id no:38 (mab 19-cqts 086). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111909262A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (monoclonal antibody 4-cqts 069). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111909262A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (monoclonal antibody 7-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (monoclonal antibody 8-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(23/22)  the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 076). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111909262A/en,,,,,(25/24)  the light chain amino acid sequence can also be shown as seq id no:24 (monoclonal antibody 12-cqts 077). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111909262A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to a novel coronavirus rbd, the heavy chain amino acid sequence of which is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111909262A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (monoclonal antibody 3-cqts 068). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111909262A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence can also be shown as seq id no:24 (monoclonal antibody 12-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(3/2)  the light chain amino acid sequence is shown as seq id no:2 (monoclonal antibody 1-cqts 066). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111909262A/en,,,,,(31/30)  the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 080). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111909262A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(27/26)  the light chain amino acid sequence may also be shown as seq id no:26 (mab 13-cqts 078). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111909262A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence may also be shown as seq id no:34 (monoclonal antibody 17-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 075). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111909262A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence may also be shown as seq id no:26 (mab 13-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (monoclonal antibody 8-cqts 073). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111909262A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (monoclonal antibody 4-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(33/32)  the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 081). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111909262A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 
https://patents.google.com/patent/CN111909262A/en,,,,,(35/34)  the light chain amino acid sequence may also be shown as seq id no:34 (monoclonal antibody 17-cqts 082). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111909262A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 
https://patents.google.com/patent/CN113264998A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Arg Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Thr Arg Trp Ile Ser Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Arg Ile Asp Pro Ser Asp Ser Tyr Ser His Tyr Ser Pro Ser Phe Gln Gly His Val Thr Ile Ser Ala Asp Arg Ser Ile Thr Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Val Ser Gly Gly Asn Trp Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ala Pro Arg Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Pro Val Asn Trp Tyr Gln Gln Val Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Asn Asp Leu Leu Pro Ser Gly Val Ser Gly Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Synthesis, Artificial Synthesis,"(4/8) in certain preferred embodiments, the heavy chain variable region of the scfv-22 sequence of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the single chain antibody comprises an amino acid sequence that is at least 70% homologous to the amino acid sequence set forth in seq id no:8"
https://patents.google.com/patent/CN113264998A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Ser Ser Gly Arg Val Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Asn Gly Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Ala Tyr Tyr Cys Gln Gln Leu Ile Val Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Synthesis, Artificial Synthesis,"(12/16) the heavy chain variable region of the scfv-24 sequence of the single-chain antibody comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:12, and the light chain variable region of the scfv-24 sequence of the single-chain antibody comprises an amino acid sequence which is at least 70% homologous to the amino acid sequence shown in seq id no:16."
https://patents.google.com/patent/CN112961222A/en, Gln Val Gln Leu Lys Glu Ser Gly Glu Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Ser Val His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Ile Tyr Phe Cys Thr Arg Ser Thr Ala Thr Ser Asp Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Lys Leu Val Tyr Pro Leu Ala Pro , Asp Ile Leu Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Val Leu Ile Tyr Thr Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Thr Asn Ala Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(7/6) the amino acid sequences of the variable region of the light chain and the variable region of the heavy chain of the monoclonal antibody clone4g1 are respectively shown as seq id no:6 and 7
https://patents.google.com/patent/CN112961222A/en, Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Leu Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr Tyr Ile Tyr Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Tyr Thr Ile Tyr Asp Pro Lys Phe Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Ser Ser Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Thr Leu Thr Leu Ser Val Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly Ala His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(9/8) the monoclonal antibody has the amino acid sequences of the light chain variable region and the heavy chain variable region of clone 11d5 shown in seq id no:8 and seq id no:9.
https://patents.google.com/patent/CN113861288A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Phe Glu Val Thr Trp Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ser Ile Ser Arg Gly Gly Gly Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu His Gln Thr Val Leu Thr Ser Val Glu Trp Glu Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence (Artificial sequence),,"(1)  having the amino acid sequence of seq id no:1 is named b3a3, and the single domain antibody (heavy chain variable regio"
https://patents.google.com/patent/CN113861288A/en, caggtgcagc tggtggaatc gggtggggga ttggttcagg cggggggaag tttacgctta tcgtgtgcgg catctggtcg tattttcgaa gttacttgga tgggttggta tcgccaggca ccaggtaaag aacgtgaatt cgttgcctct atttctcgtg gcggtggtac caactacgcg gactcagtga aaggccgctt cactatctcc cgtgataatg ctaagaacac cgtttatctg cagatgaatt ctttgaaacc tgaagacact gccgtttatt attgcgcagc tctgcatcag actgttctga cttctgttga atgggaaggt tacgactact ggggtcaggg aacccaggtt acggtttctt ct ,, Artificial sequence (Artificial sequence),,(3) the nucleic acid molecule encoding the single domain antibody b3a3 is shown in seq id no:3.
https://patents.google.com/patent/CN113861288A/en, caggtgcagc tggtggaatc gggtggggga ttggttcagg cggggggaag tttacgctta tcgtgtgcgg catctggtcg tattctggct gttttcgtta tgggttggta tcgccaggca ccaggtaaag aacgtgaatt cgttgcctct attactcatg gcggtactac caactacgcg gactcagtga aaggccgctt cactatctcc cgtgataatg ctaagaacac cgtttatctg cagatgaatt ctttgaaacc tgaagacact gccgtttatt attgcgcagc tcaggacctg gactacaacg tttacttcca tccgtactgg cagctgtacg actactgggg tcagggaacc caggttacgg tttcttct ,, Artificial sequence (Artificial sequence),,(4) the dna molecule shown in seq id no:4 encodes the single domain antibody i3a10 shown in seq id no:2.
https://patents.google.com/patent/CN113861288A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Leu Ala Val Phe Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ser Ile Thr His Gly Gly Thr Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gln Asp Leu Asp Tyr Asn Val Tyr Phe His Pro Tyr Trp Gln Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence (Artificial sequence),,(2) the dna molecule shown in seq id no:4 encodes the single domain antibody i3a10 shown in seq id no:2.
https://patents.google.com/patent/US10421802B2/en,,,,,"(1/2) the polypeptide of claim 2, wherein the vh region comprises seq id no:1 and the vl region comprises seq id no:2."
https://patents.google.com/patent/US10421802B2/en,,,,,"(9/10)  can comprise one or both of the heavy and light chains of the m337 antibody, which correspond to the amino acid sequences of seq id no:9 and seq id no:10, respectively."
https://patents.google.com/patent/US10421802B2/en,,,,,"(16/17)  can comprise one or both of the heavy and light chains of the m338 antibody, which correspond to the amino acid sequences of seq id no:16 and seq id no:17, respectively."
https://patents.google.com/patent/KR20220012792A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018."
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Ser Glu Val Arg Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(21/27) cs 2: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:21, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:27"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Arg Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Ser Glu Val Arg Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(23/30) cs 5: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:23, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:30"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Ser Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Ala Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ala Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(24/32) cs 7: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:24, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:32"
https://patents.google.com/patent/CN113683687A/en, Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Val Gly Arg Gly Tyr Ser Tyr Gly Phe Leu Pro Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Ala Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asp Gly Tyr Ser Tyr Leu His Trp Tyr Val Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Ser Ala Asp Ser Asn Arg Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(20/26) cs 1: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:20, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:26"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ala Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Ser Glu Val Arg Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Gln Val Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(22/31) cs 6: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:31"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Leu Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Val Ser Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(22/28) cs 3: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:28"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Gly Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Val Ile Ser Glu Val Arg Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Asp Thr Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(22/29) cs 4: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:22, and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:29"
https://patents.google.com/patent/CN113683687A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Asp Val Tyr Gly Gly Asn Ser Arg Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ala Val Leu Thr Gln Pro Ser Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Glu Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(25/33) cs 8: the heavy chain variable region comprises or consists of the amino acid sequence shown as seq id no:25 and the light chain variable region comprises or consists of the amino acid sequence shown as seq id no:33.
https://patents.google.com/patent/WO2021243185A9/en,,,,,(56/57)  provided herein comprises a vh comprising an amino acid sequence of seq id no:56 and a vl comprising an amino acid sequence of seq id no:57. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(25/26)  provided herein comprises a vh comprising an amino acid sequence of seq id no:25 and a vl comprising an amino acid sequence of seq id no:26. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(49/50)  provided herein comprises a vh comprising an amino acid sequence of seq id no:49 and a vl comprising an amino acid sequence of seq id no:50. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(76/77)  provided herein comprises a vh comprising an amino acid sequence of seq id no:76 and a vl comprising an amino acid sequence of seq id no:77. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(83/84)  provided herein comprises a vh comprising an amino acid sequence of seq id no:83 and a vl comprising an amino acid sequence of seq id no:84. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(106/107)  provided herein comprises a vh comprising an amino acid sequence of seq id no:106 and a vl comprising an amino acid sequence of seq id no:107. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(142/143)  provided herein comprises a vh comprising an amino acid sequence of seq id no:142 and a vl comprising an amino acid sequence of seq id no:143. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(167/168)  provided herein comprises a vh comprising an amino acid sequence of seq id no:167 and a vl comprising an amino acid sequence of seq id no:168. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(97/98)  provided herein comprises a vh comprising an amino acid sequence of seq id no:97 and a vl comprising an amino acid sequence of seq id no:98. 
https://patents.google.com/patent/WO2021243185A9/en,,,,,(65/57)  provided herein comprises a vh comprising an amino acid sequence of seq id no:65 and a vl comprising an amino acid sequence of seq id no:57. 
https://patents.google.com/patent/US11028167B1/en,,,,,"(166/190) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:166 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:190."
https://patents.google.com/patent/US11028167B1/en,,,,,"(158/182) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:158 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:182."
https://patents.google.com/patent/US11028167B1/en,,,,,"(150/174) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:150 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:174."
https://patents.google.com/patent/US11028167B1/en,,,,,"(159/183) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:159 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:183."
https://patents.google.com/patent/US11028167B1/en,,,,,"(156/180) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:156 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:180."
https://patents.google.com/patent/US11028167B1/en,,,,,"(167/191) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:167 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:191."
https://patents.google.com/patent/US11028167B1/en,,,,,"(147/171) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:147 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:171."
https://patents.google.com/patent/US11028167B1/en,,,,,"(145/169) in further embodiments, the 3bgf-derived antibody or antigen-binding fragment comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:169-192, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:145-168"
https://patents.google.com/patent/US11028167B1/en,,,,,"(151/175) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:151 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:175."
https://patents.google.com/patent/US11028167B1/en,,,,,"(162/186) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:162 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:186."
https://patents.google.com/patent/US11028167B1/en,,,,,"(155/179) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh chain having an amino acid sequence of seq id no:155 and a vl chain having an amino acid sequence of seq id no:179."
https://patents.google.com/patent/US11028167B1/en,,,,,"(163/187) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:163 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:187."
https://patents.google.com/patent/US11028167B1/en,,,,,"(165/189) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:165 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:189."
https://patents.google.com/patent/US11028167B1/en,,,,,"(146/170) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:146 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:170."
https://patents.google.com/patent/US11028167B1/en,,,,,"(160/184) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:160 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:184."
https://patents.google.com/patent/US11028167B1/en,,,,,"(153/177) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:153 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:177."
https://patents.google.com/patent/US11028167B1/en,,,,,"(152/176) in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:152 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:176."
https://patents.google.com/patent/US11028167B1/en,,,,,"(154/178) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:154 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:178."
https://patents.google.com/patent/US11028167B1/en,,,,,"(208/209) a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to seq id no:208 and a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to seq id no:209"
https://patents.google.com/patent/US11028167B1/en,,,,,"(161/185) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:161 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:185."
https://patents.google.com/patent/US11028167B1/en,,,,,"(149/173) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:149 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:173."
https://patents.google.com/patent/US11028167B1/en,,,,,"(168/192) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:168 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:192."
https://patents.google.com/patent/US11028167B1/en,,,,,"(148/172) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:148 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:172."
https://patents.google.com/patent/US11028167B1/en,,,,,"(157/181) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:157 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:181."
https://patents.google.com/patent/US11028167B1/en,,,,,"(164/188) in one instance, a 3bgf-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:164 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:188."
https://patents.google.com/patent/WO2021186190A1/en,,,,,"(66/74) preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of seq id no:66 and a light chain variable region comprising or consisting of seq id no:74"
https://patents.google.com/patent/WO2021186190A1/en,,,,,"(34/42) preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of seq id no:34 and a light chain variable region comprising or consisting of seq id no:42"
https://patents.google.com/patent/WO2021186190A1/en,,,,,"(50/58) preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of seq id no:50 and a light chain variable region comprising or consisting of seq id no:58"
https://patents.google.com/patent/WO2021186190A1/en,,,,,"(18/26) preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of seq id no:18 and a light chain variable region comprising or consisting of seq id no:26"
https://patents.google.com/patent/CN111518203B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Arg His Ser Ser Gly Trp Asp Asn Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Leu Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody or antigen-binding portion thereof according to claim 1, wherein the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof has an amino acid sequence shown in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof has an amino acid sequence shown in seq id no:8."
https://patents.google.com/patent/CN111518203B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/WO2021218947A1/en,,,,,"(721/1081) , wherein the vh comprises a sequence selected from seq id no:721-1080 and 3111-3145 having at least 80 %, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99% identity sequence, and/or the vl therein the sequence comprising and selected from seq id no:1081-1440 and 3146-3180 has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98 %, 99%, or 99% identity sequence."
https://patents.google.com/patent/US20210371822A1/en,,,,,"(1219/1099)  in fusion with the gluc, tluc and mluc7 are represented by seq id no:1099, 1116 and 1133, respectively. the corresponding amino acid sequences are represented by seq id no:1219, 1236 and 1253, respectively. finally, essentially similar results are obtained when the sarscov2-cr3022-(vl-vh"
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(51/52)  a vh amino acid sequence having seq id no:51, and a vl amino acid sequence having seq id no:52; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(85/86)  a vh amino acid sequence having seq id no:85, and a vl amino acid sequence having seq id no:86; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(41/42)  a vh amino acid sequence having seq id no:41, and a vl amino acid sequence having seq id no:42; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(736/737)  a vh amino acid sequence having seq id no:736, and a vl amino acid sequence having seq id no:737; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(5/6)  a vh amino acid sequence having seq id no:5, and a vl amino acid sequence having seq id no:6; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(71/72)  a vh amino acid sequence having seq id no:71, and a vl amino acid sequence having seq id no:72; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(738/739)  a vh amino acid sequence having seq id no:738, and a vl amino acid sequence having seq id no:739; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(61/62)  a vh amino acid sequence having seq id no:61, and a vl amino acid sequence having seq id no:62; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(49/50)  a vh amino acid sequence having seq id no:49, and a vl amino acid sequence having seq id no:50; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(39/40)  a vh amino acid sequence having seq id no:39, and a vl amino acid sequence having seq id no:40; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(69/70)  a vh amino acid sequence having seq id no:69, and a vl amino acid sequence having seq id no:70; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(77/78)  a vh amino acid sequence having seq id no:77, and a vl amino acid sequence having seq id no:78; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(748/749)  a vh amino acid sequence having seq id no:748, and a vl amino acid sequence having seq id no:749; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(35/36)  a vh amino acid sequence having seq id no:35, and a vl amino acid sequence having seq id no:36; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(67/68)  a vh amino acid sequence having seq id no:67, and a vl amino acid sequence having seq id no:68; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(47/48) a vh amino acid sequence having seq id no:47, and a vl amino acid sequence having seq id no:48"
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(37/38)  a vh amino acid sequence having seq id no:37, and a vl amino acid sequence having seq id no:38; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(59/60)  a vh amino acid sequence having seq id no:59, and a vl amino acid sequence having seq id no:60; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(730/731)  a vh amino acid sequence having seq id no:730, and a vl amino acid sequence having seq id no:731; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(53/54)  a vh amino acid sequence having seq id no:53, and a vl amino acid sequence having seq id no:54; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(13/14)  a vh amino acid sequence having seq id no:13, and a vl amino acid sequence having seq id no:14; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(15/16)  a vh amino acid sequence having seq id no:15, and a vl amino acid sequence having seq id no:16; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(79/80)  a vh amino acid sequence having seq id no:79, and a vl amino acid sequence having seq id no:80; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(722/723)  a vh amino acid sequence having seq id no:722, and a vl amino acid sequence having seq id no:723; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(43/44)  s) a vh amino acid sequence having seq id no:43, and a vl amino acid sequence having seq id no:44"
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(981/982)  a vh amino acid sequence having seq id no:981, and a vl amino acid sequence having seq id no:982. "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(55/56)  a vh amino acid sequence having seq id no:55, and a vl amino acid sequence having seq id no:56; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(83/84)  a vh amino acid sequence having seq id no:83, and a vl amino acid sequence having seq id no:84; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(724/725)  a vh amino acid sequence having seq id no:724, and a vl amino acid sequence having seq id no:725; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(732/733)  a vh amino acid sequence having seq id no:732, and a vl amino acid sequence having seq id no:733; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(750/751)  o) a vh amino acid sequence having seq id no:750, and a vl amino acid sequence having seq id no:751"
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(81/82)  a vh amino acid sequence having seq id no:81, and a vl amino acid sequence having seq id no:82; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(11/12)  a vh amino acid sequence having seq id no:11, and a vl amino acid sequence having seq id no:12; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(1/2)  a vh amino acid sequence having seq id no:1, and a vl amino acid sequence having seq id no:2; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(23/24)  a vh amino acid sequence having seq id no:23, and a vl amino acid sequence having seq id no:24; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(746/747)  a vh amino acid sequence having seq id no:746, and a vl amino acid sequence having seq id no:747; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(752/753)  a vh amino acid sequence having seq id no:752, and a vl amino acid sequence having seq id no:753. "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(740/741)  a vh amino acid sequence having seq id no:740, and a vl amino acid sequence having seq id no:741; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(726/727)  a vh amino acid sequence having seq id no:726, and a vl amino acid sequence having seq id no:727; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(87/88)  a vh amino acid sequence having seq id no:87, and a vl amino acid sequence having seq id no:88; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(57/58)  a vh amino acid sequence having seq id no:57, and a vl amino acid sequence having seq id no:58; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(31/32)  a vh amino acid sequence having seq id no:31, and a vl amino acid sequence having seq id no:32; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(9/10)  a vh amino acid sequence having seq id no:9, and a vl amino acid sequence having seq id no:10; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(21/22)  a vh amino acid sequence having seq id no:21, and a vl amino acid sequence having seq id no:22; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(29/30)  a vh amino acid sequence having seq id no:29, and a vl amino acid sequence having seq id no:30; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(63/64)  a vh amino acid sequence having seq id no:63, and a vl amino acid sequence having seq id no:64; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(734/735)  a vh amino acid sequence having seq id no:734, and a vl amino acid sequence having seq id no:735; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(33/34)  a vh amino acid sequence having seq id no:33, and a vl amino acid sequence having seq id no:34; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(3/4)  a vh amino acid sequence having seq id no:3, and a vl amino acid sequence having seq id no:4; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(17/18)  b) a vh amino acid sequence having seq id no:17, and a vl amino acid sequence having seq id no:18"
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(25/26)  a vh amino acid sequence having seq id no:25, and a vl amino acid sequence having seq id no:26; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(744/745)  a vh amino acid sequence having seq id no:744, and a vl amino acid sequence having seq id no:745; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(75/76)  a vh amino acid sequence having seq id no:75, and a vl amino acid sequence having seq id no:76; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(73/74)  a vh amino acid sequence having seq id no:73, and a vl amino acid sequence having seq id no:74; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(65/66)  a vh amino acid sequence having seq id no:65, and a vl amino acid sequence having seq id no:66; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(742/743)  a vh amino acid sequence having seq id no:742, and a vl amino acid sequence having seq id no:743; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(91/92) a vh amino acid sequence having seq id no:91, and a vl amino acid sequence having seq id no:92"
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(7/8)  a vh amino acid sequence having seq id no:7, and a vl amino acid sequence having seq id no:8; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(89/90)  a vh amino acid sequence having seq id no:89, and a vl amino acid sequence having seq id no:90; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(27/28)  a vh amino acid sequence having seq id no:27, and a vl amino acid sequence having seq id no:28. "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(728/729)  a vh amino acid sequence having seq id no:728, and a vl amino acid sequence having seq id no:729; "
https://patents.google.com/patent/WO2022006562A1/en,,,,,"(19/20)  a vh amino acid sequence having seq id no:19, and a vl amino acid sequence having seq id no:20; "
https://patents.google.com/patent/WO2021224606A1/en,,,,,"(87) the anti-sars-cov-2 single domain antibody of claim 8, comprising an amino acid sequence selected from the group consisting of: seq id no:87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 and 99"
https://patents.google.com/patent/WO2021224606A1/en,,,,,"(108) in one embodiment, an anti-sars-cov-2 single domain antibody comprising a polynucleotide sequence having at least 70% identity to a sequence selected from the group consisting of seq id no:108, 109, 110, 111 and 112"
https://patents.google.com/patent/WO2021224606A1/en,,,,,"(109) in one embodiment, an anti-sars-cov-2 single domain antibody comprising a polynucleotide sequence having at least 70% identity to a sequence selected from the group consisting of seq id no:108, 109, 110, 111 and 112. in one embodiment, the polynucleotide sequence has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% identity to a sequence selected from the group consisting of seq id no:108, 109, 110, 111 and 112. in one embodiment, the polynucleotide sequence is selected from the group consisting of seq id no:108, 109, 110, 111 and 112. in one embodiment, the polynucleotide sequence is seq id no:109. "
https://patents.google.com/patent/WO2021224606A1/en,,,,,"(88) in one embodiment, an anti-sars-cov-2 single domain antibody comprising an amino acid sequence having at least 70% identity to seq id no:88"
https://patents.google.com/patent/US20220017604A1/en,,,,,"(25/30) for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:25-28 and an immunoglobulin light chain variable region comprising seq id no:30."
https://patents.google.com/patent/US20220017604A1/en,,,,,"(25/29) for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:25 and an immunoglobulin light chain variable region comprising any one of seq id no:29-32."
https://patents.google.com/patent/US20220017604A1/en,,,,,"(25/31) for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:25-28 and an immunoglobulin light chain variable region comprising seq id no:31."
https://patents.google.com/patent/US20220017604A1/en,,,,,"(26/29) for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:26 and an immunoglobulin light chain variable region comprising any one of seq id no:29-32."
https://patents.google.com/patent/US20220017604A1/en,,,,,"(27/29) for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:27 and an immunoglobulin light chain variable region comprising any one of seq id no:29-32."
https://patents.google.com/patent/US20220017604A1/en,,,,,"(25/32) for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:25-28 and an immunoglobulin light chain variable region comprising seq id no:32."
https://patents.google.com/patent/US20220017604A1/en,,,,,"(28/29) for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:28 and an immunoglobulin light chain variable region comprising any one of seq id no:29-32."
https://patents.google.com/patent/US20220017604A1/en,,,,,"(1/13) in various embodiments, the antibodies and antigen-binding fragments can comprise an immunoglobulin heavy chain variable region comprising an amino acid sequence having at least 70% identity to any one of seq id no:1-12 or 25-28; or an immunoglobulin light chain variable region comprising an amino acid sequence having at least 70% identity to any one of seq id no:13-24 or 29-32"
https://patents.google.com/patent/US20220017604A1/en,,,,,(26/30) another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:26 and an immunoglobulin light chain variable region comprising seq id no:30.
https://patents.google.com/patent/US20220017604A1/en,,,,,(28/32) an immunoglobulin heavy chain variable region comprising an amino acid sequence of seq id no:28 and an immunoglobulin light chain variable region comprising an amino acid sequence of seq id no:32.
https://patents.google.com/patent/US20220017604A1/en,,,,,"(27/31) an immunoglobulin heavy chain variable region comprising an amino acid sequence of seq id no:27 and an immunoglobulin light chain variable region comprising an amino acid sequence of seq id no:31, or"
https://patents.google.com/patent/CN102015767A/en,,,,,"(94/96) in certain embodiments, comprise as the antibody that this paper provided and have the heavy chain of sequence shown in any among the seq id no:94,90 and 98.in other embodiments, antibody of the present invention comprises and has the light chain of sequence shown in any among the seq id no:96,92 and 101."
https://patents.google.com/patent/WO2021222772A2/en,,,,,"(27/41) in some aspects, a secretion signal can be included as part of the recombinant polypeptide for secretion into the supernatant of the cells for downstream collection. in some aspects, the secretion signal can be mdwiwrilfl v gaat gahs (seq id no:27) or mgwsciilflvatatgvhs (seq id no:41). in some aspects, the secretion signal can be from a human immunoglobulin heavy chain, a human immunoglobulin light chain, a mouse immunoglobulin heavy chain, a mouse immunoglobulin light chain, or a cytokine. other secretion signals known in the art can also be used. "
https://patents.google.com/patent/CN113045646A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Phe Leu Thr Ile Thr Phe Tyr Tyr Met Asn Lys Phe Arg Asp Lys Gly Phe Asn Pro Ile Val Gly Gly Thr Ser Tyr Pro Gln Lys Phe Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Ser Thr Leu Thr Asp Tyr Thr Lys Gly Ala Glu Arg Tyr Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Gly Leu Glu Trp Ile Gly Asp Leu Asn Pro Ile Asn Gly Gly Thr Ala Tyr Gln Gln Lys Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Val His Thr Phe Pro Ala Leu Leu Gln Ser Gly Leu Tyr Thr Met Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala Ser Ser Thr Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser Thr Ile Asn Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala Pro Asn Leu Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile Lys Asp Val Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Ile Arg Val Val Ser Thr Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro Ser Pro Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val Arg Ala Pro Gln Val Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser Arg Lys Asp Val Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly Asp Ile Ser Val Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr Lys Asp Thr Ala Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr Ser Lys Leu Asn Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe Ser Cys Asn Val Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys Thr Ile Ser Arg Ser Pro Gly, Asp Val Val Leu Thr Gln Thr Pro Leu Thr Gln Ser Gln Tyr Ser Asn Gly Lys Ile Tyr Leu Asn Ser Leu Ser Val Thr Ile Gly Val Gln Phe Ser Lys Ile Val Pro Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Ile Ile Tyr Ser Asn Gly Lys Ile Leu Gln Asn Thr Tyr Gln Pro Tyr Thr Tyr Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Met Tyr Gln Leu Ser Lys Leu Asp Pro Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Glu Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys , Artificial sequence, Artificial sequence,"(8/10) through analysis, the antibody obtained from the hybridoma cell line 8c4 has light chains and heavy chains with sequences shown as seq id no:10 and 8."
https://patents.google.com/patent/CN113943368A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Phe Tyr Tyr Cys Thr Lys Asp His Leu Gly Glu Leu Ser Ser Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Ser Pro Ser Ala Ser Ala Ser Leu Gly Asp Ser Val Lys Leu Thr Cys Thr Leu Ser Ser Gly His Ser Ser Tyr Ala Ile Ala Trp His Gln Gln Gln Pro Glu Lys Gly Pro Arg Tyr Leu Met Lys Leu Asn Ser Asp Gly Arg His Ser Lys Gly Asp Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Ala Glu Arg Tyr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Thr Trp Gly Thr Gly Ile His Val Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8."
https://patents.google.com/patent/US11220536B1/en,,,,,"(16502/16512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15102/15112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1002/1012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15402/15412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3602/3612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15202/15212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18002/18012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6802/6812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19902/19912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21302/21312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(602/612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20102/20112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5902/5912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5602/5612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20402/20412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13302/13312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8602/8612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14902/14912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14902, and (b) the vl comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11802/11812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12602/12612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12202/12212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18302/18312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14502/14512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20802/20812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5702/5712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2502/2512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3402/3412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14402/14412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12002/12012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17302/17312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22502/22512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22512."
https://patents.google.com/patent/US11220536B1/en,,,,,"(6702/6712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22802/22812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17702/17712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4802/4812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8002/8012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8102/8112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7102/7112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21002/21012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1502/1512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8702/8712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9302/9312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15602/15612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(202/212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9402/9412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3302/3312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10002/10012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2402/2412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2602/2612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9002/9012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6902/6912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14102/14112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1702/1712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4002/4012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8902/8912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17102/17112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(802/812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2302/2312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15702/15712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1102/1112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5402/5412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10502/10512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4202/4212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10902/10912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21202/21212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5302/5312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1602/1612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2202/2212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12902/12912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7802/7812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7402/7412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11402/11412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17502/17512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17512."
https://patents.google.com/patent/US11220536B1/en,,,,,"(4402/4412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14702/14712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19202/19212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19202, and (b) the vl comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7302/7312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10802/10812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13502/13512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5202/5212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14602/14612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5802/5812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11502/11512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8502/8512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(902/912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19302/19312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12402/12412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17402/17412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20702/20712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21902/21912) the isolated antibody, or antigen-binding fragment thereof, of claim 1, wherein the vh comprises seq id no:21902 and the vl comprises seq id no:21912."
https://patents.google.com/patent/US11220536B1/en,,,,,"(13802/13812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20602/20612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6302/6312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7902/7912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10702/10712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2002/2012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7202/7212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7202, and (b) the vl comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9802/9812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17602/17612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14002/14012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8802/8812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21802/21812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22002/22012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22012; or("
https://patents.google.com/patent/US11220536B1/en,,,,,"(302/312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9502/9512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5002/5012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(23002/23012) (230) (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:23002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:23012"
https://patents.google.com/patent/US11220536B1/en,,,,,"(21502/21512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22702/22712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22712("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16902/16912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3002/3012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9702/9712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1902/1912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15002/15012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10402/10412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19702/19712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20902/20912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5502/5512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19502/19512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13202/13212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16802/16812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21702/21712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4102/4112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(702/712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19102/19112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4702/4712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4502/4512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22102/22112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22112,("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22202/22212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18702/18712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20002/20012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3102/3112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(102/112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11202/11212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11302/11312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18102/18112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13602/13612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17202/17212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16202/16212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10602/10612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19002/19012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3702/3712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8202/8212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3902/3912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1402/1412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8302/8312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6602/6612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3802/3812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10102/10112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19602/19612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10202/10212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11002/11012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19802/19812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17902/17912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16002/16012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18602/18612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7702/7712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13902/13912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1302/1312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18202/18212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20302/20312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(23102/23112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:23102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:23112."
https://patents.google.com/patent/US11220536B1/en,,,,,"(9202/9212)  (a) the vh may comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22602/22612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9902/9912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12802/12812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18502/18512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7002/7012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6102/6112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22402/22412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2802/2812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16102/16112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14202/14212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13702/13712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22302/22312) the pharmaceutical composition of claim 15, wherein the vh of the second antibody, or antigen-binding fragment thereof, comprises seq id no:22302 and wherein the vl of the second antibody, or antigen-binding fragment thereof, comprises seq id no:22312."
https://patents.google.com/patent/US11220536B1/en,,,,,"(17802/17812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(19402/19412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:19412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(8402/8412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8402, and (b) the vl nay comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:8412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2702/2712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7602/7612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7602, and (b) the vl comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11702/11712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3502/3512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1202/1212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(1802/1812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:1812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18902/18912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16302/16312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2902/2912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16402/16412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6502/6512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(17002/17012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:17012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15302/15312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15502/15512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15802/15812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(5102/5112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:5112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12502/12512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21602/21612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6202/6212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6002/6012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(502/512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(15902/15912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:15912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11102/11112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(7502/7512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:7512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12302/12312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12102/12112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(22902/22912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:22912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20202/20212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18402/18412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13002/13012)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13002, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13012;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4602/4612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(402/412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13102/13112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(10302/10312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:10312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4902/4912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16602/16612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(18802/18812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:18812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(13402/13412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:13412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(6402/6412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:6412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11902/11912)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11902, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11912;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21402/21412)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21402, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21412;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9102/9112)  (a) the vh may comprises an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(20502/20512)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20502, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:20512;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(4302/4312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:4312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(21102/21112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21112;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(9602/9612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:9612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(3202/3212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:3212;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(12702/12712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:12712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(11602/11612)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11602, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:11612;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14302/14312)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14302, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14312;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(16702/16712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:16712;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(14802/14812)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14802, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:14812;("
https://patents.google.com/patent/US11220536B1/en,,,,,"(2102/2112)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2102, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:2112;("
https://patents.google.com/patent/CN112625136B/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(22/23) the polypeptide complex of claim 7 wherein the first epitope-binding portion comprises a heavy chain comprising the heavy chain variable region and a light chain comprising the light chain variable region, and wherein the heavy chain comprises the sequence set forth in seq id no:22 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto; and/or the light chain comprises the sequence shown as seq id no:23 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto."
https://patents.google.com/patent/CN112625136B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Gly Ser Tyr Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Pro Glu Trp Val Ser Asp Ile Asn Thr Arg Gly Glu Thr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Ala Ala Ser Pro Ala Thr Phe Glu Gly Arg Ser Asp Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(5) in some embodiments, the single domain antibody or vhh fragment thereof comprises or consists of the sequence: a vhh amino acid sequence as set forth in seq id no:5,6 or 7 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto."
https://patents.google.com/patent/CN112625136B/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Gly Ser Tyr Val Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Ala Pro Glu Trp Val Ser Asp Ile Asn Thr Arg Gly Ile Val Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Ala Ala Ser Gly Asp Thr Phe Glu Gly Arg Ser Asp Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(29/23) in some embodiments, the polypeptide complex is a bispecific antibody complex consisting of 2 heavy chains consisting of the amino acid sequence set forth in seq id no:29, 30, or 31 and 2 light chains consisting of the amino acid sequence set forth in seq id no:23."
https://patents.google.com/patent/CN113929774A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Gly Leu Ser Cys Ala Val Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Leu Ile Ser Asn Asp Gly Thr Ile Asp Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Arg Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Lys Glu Gln Leu Val Pro Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Pro Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Gly Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8."
https://patents.google.com/patent/US11053304B1/en,,,,,"(394/456) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:394 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:456."
https://patents.google.com/patent/US11053304B1/en,,,,,"(422/484) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:422 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:484."
https://patents.google.com/patent/US11053304B1/en,,,,,"(369/430) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:369 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:430."
https://patents.google.com/patent/US11053304B1/en,,,,,"(389/450) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:389 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:450."
https://patents.google.com/patent/US11053304B1/en,,,,,"(421/483) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:421 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:483."
https://patents.google.com/patent/US11053304B1/en,,,,,"(423/485) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:423 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:485."
https://patents.google.com/patent/US11053304B1/en,,,,,"(416/478) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:416 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:478."
https://patents.google.com/patent/US11053304B1/en,,,,,"(382/443) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:382 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:443."
https://patents.google.com/patent/US11053304B1/en,,,,,"(375/436) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:375 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:436."
https://patents.google.com/patent/US11053304B1/en,,,,,"(390/451) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:390 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:451."
https://patents.google.com/patent/US11053304B1/en,,,,,"(391/452) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:391 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:452."
https://patents.google.com/patent/US11053304B1/en,,,,,"(404/466) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:404 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:466."
https://patents.google.com/patent/US11053304B1/en,,,,,"(411/473) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:411 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:473."
https://patents.google.com/patent/US11053304B1/en,,,,,"(419/481) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:419 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:481."
https://patents.google.com/patent/US11053304B1/en,,,,,"(381/442) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:381 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:442."
https://patents.google.com/patent/US11053304B1/en,,,,,"(415/477) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:415 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:477."
https://patents.google.com/patent/US11053304B1/en,,,,,"(427/489) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:427 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:489."
https://patents.google.com/patent/US11053304B1/en,,,,,"(408/470) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:408 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:470."
https://patents.google.com/patent/US11053304B1/en,,,,,"(376/437) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:376 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:437."
https://patents.google.com/patent/US11053304B1/en,,,,,"(417/479) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:417 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:479."
https://patents.google.com/patent/US11053304B1/en,,,,,"(412/474) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:412 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:474."
https://patents.google.com/patent/US11053304B1/en,,,,,"(378/439) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:378 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:439."
https://patents.google.com/patent/US11053304B1/en,,,,,"(428/490) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh chain having an amino acid sequence of seq id no:428 and a vl chain having an amino acid sequence of seq id no:490."
https://patents.google.com/patent/US11053304B1/en,,,,,"(401/463) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:401 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:463."
https://patents.google.com/patent/US11053304B1/en,,,,,"(368/429) in further embodiments, the 6nb6-derived antibody or antigen-binding fragment comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:429-454 and 456-490, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:368-428"
https://patents.google.com/patent/US11053304B1/en,,,,,"(371/432) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:371 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:432."
https://patents.google.com/patent/US11053304B1/en,,,,,"(374/435) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:374 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:435."
https://patents.google.com/patent/US11053304B1/en,,,,,"(386/447) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:386 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:447."
https://patents.google.com/patent/US11053304B1/en,,,,,"(405/467) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:405 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:467."
https://patents.google.com/patent/US11053304B1/en,,,,,"(384/445) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:384 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:445."
https://patents.google.com/patent/US11053304B1/en,,,,,"(424/486) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:424 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:486."
https://patents.google.com/patent/US11053304B1/en,,,,,"(388/449) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:388 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:449."
https://patents.google.com/patent/US11053304B1/en,,,,,"(396/458) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:396 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:458."
https://patents.google.com/patent/US11053304B1/en,,,,,"(385/446) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:385 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:446."
https://patents.google.com/patent/US11053304B1/en,,,,,"(403/465) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:403 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:465."
https://patents.google.com/patent/US11053304B1/en,,,,,"(400/462) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:400 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:462."
https://patents.google.com/patent/US11053304B1/en,,,,,"(392/453) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:392 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:453."
https://patents.google.com/patent/US11053304B1/en,,,,,"(370/431) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:370 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:431."
https://patents.google.com/patent/US11053304B1/en,,,,,"(414/476) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:414 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:476."
https://patents.google.com/patent/US11053304B1/en,,,,,"(373/434) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:373 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:434."
https://patents.google.com/patent/US11053304B1/en,,,,,"(398/460) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:398 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:460."
https://patents.google.com/patent/US11053304B1/en,,,,,"(402/464) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:402 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:464."
https://patents.google.com/patent/US11053304B1/en,,,,,"(413/475) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:413 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:475."
https://patents.google.com/patent/US11053304B1/en,,,,,"(420/482) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:420 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:482."
https://patents.google.com/patent/US11053304B1/en,,,,,"(410/472) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:410 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:472."
https://patents.google.com/patent/US11053304B1/en,,,,,"(425/487) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:425 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:487."
https://patents.google.com/patent/US11053304B1/en,,,,,"(407/469) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:407 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:469."
https://patents.google.com/patent/US11053304B1/en,,,,,"(418/480) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:418 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:480."
https://patents.google.com/patent/US11053304B1/en,,,,,"(379/440) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:379 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:440."
https://patents.google.com/patent/US11053304B1/en,,,,,"(372/433) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:372 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:433."
https://patents.google.com/patent/US11053304B1/en,,,,,"(383/444) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:383 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:444."
https://patents.google.com/patent/US11053304B1/en,,,,,"(380/441) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:380 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:441."
https://patents.google.com/patent/US11053304B1/en,,,,,"(387/448) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:387 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:448."
https://patents.google.com/patent/US11053304B1/en,,,,,"(393/454) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:393 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:454."
https://patents.google.com/patent/US11053304B1/en,,,,,"(397/459) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:397 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:459."
https://patents.google.com/patent/US11053304B1/en,,,,,"(399/461) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:399 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:461."
https://patents.google.com/patent/US11053304B1/en,,,,,"(406/468) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:406 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:468."
https://patents.google.com/patent/US11053304B1/en,,,,,"(395/457) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:395 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:457."
https://patents.google.com/patent/US11053304B1/en,,,,,"(409/471) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:409 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:471."
https://patents.google.com/patent/US11053304B1/en,,,,,"(426/488) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:426 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:488."
https://patents.google.com/patent/US11053304B1/en,,,,,"(377/438) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:377 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:438."
https://patents.google.com/patent/CN112552399A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Arg Ser Ala Tyr Gly Asp Lys Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Gln Glu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , synthetic, synthetic,(17/18)  b) a heavy chain variable region comprising the sequence of seq id no:17 and a light chain variable region comprising the sequence of seq id no:18
https://patents.google.com/patent/CN112552399A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Ala Asn Pro Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Val Thr Ile His Tyr Asp Ile Leu Thr Gly Tyr Tyr Ser Asn Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Ala Val Ser Ser, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Phe Met Tyr Thr Phe Gly Gln Gly Thr Met Leu Glu Ile Lys , synthetic, synthetic,(7/8)  a heavy chain variable region comprising the sequence of seq id no:7 and a light chain variable region comprising the sequence of seq id no:8; 
https://patents.google.com/patent/CN112552399A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Leu Gly Gly Phe Ala Asp Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Val Leu Ile Tyr Asp Ala Phe Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , synthetic, synthetic,(27/28)  a heavy chain variable region comprising the sequence of seq id no:27 and a light chain variable region comprising the sequence of seq id no:28.
https://patents.google.com/patent/CN112239500B/en, Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Tyr Ala Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Leu Asn Thr Tyr Ser Gly Glu Pro Thr Tyr Ala Glu Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Thr Ala Ile Leu Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Glu Asp Leu Ser Thr Ala Leu Ala Trp Cys Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Gly Ser Thr Arg His Ser Gly Val Pro Asp Arg Phe Thr Gly Ile Arg Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Leu Tyr Tyr Cys Gln Gln His Trp Ser Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys , Artificial sequence, Artificial sequence,"(14/13) mu.g of an external control antibody was used as a control, and the electrophoretogram showed two bands, 1 of which mr was 50kd (heavy chain, seq id no:14) and the other mr was 28kd (light chain, seq id no:13), as shown in fig"
https://patents.google.com/patent/CN112239500B/en,,,,,"(5/1) in alternative embodiments, the antibody comprises the light chain framework regions fr1-l, fr2-l, fr3-l and fr4-l in sequence as set forth in seq id no:1-4, and/or the heavy chain framework regions fr1-h, fr2-h, fr3-h and fr4-h in sequence as set forth in seq id no:5-8."
https://patents.google.com/patent/CN112300274A/en, Gln Leu Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Phe Gly Glu Phe Gly Phe Val Pro Gly Ala Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Pro Val Leu Thr Gln Pro Pro Ser Val Ser Ala Thr Pro Gly Gln Thr Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Pro Val Asn Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu Ile Tyr Thr Asn Asp Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Ala Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Trp His Asp Ser Leu Asn Thr Tyr Val Phe Gly Thr Gly Thr Glu Leu Thr Val Leu , Artificial Sequence, Artificial Sequence,"(7/9)  vh comprises the amino acid sequence as set forth in seq id no:7, and vl comprises the amino acid sequence set forth in seq id no:9;"
https://patents.google.com/patent/CN112300274A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser Ile Asn Ser Asp Asn Trp Trp Ser Trp Val Arg Gln Thr Pro Glu Lys Gly Leu Glu Trp Ile Gly Glu Val Tyr His Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu Asn Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ser Thr Ser Ser Asp Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ala Gly Leu Thr Gln Pro Pro Ser Leu Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asn Ala Leu Pro Lys Gln Tyr Ala Tyr Trp Tyr Arg Gln Arg Pro Gly Gln Ala Pro Glu Leu Val Met Ser Arg Asp Val Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Val Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Ala Asp Asn Ser Gly Thr Phe Val Val Phe Gly Gly Gly Thr Gln Leu Ile Ile Leu , Artificial Sequence, Artificial Sequence,"(1/5)  vh comprises the amino acid sequence as set forth in seq id no:1, and vl comprises the amino acid sequence set forth in seq id no:5;"
https://patents.google.com/patent/WO2021252620A2/en,,,,,(2/4)  a heavy chain variable region comprising the amino acid sequence of seq id no:2 and a light chain variable region comprising the amino acid sequence of seq id no:4;
https://patents.google.com/patent/WO2021252620A2/en,,,,,(6/8)  a heavy chain variable region comprising the amino acid sequence of seq id no:6 and a light chain variable region comprising the amino acid sequence of seq id no:8;
https://patents.google.com/patent/WO2021252620A2/en,,,,,(128/130)  a heavy chain variable region comprising the amino acid sequence of seq id no:128 and a light chain variable region comprising the amino acid sequence of seq id no:130. 
https://patents.google.com/patent/WO2021252620A2/en,,,,,(30/38)  a heavy chain variable region comprising the amino acid sequence of seq id no:30 and a light chain variable region comprising the amino acid sequence of seq id no:38; (1
https://patents.google.com/patent/WO2021252620A2/en,,,,,(84/92)  a heavy chain variable region comprising the amino acid sequence of seq id no:84 and a light chain variable region comprising the amino acid sequence of seq id no:92; (
https://patents.google.com/patent/WO2021252620A2/en,,,,,(42/44)  (1) a heavy chain variable region comprising the amino acid sequence of seq id no:42 and a light chain variable region comprising the amino acid sequence of seq id no:44
https://patents.google.com/patent/WO2021252620A2/en,,,,,(112/120)  a heavy chain variable region comprising the amino acid sequence of seq id no:112 and a light chain variable region comprising the amino acid sequence of seq id no:120; (
https://patents.google.com/patent/WO2021252620A2/en,,,,,(94/96)  a heavy chain variable region comprising the amino acid sequence of seq id no:94 and a light chain variable region comprising the amino acid sequence of seq id no:96; (
https://patents.google.com/patent/WO2021252620A2/en,,,,,(122/124)  (k) a heavy chain variable region comprising the amino acid sequence of seq id no:122 and a light chain variable region comprising the amino acid sequence of seq id no:124
https://patents.google.com/patent/WO2021252620A2/en,,,,,(100/102)  a heavy chain variable region comprising the amino acid sequence of seq id no:100 and a light chain variable region comprising the amino acid sequence of seq id no:102; (
https://patents.google.com/patent/WO2021252620A2/en,,,,,(18/20)  a heavy chain variable region comprising the amino acid sequence of seq id no:18 and a light chain variable region comprising the amino acid sequence of seq id no:20; (
https://patents.google.com/patent/CN112409488A/en, Glu Val Gln Leu Glu Glu Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Phe Gly Tyr Thr Phe Thr Asn His His Ile Asn Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Asp Trp Ile Gly Tyr Val Asn Pro Tyr Asn Asp Tyr Thr Lys Tyr Ser Gln Asn Phe Lys Gly Lys Ala Thr Leu Ser Val Asp Arg Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Trp Arg Asp Tyr Asp Arg Asp Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Ile Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Arg Asp Tyr Leu Tyr Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Pro Glu Asp Val Gly Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg , heavy chain variable region, light chain variable region,"(4/8) in a specific embodiment, the amino acid sequence of the heavy chain variable region is seq id no:4 and the amino acid sequence of the light chain variable region is seq id no:8."
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro His Trp Asn Ala Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , VacW-89 heavy chain variable region, VacW-89 light chain variable region,"(1/2) the variable region of the heavy chain sequence of vacw-89 is the sequence shown in seq id no:1, and the variable region of the light chain sequence is the sequence shown in seq id no:2"
https://patents.google.com/patent/CN113912709A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Val Ile Asn Pro Ser Gly Gly Asn Thr Arg Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Phe Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Pro Ser Lys Leu Leu Trp Phe Gly Glu Leu His Ile Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser, Gln Ala Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Ser Ser Thr Gly Ala Val Thr Ser Gly His Tyr Pro Tyr Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asp Thr Ser Asn Lys His Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Gly Lys Ala Ala Leu Thr Leu Ser Gly Ala Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Ser Tyr Ser Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , VacW-92 heavy chain variable region, VacW-92 light chain variable region,"(3/4) the variable region of the heavy chain sequence of vacw-92 is the sequence shown in seq id no:3, and the variable region of the light chain sequence is the sequence shown in seq id no:4"
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Thr Trp Leu Arg Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn His Phe Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , VacW-215 heavy chain variable region, VacW-215 light chain variable region,"(17/18) the variable region of the heavy chain sequence of vacw-215 is the sequence shown in seq id no:17, and the variable region of the light chain sequence is the sequence shown in seq id no:18."
https://patents.google.com/patent/CN113912709A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Arg Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Leu Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Ala Pro Val Glu Ser Ala Ala Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Pro Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , VacW-105 heavy chain variable region, VacW-105 light chain variable region,"(5/6) the variable region of the heavy chain sequence of vacw-105 is the sequence shown in seq id no:5, and the variable region of the light chain sequence is the sequence shown in seq id no:6"
https://patents.google.com/patent/CN113912709A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ile Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Ser Phe Asp Gly Ser Ile Lys Tyr Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Val Gln Gly Tyr Tyr Asp Arg Ser Gly Tyr Tyr Asn Leu Asp Tyr Asn Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , VacW-209 heavy chain variable region, VacW-209 light chain variable region,"(13/14) the variable region of the heavy chain sequence of vacw-209 is the sequence shown in seq id no:13, and the variable region of the light chain sequence is the sequence shown in seq id no:14"
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Glu Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met Glu Tyr Pro Tyr Gly Gly Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Arg Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , VacW-212 heavy chain variable region, VacW-212 light chain variable region,"(15/16) the variable region of the heavy chain sequence of vacw-212 is shown as seq id no:15, and the variable region of the light chain sequence is shown as seq id no:16"
https://patents.google.com/patent/CN113912709A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Pro Asn Tyr Tyr Asp Ser Ser Gly Leu Gly Ile Val Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Phe Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Val Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , VacW-120 heavy chain variable region, VacW-120 light chain variable region,"(7/8) the variable region of the heavy chain sequence of vacw-120 is the sequence shown in seq id no:7, and the variable region of the light chain sequence is the sequence shown in seq id no:8"
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Val Ala Tyr Pro Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Ala Ile Gln Leu Thr Gln Ser Pro Phe Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Ala Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Val Asp Thr Tyr Gln Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , VacW-138 heavy chain variable region, VacW-138 light chain variable region,"(9/10) the variable region of the heavy chain sequence of vacw-138 is the sequence shown in seq id no:9, and the variable region of the light chain sequence is the sequence shown in seq id no:10"
https://patents.google.com/patent/CN113912709A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Met Glu Tyr Pro Tyr Gly Gly Val Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Arg Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , VacW-201 heavy chain variable region, VacW-201 light chain variable region,"(11/12) the variable region of the heavy chain sequence of vacw-201 is the sequence shown in seq id no:11, and the variable region of the light chain sequence is the sequence shown in seq id no:12"
https://patents.google.com/patent/CN112961238A/en, atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat atggctagca tgtcggactc agaagtcaat caagaagcta agccagaggt caagccagaa gtcaagcctg agactcacat caatttaaag gtgtccgatg gatcttcaga gatcttcttc aagatcaaaa agaccactcc tttaagaagg ctgatggaag cgttcgctaa aagacagggt aaggaaatgg actccttaag attcttgtac gacggtatta gaatccaagc tgatcagacc cctgaagatt tggacatgga ggataacgat attattgagg ctcacagaga acagattggt ggatcccagg tgcagctgca ggagtctgga ggaggcttgg tgcaggctgg agggtctctg agactctctt gtgccgccag cggatacacc aacagtcgct actacatggg ctggttccgc caggctccag ggaaggagcg tgagttcgta gcagcgattt ctgctattgg tcgcacatac tatgcagact ccgtgaaggg ccgattcacc atctccagag acaacgccaa gaacacggtg tatcttcaaa tgaacagcct gaaacctgag gacacggccg tttattactg tgcagccgac tcttctctgg ctggtctgcg tggtcgtctg tacgactact ggggtcaggg tactcaggtc accgtctcct cagcggccgc atacccgtac gacgttccgg actacggttc ctgactcgag ,, Artificial Sequence (Artificial Sequence),,"(1) the expression cassette sequence of the sumo-nano antibody is shown in seq id no:1, and the amino acid sequence is shown in seq id no:2; also shown in fig. 6, the structural regions of his, sumo, nanobody and ha tag are distinguished by different gray scales or underlines, respectively, and correspond to the gray scale or underline portion in the name."
https://patents.google.com/patent/CN112961238A/en, caggtgcagc tgcaggagtc tggaggaggc ttggtgcagg ctggagggtc tctgagactc tcttgtgccg ccagcggata caccaacagt cgctactaca tgggctggtt ccgccaggct ccagggaagg agcgtgagtt cgtagcagcg atttctgcta ttggtcgcac atactatgca gactccgtga agggccgatt caccatctcc agagacaacg ccaagaacac ggtgtatctt caaatgaaca gcctgaaacc tgaggacacg gccgtttatt actgtgcagc cgactcttct ctggctggtc tgcgtggtcg tctgtacgac tactggggtc agggtactca ggtcaccgtc tcctca ,, Artificial Sequence (Artificial Sequence),,"(7) the nanobody of claim 1, based on the s1 subunit of the s protein of a novel coronavirus, characterized in that: the nucleotide sequence of the sdab antibody fragment is shown in seq id no:7."
https://patents.google.com/patent/CN112961238A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Leu Ala Gly Leu Arg Gly Arg Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(6) a nanobody based on the s1 subunit of the s protein of a novel coronavirus is disclosed, which comprises an sdab antibody fragment, wherein the amino acid sequence of the sdab antibody fragment is shown as seq id no:6."
https://patents.google.com/patent/CN112961238A/en, Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro Arg Gly Ser His Met Ala Ser Met Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg Glu Gln Ile Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Leu Ala Gly Leu Arg Gly Arg Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Ala Ala Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Gly Ser,, Artificial Sequence (Artificial Sequence),,"(2) the expression cassette sequence of the sumo-nano antibody is shown in seq id no:1, and the amino acid sequence is shown in seq id no:2; also shown in fig. 6, the structural regions of his, sumo, nanobody and ha tag are distinguished by different gray scales or underlines, respectively, and correspond to the gray scale or underline portion in the name."
https://patents.google.com/patent/US20210395345A1/en,,,,,"(42/50) in some cases, the anti-sars-cov-2 spike glycoprotein antibody or antigen-binding fragment comprises a hcvr comprising the amino acid sequence of seq id no:42, and a lcvr comprising the amino acid sequence of seq id no:50"
https://patents.google.com/patent/US20210395345A1/en,,,,,"(2/18) in some embodiments, the antigen-binding molecule is an anti-sars-cov-2 spike glycoprotein antibody that has the same binding and/or blocking properties as a reference antibody comprising a hcvr/lcvr amino acid sequence pair comprising the amino acid sequences selected from the group consisting of seq id no:2/10, 22/30, 42/50, and 73/81. in some embodiments, the antigen-binding molecule is an anti-sars-cov-2 spike glycoprotein antibody that has the same binding and/or blocking properties as a reference antibody comprising a heavy chain and light chain amino acid sequence pair selected from the group consisting of seq id no:18/20, 38/40, 56/58, and 89/91."
https://patents.google.com/patent/US20210395345A1/en,,,,,"(42/56) in some embodiments, the antigen-binding molecule is an anti-sars-cov-2 spike glycoprotein antibody that has the same binding and/or blocking properties as a reference antibody comprising a hcvr/lcvr amino acid sequence pair comprising the amino acid sequences of seq id no:42/50. in some embodiments, the antigen-binding molecule is an anti-sars-cov-2 spike glycoprotein antibody that has the same binding and/or blocking properties as a reference antibody comprising a heavy chain and light chain pair comprising the amino acid sequences of seq id no:56/58."
https://patents.google.com/patent/US20210395345A1/en,,,,,"(18/38) in some embodiments, the first antigen-binding molecule is a first anti-sars-cov-2 spike glycoprotein antibody or antigen-binding fragment thereof that has the same binding and/or blocking properties as a reference antibody comprising a heavy chain and a light chain pair comprising the amino acid sequences of seq id no:18/20, and the second antigen-binding molecule is a first anti-sars-cov-2 spike glycoprotein antibody or antigen-binding fragment thereof that has the same binding and/or blocking properties as a reference antibody comprising a heavy chain and a light chain pair comprising the amino acid sequences of seq id no:38/40."
https://patents.google.com/patent/US20210395345A1/en,,,,,"(2/22) in some cases, the first anti-sars-cov-2 spike glycoprotein antibody or antigen-binding fragment comprises a hcvr/lcvr amino acid sequence pair comprising the amino acid sequences of seq id no:2/10, and the second anti-sars-cov-2 spike glycoprotein antibody or antigen-binding fragment comprises a hcvr/lcvr amino acid sequence pair comprising the amino acid sequences of seq id no:22/30"
https://patents.google.com/patent/US20210395345A1/en,,,,,"(56/58) in some cases, the anti-sars-cov-2 spike glycoprotein antibody comprises a heavy chain comprising the amino acid sequence of seq id no:56, and a light chain comprising the amino acid sequence of seq id no:58."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Thr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Arg Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Tyr Gly Gly Arg Leu Gly Arg Arg Ile Asp Asp Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH21,,"(102) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Gly Thr Tyr Arg Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Phe Trp Ser Gly Gly Gly Ala Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Ala Pro Thr Thr Gln Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH26,,"(107) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe His Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Gly Arg Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Leu His Tyr Cys Ser Gly Leu Val Gly Glu Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH12,,"(93) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Gly Thr Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Tyr Tyr Tyr Thr Ser Leu His Gln Thr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH9,,"(90) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Asn Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Leu Ser Gly Asp Ile Ile Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Phe Pro Ser Leu Leu Tyr Cys Ser Leu Cys Pro Ser Asn Pro Glu Phe Cys Arg His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, VHH6,,"(87) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Thr Leu Asn Asn Asn Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Ile Val Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Leu Gln Trp Asn Gly Ala Gly Leu Pro Ser Pro Leu Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH4,,"(85) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Thr Arg Tyr Pro Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Gly Ser Gly Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Asp Asn Ala Pro Thr Ser Ser Leu Pro Leu Thr Pro Gly Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH19,,"(100) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Leu Ser Thr Tyr Glu Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Val Thr Pro Thr Gly Phe Gly Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Ser Gly Lys Gly Leu Gly Ser Leu Gln Arg Ser Pro Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH27,,"(108) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Ser Leu Asp Gly Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Gly Arg Leu Gly Thr Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Lys Arg Ser Thr Trp Phe Gly Cys Ser Thr Leu Asp Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH7,,"(88) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Ser Leu Glu His Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Asp Ser Gly Ala Thr Arg Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ser Ala Thr Pro Gly Ala Phe Arg Thr Cys Ala Phe Arg Asp Phe Ser His Leu Ala Asn Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH1,,"(82) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ala Thr Ser Asp Ile Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ser Pro Ser Trp His Tyr Cys Ser Gly Tyr Glu His Glu Tyr Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH10,,"(91) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Leu Asp Val Thr Gly Arg Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Tyr Thr Pro Phe Arg Phe Ala Phe Lys Thr Asp Pro Asp Arg Gln Asp His Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH25,,"(106) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Val Ser Ser Tyr Val Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Ile Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Gln Thr Gln Val Leu Pro Thr Glu Asp Arg Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH18,,"(99) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Phe Asp Asp Phe Ala Ile Gly Trp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ser Ala Arg Gly Ile Val Asn Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Val Gly Leu Asn Asp Arg Ser Leu Pro His Glu Ala Glu Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH15,,"(96) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Asn Tyr Glu Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Val Ile Phe Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Phe Arg Ala Gly Leu Val Gln Ser Leu Cys Gln Ser Thr Pro Glu Phe Tyr Gln Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, VHH5,,"(86) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Pro Ser Gly Thr Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asn Pro Ser Tyr Tyr Tyr Cys Ser Gly Tyr Pro His Glu Tyr Asp Asp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH11,,"(92) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Phe Lys Ser Tyr His Ile Ala Trp Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ser Leu Thr Gly Ala Ser Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Tyr Ala Ser Ser Leu Tyr Cys Ser Arg Asn Glu Ala Met Tyr Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH13,,"(94) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Gly Val Ser Thr Gly Ser Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Tyr Thr Ser Val Gly Ser Ile Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Phe Phe Val Pro Phe Gly Asp Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH22,,"(103) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Val Ser Met Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Arg Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Gly Gly Leu His Tyr Ala Leu Tyr Val Glu Ala Ser His Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH24,,"(105) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Thr Lys His Gly Gly Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp His Arg Ala Leu Arg Phe Gly Cys Ala Val Val Pro Gly Pro Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH3,,"(84) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Asp Arg Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Thr Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Thr Gln Leu Arg Tyr Gly Cys Ser Arg Gln Ala Arg Arg Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH8,,"(89) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Arg Leu Gly Gly Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Gly Ser Gly Ile Ile Ser Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro Ser Gly Ser Ser Tyr Gly Ser Arg Arg Leu Pro Cys Gly Ile Asp Ser Gln Asp Tyr Gln Thr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH14,,"(95) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Gly Gly Ile Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asn Arg Gly Arg Phe Thr Gly Trp Arg Ser Leu Thr Asp Tyr Thr Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH20,,"(101) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Ala Ser Gly Arg Thr Ser Ser Thr Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Thr Trp Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gly Leu Ser Pro Leu Met Leu Thr Ala Ser Arg Arg Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH23,,"(104) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly His Thr Gly Ser Thr Tyr Ile Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Arg Ser Gly Ile Leu Arg Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Arg Asp Ser Leu Thr Gly Val Ile Gly Asn Thr Pro Gly Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH17,,"(98) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ser Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Phe Ser Ser Leu Asp Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Thr Arg Gly Ser Ser Trp Tyr Trp Tyr Arg Pro Ser Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH16,,"(97) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN111647077B/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Leu Ser Leu Glu His Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Asp Ser Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ala Val Tyr Leu Glu Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Gln Gly Ser Tyr Tyr Tyr Thr Ser Leu His Gln Thr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH2,,"(83) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:82-108."
https://patents.google.com/patent/CN112225797B/en, ttcacgagtc cagcctcaag cagtcaggtc caactgcagc agtctggacc tgatctggcg aggcccgggg cttcagtgaa gctgtcctgc aaggcttctg gcgacacctt cactgaccac tatataatct gggtgaagca gaggactgga cagggccttg aatggattgg agagatttat cctggaaatg gtcatactta ctacaatgag aggttcaagg gcaaggccac actgactgca gacgattcct ccagcacggc ctacatgcag ctcagcagcc tgacatctga ggactctgca gtctatttct gtgcaagatc gaggtactac ggtccctttg cttactgggg ccaagggact ctggtcactg tctctgcggc gcgcctagat , gacattgtga tgacacagtc tccagcctcc ctatctgtat ctgtgggaga aactgtcacc atcacatgtc gagcaagtga gaatatttac agtagtttag catggtatca gcagaaacag ggaaaatctc ctcagctcct ggtctatgtt gcaactgact tagcagatgg tgtgccatca aggttcagtg gcagtggatc aggcacacag tattccctca agatcaacag cctccagtct gaagattttg ggagttatta ctgtcaacat ttttggggta ctccgtggac gttcggtgga ggcaccaagc tggaaatcaa acgggctgat gctgcaccaa ctgtatcc , mouse (Mus musculus), mouse (Mus musculus),"(3/2) the gene of claim 4, wherein the gene encoding the light chain variable region has the sequence shown in seq id no:2; the gene sequence of the coding heavy chain variable region is shown in seq id no:3."
https://patents.google.com/patent/CN112225797B/en, Phe Thr Ser Pro Ala Ser Ser Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Ala Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Asp Thr Phe Thr Asp His Tyr Ile Ile Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Tyr Pro Gly Asn Gly His Thr Tyr Tyr Asn Glu Arg Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Asp Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Ser Arg Tyr Tyr Gly Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Arg Leu Asp , Asp Ile Gln Met Ile Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Ser Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val Tyr Val Ala Thr Asp Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser , mouse (Mus musculus), mouse (Mus musculus),"(5/4) preferably, the monoclonal antibody has the amino acid sequence of the light chain variable region shown in seq id no:4 and the amino acid sequence of the heavy chain variable region shown in seq id no:5."
https://patents.google.com/patent/CN111978396A/en,,,,,"(19/5) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: comprises the amino acid sequence shown in seq id no:5 in the light chain variable region; and a polypeptide comprising seq id no:19 in a heavy chain variable region of the amino acid sequence of seq id no."
https://patents.google.com/patent/CN111978396A/en,,,,,"(1/18) in particular, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of seq id no:1-17 (see table 1) and a light chain variable region comprising an amino acid sequence selected from seq id no:18-26 (see table 2)"
https://patents.google.com/patent/CN111978396A/en,,,,,"(18/1) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: a light chain variable region comprising a sequence selected from seq id no:1-4; and a heavy chain variable region comprising seq id no:18."
https://patents.google.com/patent/CN111978396A/en,,,,,"(78/80)  and seq id no:78, and a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the heavy chain set forth in seq id no:80, or a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto."
https://patents.google.com/patent/CN112210004B/en,,,,,"(19/5) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: comprises the amino acid sequence shown in seq id no:5 in the light chain variable region; and a polypeptide comprising seq id no:19 in a heavy chain variable region of the amino acid sequence of seq id no."
https://patents.google.com/patent/CN112210004B/en,,,,,"(18/1) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: a light chain variable region comprising a sequence selected from seq id no:1-4; and a heavy chain variable region comprising seq id no:18."
https://patents.google.com/patent/CN112210004B/en,,,,,"(78/80) the monoclonal antibody of claim 1, comprising: (a) the heavy chain shown in seq id no:78, and (b) the light chain shown in seq id no:80."
https://patents.google.com/patent/CN105859882B/en,,,,,"(2/1) the neutralizing antibody a1 according to claim 1, wherein the amino acid sequences of the light and heavy chain variable regions are shown in seq id no:1 and seq id no:2, respectively."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Gly Gly Gly Tyr Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Gly Gly Ser Ala Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Tyr Tyr Arg Tyr Asn Arg Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy c hain variable region of R3 , light chain variable region of R3 ,"(23/24)  in one embodiment of the present invention, the heavy chain variable region of (b) comprises the amino acid sequence of seq id no:23, and the light chain variable region of (b) comprises the amino acid sequence of seq id no:24."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Gly Tyr Tyr Tyr Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Ser Tyr Asp Tyr Ser Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ser Ala Asn Asp Tyr Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy chain variable region of R15 , light chain variable region of R15 ,"(71/72)  in one embodiment of the present invention, the heavy chain variable region of (e) includes the amino acid sequence of seq id no:71, and the light chain variable region of (e) includes the amino acid sequence of seq id no:72."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Gly His Tyr Gly Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Ser Tyr Ser Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg A sn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ser Gly Asn Tyr Arg Ser Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy chain variable region of R17 , light chain variable region of R17 ,"(87/88)  in one embodiment of the present invention, the heavy chain variable region of (f) comprises the amino acid sequence of seq id no:87, and the light chain variable region of (f) comprises the amino acid sequence of seq id no:88."
https://patents.google.com/patent/KR20220003405A/en,, Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ala Pro Ser Pro Ser Tyr Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly ,, light chain variable region of R4 ,"(39/40)  in one embodiment of the present invention, the heavy chain variable region of (c) includes the amino acid sequence of seq id no:39, and the light chain variable region of (c) includes the amino acid sequence of seq id no:40."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ser Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Tyr Tyr Tyr Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Gly Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ser Pro Ala Tyr Tyr Tyr Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy chain variable region of R1 , light chain variable region of R1 ,"(7/8)  in one embodiment of the present invention, the heavy chain variable region of (a) comprises the amino acid sequence of seq id no:7, and the light chain variable region of (a) comprises the amino acid sequence of seq id no:8."
https://patents.google.com/patent/KR20220003405A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Tyr Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Ser Ser Tyr Tyr Ser Tyr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Gly Gly Ser Tyr Pro Tyr Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg As n Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Ala Pro Asp Tyr Ala Ser Tyr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly , Heavy chain variable regi on of R9 , light chain variable region of R9 ,"(55/56)  in one embodiment of the present invention, the heavy chain variable region of (d) comprises the amino acid sequence of seq id no:55, and the light chain variable region of (d) comprises the amino acid sequence of seq id no:56."
https://patents.google.com/patent/CN112661841A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Ala Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Ser Gly Ser Val Ser Ser Asp Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asp Ser Val Thr Ala Ala Asp Thr Ala Ala Tyr Tyr Cys Ala Arg Gly Pro Leu Gly Leu Tyr Tyr Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asn Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ala Leu Thr Ile Ser Gly Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Ser Asn Ser Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , 17-2 heavy chain amino acid sequence (17-2 heavy chain amino acid sequence), 17-2 light chain amino acid sequence (17-2 light chain amino acid sequence),"(1/2) a monoclonal antibody 17-2, the heavy chain amino acid sequence of said monoclonal antibody 17-2 is shown in seq id no:1; the light chain amino acid sequence of the monoclonal antibody 17-2 is shown as seq id no:2."
https://patents.google.com/patent/US11028150B1/en,,,,,"(227/268) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:227 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:268."
https://patents.google.com/patent/US11028150B1/en,,,,,"(199/240) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:199 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240."
https://patents.google.com/patent/US11028150B1/en,,,,,"(230/271) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:230 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:271."
https://patents.google.com/patent/US11028150B1/en,,,,,"(229/270) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:270."
https://patents.google.com/patent/US11028150B1/en,,,,,"(195/236) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236."
https://patents.google.com/patent/US11028150B1/en,,,,,"(192/233) in further embodiments, the 2dd8-derived antibody or antigen-binding fragment comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:233-273, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:192-232"
https://patents.google.com/patent/US11028150B1/en,,,,,"(200/241) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:241."
https://patents.google.com/patent/US11028150B1/en,,,,,"(220/261) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:220 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:261."
https://patents.google.com/patent/US11028150B1/en,,,,,"(221/262) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:221 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:262."
https://patents.google.com/patent/US11028150B1/en,,,,,"(215/256) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:215 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:256."
https://patents.google.com/patent/US11028150B1/en,,,,,"(232/273) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:232 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:273."
https://patents.google.com/patent/US11028150B1/en,,,,,"(207/248) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, wherein the antibody or the antigen-binding fragment comprises a vh chain having an amino acid sequence of seq id no:207 and a vl chain having an amino acid sequence of seq id no:248."
https://patents.google.com/patent/US11028150B1/en,,,,,"(202/243) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:243."
https://patents.google.com/patent/US11028150B1/en,,,,,"(203/244) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:203 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:244."
https://patents.google.com/patent/US11028150B1/en,,,,,"(197/238) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:197 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:238."
https://patents.google.com/patent/US11028150B1/en,,,,,"(226/267) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:226 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:267."
https://patents.google.com/patent/US11028150B1/en,,,,,"(223/264) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:223 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:264."
https://patents.google.com/patent/US11028150B1/en,,,,,"(211/252) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:211 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:252."
https://patents.google.com/patent/US11028150B1/en,,,,,"(219/260) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:219 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:260."
https://patents.google.com/patent/US11028150B1/en,,,,,"(201/242) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:201 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:242."
https://patents.google.com/patent/US11028150B1/en,,,,,"(222/263) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:222 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:263."
https://patents.google.com/patent/US11028150B1/en,,,,,"(208/249) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:208 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:249."
https://patents.google.com/patent/US11028150B1/en,,,,,"(196/237) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:196 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:237."
https://patents.google.com/patent/US11028150B1/en,,,,,"(224/265) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:224 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:265."
https://patents.google.com/patent/US11028150B1/en,,,,,"(231/272) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:231 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:272."
https://patents.google.com/patent/US11028150B1/en,,,,,"(214/255) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:214 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:255."
https://patents.google.com/patent/US11028150B1/en,,,,,"(216/257) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:216 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:257."
https://patents.google.com/patent/US11028150B1/en,,,,,"(194/235) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:194 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:235."
https://patents.google.com/patent/US11028150B1/en,,,,,"(217/258) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:217 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:258."
https://patents.google.com/patent/US11028150B1/en,,,,,"(225/266) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:225 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:266."
https://patents.google.com/patent/US11028150B1/en,,,,,"(205/246) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:205 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:246."
https://patents.google.com/patent/US11028150B1/en,,,,,"(218/259) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:218 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:259."
https://patents.google.com/patent/US11028150B1/en,,,,,"(228/269) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:228 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:269."
https://patents.google.com/patent/US11028150B1/en,,,,,"(209/250) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:209 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:250."
https://patents.google.com/patent/US11028150B1/en,,,,,"(210/251) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:251."
https://patents.google.com/patent/US11028150B1/en,,,,,"(212/253) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:212 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:253."
https://patents.google.com/patent/US11028150B1/en,,,,,"(206/247) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:206 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:247."
https://patents.google.com/patent/US11028150B1/en,,,,,"(213/254) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:213 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:254."
https://patents.google.com/patent/US11028150B1/en,,,,,"(193/234) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:193 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:234."
https://patents.google.com/patent/US11028150B1/en,,,,,"(204/245) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:204 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:245."
https://patents.google.com/patent/US11028150B1/en,,,,,"(198/239) in one instance, a 2dd8-derived antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:198 and a vl amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:239."
https://patents.google.com/patent/US20210395346A1/en,,,,,(6/5)  a vl amino acid sequence of seq id no:5 and a vh amino acid sequence of seq id no:6;
https://patents.google.com/patent/US20210395346A1/en,,,,,(20/19)  a vl amino acid sequence of seq id no:19 and a vh amino acid sequence of seq id no:20;
https://patents.google.com/patent/US20210395346A1/en,,,,,(14/13)  a vl amino acid sequence of seq id no:13 and a vh amino acid sequence of seq id no:14;
https://patents.google.com/patent/US20210395346A1/en,,,,,(8/7)  a vl amino acid sequence of seq id no:7 and a vh amino acid sequence of seq id no:8;
https://patents.google.com/patent/US20210395346A1/en,,,,,(16/15)  a vl amino acid sequence of seq id no:15 and a vh amino acid sequence of seq id no:16;
https://patents.google.com/patent/US20210395346A1/en,,,,,(10/9)  a vl amino acid sequence of seq id no:9 and a vh amino acid sequence of seq id no:10;
https://patents.google.com/patent/US20210395346A1/en,,,,,(4/3)  a vl amino acid sequence of seq id no:3 and a vh amino acid sequence of seq id no:4;
https://patents.google.com/patent/US20210395346A1/en,,,,,(12/11)  a vl amino acid sequence of seq id no:11 and a vh amino acid sequence of seq id no:12;
https://patents.google.com/patent/US20210395346A1/en,,,,,(24/23)  a vl amino acid sequence of seq id no:23 and a vh amino acid sequence of seq id no:24; or
https://patents.google.com/patent/US20210395346A1/en,,,,,(22/21)  a vl amino acid sequence of seq id no:21 and a vh amino acid sequence of seq id no:22;
https://patents.google.com/patent/US20210395346A1/en,,,,,(2/1)  a vl amino acid sequence of seq id no:1 and a vh amino acid sequence of seq id no:2;
https://patents.google.com/patent/US20210395346A1/en,,,,,(26/25)  a vl amino acid sequence of seq id no:25 and a vh amino acid sequence of seq id no:26;
https://patents.google.com/patent/US20210395346A1/en,,,,,(18/17)  a vl amino acid sequence of seq id no:17 and a vh amino acid sequence of seq id no:18;
https://patents.google.com/patent/CN113667016A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Leu Gly Phe Gly Glu Leu Phe Arg Lys Thr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Thr Arg Ala Thr Ala Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Asn Lys Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(11/16) in one embodiment, the antibody is 89c8, the amino acid sequence of its heavy chain is set forth in seq id no:11, and the amino acid sequence of its light chain is set forth in seq id no:16."
https://patents.google.com/patent/CN113667016A/en, Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(21/22) in one embodiment, the antibody is cr3022, the heavy chain has the amino acid sequence shown in seq id no:21, and the light chain has the amino acid sequence shown in seq id no:22."
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Arg Gly Tyr Phe Asp Trp Leu Phe Arg Ser Asp Lys Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(10/21) (10) the heavy chain variable region shown as seq id no:10 and the light chain variable region shown as seq id no:21
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Arg Gly Tyr Phe Asp Trp Leu Phe Arg Ser Asp Lys Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Gln Val Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(2/13)  the heavy chain variable region as set forth in seq id no:2, and the light chain variable region as set forth in seq id no:13;"
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Glu Thr Pro Gly Phe Asp Glu Ser Ile Ala Ala Ala Leu Gly Gly Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(8/19)  the heavy chain variable region as set forth in seq id no:8 and the light chain variable region as set forth in seq id no:19;
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Leu Gly Phe Gly Glu Leu Phe Arg Lys Thr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Thr Arg Ala Thr Ala Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Asn Lys Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(11/22)  the heavy chain variable region shown as seq id no:11, and the light chain variable region shown as seq id no:22."
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Tyr Tyr Asp Ile Leu Thr Gly Tyr Leu Arg Pro Pro Ser Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Lys Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala, Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(4/15)  the heavy chain variable region as set forth in seq id no:4, and the light chain variable region as set forth in seq id no:15;"
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Asp Leu Pro Lys Thr Arg Tyr Phe Asp Trp Leu Phe His Ser Asp Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ala Ile Ser Thr Ser Leu Ala Trp Tyr His Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Thr Phe Gly Gly Gly Thr Lys Val Glu , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(6/17)  the heavy chain variable region as set forth in seq id no:6, and the light chain variable region as set forth in seq id no:17;"
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Tyr Tyr Asp Ile Leu Thr Gly Tyr Leu Arg Pro Pro Ser Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Asn Tyr Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Ser Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Asn Thr Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(7/18)  the heavy chain variable region as set forth in seq id no:7, and the light chain variable region as set forth in seq id no:18;"
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Tyr Tyr Asp Ile Leu Thr Gly Tyr Leu Arg Pro Pro Ser Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(1/12)  a heavy chain variable region as set forth in seq id no:1, and a light chain variable region as set forth in seq id no:12;"
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Arg Gly Tyr Phe Asp Trp Leu Phe Arg Ser Asp Lys Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(5/16)  the heavy chain variable region as set forth in seq id no:5, and the light chain variable region as set forth in seq id no:16;"
https://patents.google.com/patent/CN113667010A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Asp Leu Pro Lys Thr Arg Tyr Phe Asp Trp Leu Phe His Ser Asp Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(3/14)  the heavy chain variable region as set forth in seq id no:3 and the light chain variable region as set forth in seq id no:14;
https://patents.google.com/patent/CN113667010A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly His Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asp His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Thr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gly Arg Gly Tyr Phe Asp Trp Leu Phe Arg Ser Asp Lys Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Arg Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(9/20)  the heavy chain variable region as set forth in seq id no:9 and the light chain variable region as set forth in seq id no:20;
https://patents.google.com/patent/WO2021207433A2/en,,,,,"(7/8)   [00146] in some embodiments, the anti-sars-cov-2-spike antibodies in the present disclosure include a heavy chain variable region having an amino acid sequence at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to seq id no:7 and a light chain variable region having an amino acid sequence at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to seq id no:8"
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Arg Glu Tyr Ser Gly Arg Val Phe Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Phe Tyr Ala Thr Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(6/16)  a heavy chain variable region consisting of the amino acid sequence of seq id no:6 and a light chain variable region consisting of the amino acid sequence of seq id no:16
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Thr Lys Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Thr Gly Val Gly Leu Thr Ser Thr Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(4/14)  a heavy chain variable region consisting of the amino acid sequence of seq id no:4 and a light chain variable region consisting of the amino acid sequence of seq id no:14
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Glu Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Ser Ser Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ile Gly Leu Tyr Trp Thr Ser Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(8/18)  a heavy chain variable region consisting of the amino acid sequence of seq id no:8 and a light chain variable region consisting of the amino acid sequence of seq id no:18
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Glu Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Thr Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ser Gly Tyr Ser Trp Val Ser Val Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(10/20)  or a heavy chain variable region consisting of the amino acid sequence of seq id no:10 and a light chain variable region consisting of the amino acid sequence of seq id no:20
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Glu Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Glu Val Thr Gly Tyr Ala Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Trp Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(2/12)  a heavy chain variable region consisting of the amino acid sequence of seq id no:2 and a light chain variable region consisting of the amino acid sequence of seq id no:12
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Arg Ile Ser Ser Ser Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Arg Glu Tyr Gly Gly Glu Val Tyr Ala Phe Asp His Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(9/19)  a heavy chain variable region consisting of the amino acid sequence of seq id no:9 and a light chain variable region consisting of the amino acid sequence of seq id no:19
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Trp His Gly Gly Gly Trp Gln Val Tyr Thr Ala Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Trp Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,"(1/11)  the method of claim 1, the antibody or antigen-binding fragment thereof a heavy chain variable region consisting of the amino acid sequence of seq id no:1 and a light chain variable region consisting of the amino acid sequence of seq id no:11"
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gln Leu Tyr Ala Gly Trp Ile Thr Tyr Trp Gly Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(3/13)  a heavy chain variable region consisting of the amino acid sequence of seq id no:3 and a light chain variable region consisting of the amino acid sequence of seq id no:13
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Thr Lys Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ile Gly Val Tyr Tyr Thr Thr Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(7/17)  a heavy chain variable region consisting of the amino acid sequence of seq id no:7 and a light chain variable region consisting of the amino acid sequence of seq id no:17
https://patents.google.com/patent/KR102233689B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Ser Ser Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Arg Ala Trp Gly Trp Val Glu Val Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,(5/15)  a heavy chain variable region consisting of the amino acid sequence of seq id no:5 and a light chain variable region consisting of the amino acid sequence of seq id no:15
https://patents.google.com/patent/CN111647076B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Ala Phe Ser Ser Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Leu Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Lys Asp Phe Gly His Leu Gly Gln Met Ala Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(5) preferably, the amino acid sequence of the single domain antibody is shown in one of seq id no:5 to seq id no:8."
https://patents.google.com/patent/CN111647076B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Tyr Phe Ala Asp Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Glu Trp His Ser Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(8) preferably, the amino acid sequence of the single domain antibody is shown in one of seq id no:5 to seq id no:8."
https://patents.google.com/patent/CN114031685A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Thr Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu His Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Asn Ser Asp Tyr Ser Gly Tyr Tyr Trp Glu Leu Glu Asn Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Phe Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Arg Leu Thr Val Leu , Homo sapiens, Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(14/15)  the heavy chain variable region includes the amino acid sequence shown in seq id no:14, and the light chain variable region includes the amino acid sequence shown in seq id no:15;"
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(18/19)  the heavy chain variable region comprises the amino acid sequence shown in seq id no:18, and the light chain variable region comprises the amino acid sequence shown in seq id no:19; or"
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(12/13)  the heavy chain variable region includes the amino acid sequence shown in seq id no:12, and the light chain variable region includes the amino acid sequence shown in seq id no:13;"
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(20/21)  the heavy chain variable region includes the amino acid sequence shown in seq id no:20, and the light chain variable region includes the amino acid sequence shown in seq id no:21."
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(6/7)  the heavy chain variable region includes the amino acid sequence shown in seq id no:6, and the light chain variable region includes the amino acid sequence shown in seq id no:7;"
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(16/17)  the heavy chain variable region includes the amino acid sequence shown in seq id no:16, and the light chain variable region includes the amino acid sequence shown in seq id no:17;"
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(8/9)  the heavy chain variable region includes the amino acid sequence shown in seq id no:8, and the light chain variable region includes the amino acid sequence shown in seq id no:9;"
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(2/3)  the heavy chain variable region includes the amino acid sequence shown in seq id no:2, and the light chain variable region includes the amino acid sequence shown in seq id no:3;"
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(4/5)  the heavy chain variable region includes the amino acid sequence shown in seq id no:4, and the light chain variable region includes the amino acid sequence shown in seq id no:5;"
https://patents.google.com/patent/WO2021233433A1/en,,,,,"(10/11)  the heavy chain variable region includes the amino acid sequence shown in seq id no:10, and the light chain variable region includes the amino acid sequence shown in seq id no:11;"
https://patents.google.com/patent/US7696330B2/en,,,,,"(37/41)  and having sars-cov neutralizing activity,wherein the binding molecule comprises a variable heavy chain comprising amino acid sequence seq id no:37; andwherein the binding molecule comprises a variable light chain comprising amino acid sequence seq id no:41."
https://patents.google.com/patent/US7696330B2/en,,,,,"(86/41) the isolated binding molecule of claim 3,wherein the binding molecule comprises a variable heavy chain comprising the amino acid sequence of seq id no:86; andwherein the binding molecule comprises a variable light chain comprising amino acid sequence seq id no:41."
https://patents.google.com/patent/US7396914B2/en,,,,,"(18/21) the invention also provides isolated monoclonal antibodies, or antigen-binding portions thereof, that include: (a) a heavy chain variable region that is the product of or derived from a human vh dp44, vh 3-23, or vh 3-7 gene (which encode the amino acid sequences set forth in seq id no:18, 19 and 20, respectively); (b) a light chain variable region that is the product of or derived from a human vk l6 gene (which encodes the amino acid sequences set forth in seq id no:21); and (c) specifically bind to the s protein."
https://patents.google.com/patent/US7396914B2/en,,,,,"(17/14) in another embodiment, the antibody includes a heavy chain variable region including the amino acid sequence of seq id no:17 and a light chain variable region including the amino acid sequence of seq id no:14."
https://patents.google.com/patent/US7396914B2/en,,,,,(13/14)  and antigen binding portions thereof. the vh amino acid sequence of 201.2 is shown in seq id no:13. the vl amino acid sequence of 201.2 is shown in seq id no:14.
https://patents.google.com/patent/CN112625136A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Gly Ser Tyr Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Pro Glu Trp Val Ser Asp Ile Asn Thr Arg Gly Glu Thr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Ala Ala Ser Pro Ala Thr Phe Glu Gly Arg Ser Asp Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(5) in some embodiments, the single domain antibody or vhh fragment thereof comprises or consists of the sequence: a vhh amino acid sequence as set forth in seq id no:5,6 or 7 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto."
https://patents.google.com/patent/CN112625136A/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Gly Ser Tyr Val Met Ser Trp Phe Arg Gln Ala Pro Gly Lys Ala Pro Glu Trp Val Ser Asp Ile Asn Thr Arg Gly Ile Val Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val Ala Ala Ser Gly Asp Thr Phe Glu Gly Arg Ser Asp Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(29/23) in some embodiments, the polypeptide complex is a bispecific antibody complex consisting of 2 heavy chains consisting of the amino acid sequence set forth in seq id no:29, 30, or 31 and 2 light chains consisting of the amino acid sequence set forth in seq id no:23."
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ala Asp Ala Phe Val Ile Ile Gly Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Ala Trp Thr Asp Gln His Glu Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gln Asp Ser Ala Tyr Ile Lys Ser Lys Gly Ser Arg Ala Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(1)  a single domain antibody as set forth in seq id no:1 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Asn Ala Ala Glu Arg Met Ala Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Tyr Tyr Ala Lys Phe Gly Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Glu Ala Phe Val Gln Ser ProTyr Ser Gly Ser His Thr Thr Lys Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(3)  a single domain antibody as set forth in seq id no:3 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Gln Ala Val Val Phe Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile His Val Pro Ala Lys Asn Arg Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala His Tyr Glu Phe Asn Asp Phe Val Trp Gln Gly Tyr Ser Ser Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(5)  a single domain antibody as set forth in seq id no:5 or a functionally active variant thereof.
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ala Gln Ser Lys Trp Ala Tyr Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Asp Val Ala Thr Gly Pro Trp Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala His His Ile Pro Thr Lys His Pro Ala Phe Pro Asp Phe Arg Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(2)  a single domain antibody as set forth in seq id no:2 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtgg taacgctgct gaacgtatgg ctgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc atttactacg ctaaattcgg tccgtattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcagaagct ttcgttcagt ctccgtactc tggttctcat actactaaat attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(8) the nucleic acid molecule encoding the single domain antibody 3f11 is shown in seq id no:8.
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtaa catcgactct actcgttacc atgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attaaaggtg tttggccgga agactattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcagaccag tacgaatggt gggttccggg tgaagttggt ccgtacctgt attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(9) the nucleic acid molecule encoding the single domain antibody 4d8 is shown in seq id no:9.
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtcg tcaggctgtt gttttcgggt ggttccgtca ggctccgggc aaaggcctgg aagcagttgc ggccattcat gttccggcta aaaaccgtta ttacgcggat tccgttaagg gccgttttac gatcagccgt gataattcaa agaacacgct ttatctgcag atgaacagcc tgcgcgctga agatactgcg gtctactatt gcgcggcaca ttacgaattc aacgacttcg tttggcaggg ttactcttct gactattggg gccaggggac ccaagtaaca gttagcagt ,, Artificial Sequence (Artificial Sequence),,(10) the nucleic acid molecule encoding the single domain antibody 5f8 is shown in seq id no:10.
https://patents.google.com/patent/CN111303279A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ile Asp Ser Thr Arg Tyr His Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Lys Gly Val Trp Pro Glu Asp Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Gln Tyr Glu Trp Trp Val Pro Gly Glu Val Gly Pro Tyr Leu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(4)  a single domain antibody as set forth in seq id no:4 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtct ggctcagtct aaatgggctt acgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attgacgttg ctactggtcc gtggtattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcacatcat atcccgacta aacatccggc tttcccggac ttccgtgact attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(7) the nucleic acid molecule encoding the single domain antibody 2f2 is shown in seq id no:7.
https://patents.google.com/patent/CN111303279A/en,caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtgc tgacgctttc gttatcatcg gtgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attgcttgga ctgaccagca tgaatattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcacaggac tctgcttaca tcaaatctaa aggttctcgt gcttacgaat attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(6) the nucleic acid molecule encoding the single domain antibody 1e2 is shown in seq id no:6.
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Ala Val Thr Ile Tyr His Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Pro Ser Arg Val Ile Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Thr Arg Gly Ser Phe Asp Arg Asn Arg Val Asn Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-1,,"(64) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Arg Thr Phe Ser Val Gly Glu Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Arg Trp Gly Ser Glu Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Thr Glu Lys Val Tyr Ser Ala Tyr Tyr Tyr Tyr Ser Arg Asp Arg Leu Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, VHH-7,,"(70) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Leu Asp Tyr Tyr Arg Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Thr Gly Pro Leu Thr Tyr Tyr Ser Gly Arg Tyr Tyr Leu Gly Gly Cys Phe Asp Thr Tyr Ala Met Asp Phe Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-15,,"(78) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly His Thr Phe Ser Arg Phe Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Arg Asn Asp Gly Gly Phe Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Thr Ser Pro Glu Ser Gly Arg Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-6,,"(69) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Ala Ser Gly Arg Ser Thr His Arg Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Met Pro Gly Gly Gly Phe Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Arg Ser Glu Thr Gly Glu Tyr Asp Asn Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-14,,"(77) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Thr Leu Arg Ser Phe Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Trp Ser Gly Asp Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Gly Gly His Thr Ile Asn His Asp Ile Ile Ser Pro Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-12,,"(75) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Asn Thr Leu Asp Tyr Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Lys Ser Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ile Gly Pro Leu Thr Tyr Tyr Ser Gly Arg Tyr Tyr Phe Pro Tyr Asp Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-17,,"(80) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Ser Ile Ala Ser Ile Thr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ser Asn Ser Arg Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Tyr Val Asn Thr Leu Arg Ala Glu Met Pro Glu Ala Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-19,,"(82) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Arg Cys Thr Phe Asn Trp Asp Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Trp Ser Gly Gln Glu Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ala Gln Tyr Thr Gly Ala Ser Tyr Ser Ile Leu Arg Asp Gln Val Gly Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, VHH-9,,"(72) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Gly Ser Arg Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Pro Asp Ser Val Ser Tyr Tyr Gly Trp Ser Leu Asn Pro Tyr Glu Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-4,,"(67) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Gly Thr Phe Ser Arg Ser Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Arg Ala Asp Val Gly Phe Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Thr Ser Leu Gln Ser Gly Lys Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-5,,"(68) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Leu Asp Tyr Tyr Thr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Thr Ser Ser Ala Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ala Pro Gly Ala Tyr Tyr Ser Gly Thr Tyr Tyr Arg Ala Cys His Ser Ala Gly Met Glu Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-3,,"(66) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Thr Phe Ser Ser Tyr Thr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Arg Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Ser Arg Arg Val Leu Leu Thr Asp Thr Pro Arg Asp Tyr Asp Arg Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-16,,"(79) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Ile Pro Ser Trp Asn Ile Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Arg Trp Thr Ser Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Trp Arg Arg Gly Gly Val Gln Gln Ile Ser Thr Gly Ser His Asp Tyr Asp Pro Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-21,,"(84) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Ser Arg Asp Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asn His Leu Thr Tyr Tyr Ser Gly Ser Tyr Tyr Phe Pro Tyr Glu Tyr His Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-8,,"(71) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Thr Phe Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Trp Thr Gly Asp Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asp Arg Gly Leu Ser Tyr Tyr Tyr Tyr Arg Thr Gln Asp Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-2,,"(65) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Thr Arg Thr Phe Ser Asn Tyr Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ser Arg Ala Gly Ala Glu Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Ala Arg Val Met Gly Val Ser Pro Ala Ile Tyr Asn Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-10,,"(73) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Leu Thr Gly Ser Thr Phe Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Arg Trp Thr Tyr Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Arg Glu Gly Tyr Arg Gly Ser Ala Tyr Gln Thr Ser Asp Phe Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-13,,"(76) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Arg Thr Ser Ser Arg Tyr Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Thr Ser Thr Gly Phe Gly Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asp Thr Ser Leu Leu Thr Arg Arg Pro Ser Asp Ser Ala Ser Pro Tyr Asp Tyr Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-18,,"(81) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly His Thr Phe Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Asp Trp Ser Gly Asp Glu Ala Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asp Arg Gly Leu Ser Tyr Tyr Tyr Asp Arg Thr Gln Glu Tyr Gly Ile Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, SP11,,"(74) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/CN112513076A/en, Gln Leu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Asp Thr Phe Asn Asn Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Gly Ile Ala Arg Ser Gly Arg Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Gly Lys Thr Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Asp Pro Ala Pro Leu Trp Phe Ala Trp Thr Ser Asp Met Ala Lys Tyr Lys Phe Arg Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, VHH-20,,"(83) preferably, the single domain antibody comprises any one of the amino acid sequences of seq id no:64-84."
https://patents.google.com/patent/WO2021242815A1/en,,,,,"(640/646) [00041] in some embodiments, b-hcvr comprises the amino acid sequence set forth in seq id no:640 and b-lcvr comprises the amino acid sequence set forth in seq id no:646"
https://patents.google.com/patent/WO2021242815A1/en,,,,,"(202/210) [00037] in some embodiments, a-hcvr comprises the amino acid sequence set forth in seq id no:202 and a-lcvr comprises the amino acid sequence set forth in seq id no:210"
https://patents.google.com/patent/WO2021242815A1/en,,,,,"(608/614) [00045] in some embodiments, c-hcvr comprises the amino acid sequence set forth in seq id no:608 and c-lcvr comprises the amino acid sequence set forth in seq id no:614"
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Phe Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Glu Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ala Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(47) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Ile Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Leu Ala Thr Ile Ala Ala Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ile Lys Asn Lys Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Ser Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(40) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Phe Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Asp Gly Ser Ala Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Glu Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(43) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Ile Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Lys Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ala Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(46) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Ser Ala Ser Gly Phe Phe Phe Asn Gly Tyr Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ser Glu Ala Gly Thr Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu His Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(49) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Ser Ala Ser Gly Phe Phe Phe Asn Gly Tyr Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ser Glu Ala Gly Thr Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu His Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(35) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Ala Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val Ala Thr Val Ala Ala Gly Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Met Lys Val Asp Leu Gln Met Asn Ser Leu Lys Leu Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(37) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Ala Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Leu Phe Lys Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Ser Ile Ala Asn Asp Gly Ser Thr Gly Tyr Gly Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala His Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Thr ,, Artificial sequence,,"(45) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Arg Ala Gly Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Cys Glu Trp Val Ala Thr Ile Thr Ile Thr Gly Gly Asn Ser Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Gln Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala Asp Pro Gly Cys Pro Leu Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, Artificial sequence,,"(51) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en,,,,,"(52) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Thr Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Glu Cys Glu Trp Val Ala Thr Ile Thr Ile Thr Gly Gly Asn Ser Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala Asp Pro Ser Cys Pro Leu Gly Gln Gly Thr Gln Val Thr Val Ser Ser,, Artificial sequence,,"(50) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Ala Val Gln Leu Val Asp Ser Gly Gly Gly Met Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Ile Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Gly Gly Asn Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Lys Val Asn Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(38) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Gly Phe Asn Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Arg Asp Gly Ser Thr Gly Tyr Ala Ile Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Tyr Ala Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(44) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Gln Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Phe Asn Phe Asn Ile Tyr Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Gly Gly Ser Thr Gly Tyr Ala Asp Pro Val Lys Gly Arg Phe Ala Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(41) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Lys Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Leu Gln Arg Glu Ser Val Ala Ser Ile Ala Gln Asp Gly Ser Ala Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala His Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(39) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Asn Met Tyr Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Lys Asp Gly Ser Thr Gly Tyr Ala Ile Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Tyr Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(42) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Gln Ala Gln Leu Val Glu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Lys Ser Ala Phe Ala Ile Phe Ala Met Ser Trp Tyr Arg Gln Ala Pro Gly Lys Glu Cys Glu Trp Val Ala Thr Ile Thr Ile Thr Gly Gly Asn Ser Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Gln Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala Asp Pro Gly Cys Pro Leu Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(48) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN113943367A/en, Met Ala Ala Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Ile Tyr Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Ala Ala Asp Gly Ser Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Val Lys Asn Lys Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys Arg Glu Leu Gly Pro Phe Ser Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(36) the single domain antibody of claim 1 or 2, wherein the amino acid sequence of said single domain antibody is set forth in any one of seq id no:35-52."
https://patents.google.com/patent/CN112010967B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ala Cys Ala Ala Thr Gly Arg Thr Leu Ser Asn Tyr Ile Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Pro Leu Phe Val Ala Ala Ile Ser Arg Ser Gly Val Ile Thr Lys Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Ala Tyr Leu Gln Met Thr Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ser Ser Lys Tyr Met Ala Thr Arg Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(1) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN112010967B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Thr Gly Met Gly Trp Phe Arg Gln Gly Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Gly Asp Gly Asp Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ala Arg Phe Thr Trp Gly Leu Tyr Ser Asp Phe Val Asn Ser Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(3) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN112010967B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala Ser Leu Arg Leu Phe Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Thr Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Gly Pro Gly Asp Thr Thr Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ala Gly Phe Thr Trp Gly Leu Tyr Ser Asp Phe Val Asn Ser Tyr Glu Tyr Asn Tyr Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(4) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN112010967B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Thr Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Gly Asp Gly Asp Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Trp Asp Thr Ala Val Tyr Tyr Cys Ala Ser Thr Arg Phe Thr Trp Gly Leu Tyr Ser Asp Phe Val Asn Ser Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(2) according to some embodiments of the invention, the nanobody has an amino acid sequence as shown in seq id no:1, seq id no:2, seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN111269313B/en, Gln Ile Gln Leu Gln Gln Ser Gly Ala Ser Leu Val Arg Pro Gly Ala Leu Val Lys Leu Ser Cys Lys Ala Ser Asp Ser His Tyr Tyr Ser Gln Ser Leu His Trp Val Lys Gln Arg Pro Val Gln Gly Leu Glu Trp Ile Gly Asp Ile Gly Ser Ala Asp Asn Ser Thr Lys Tyr Ala Pro Pro Phe Leu Gly Lys Ala Gln Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ile Arg Tyr Ala Ser Ser Gly Trp Gly Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Ile Thr Gln Ser Pro Ala Leu Met Ala Asp Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Asp Tyr Ser Glu Glu Ile Ser Met Ser Tyr Leu Ala Trp Tyr Gln Gln Ser Ser Gly Ile Ser Pro Lys Pro Trp Ile Tyr Thr Thr Ala Gly Leu Ala Pro Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Thr Ser Ala Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Ser Ser Ala Ser Ser Leu Pro Cys Arg Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , 2 Ambystoma laterale x Ambystoma jeffersonianum, 2 Ambystoma laterale x Ambystoma jeffersonianum,"(9/10) an anti-n protein monoclonal antibody characterized by: wherein the heavy chain variable region amino acid sequence of the antibody is seq id no:9, the amino acid sequence of the light chain variable region sequence is seq id no:10."
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(7/23) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:7 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:23"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(14/33) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:14 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:33"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(121/122) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:121 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:122"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(19/35) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:19 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:35"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(11/22) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:11 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:22"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(17/27) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:17 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:27"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(13/37) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:13 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:37"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(8/31) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:8 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:31"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(6/24) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:6 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:24"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(16/28) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:16 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:28"
https://patents.google.com/patent/WO2022027037A1/en,,,,,(4/21)  of a heavy chain variable domain that comprises seq id no:4 and a light chain variable domain that comprises seq id no:21; (sct-oa002
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(15/26) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:15 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:26"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(125/126) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:125 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:126"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(127/128) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:127 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:128"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(10/25) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:10 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:25"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(123/124) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:123 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:124"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(18/34) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:18 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:34"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(12/36) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:12 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:36"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(9/29) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:9 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:29"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(5/30) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:5 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:30"
https://patents.google.com/patent/WO2022027037A1/en,,,,,"(20/32) the disclosure also provides an antibody comprising, or consisting essentially of, or yet further consisting of a heavy chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:20 and a light chain variable domain that is at least 80%, or at least 85%, or at least 90%, or at least 95% , or at least 96%, or at least 97%, or at least 98%, or at least 99% or higher identical to seq id no:32"
https://patents.google.com/patent/CN113354730A/en,,,,,"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8."
https://patents.google.com/patent/CN112979791B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Phe Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Trp Phe Gly Glu Thr Trp Glu Gly Met Asp Ala Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody or antigen-binding fragment thereof according to claim 1, wherein the amino acid sequence of the heavy chain variable region is represented by seq id no:4; the amino acid sequence of the light chain variable region is shown in seq id no:8."
https://patents.google.com/patent/CN112979791B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN113354729A/en,,,,,"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8."
https://patents.google.com/patent/CN112341541A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Glu Ile Ile Val Asn Arg Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Met Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Gly Asp Phe Tyr Val Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Gly Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) the amino acid sequences of the light and heavy chain variable regions of antibody ncov-163 are shown in seq id no:1 and 2, respectively."
https://patents.google.com/patent/WO2021227138A1/en,,,,,"(20/24)  more preferably, the heavy chain variable region comprises the amino acid sequence shown in seq id no:20; the light chain variable region comprises the amino acid sequence shown in seq id no:24."
https://patents.google.com/patent/WO2021227138A1/en,,,,,"(4/8)  more preferably, the heavy chain variable region comprises the amino acid sequence shown in seq id no:4; the light chain variable region comprises the amino acid sequence shown in seq id no:8."
https://patents.google.com/patent/WO2021227138A1/en,,,,,"(12/16)  more preferably, the heavy chain variable region includes the amino acid sequence shown in seq id no:12; the light chain variable region includes the amino acid sequence shown in seq id no:16."
https://patents.google.com/patent/CN111727199A/en,Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Arg Ile Ile Pro Ile Phe Gly Thr Val Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Pro Gly Asp Ser Arg Asp Gly Tyr Asn Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Leu Ala Ser Thr Lys Gly Pro Ser Val Thr Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys,Gly Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Asn Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu Gly Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , antibody 1 heavy chain variable region, antibody 1 light chain variable region,"(37/38) i) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:37, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:38"
https://patents.google.com/patent/CN111727199A/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Ser Arg Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Arg Glu His Val Trp Gly Ser Tyr Asp Gly Pro Gly Ser Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Thr Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys,Gly Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Gln Asp Glu Ala Asp Tyr His Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Gly Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , antibody 3 heavy chain variable region, antibody 3 light chain variable region,(41/42) iii) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:41 and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:42
https://patents.google.com/patent/CN111727199A/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Ser Arg Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Asp Arg Glu Tyr Val Trp Gly Ser Tyr Asp Gly Pro Gly Ser Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Thr Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys,Gly Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ala Pro Arg Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Ala Val Asn Trp Tyr Leu Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asp His Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ser Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , antibody 4 heavy chain variable region, antibody 4 light chain variable region,"(43/44) iv) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:43, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:44"
https://patents.google.com/patent/CN111727199A/en,Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Phe Gly Ile Ala Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Pro Gly Asp Ser Arg Asp Gly Tyr Asn Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Thr Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys,Gly Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Arg Ser Leu Ser Val Glu Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , antibody 2 heavy chain variable region, antibody 2 light chain variable region,"(39/40) ii) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:39, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:40"
https://patents.google.com/patent/CN111727199A/en,Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Phe Gly Ile Ala Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Arg Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Thr Arg Ser Gly Asp Tyr Ser Gly Ser Ser Gly Leu Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Thr Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ,Gly Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , antibody 5 heavy chain variable region, antibody 5 light chain variable region,"(45/46) v) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:45, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:46"
https://patents.google.com/patent/CN111727199A/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Leu Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Trp Ser Ser Gly Trp Ser Ser Pro Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Thr Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys ,, antibody 6 heavy chain variable region,,"(47/48) vi) a binding molecule comprising a) a heavy chain variable region having 95% or more sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:47, and b) a light chain variable region having 95% or more sequence identity to the light chain variable region of the polypeptide sequence of seq id no:48."
https://patents.google.com/patent/CN113735970A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Thr Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser His Tyr Val Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val Ala Ile Ile Ser Phe Asp Gly Ser Ser Gln Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asp Thr Leu Tyr Leu Gln Met His Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ile His Gly Gly Thr Tyr Tyr Tyr Asp Lys Asn Ile Leu Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Ala Ile Arg Met Thr Gln Ser Pro Pro Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Thr Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Thr Phe Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg ,  Homo sapiens,  Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/WO2021211775A1/en,,,,,"(54/58) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:54 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:58, and wherein the antibody or antigen-binding fragment is capable of binding to a sars-cov-2 surface glycoprotein ("
https://patents.google.com/patent/WO2021211775A1/en,,,,,"(22/26) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:22 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:26, and wherein the antibody or antigen-binding fragment is capable of binding to a sars-cov-2 surface glycoprotein ("
https://patents.google.com/patent/WO2021211775A1/en,,,,,"(37/41) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:37 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:41, and wherein the antibody or antigen-binding fragment is capable of binding to a sars-cov-2 surface glycoprotein ("
https://patents.google.com/patent/WO2021211775A1/en,,,,,"(200/204)  a second antibody or antigen-binding fragment comprising, a vh comprising or consisting of the amino acid sequence as set forth in seq id no:200 and a vl comprising of consisting of the amino acid sequence as set forth in seq id no:204. "
https://patents.google.com/patent/WO2021211775A1/en,,,,,"(172/176) (i)a first antibody or antigen-binding fragment, comprising a vh comprising or consisting of the amino acid sequence as set forth in seq id no:172 and a vl comprising or consisting of the amino acid sequence as set forth in seq id no:176"
https://patents.google.com/patent/WO2019151632A1/en,,,,,(41/42)  iii) a) a heavy chain variable region having at least 95% sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:41 and b) a light chain variable region having at least 95% sequence identity to the light chain variable region of the polypeptide sequence of seq id no:42
https://patents.google.com/patent/WO2019151632A1/en,,,,,(43/44)  iv) a) a heavy chain variable region having at least 95% sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:43 and b) a light chain variable region having at least 95% sequence identity to the light chain variable region of the polypeptide sequence of seq id no:44 binding molecules comprising
https://patents.google.com/patent/WO2019151632A1/en,,,,,(39/40)  ii) a heavy chain variable region having at least 95% sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:39 and b) a light chain variable region having at least 95% sequence identity to the light chain variable region of the polypeptide sequence of seq id no:40 binding molecules comprising
https://patents.google.com/patent/WO2019151632A1/en,,,,,(45/46)  v) a) a heavy chain variable region having at least 95% sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:45 and b) a light chain variable region having at least 95% sequence identity to the light chain variable region of the polypeptide sequence of seq id no:46 binding molecules comprising
https://patents.google.com/patent/WO2019151632A1/en,,,,,(47/48)  vi) a) a heavy chain variable region having at least 95% sequence identity to the heavy chain variable region of the polypeptide sequence of seq id no:47 and b) a light chain variable region having at least 95% sequence identity to the light chain variable region of the polypeptide sequence of seq id no:48 binding molecule comprising.
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(41/42) in some embodiments, the heavy chain variable domain comprises seq id no:41 and the light chain variable domain comprises seq id no:42"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(5/6) [0111] in some embodiments, the heavy chain variable domain comprises seq id no:5 and the light chain variable domain comprises seq id no:6"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(39/40) in some embodiments, the heavy chain variable domain comprises seq id no:39 and the light chain variable domain comprises seq id no:40"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(35/36) in some embodiments, the heavy chain variable domain comprises seq id no:35 and the light chain variable domain comprises seq id no:36"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(37/38) in some embodiments, the heavy chain variable domain comprises seq id no:37 and the light chain variable domain comprises seq id no:38"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(13/14) in some embodiments, the heavy chain variable domain comprises seq id no:13 and the light chain variable domain comprises seq id no:14"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(43/44) in some embodiments, the heavy chain variable domain comprises seq id no:43 and the light chain variable domain comprises seq id no:44"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(11/12) in some embodiments, the heavy chain variable domain comprises seq id no:11 and the light chain variable domain comprises seq id no:12"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(1/2) in some embodiments, the heavy chain variable domain comprises seq id no:1 and the light chain variable domain comprises seq id no:2"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(23/24) in some embodiments, the heavy chain variable domain comprises seq id no:23 and the light chain variable domain comprises seq id no:24"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(31/32) in some embodiments, the heavy chain variable domain comprises seq id no:31 and the light chain variable domain comprises seq id no:32"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(9/10) in some embodiments, the heavy chain variable domain comprises seq id no:9 and the light chain variable domain comprises seq id no:10"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(21/22) in some embodiments, the heavy chain variable domain comprises seq id no:21 and the light chain variable domain comprises seq id no:22"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(29/30) in some embodiments, the heavy chain variable domain comprises seq id no:29 and the light chain variable domain comprises seq id no:30"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(33/34) in some embodiments, the heavy chain variable domain comprises seq id no:33 and the light chain variable domain comprises seq id no:34"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(3/4) [0069] in some embodiments, the heavy chain variable domain comprises seq id no:3 and the light chain variable domain comprises seq id no:4"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(17/18) in some embodiments, the heavy chain variable domain comprises seq id no:17 and the light chain variable domain comprises seq id no:18"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(25/26) in some embodiments, the heavy chain variable domain comprises seq id no:25 and the light chain variable domain comprises seq id no:26"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(7/8) in some embodiments, the heavy chain variable domain comprises seq id no:7 and the light chain variable domain comprises seq id no:8"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(45/46) in some embodiments, the heavy chain variable domain comprises seq id no:45 and the light chain variable domain comprises seq id no:46"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(27/28) in some embodiments, the heavy chain variable domain comprises seq id no:27 and the light chain variable domain comprises seq id no:28"
https://patents.google.com/patent/WO2021236996A2/en,,,,,"(19/20) in some embodiments, the heavy chain variable domain comprises seq id no:19 and the light chain variable domain comprises seq id no:20"
https://patents.google.com/patent/US20220017606A1/en,,,,,(6/5) 13b) virus neutralization assay for the 49f1 antibody having the vh domain of seq id no:6 and the vl domain of seq id no:5 (sup
https://patents.google.com/patent/US20220017606A1/en,,,,,"(6/48) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:48 and a heavy chain variable region of the amino acid sequence of seq id no:6."
https://patents.google.com/patent/US20220017606A1/en,,,,,"(7/3) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:3 and a heavy chain variable region of the amino acid sequence of seq id no:7."
https://patents.google.com/patent/US20220017606A1/en,,,,,(47/48) the vh domain of the 49f1 antibody can bind to either of the alternative vl domains of seq id no:47 and 48.
https://patents.google.com/patent/US20220017606A1/en,,,,,"(10/9) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:9 and a heavy chain variable region of the amino acid sequence of seq id no:10."
https://patents.google.com/patent/US20220017606A1/en,,,,,"(4/3) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:3 and a heavy chain variable region of the amino acid sequence of seq id no:4."
https://patents.google.com/patent/US20220017606A1/en,,,,,"(66/65) , wherein the antibody comprises two heavy and two light chains, wherein each heavy chain comprises the amino acid sequence set forth as seq id no:65, and wherein each light chain comprises the amino acid sequence set forth as seq id no:66."
https://patents.google.com/patent/US20220017606A1/en,,,,,"(6/47) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:47 and a heavy chain variable region of the amino acid sequence of seq id no:6"
https://patents.google.com/patent/US20220017606A1/en,,,,,"(2/1) in some embodiments, the antibody comprises a light chain variable region of the amino acid sequence of seq id no:1 and a heavy chain variable region of the amino acid sequence of seq id no:2."
https://patents.google.com/patent/US20220017606A1/en,,,,,"(9/10) , wherein the antibody is a fully human igg antibody, and wherein the antibody comprises two heavy and two light chains, wherein each heavy chain comprises a heavy chain variable region comprising an amino acid sequence set forth as seq id no:10, and wherein each light chain comprises a light chain variable region comprising an amino acid sequence set forth as seq id no:9."
https://patents.google.com/patent/CN111620946B/en, Glu Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Arg Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Thr Thr Pro Phe Ser Ser Ser Phe Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Ala Pro Ser Val Ser Gly Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof of the invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof of the invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:8."
https://patents.google.com/patent/CN113671184A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val Ser Gly Ile Asn Trp Asn Gly Gly Arg Thr Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Tyr Leu Gln His Ser Tyr Phe Asp Leu Leu Leu Pro Asn Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Val Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Arg Leu Glu Ala Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , 12-5 VH, 12-5 VL,"(24/25) the vh comprises an amino acid sequence shown as seq id no:24, and the vl comprises an amino acid sequence shown as seq id no:25"
https://patents.google.com/patent/CN113671184A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly Tyr Ile His Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Arg Ser Arg Leu Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gln Gly Tyr Ser Ser Gly Trp Pro Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Ile Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Asp Ile Pro Ala Arg Phe Ser Asp Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , 12-8 VH, 12-8 VL,"(27/28) the vh comprises an amino acid sequence shown as seq id no:27, and the vl comprises an amino acid sequence shown as seq id no:28."
https://patents.google.com/patent/CN113671184A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Glu Ile Asn Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ala Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Phe Tyr Tyr Cys Ala Arg Glu Ala Tyr Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Leu Asn Ser Tyr Pro Pro Ser Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , 32-1 VH, 32-1 VL,"(21/22) the vh comprises an amino acid sequence shown as seq id no:21, and the vl comprises an amino acid sequence shown as seq id no:22"
https://patents.google.com/patent/WO2021174594A1/en,,,,,"(7/8)  preferably, it includes: vh shown in seq id no:7 and/or vl shown in seq id no:8."
https://patents.google.com/patent/CN113004395B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ala Tyr Gly Pro Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the heavy chain variable region of the monoclonal antibody or antigen-binding portion thereof of the present invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:4, and the light chain variable region of the monoclonal antibody or antigen-binding portion thereof of the present invention comprises an amino acid sequence that is at least 80% homologous to the amino acid sequence set forth in seq id no:8."
https://patents.google.com/patent/CN113004395B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN113583115A/en, Gln Ser Val Lys Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Pro Met Leu Thr Gln Thr Ala Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gly Gly Thr Glu Leu Glu Ile Leu , 3F4 VH, 3F4 VL,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2."
https://patents.google.com/patent/CN113583115A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Leu , h3F4-4-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,(18/19)  a vh comprising the sequence shown as seq id no:18 and a vl comprising the sequence shown as seq id no:19.
https://patents.google.com/patent/CN113583115A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Leu , h3F4-2-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,(16/19)  a vh comprising the sequence shown as seq id no:16 and a vl comprising the sequence shown as seq id no:19;
https://patents.google.com/patent/CN113583115A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Leu , h3F4-1-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,(15/19)  a vh comprising the sequence shown as seq id no:15 and a vl comprising the sequence shown as seq id no:19;
https://patents.google.com/patent/CN113583115A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Phe Thr Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Thr Ser Tyr Tyr Asp Val Ser Gly Trp Gly Val Gly Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Trp Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Gly Asn Ile Phe Ala Phe Gly Gln Gly Thr Lys Leu Glu Ile Leu , h3F4-3-VH, h3F4-1/ h3F4-2/h3F4-3/h3F4-4-VL,(17/19) (3) a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:19
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Lys Pro Asp Glu Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ala Tyr Tyr Gly Asp Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Glu Ala Met Thr Met Val Thr Leu Asp Arg Leu Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Arg Cys Ala Tyr Asp Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Asn Ile Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Tyr Ser Asn Leu Glu Tyr Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN5502 heavy chain variable region amino acid sequence, RN5502 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Thr Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Ile Ile Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Val Glu Trp Asp Thr Tyr Asp Asp Tyr Gly Asp Tyr Ile Phe Gly Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Arg Cys Ala Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Glu Asp Ile Tyr Ser Leu Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Gly Tyr Tyr Ser Gly Ser Gly Thr Gly Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN8105 heavy chain variable region amino acid sequence, RN8105 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Asp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Gly Ile Gly Gly Asn Ser Ile Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Val Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp Asp Asp Tyr Gly Asp Trp Phe Ala Phe Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Thr Phe Ala Gln Val Leu Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Ser Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Val Tyr Asn Asn Asp Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Lys Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Glu Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Glu Phe Ser Cys Ser Ser Ala Asp Cys Thr Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN0510 heavy chain variable region amino acid sequence, RN0510 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Val Ser Gly Ile Asp Leu Asn Asn Tyr Ala Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly Ile Ile Ser Phe Gly Gly Ser Thr Tyr Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Leu Thr Ser Pro Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Phe Ser Thr Tyr Asp Asp Tyr Gly Asp Tyr Phe Arg Ala Phe Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Thr Phe Ala Leu Val Met Thr Gln Thr Pro Ser Ser Thr Ser Glu Pro Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Gly Ser Asp Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Tyr Ser Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Val Tyr Gly Phe Ser Ser Asp Asp Gly Ile Ala Phe Gly Gly Gly Thr Val Val Val Val Lys , RN2604 heavy chain variable region amino acid sequence, RN2604 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Ser Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr Asn Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly Tyr Ile Gly Pro Thr Gly Ser Ala Tyr Tyr Ala Asn Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Gln Met Thr Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Glu Asp Ala Thr Asp Trp Gly Leu Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Arg Cys Ala Tyr Asp Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Glu Ser Ile Gly Asn Ala Leu Ser Trp Tyr Gln Gln Lys Pro Arg Gln Arg Pro Arg Leu Leu Ile Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Arg Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ile Phe Ser Gly Ala Asn Ile Asp Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN1245 heavy chain variable region amino acid sequence, RN1245 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Ser Leu Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Leu Ser Ser Tyr Asn Met Gly Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly Thr Thr Ser Asp Ser Gly Ile Thr Tyr Tyr Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Thr Thr Val Asp Leu Lys Ile Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Gly Trp Leu Tyr Phe Asn Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Ala Thr Phe Ala Gln Val Leu Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Lys Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn Ala Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Phe Leu Ile Tyr Asp Ala Ser Asp Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Asp Ala Ile Val Asn Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN1279 heavy chain variable region amino acid sequence, 279 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN113817052A/en, Met Glu Thr Gly Leu Arg Trp Leu Leu Leu Val Ala Val Leu Lys Gly Val Gln Cys Gln Gln Leu Glu Gln Ser Gly Gly Gly Ala Glu Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Glu Leu Cys Cys Lys Ala Ser Gly Phe Ser Leu Ser Asn Ser Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Cys Ile Tyr Pro Gly Ser Ser Gly Ser Ala Tyr Tyr Ala Ser Trp Val Asn Gly Arg Phe Thr Leu Ser Arg Asp Ile Asp Gln Ser Thr Gly Cys Leu Gln Leu Asn Ser Leu Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Arg Ser Tyr Asp Asp Tyr Gly Asp Tyr Pro Asp Tyr Phe Asn Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser, Met Asp Thr Arg Ala Pro Thr Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro Gly Val Thr Phe Ala Ile Glu Met Thr Gln Thr Pro Phe Ser Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Tyr Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Gln Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Glu Ser Ser Val Val Tyr Thr Val Phe Gly Gly Gly Thr Glu Val Val Val Lys , RN1248 heavy chain variable region amino acid sequence, RN1248 light chain variable region amino acid sequence,
https://patents.google.com/patent/CN111748032B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Gly Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Gly Trp Ser Val Ser Pro Leu Lys Tyr Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Ser Ile Ser Cys Ser Gly Ser Thr Ser Ser Ile Gly Arg Asn Thr Val Ser Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Glu Tyr Tyr Cys Ser Ala Trp His Asp Thr Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody according to claim 1, which comprises a heavy chain variable region consisting of the amino acid sequence shown in seq id no:4 and a light chain variable region consisting of the amino acid sequence shown in seq id no:8."
https://patents.google.com/patent/CN111748032B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN113999303A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Tyr Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Asp Lys Ser Met Gly Phe Gly Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Asn Tyr Leu His Trp Tyr Gln Gln Arg Pro Gly Phe Ser Pro Lys Leu Leu Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly His Ser Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , VH, VL,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18."
https://patents.google.com/patent/CN113999303A/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Pro Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asn Ile Glu Asp Tyr Ala Tyr Tyr Ala Pro Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Val Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Gly Gly Tyr Ala Ala Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser, Asp Val Val Met Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Glu Ser Val Tyr Thr Asn Asn Arg Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr Arg Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Ile Ile Ser Asp Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Val Gly Ser Gly Gly Thr Asp Ile Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , VH, VL,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8."
https://patents.google.com/patent/CN113249337B/en, Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Gln Gly Arg Phe Asp Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Ala Thr Ala Thr Tyr Phe Cys Ser Arg Gly Gly Tyr Asp Ser Asp Gly Gly Tyr Tyr Ala Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys , Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Ala Cys Gly Thr Thr Glu Asn Ile Tyr Gly Ala Leu Asn Trp Tyr Gln Arg Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile Tyr Gly Ala Ile Asn Leu Val Asp Gly Met Ser Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Gln Tyr Ser Leu Lys Ile Ser Ser Leu His Pro Asp Asp Val Ala Thr Tyr Tyr Cys Gln Asn Val Leu Ser Pro Pro Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/9) the amino acid sequence of the heavy chain variable region of the antibody dg8 is shown as seq id no:7, and the amino acid sequence of the light chain variable region is shown as seq id no:9"
https://patents.google.com/patent/CN113249337B/en, Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Arg Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Ile Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ser Pro Leu Ile Arg Ser Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala, Asp Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Leu Ser Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Phe Ser Leu Thr Ile Ser Ser Met Glu Val Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(17/19) the amino acid sequence of the heavy chain variable region of the antibody bg1 is shown as seq id no:17, and the amino acid sequence of the light chain variable region is shown as seq id no:19"
https://patents.google.com/patent/CN113999301A/en, Met Tyr Leu Gly Leu Asn Tyr Val Phe Ile Val Phe Leu Leu Asn Gly Val Gln Ser Glu Val Lys Phe Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Ala Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg Asn Lys Ala Asn Asn His Ala Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr Tyr Cys Thr Pro Tyr Asp Tyr Ala Tyr Pro Trp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Met Gln Ile Ile Ser Leu Leu Leu Ile Ser Val Thr Val Ile Val Ser Asn Gly Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser His Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Leu Leu Ile Tyr Arg Ser Tyr Ser Leu Ala Ser Gly Phe Pro Gly Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Phe Ser Leu Ser Ile Gly Thr Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Arg Ile Thr Pro Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , mouse (Mus musculus), mouse (Mus musculus),(7/8) seq id no:7 and seq id no:8 are the amino acid sequences of the heavy chain variable region and the light chain variable region of the anti-sars-cov-2 (covid-
https://patents.google.com/patent/CN111592594A/en,Gln Val Gln Leu Val Gln Ser Gly Ser Glu Leu Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Thr Asn Thr Gly Asn Pro Thr Tyr Ala Gln Gly Phe Thr Gly Arg Phe Val Phe Ser Leu Asp Thr Ser Val Ser Thr Ala Tyr Leu Gln Ile Ser Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Gln Gly Gly Ser Ser Trp Tyr Arg Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys AlaSer Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys ,Homo sapiens,Homo sapiens,"(7/8)  preferably, it comprises: vh shown as seq id no:7 and/or vl shown as seq id no:8."
https://patents.google.com/patent/WO2021239949A1/en,,,,,"(56/57) in one embodiment, the antibody or antibody fragment according to cv07-209 comprises: a heavy chain variable (vh) domain, said vh domain comprising a sequence of at least 70%, 80%, 85%, 90%, at least 95% or complete identity to seq id no:56, and a light chain variable (vl) domain, said vl domain comprising a sequence of at least 70%, 80%, 85%, 90%, at least 95% or complete identity to seq id no:57"
https://patents.google.com/patent/WO2021239949A1/en,,,,,"(88/89) in one embodiment, the antibody or antibody fragment according to cv38-138 comprises: a heavy chain variable (vh) domain, said vh domain comprising a sequence of at least 70%, 80%, 85%, 90%, at least 95% or complete identity to seq id no:88, and a light chain variable (vl) domain, said vl domain comprising a sequence of at least 70%, 80%, 85%, 90%, at least 95% or complete identity to seq id no:89"
https://patents.google.com/patent/WO2021239949A1/en,,,,,"(16/17) in one embodiment, the antibody or antibody fragment comprises vh and vl domains that comprise the sequences according to seq id no:16 and 17, 24 and 25, 32 and 33, 40 and 41 , 48 and 49, 56 and 57, 64 and 65, 72 and 73, 80 and 81 , 88 and 89, 96 and 97, 104 and 105, 112 and 113, 120 and 121 , 128 and 129, 136 and 137, 144 and 145, 152 and 153, and 160 and 161 , respectively"
https://patents.google.com/patent/CN111620945A/en,Glu Val Gln Leu Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Glu Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) preferably, the first variable region is an antibody light chain variable region comprising seq id no:8; wherein said second variable region is an antibody heavy chain variable region comprising the amino acid sequence of seq id no:4."
https://patents.google.com/patent/CN111620945A/en,gaggtgcagc tgttgcagca gtcaggggct gaggtgaaga agcctgggtc ctcagtgaag gtctcctgca aggcttctgg aggcaccttc agcagctatg ctatcagctg ggtgcgacag gcccctggac aagggcttga gtggatggga gggatcatcc ctatccttgg tatagcaaac tacgcacaga agttccaggg cagagtcacg attaccgcgg acaaatccac gagcacagcc tacatggagc tgagcagcct gagatctgag gacacggccg tgtattactg tgtgagagaa cgtggatata gtggctacgg ggcggcttac tactttgact actggggcca gggaaccctg gtcaccgtct cctca ,cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc tcctgcactg ggagcagctc caacatcggg gcaggttatg atgtacactg gtaccagcag cttccaggaa cagcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc caggctgagg atgaggctga ttattactgc cagtcctatg acagcagcct gagtggttcg gtattcggcg gagggaccaa gctgaccgtc cta , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(9/10) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:10, and the variable region of the antibody heavy chain is seq id no:9."
https://patents.google.com/patent/CN111518204B/en, gaggtgcagc tgctcgagtc tgggggaggc ttggtaaagc ctggggggtc ccttagactc tcctgtgcag cctctggatt cactttcagt aacgcctgga tgagctgggt ccgccaggct ccagggaagg ggctggagtg ggttggccgt attaaaagca aaactgatgg tgggacaaca gactacgctg cacccgtgaa aggcagattc accatctcaa gagatgattc aaaaaacacg ctgtatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtatta ctgtaccaca gaaggggcta tggttcggcg agttatatac ggtatggacg tctggggcca agggaccacg gtcaccgtct cctca , gagaatgtgc tcacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc ctctcctgca gggccagaca gagtgttagc agcagctact tagcctggta ccagcagaaa cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag cctgaagatt ttgcagtgta ttactgtcag cagtatggta gctcaccgat caccttcggc caagggacac gactggagat taaa , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(17/18) as a preferred embodiment of the present invention, the variable region of the antibody light chain is seq id no:18, and the variable region of the antibody heavy chain is seq id no:17."
https://patents.google.com/patent/CN111518204B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Ser Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Glu Gly Ala Met Val Arg Arg Val Ile Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Arg Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody of claim 1, wherein the first variable region is an antibody light chain variable region as set forth in seq id no:8; wherein said second variable region is an antibody heavy chain variable region represented by seq id no:4."
https://patents.google.com/patent/CN111518204B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16)  wherein the heavy chain variable region comprises seq id no:12 and the light chain variable region comprises the amino acid sequence shown in seq id no:16.
https://patents.google.com/patent/CN112979793B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Gly Pro Thr Gly Trp Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ser Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Arg Ser Asn Trp Lys Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody of claim 1, wherein said antibody comprises the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/CN112979793B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/WO2021148884A1/en,,,,,"(1/78) an antibody, or antigen-binding fragment thereof, comprising: i) a heavy chain variable region sequence of any one of seq id no:1-77 or 123, and/or ii) a light chain variable region sequence of any one of seq id no:78-122 or 124"
https://patents.google.com/patent/CN112979790B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/WO2022022445A1/en,,,,,"(7/8)  according to the imgt numbering system scheme, the amino acid sequence of the heavy chain variable region of monoclonal antibody gw01 is shown in seq id no:7, and the amino acid sequence of the light chain variable region is shown in seq id no:8."
https://patents.google.com/patent/WO2022022445A1/en,,,,,"(9/10)  after sequencing, the heavy chain variable region dna sequence is shown in seq id no:9; the light chain variable region dna sequence is shown in seq id no:10."
https://patents.google.com/patent/WO2022022445A1/en,,,,,"(11/12)  similarly, the amino acid sequence of the heavy chain can be based on the sequence shown in seq id no:11 by deletion, insertion or amino acid mutation of a small number of amino acids; the amino acid sequence of the light chain can be based on the sequence shown in seq id no:12"
https://patents.google.com/patent/CN111793129B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asp Asp His Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Ser Tyr Gly Pro Pro Asp Val Phe Asn Tyr Glu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(11/12) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:11, and the light chain amino acid sequence is shown as seq id no:12."
https://patents.google.com/patent/WO2021237051A1/en,,,,,(11/15) a vh domain having the amino acid sequence of seq id no:11 and a vl domain having the amino acid sequence of seq id no:15; iii
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(74/78) [0087] in certain embodiments of such aspects, an antibody, or an antigen-binding fragment thereof, comprises a vh domain having the amino acid sequence of seq id no:74 and a vl domain having the amino acid sequence of seq id no:78"
https://patents.google.com/patent/WO2021237051A1/en,,,,,(20/24) a vh domain having the amino acid sequence of seq id no:20 and a vl domain having the amino acid sequence of seq id no:24; iv
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(55/54)  a heavy chain of seq id no:55 and a light chain of seq id no:54, or ("
https://patents.google.com/patent/WO2021237051A1/en,,,,,(56/60) a vh domain having the amino acid sequence of seq id no:56 and a vl domain having the amino acid sequence of seq id no:60; viii
https://patents.google.com/patent/WO2021237051A1/en,,,,,(38/42) a vh domain having the amino acid sequence of seq id no:38 and a vl domain having the amino acid sequence of seq id no:42; vi
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(28/48)  a  heavy chain of seq id no:28 and a light chain of seq id no:48, ("
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(37/49)  a heavy chain of seq id no:37 and a light chain of seq id no:49, ("
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(73/83) [0094] in some aspects, an antibody comprises a heavy chain comprising the amino acid sequence of seq id no:73 and a light chain comprising the amino acid sequence of seq id no:83"
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(19/44)  a heavy chain of seq id no:19 and a light chain of seq id no:44, ("
https://patents.google.com/patent/WO2021237051A1/en,,,,,(47/51) a vh domain having the amino acid sequence of seq id no:47 and a vl domain having the amino acid sequence of seq id no:51; vii
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(1/13)  a heavy chain of seq id no:1 and a light chain of seq id no:13, ("
https://patents.google.com/patent/WO2021237051A1/en,,,,,(64/82) an amino acid sequence having a heavy chain of seq id no:64 and a light chain of seq id no:82; d
https://patents.google.com/patent/WO2021237051A1/en,,,,,(2/6) a vh domain having the amino acid sequence of seq id no:2 and a vl domain having the amino acid sequence of seq id no:6; ii
https://patents.google.com/patent/WO2021237051A1/en,,,,,(65/69) a vh domain having the amino acid sequence of seq id no:65 and a vl domain having the amino acid sequence of seq id no:69
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(46/53)  a heavy chain of seq id no:46 and a light chain of seq id no:53, ("
https://patents.google.com/patent/WO2021237051A1/en,,,,,(29/33) a vh domain having the amino acid sequence of seq id no:29 and a vl domain having the amino acid sequence of seq id no:33; v
https://patents.google.com/patent/WO2021237051A1/en,,,,,"(10/43)  a heavy chain of seq id no:10 and a light chain of seq id no:43, ("
https://patents.google.com/patent/KR20210134300A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ser Asp Tyr Gly Asp Tyr Leu Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Thr Ser Ile Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Synthetic , Synthetic ,"(640/646) in some embodiments, the isolated antibody comprises an hcvr comprising the amino acid sequence set forth in seq id no:640 and an lcvr comprising the amino acid sequence set forth in seq id no:646"
https://patents.google.com/patent/KR20210134300A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Thr Tyr Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Thr Thr Met Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Synthetic , Synthetic ,"(202/210) in some embodiments, the isolated antibody comprises an hcvr comprising the amino acid sequence set forth in seq id no:202 and an lcvr comprising the amino acid sequence set forth in seq id no:210"
https://patents.google.com/patent/KR20210134300A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Thr Tyr Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Thr Thr Met Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Gly Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Synthetic , Synthetic ,"(216/218) in some embodiments, the isolated antibody comprises a heavy chain comprising the amino acid sequence set forth in seq id no:216 and a light chain comprising the amino acid sequence set forth in seq id no:218"
https://patents.google.com/patent/KR20210134300A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ser Asp Tyr Gly Asp Tyr Leu Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Leu Thr Ser Ile Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Synthetic , Synthetic ,"(654/656) in some embodiments, the isolated antibody comprises a heavy chain comprising the amino acid sequence set forth in seq id no:654 and a light chain comprising the amino acid sequence set forth in seq id no:656"
https://patents.google.com/patent/CN113234151B/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Met Ile Gly Arg Thr Tyr Asp Ala Asp Ser Val Lys Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ala Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala Gly Ser Ser Arg Ser Ser Leu Leu Arg Tyr Gly Tyr Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(1) the nanobody ansp-1 of claim 1, wherein the nanobody amino acid sequence is set forth in seq id no:1."
https://patents.google.com/patent/CN113234151B/en,,,,,"(12) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is shown."
https://patents.google.com/patent/CN113234151B/en,,,,,"(8) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is shown."
https://patents.google.com/patent/CN113234151B/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Met Ile Gly Arg Thr Tyr Asp Ala Asp Ser Val Lys Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ala Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala Gly Ser Ser Arg Ser Ser Leu Leu Arg Tyr Gly Tyr Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Met Ile Gly Arg Thr Tyr Asp Ala Asp Ser Val Lys Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ala Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala Gly Ser Ser Arg Ser Ser Leu Leu Arg Tyr Gly Tyr Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Met Ile Gly Arg Thr Tyr Asp Ala Asp Ser Val Lys Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ala Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala Gly Ser Ser Arg Ser Ser Leu Leu Arg Tyr Gly Tyr Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(13) the trimeric nanobody of claim 3, wherein it is represented by seq id no:13."
https://patents.google.com/patent/CN113234151B/en,,,,,"(9) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is shown."
https://patents.google.com/patent/CN113234151B/en,,,,,"(10) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is shown."
https://patents.google.com/patent/CN113234151B/en,,,,,"(11) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is shown."
https://patents.google.com/patent/CN113234151B/en,,,,,"(7) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is shown."
https://patents.google.com/patent/CN113234151B/en,,,,,"(6) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is shown."
https://patents.google.com/patent/CN113512113A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Thr Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ser Phe Ser Asn Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Ala Thr Leu Gly Ile Ser Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Ile Thr Asn Phe Gly Val Leu Ile Glu Val Asp Ala Phe His Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser , Glu Ile Val Leu Thr Gln Ser Pro Phe Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Asp Gly Ser Ser Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln Tyr Ser Thr Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(9/11)  seq id no:9 and seq id no:11; in the present invention, an antibody having the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain is designated as ""cz-d7""."
https://patents.google.com/patent/CN113512113A/en, Gln Met Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asn Ser Ala Met Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Val Val Ala Ser Gly Asn Ala Asn Ser Ala Arg Arg Phe His Asp Arg Val Thr Ile Thr Ser Asp Met Ser Thr Ser Thr Ala Tyr Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Leu Asn His Cys Ser Asn Thr Thr Cys Leu Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Met Val Ser Val Ser Ser Ala Ser , Glu Ile Val Leu Thr Gln Ser Pro Val Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Asn Ser Leu Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ala Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Val Val Tyr Tyr Cys Gln Gln His Gly Ser Ser Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Phe Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(1/3) an antibody composition comprising a first antibody and a second antibody, wherein the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain of the first antibody are represented by seq id no:1 and seq id no:3, respectively, and the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain of the second antibody are represented by:"
https://patents.google.com/patent/CN111732655B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Asp Tyr Gly Asp Tyr Val Leu Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Lys Phe Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens,  Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/CN113557431A/en, Val Asn Leu Thr Thr Arg Thr Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe Thr Arg Gly Val Tyr Tyr Pro Asp Lys Val Phe Arg Ser Ser Val Leu His Ser Thr Gln Asp Leu Phe Leu Pro Phe Phe Ser Asn Val Thr Trp Phe His Ala Ile His Val Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp Asn Pro Val Leu Pro Phe Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu Lys Ser Asn Ile Ile Arg Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser Lys Thr Gln Ser Leu Leu Ile Val Asn Asn Ala Thr Asn Val Val Ile Lys Val Cys Glu Phe Gln Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr Tyr His Lys Asn Asn Lys Ser Trp Met Glu Ser Glu Phe Arg Val Tyr Ser Ser Ala Asn Asn Cys Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu Met Asp Leu Glu Gly Lys Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe Val Phe Lys Asn Ile Asp Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr Pro Ile Asn Leu Val Arg Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu Pro Leu Val Asp Leu Pro Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr Leu Leu Ala Leu His Arg Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser Gly Trp Thr Ala Gly Ala Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro Arg Thr Phe Leu Leu Lys Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala Val Asp Cys Ala Leu Asp Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys Ser Phe Thr Val Glu Lys Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Cys Val Asn Phe Asn Phe Asn Gly Leu Thr Gly Thr Gly Val Leu Thr Glu Ser Asn Lys Lys Phe Leu Pro Phe Gln Gln Phe Gly Arg Asp Ile Ala Asp Thr Thr Asp Ala Val Arg Asp Pro Gln Thr Leu Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe Gly Gly Val Ser Val Ile Thr Pro Gly Thr Asn Thr Ser Asn Gln Val Ala Val Leu Tyr Gln Asp Val Asn Cys Thr Glu Val Pro Val Ala Ile His Ala Asp Gln Leu Thr Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser Asn Val Phe Gln Thr Arg Ala Gly Cys Leu Ile Gly Ala Glu His Val Asn Asn Ser Tyr Glu Cys Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Tyr Gln Thr Gln Thr Asn Ser Pro Arg Arg Ala Arg , Met Ser His His His His His His His His Ser Pro Met Tyr Ser Ile Ile Thr Pro Asn Ile Leu Arg Leu Glu Ser Glu Glu Thr Met Val Leu Glu Ala His Asp Ala Gln Gly Asp Val Pro Val Thr Val Thr Val His Asp Phe Pro Gly Lys Lys Leu Val Leu Ser Ser Glu Lys Thr Val Leu Thr Pro Ala Thr Asn His Met Gly Asn Val Thr Phe Thr Ile Pro Ala Asn Arg Glu Phe Lys Ser Glu Lys Gly Arg Asn Lys Phe Val Thr Val Gln Ala Thr Phe Gly Thr Gln Val Val Glu Lys Val Val Leu Val Ser Leu Gln Ser Gly Ile Glu Gly Arg Met Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln, SARS-CoV-2S1 domain derived from S protein, SARS-CoV-2 antibody-reactive SEQ ID NO: 1-derived peptides,(1/48) seq id no:48 (peptide derived from seq id no:1 with gst fusion reactive with sars-cov-2 antibody) mshhhhhhhhspmysiitpnilrleseetmvleahdaqgdvpv tvtvhdfpgkklvlssektvltpatnhmgnvtftipanrefkse kgrnkfvtvqatfgtqvvekvvlvslqsgiegrmygfqptngv gyqygfqptngvgyq
https://patents.google.com/patent/CN113698475A/en, Val Leu Ser Thr Ser Gln Ser Leu Ser Ile Thr Cys Thr Ile Ser Gly Phe Ser Leu Thr Ser Tyr Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Val Gly Asn Thr Thr Tyr Asn Ser Thr Leu Arg Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gln Val Tyr Gly Asn Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Ala Leu Leu Leu Ser Ser Trp Arg Ser Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp His Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Gly Thr His Val Met Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(1/2) the amino acid sequence of the heavy chain variable region of the monoclonal antibody e8 for resisting the porcine delta coronavirus n protein is shown as seq id no:1, the amino acid sequence of the light chain variable region is shown as seq id no:2 is shown in the specification"
https://patents.google.com/patent/CN113698475A/en, Met Gln Ala Ser Val Arg Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Tyr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Arg Phe Leu Gly Lys Ala Thr Met Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Gly Val Tyr Tyr Cys Lys Val Tyr Asp Gly Tyr Tyr Phe Asp Phe Trp Gly Gln Gly Thr Pro Leu Thr Val Ser Ser , Ala Arg Cys Leu Leu His Trp Thr Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Ala Thr His Phe Pro His Thr Phe Gly Gly Gly Thr Lys Leu Glu Arg , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(3/4) the amino acid sequence of the heavy chain variable region of the monoclonal antibody a10 for resisting the porcine delta coronavirus n protein is shown as seq id no:3, the amino acid sequence of the light chain variable region is shown as seq id no:4, respectively."
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(102/218) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:102 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:218"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(181/349) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:181 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:349"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(169/271) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:169 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:271"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(157/223) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:157 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:223"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(172/244) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:172 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:244"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(23/264) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:264"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(67/227) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:67 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:227"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(136/226) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:136 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:226"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(82/282) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:82 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:282"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(156/311) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:156 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:311"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(131/337) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:131 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:337"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(83/280) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:280"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(39/270) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:39 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:270"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(58/199) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:58 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:199"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(78/277) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:78 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:277"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(134/216) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:134 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:216"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(41/260) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:41 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:260"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(85/279) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:85 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:279"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(56/197) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:56 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:197"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(161/366) the antibody, or antigen binding fragment thereof, of claim 5, wherein the vh has the amino acid sequence of seq id no:161, and the vl has the amino acid sequence of seq id no:366"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(179/203) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:179 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:203"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(100/301) the antibody, or antigen binding fragment thereof, of claim 5, wherein the vh has the amino acid sequence of seq id no:100, and the vl has the amino acid sequence of seq id no:301"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(116/290) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:116 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:290"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(72/247) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:72 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:247"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(19/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:19 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(57/204) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:57 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:204"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(174/358) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:174 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:358"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(16/303) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:303"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(21/256) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:256"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(110/267) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:110 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:267"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(15/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:15 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(77/278) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:77 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:278"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(150/327) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:150 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:327"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(183/341) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:183 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:341"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(23/254) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:254"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(92/241) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:92 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:241"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(23/258) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:258"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(190/377) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:190 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:377"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(111/237) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:111 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:237"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(29/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:29 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(74/285) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:74 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:285"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(26/260) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:26 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:260"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(12/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:12 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(21/252) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:252"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(112/233) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:112 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:233"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(166/363) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:166 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:363"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(178/232) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:178 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:232"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(49/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:49 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(30/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:30 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(139/356) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:139 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:356"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(187/378) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:187 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:378"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(73/283) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:73 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:283"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(47/345) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:47 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:345"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(183/375) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:183 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:375"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(191/315) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:191 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:315"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(71/196) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:71 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:196"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(121/381) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:121 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:381"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(149/211) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:149 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:211"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(27/254) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:27 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:254"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(65/193) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:65 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:193"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(146/321) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:146 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:321"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(130/210) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:130 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:210"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(35/296) [0044] the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:35 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(11/300) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:11 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:300"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(91/246) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:91 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:246"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(98/217) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:98 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:217"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(32/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:32 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(52/294) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:52 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:294"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(44/249) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:44 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:249"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(26/344) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:26 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:344"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(107/238) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:107 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:238"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(126/220) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:126 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:220"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(93/248) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:93 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:248"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(54/261) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:54 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:261"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(103/319) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:103 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:319"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(97/354) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:97 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:354"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(148/266) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:148 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:266"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(46/343) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:46 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:343"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(176/379) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:176 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:379"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(7/376) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:7 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:376"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(184/347) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:184 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:347"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(5/274) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:5 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:274"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(9/265) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:9 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:265"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(50/260) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:50 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:260"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(24/368) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:24 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:368"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(163/351) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:163 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:351"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(165/364) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:165 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:364"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(164/365) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:164 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:365"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(117/316) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:117 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:316"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(118/194) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:118 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:194"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(189/308) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:189 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:308"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(160/273) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:160 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:273"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(99/357) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:99 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:357"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(170/330) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:170 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:330"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(104/310) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:104 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:310"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(20/251) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:20 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:251"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(109/239) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:109 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:239"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(21/253) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:253"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(147/317) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:147 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:317"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(98/360) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:98 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:360"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(188/306) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:188 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:306"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(128/213) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:128 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:213"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(141/356) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:141 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:356"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(66/224) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:66 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:224"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(103/318) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:103 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:318"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(108/238) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:108 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:238"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(138/352) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:138 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:352"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(18/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:18 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(162/346) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:162 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:346"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(75/228) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:75 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:228"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(80/281) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:80 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:281"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(44/240) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:44 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:240"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(154/335) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:154 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:335"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(55/261) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:55 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:261"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(10/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:10 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(129/337) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:129 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:337"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(143/234) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:143 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:234"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(153/328) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:153 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:328"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(16/192) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:192"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(64/326) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:64 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:326"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(90/243) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:90 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:243"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(34/314) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:34 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:314"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(27/250) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:27 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:250"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(37/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:37 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(45/250) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:45 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:250"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(36/305) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:36 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:305"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(33/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:33 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(40/258) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:40 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:258"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(180/373) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:180 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:373"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(123/312) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:123 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:312"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(127/331) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:127 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:331"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(135/212) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:135 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:212"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(48/299) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:48 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:299"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(21/373) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:373"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(94/201) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:94 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:201"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(132/231) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:132 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:231"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(149/337) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:149 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:337"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(171/245) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:171 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:245"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(183/374) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:183 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:374"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(113/332) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:113 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:332"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(125/362) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:125 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:362"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(63/336) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:63 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:336"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(167/275) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:167 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:275"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(40/262) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:40 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:262"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(17/292) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:17 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:292"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(119/202) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:119 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:202"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(22/255) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:22 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:255"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(14/298) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:14 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:298"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(152/266) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:152 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:266"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(122/269) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:122 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:269"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(185/371) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:185 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:371"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(61/198) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:61 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:198"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(21/262) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:262"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(83/288) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:288"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(21/236) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:236"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(38/313) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:38 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:313"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(81/276) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:81 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:276"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(173/361) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:173 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:361"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(102/320) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:102 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:320"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(140/359) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:140 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:359"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(114/217) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:114 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:217"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(153/329) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:153 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:329"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(159/367) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:159 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:367"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(8/259) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:8 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:259"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(5/272) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:5 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:272"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(25/369) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:25 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:369"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(148/339) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:148 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:339"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(28/302) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:28 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:302"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(145/355) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:145 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:355"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(51/297) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:51 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(152/338) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:152 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:338"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(87/334) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:87 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:334"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(101/242) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:101 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:242"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(23/257) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:257"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(21/260) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:260"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(142/356) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:142 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:356"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(23/229) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:23 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:229"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(96/333) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:96 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:333"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(64/209) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:64 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:209"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(60/222) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:60 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:222"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(144/221) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:144 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:221"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(86/282) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:86 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:282"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(43/293) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:43 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:293"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(137/214) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:137 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:214"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(133/230) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:133 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:230"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(88/322) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:88 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:322"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(13/296) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:13 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:296"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(175/353) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:175 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:353"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(64/208) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:64 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:208"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(163/350) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:163 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:350"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(79/286) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:79 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:286"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(168/273) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:168 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:273"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(42/263) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:42 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:263"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(13/291) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:13 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:291"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(7/225) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:7 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:225"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(95/200) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:95 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:200"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(124/309) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:124 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:309"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(105/235) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:105 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:235"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(6/192) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:6 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:192"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(177/380) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:177 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:380"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(68/219) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:68 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:219"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(155/324) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:155 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:324"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(21/342) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:21 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:342"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(31/297) the antibody, or antigen binding fragment thereof, of claim 5, wherein the vh has the amino acid sequence of seq id no:31, and the vl has the amino acid sequence of seq id no:297"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(106/235) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:106 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:235"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(89/268) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:89 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:268"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(186/370) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:186 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:370"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(83/287) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:83 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:287"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(151/215) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:151 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:215"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(153/323) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:153 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:323"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(115/307) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:115 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:307"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(120/340) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:120 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:340"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(158/308) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:158 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:308"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(182/372) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:182 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:372"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(76/289) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:76 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:289"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(69/205) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:69 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:205"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(70/207) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:70 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:207"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(62/206) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:62 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:206"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(151/325) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:151 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:325"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(50/295) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:50 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:295"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(16/304) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:16 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:304"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(59/195) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:59 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:195"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(53/263) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:53 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:263"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(84/284) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:84 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:284"
https://patents.google.com/patent/WO2021213520A1/en,,,,,"(181/348) the disclosure also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:181 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to seq id no:348"
https://patents.google.com/patent/US20220010002A1/en,,,,,"(21202/21212)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21202, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21212;"
https://patents.google.com/patent/US20220010002A1/en,,,,,"(21702/21712)  (a) the vh may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21702, and (b) the vl may comprise an amino acid sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity to the amino acid sequence of seq id no:21712;"
https://patents.google.com/patent/US20220010002A1/en,,,,,"(22302/22312) the pharmaceutical composition of claim 61, wherein the vh of the second antibody, or antigen-binding fragment thereof, comprises seq id no:22302 and wherein the vl of the second antibody, or antigen-binding fragment thereof, comprises seq id no:22312."
https://patents.google.com/patent/US20220010002A1/en,,,,,"(21902/21912) the isolated antibody, or antigen-binding fragment thereof, of claim 47, wherein the vh comprises seq id no:21902 and the vl comprises seq id no:21912 ."
https://patents.google.com/patent/CN112076316A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Asp Tyr Gly Asp Tyr Val Leu Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Lys Phe Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Cys Ser Tyr Ala Gly Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu ,  Homo sapiens,  Homo sapiens,"(1/5) the antibody composition of claim 1, wherein the amino acid sequence of the heavy chain variable region of the monoclonal antibody that specifically binds to the s protein receptor binding region of sars-cov-2 is set forth in seq id no:1, and the amino acid sequence of the light chain variable region is set forth in seq id no:5."
https://patents.google.com/patent/CN112076316A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Met Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Thr Ala Val Ala Gly Thr Pro Asp Leu Phe Asp Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Leu Ser Ser Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asp Gly Asn Thr Tyr Leu Ser Trp Leu Gln Gln Arg Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Lys Ile Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Thr Gln Ala Thr Gln Phe Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys ,  Homo sapiens,  Homo sapiens,"(11/12) the antibody composition of claim 4, wherein the amino acid sequence of the heavy chain variable region of the antibody that specifically binds to the n-terminal domain of the s protein of sars-cov-2 is set forth in seq id no:11, and the amino acid sequence of the light chain variable region is set forth in seq id no:12."
https://patents.google.com/patent/JP2021533175A/en,,,,,"(7/8)    the monoclonal antibody according to claim 1, wherein the monoclonal antibody is a heavy chain containing the polypeptide sequence set forth in seq id no:7 and a light chain containing the polypeptide sequence set forth in seq id no:8"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(166/190) [0094] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:166 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:190"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(158/182) [0086] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:158 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:182"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(150/174) [0078] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:150 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:174"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(159/183) [0087] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:159 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:183"
https://patents.google.com/patent/WO2021194886A1/en,,,,,(156/180) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:156 and a vl having an amino acid sequence of seq id no:180
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(167/191) [0095] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:167 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:191"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(147/171) [0075] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:147 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:171"
https://patents.google.com/patent/WO2021194886A1/en,,,,,(145/169) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:145 and a vl having an amino acid sequence of seq id no:169
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(151/175) [0079] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:151 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:175"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(162/186) [0090] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:162 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:186"
https://patents.google.com/patent/WO2021194886A1/en,,,,,(155/179) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:155 and a vl having an amino acid sequence of seq id no:179
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(163/187) [0091] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:163 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:187"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(165/189) [0093] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:165 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:189"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(146/170) [0074] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:146 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:170"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(160/184) [0088] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:160 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:184"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(153/177) [0081] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:153 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:177"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(152/176) [0080] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:152 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:176"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(154/178) [0082] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:154 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:178"
https://patents.google.com/patent/WO2021194886A1/en,,,,,(208/209) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:208 and a vl having an amino acid sequence of seq id no:209
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(161/185) [0089] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:161 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:185"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(149/173) [0077] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:149 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:173"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(168/192) [0096] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:168 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:192"
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(148/172) [0076] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:148 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:172"
https://patents.google.com/patent/WO2021194886A1/en,,,,,(157/181) the antibody or the antigen- binding fragment can comprise a vh having an amino acid sequence of seq id no:157 and a vl having an amino acid sequence of seq id no:181
https://patents.google.com/patent/WO2021194886A1/en,,,,,"(164/188) [0092] in one instance, an antibody or antigen-binding fragment herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:164 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:188"
https://patents.google.com/patent/WO2022010912A1/en,,,,,"(7/14) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:7; and b) the vl comprises seq id no:14"
https://patents.google.com/patent/WO2022010912A1/en,,,,,"(44/48) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:44; and b) the vl comprises seq id no:48"
https://patents.google.com/patent/WO2022010912A1/en,,,,,"(31/35) [0050] in another aspect, the invention provides a polypeptide that specifically binds an sars-cov-2 spike protein, wherein the polypeptide comprises: a) an immunoglobulin heavy chain variable region (vh) comprising an amino acid sequence that is at least 55% (e.g., at least 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) identical to seq id no:4; b) an immunoglobulin light chain variable region (vl) comprising an amino acid sequence that is at least 55% (e.g, at least 60, 65, 70, 75, 80, 85, 90, 95, 98, or 99%) identical to seq id no:55; or c) both a) and b), wherein the polypeptide does not comprise all five of seq id no:17, seq id no:21, seq id no:24, seq id no:31 and seq id no:35"
https://patents.google.com/patent/WO2022010912A1/en,,,,,"(3/12) in some embodiments, the reference antibody comprises a vh sequence of seq id no:3 and a vl sequence of seq id no:12"
https://patents.google.com/patent/WO2022010912A1/en,,,,,"(43/47) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:43; and b) the vl comprises seq id no:47"
https://patents.google.com/patent/WO2022010912A1/en,,,,,"(45/49) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:45; and  b) the vl comprises seq id no:49"
https://patents.google.com/patent/WO2022010912A1/en,,,,,"(35/31)  and comprises an immunoglobulin light chain variable region, an immunoglobulin heavy chain variable region, or an immunoglobulin light chain variable region and an immunoglobulin heavy chain variable region, wherein the polypeptide does not comprise all five of seq id no:17, seq id no:21, seq id no:24, seq id no:31 and seq id no:35. in some embodiments, the polypeptide comprises 1, 2,"
https://patents.google.com/patent/WO2022010912A1/en,,,,,"(8/15) the polypeptide of any one of claims 2-22, wherein: a) the vh comprises seq id no:8; and b) the vl comprises seq id no:15"
https://patents.google.com/patent/CN111690059A/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Trp Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Gly Met Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/KR20220010410A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising "
https://patents.google.com/patent/CN101102794B/en,,,,,(107/111) wherein first kind of immunoglobulin comprises variable region of heavy chain with aminoacid sequence shown in the seq id no:107 and the variable region of light chain with aminoacid sequence shown in the seq id no:111
https://patents.google.com/patent/CN101102794B/en,,,,,(109/113) wherein second kind of immunoglobulin comprises variable region of heavy chain with aminoacid sequence shown in the seq id no:109 and the variable region of light chain with aminoacid sequence shown in the seq id no:113.
https://patents.google.com/patent/WO2021244601A1/en,,,,,(2/1)  (1) the light chain variable region shown in seq id no:1 and/or the heavy chain variable region shown in seq id no:2
https://patents.google.com/patent/WO2021244601A1/en,,,,,"(2/3)  (2) the light chain variable region shown in seq id no:3, and/or the heavy chain variable region shown in seq id no:2"
https://patents.google.com/patent/WO2021244601A1/en,,,,,"(2/20)  (4) the light chain variable region shown in seq id no:20, and/or the heavy chain variable region shown in seq id no:2"
https://patents.google.com/patent/WO2021244601A1/en,,,,,"(5/4)  (3) the light chain variable region shown in seq id no:4, and/or the heavy chain variable region shown in seq id no:5"
https://patents.google.com/patent/CN112250763B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr Ser Ser Ser Trp Leu Leu Gln Ser Phe Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asn Ile Gln Leu Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Gly Tyr Ser Leu Val Trp Tyr Gln Lys Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Val Ile His Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,(11/12)  a heavy chain variable region comprising the amino acid sequence set forth in seq id no:11; and the variable region of the light chain of the amino acid sequence shown as seq id no:12.
https://patents.google.com/patent/CN112250763B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Glu Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asp Thr Ala Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu His Thr Val Ala Pro Val Tyr Gly Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Ser Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,(3/4)  a heavy chain variable region comprising the amino acid sequence set forth in seq id no:3; and the variable region of the light chain of the amino acid sequence shown as seq id no:4;
https://patents.google.com/patent/KR20210128252A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Glu Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ser Gly Asp Gly Phe Phe Thr His Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Phe Gly Gly His Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Ser Arg Arg Leu Ala Trp Tyr Gln Arg Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Val Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Thr Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Ser Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg , JS_VH 4, JS 1_VL,"(78/67)  in one embodiment, the antibody or fragment having immunological activity specific for the corona-19 virus of the present invention comprises any one selected from seq id no:78 to 81, 66, 68, 70, 72, 74 and 76 vh, and/or a vl comprising any one selected from seq id no:67, 69, 71, 73, 75 and 77."
https://patents.google.com/patent/KR20210128252A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Ser Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Ala Ile Gly Asp Asn Ala Leu Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Tyr Ile Arg Ser Asn Ser Tyr Gly Gly Thr Ala Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Glu Ser Lys Asn Ile Ala Tyr Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg Ala His Tyr Tyr Gly Asp Ser Thr Tyr Asn Pro Ser Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Pro Val Thr Val Ser Ser , Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Glu Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Leu Ser Gly Asp Gly Phe Phe Thr His Tyr Ala Asp Ser Val Glu Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Phe Gly Gly His Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , JS 1_VH, JS_VH 4,"(66/78)  in order to confirm the gene sequence of the scfv mutant clones obtained in example 2, the dna base sequence was analyzed using sanger sequencing. six scfv antibody variants with antibody sequences were selected through analysis. in this process, only the vh of scfv was additionally selected four vh antibody variants with increased binding affinity to the corona-19 virus-rbd region. in addition, the vh and vl amino acid sequences of six scfv variants (seq id no:66 to 77) (fig. 4) and the amino acid sequences of four vh variants (seq id no:78 to 81) (fig. 5) were identified."
https://patents.google.com/patent/CN111718411A/en,Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Asp Ile Leu Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser,Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Gln Ala Val Val Phe Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile His Val Pro Ala Lys Asn Arg Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala His Tyr Glu Phe Asn Asp Phe Val Trp Gln Gly Tyr Ser Ser Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(5)  a single domain antibody as set forth in seq id no:5 or a functionally active variant thereof.
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Asn Ala Ala Glu Arg Met Ala Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Tyr Tyr Ala Lys Phe Gly Pro Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Glu Ala Phe Val Gln Ser Pro Tyr Ser Gly Ser His Thr Thr Lys Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(3)  a single domain antibody as set forth in seq id no:3 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ala Asp Ala Phe Val Ile Ile Gly Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Ala Trp Thr Asp Gln His Glu Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Gln Asp Ser Ala Tyr Ile Lys Ser Lys Gly Ser Arg Ala Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(1)  a single domain antibody as set forth in seq id no:1 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ala Gln Ser Lys Trp Ala Tyr Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Asp Val Ala Thr Gly Pro Trp Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala His His Ile Pro Thr Lys His Pro Ala Phe Pro Asp Phe Arg Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(2)  a single domain antibody as set forth in seq id no:2 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtgg taacgctgct gaacgtatgg ctgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc atttactacg ctaaattcgg tccgtattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcagaagct ttcgttcagt ctccgtactc tggttctcat actactaaat attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(8) the nucleic acid molecule encoding the single domain antibody 3f11 is shown in seq id no:8.
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtaa catcgactct actcgttacc atgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attaaaggtg tttggccgga agactattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcagaccag tacgaatggt gggttccggg tgaagttggt ccgtacctgt attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(9) the nucleic acid molecule encoding the single domain antibody 4d8 is shown in seq id no:9.
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtcg tcaggctgtt gttttcgggt ggttccgtca ggctccgggc aaaggcctgg aagcagttgc ggccattcat gttccggcta aaaaccgtta ttacgcggat tccgttaagg gccgttttac gatcagccgt gataattcaa agaacacgct ttatctgcag atgaacagcc tgcgcgctga agatactgcg gtctactatt gcgcggcaca ttacgaattc aacgacttcg tttggcaggg ttactcttct gactattggg gccaggggac ccaagtaaca gttagcagt ,, Artificial Sequence (Artificial Sequence),,(10) the nucleic acid molecule encoding the single domain antibody 5f8 is shown in seq id no:10.
https://patents.google.com/patent/CN111303279B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ile Asp Ser Thr Arg Tyr His Gly Trp Phe Arg Gln Ala Pro Gly Lys Gly Leu Glu Ala Val Ala Ala Ile Lys Gly Val Trp Pro Glu Asp Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Gln Tyr Glu Trp Trp Val Pro Gly Glu Val Gly Pro Tyr Leu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(4)  a single domain antibody as set forth in seq id no:4 or a functionally active variant thereof;
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtct ggctcagtct aaatgggctt acgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attgacgttg ctactggtcc gtggtattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcacatcat atcccgacta aacatccggc tttcccggac ttccgtgact attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(7) the nucleic acid molecule encoding the single domain antibody 2f2 is shown in seq id no:7.
https://patents.google.com/patent/CN111303279B/en, caggttcagc tggtggaaag cggtggtgga ttagtgcaac caggtggaag cctccgcctg agctgcgccg cgtcaggtgc tgacgctttc gttatcatcg gtgggtggtt ccgtcaggct ccgggcaaag gcctggaagc agttgcggcc attgcttgga ctgaccagca tgaatattac gcggattccg ttaagggccg ttttacgatc agccgtgata attcaaagaa cacgctttat ctgcagatga acagcctgcg cgctgaagat actgcggtct actattgcgc ggcacaggac tctgcttaca tcaaatctaa aggttctcgt gcttacgaat attggggcca ggggacccaa gtaacagtta gcagt ,, Artificial Sequence (Artificial Sequence),,(6) the nucleic acid molecule encoding the single domain antibody 1e2 is shown in seq id no:6.
https://patents.google.com/patent/WO2021194891A1/en,,,,,(195/251) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:195 and a vl having an amino acid sequence of seq id no:251
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(211/266) [0129] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:211 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:266"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(231/285) [0150] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:231 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:285"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(247/299) [0167] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:247 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:299"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(205/259) [0122] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:205 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:259"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(215/270) [0133] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:215 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:270"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(194/250) [0111] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:194 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:250"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(222/277) [0140] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:222 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:277"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(225/280) [0143] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:225 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(214/269) [0132] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:214 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:269"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(202/256) [0119] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:202 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:256"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(201/248) [0118] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:201 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:248"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(244/296) [0164] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:244 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:296"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(221/276) [0139] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:221 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:276"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(238/290) [0157] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:238 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:290"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(228/280) [0147] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:228 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(218/273) [0136] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:218 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:273"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(229/283) [0148] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:283"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(229/295) [0163] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:295"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(233/280) [0152] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:233 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(227/282) [0146] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:227 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:282"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(197/253) [0114] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:197 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:253"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(195/260) [0123] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:195 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:260"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(193/249) [0109] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:193 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:249"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(246/298) [0166] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:246 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:298"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(206/261) [0124] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:206 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:261"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(230/284) [0149] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:230 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:284"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(210/265) [0128] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:210 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:265"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(245/297) [0165] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:245 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:297"
https://patents.google.com/patent/WO2021194891A1/en,,,,,(224/279) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:224 and a vl having an amino acid sequence of seq id no:279
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(232/286) [0151] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:232 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:286"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(209/264) [0127] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:209 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:264"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(207/262) [0125] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:207 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:262"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(226/281) [0145] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:226 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:281"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(239/291) [0158] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:239 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:291"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(220/275) [0138] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:220 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:275"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(196/252) [0113] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:196 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:252"
https://patents.google.com/patent/WO2021194891A1/en,,,,,(192/248) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:192 and a vl having an amino acid sequence of seq id no:248
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(213/268) [0131] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:213 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:268"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(219/274) [0137] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:219 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:274"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(208/263) [0126] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:208 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:263"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(237/289) [0156] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:237 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:289"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(235/288) [0154] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:235 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:288"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(199/255) [0116] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:199 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:255"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(241/280) [0160] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:241 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(203/257) [0120] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:203 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:257"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(204/258) [0121] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:204 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:258"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(240/292) [0159] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:292"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(236/271) [0155] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:271"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(217/272) [0135] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:217 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:272"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(212/267) [0130] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:212 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:267"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(198/254) [0115] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:198 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:254"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(242/293) [0161] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:242 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:293"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(234/287) [0153] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:234 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:287"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(223/278) [0141] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:223 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:278"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(216/271) [0134] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:216 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:271"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(200/253) [0117] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:200 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:253"
https://patents.google.com/patent/WO2021194891A1/en,,,,,"(243/294) [0162] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:243 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:294"
https://patents.google.com/patent/CN111995674B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Thr Pro Tyr Tyr Gly Asn Tyr Ala Asp Trp Phe Thr Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Artificial sequence,  Artificial sequence,"(7/8) the heavy chain amino acid sequence of the human-mouse chimeric whole antibody mhc3 is shown as seq id no:7, and the light chain amino acid sequence is shown as seq id no:8."
https://patents.google.com/patent/CN111995674B/en, gaggtgcagc ttgttgagtc tgggggagac ttagtgaagc ctggagggtc cctgaaactc tcctgtgcag cctctggatt caccttcaat acctacgcca tgaactgggt ccgccagact ccaggaaagg gtttggaatg ggttgctcgc ataagaagta aaagtaataa ttatgcaaca tattatgccg attcagtgaa agacaggttc accatctcca gagatgattc gcaaagcatg ctctatctgc aaatgaacaa cttgaaaact gaggacacag ccatgtatta ctgtgtgaca ccctactatg gtaattacgc agactggttt acttactggg gccaaggaac ctcagtcacc gtgtcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga , gatgttgtga tgacccagac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc atctcttgca gatctagtca gagccttgta cacagtaatg gaaacaccta tttacattgg tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc agcagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac acatgttccg tacacgttcg gaggggggac caagttggaa ataaaacgta cggtggcggc gccatctgtc ttcatcttcc cgccatctga tgagcagttg aaatctggta ccgctagcgt tgtgtgcctg ctgaataact tctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac ctacagcctc agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa gtcacccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg agagtgttag ,  Artificial sequence,  Artificial sequence,"(11/12) in one embodiment of the invention, the recombinant expression vector for expressing the heavy chain of the antibody is obtained by cloning seq id no:11 (encoding gene of the heavy chain of the antibody) between enzyme cutting sites hind iii and bamh i of pcdna3.1(+) vector; cloning seq id no:12 (coding gene of antibody light chain) between enzyme cutting site hind iii and bamh i of pcdna3.1(+) vector to obtain recombinant expression vector for expressing the light chain of the antibody"
https://patents.google.com/patent/CN112010962A/en,,,,,"(19/5) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: comprises the amino acid sequence shown in seq id no:5 in the light chain variable region; and a polypeptide comprising seq id no:19 in a heavy chain variable region of the amino acid sequence of seq id no."
https://patents.google.com/patent/CN112010962A/en,,,,,"(1/18) in particular, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of seq id no:1-17 (see table 1) and a light chain variable region comprising an amino acid sequence selected from seq id no:18-26 (see table 2)"
https://patents.google.com/patent/CN112010962A/en,,,,,"(18/1) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: a light chain variable region comprising a sequence selected from seq id no:1-4; and a heavy chain variable region comprising seq id no:18."
https://patents.google.com/patent/CN112010962A/en,,,,,"(78/80)  and seq id no:78, and a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the heavy chain set forth in seq id no:80, or a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto."
https://patents.google.com/patent/RU2744274C1/en,,,,,"(1/2)  binding rbd fragment in the s protein of the human sars-cov-2 virus, comprising the variable region of the heavy chain (vh) of the specified antibody containing the amino acid sequence, seq id no:1; and the variable region of the light chain (vl) of the specified antibody contains the amino acid sequence, seq id no:2"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(54/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:54 and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(56/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:56, and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(107/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:107, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(47/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:47, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(55/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:55, and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(53/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:53, and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(46/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:46, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(49/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:49, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(48/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:48, and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50"
https://patents.google.com/patent/WO2021197340A1/en,,,,,"(108/57) in some embodiments, the heavy chain of the antibody comprises the amino acid sequence shown in seq id no:108, and the light chain of the antibody comprises the amino acid sequence shown in seq id no:57."
https://patents.google.com/patent/WO2021180218A1/en,,,,,"(7/8)  preferably, it includes: vh shown in seq id no:7 and/or vl shown in seq id no:8."
https://patents.google.com/patent/CN112898416A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Val Ile Cys Ser Ser Thr Ser Cys Tyr Thr Lys Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ile Ser Asn Ile Gly Ser Ala His Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Ser Glu Arg Pro Ser Gly Ile Pro Ala Arg Phe Ser Ala Phe Lys Tyr Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Ile Ser Leu Ser Ala Gly Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8)  that specifically bind to a novel coronavirus np protein, wherein the binding protein or antibody of the novel coronavirus np protein comprises or consists of the vl sequence of seq id no:8 and the vh sequence of seq id no:4."
https://patents.google.com/patent/CN112898416A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/US20210355194A1/en,,,,,"(493/520) , wherein the vh comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of seq id no:493-519 and 721-749, and wherein the vl comprises an amino acid sequence at least about 90% identical to a sequence as set forth in any one of seq id no:520-546 and 750-778."
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Tyr Ser Ala Gly Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(54/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:54 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Ser Tyr Asp Gly Tyr Val Thr Leu Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(56/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:56 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/CN113637083A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Ile Asp Asp Ala Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(107/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:107 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50."
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Tyr Ser Ala Gly Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(47/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:47 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50."
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Asp Pro Ser Ala Ser Tyr Tyr Leu Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(53/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:53 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Leu Gly Pro Thr Tyr Gly Gly Tyr Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(55/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:55 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Asp Pro Ser Ala Ser Tyr Tyr Leu Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(46/50) in some embodiments, the fusion proteins disclosed herein include a polypeptide and an antibody or antigen-binding fragment comprising a vh set forth as seq id no:46, 47, 48, 49, or 107, a vl set forth as seq id no:50, or a biological equivalent of each"
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Thr Ser Tyr Asp Gly Tyr Val Thr Leu Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(49/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:49 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence shown in seq id no:50."
https://patents.google.com/patent/CN113637083A/en, Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Leu Gly Pro Thr Tyr Gly Gly Tyr Ala Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(48/50) in some embodiments, the heavy chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:48 and the light chain variable region of the antibody or antigen-binding fragment comprises the sequence set forth in seq id no:50."
https://patents.google.com/patent/CN113637083A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Pro Phe Gly Ile Asp Asp Ala Tyr Leu Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(108/57) in some embodiments, the fusion protein comprises an antibody having a heavy chain comprising a sequence having an amino acid sequence set forth in seq id no:108 and a light chain comprising a sequence having an amino acid sequence set forth in seq id no:57"
https://patents.google.com/patent/US20220041694A1/en,,,,,(22/23)  the second antibody or antigen-binding fragment thereof comprises a heavy chain comprising amino acids 1-460 of seq id no:22 and a light chain comprising the amino acid sequence of seq id no:23.
https://patents.google.com/patent/US20220041694A1/en,,,,,(24/25)  the first antibody or antigen-binding fragment thereof comprises a heavy chain comprising amino acids 1-460 of seq id no:24 and a light chain comprising the amino acid sequence of seq id no:25 and (
https://patents.google.com/patent/US20220041694A1/en,,,,,"(7/8)  52. the method of claim 49, wherein the first antibody comprises a variable heavy chain (vh) comprising the amino acid sequence of seq id no:7 and a variable light chain (vl) comprising the amino acid sequence of seq id no:8"
https://patents.google.com/patent/US20220041694A1/en,,,,,(15/16)  and the second antibody or antigen-binding fragment thereof comprises a vh comprising the amino acid sequence of seq id no:15 and/or a vl comprising the amino acid sequence of seq id no:16.
https://patents.google.com/patent/CN112390879B/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Arg Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Val Arg Ser Ala Tyr Tyr Tyr Gly Ser Gly Ser Tyr Arg Asp Glu Gly Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Thr Arg Ser Asn Ile Gly Ala Gly His Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ala Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Arg Thr Leu Thr Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , VH amino acids, VL amino acids,"(7/8) the antibody or antigen-binding fragment thereof targeting sars-cov-2 according to claim 1, wherein the amino acid sequence of vh is as shown in seq id no:7; the amino acid sequence of the vl is shown as seq id no:8."
https://patents.google.com/patent/CN112390879B/en, gaggtgcagc tggtggaaag cggacccggc ctggtcaagc cttctgaaac cctgagcctg acctgcaccg tgtccggcgg ctccatctct agcagcagct actactgggg ctggatcaga cagccacctg gaaaaggcct ggaatggatt ggcagcatct actaccgggg cagcacctac tacaacccca gcctgaaaag cagagtgaca atcagcgtgg acacctcaaa gaaccagttt agccttaagc tgagctctgt gaccgccgcc gacaccgccg tgtactactg cgccagacac gtgcggagtg cttattacta cggcagcggc tcttatcggg acgagggcaa ttggttcgac ccctggggcc agggcaccct ggtcaccgtg tccagc , cagagcgtgc tgacccagcc tccaagcgtg tctggagctc ctggacaaag agtgaccatc agctgtacag gcacaagaag caacatcggc gctggccacg atgtgcactg gtaccagcaa ctgcctggca ccgcccctaa gctgctgatc tacggcaaca acaatagacc ttctggcgtg cccgatagat tctccggagc caagtccggc acaagcgcca gcctggccat caccggcctg caggccgagg acgaggccga ttactattgt cagtcttacg acagaaccct gacaagctac gtgttcggca caggaacaaa ggtgaccgtg ctg , VH nucleotides, VL nucleotides,"(9/10)  the amino acid sequences of the preferred heavy and light chain variable regions are shown as seq id no:7 and 8, respectively, the nucleotide sequences of the preferred heavy and light chain variable regions are shown as seq id no:9 and 10, respectively, and the detailed description is shown in table 1 below."
https://patents.google.com/patent/CN111333722A/en,Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val Ala Leu Ile Ser Ser Asp Gly Ser Val Thr Tyr Phe Thr Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Trp Asp Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser,Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Met Ser Leu Ala Pro Gly Gln Thr Ala Thr Ile Thr Cys Ala Gly Thr Asn Ile Gly Arg Lys Tyr Val His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Val Leu Val Met Ser Asp Asn Asp Asp Arg Pro Ser Gly Ile Pro GluArg Phe Ser Ala Ser Asn Ser Gly His Thr Ala Thr Leu Ile Ile Asn Arg Val Glu Val Asp Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Thr Thr Tyr Ser Arg Pro Val Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(32/33)  the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:32, and the amino acid sequence of the light chain variable region is seq id no:33."
https://patents.google.com/patent/CN111333722A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ala Met His Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Arg Ser Lys Pro Asn Ser Tyr Ala Thr Ala Tyr Ala Ala Ser Val Thr Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ser Val Cys Ser Gly Gly Ser Cys Tyr Gln Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Pro Thr Ser Pro Lys Val Thr Ser Gly Gln Ala Gly Gln ,Glu Leu Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Arg Asn Val Leu Tyr Ser Pro Asn Asn Lys Asn Tyr Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ser Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys His Gln Tyr Phe Ser Thr Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(28/29)  or the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:28, and the amino acid sequence of the light chain variable region of the neutralizing antibody is seq id no:29"
https://patents.google.com/patent/CN111333722A/en,Glu Val Gln Leu ValGlu Ser Gly Gly Gly Leu Val Met Pro Gly Arg Ser Leu Arg Leu Ser Cys Arg His Ser Gly Phe Thr Phe Ala Asp Tyr Thr Met Asn Trp Phe Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Ile Gly Phe Ile Arg Ser Lys Thr Tyr Gly Gly Thr Ala Glu Tyr Ala Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile Ala Tyr Leu Glu Met Asn Ser Leu Asn Thr Glu Asp Thr Gly Val Tyr Arg Cys Thr Arg Ile Ser Gly Tyr Tyr Gly Ala Gly Ser Gly Gly Ala Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser ,Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Tyr Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Leu Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(30/31)  the amino acid sequence of the heavy chain variable region of the neutralizing antibody is seq id no:30, and the amino acid sequence of the light chain variable region is seq id no:31"
https://patents.google.com/patent/CN111333722A/en,Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Leu Asn Phe Gly Thr Ser Val Met His Trp Val Arg Gln Val Gln Gly Thr Gly Leu Leu Trp Val Ser Arg Ile Asp Ser Gly Gly Thr Ser Ile Thr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Gly Val Tyr Tyr Cys Ser Thr Asp Ser Gly Ser Ile Gly Glu Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Pro Thr Ser Pro Lys Val Thr Ser Gly Gln Ala Gly Gln,Glu Leu Gln Met Thr Gln Ser Pro Ser Pro Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Gly Gln Asn Ile Arg Gly Tyr Val Asn Trp Tyr Gln His Lys Ala Gly Glu Ala Pro Lys Leu Leu Ile Tyr His Ala Ser Asn Leu Gln Ser Gly Leu Pro Leu Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Leu Gln Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Ser His Asp Thr Leu Thr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(26/27) preferably, the amino acid sequence of the heavy chain variable region of the neutralizing antibody or antigen binding fragment thereof is seq id no:26, and the amino acid sequence of the light chain variable region is seq id no:27"
https://patents.google.com/patent/CN113563475A/en, gacatcgtga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca aggttcagcg gcagtggatc tgggacagag ttcactctca caatcagcag cctgcagcct gaagattttg caacttatta ctgtcaacag cttaatagtt accctccgta cacttttggc caggggacca agctggagat caaacgaact gtggctgcac caagcgtgtt tatcttccct cccagcgacg agcagctgaa gagcggcacc gccagcgtgg tctgtctcct gaacaacttc tatcccaggg aggccaaggt ccagtggaaa gtggacaacg ccctgcaaag cggcaatagc caggagtccg tcacagagca ggacagcaag gacagcacct acagcctgtc cagcaccctg accctcagca aggccgacta cgagaagcac aaggtgtacg cttgcgaggt gacccatcag ggcctgtcca gccccgtgac caagtccttc aacaggggcg aatgcagc , gaggtccagc tcgttgagtc cggtggggga ttggtgcaac ctggaggatc acttagactt tcatgcgcag catcaggatt tatcgtgtca tcaaactaca tgtcatgggt acggcaggcg ccagggaaag gcctagagtg ggtttcggtg atctactcag gaggatcaac atactacgca gattcagtga aaggaagatt tacaatctca agacacaact caaagaatac tctttacctt caaatgaact cacttagagc agaagacact gcggtgtact actgcgcacg ggaggcgtac ggaatggatg tgtgggggca gggaacaaca gtcacggtct ctagcgccag caccaaaggc ccgtctgtct ttccactcgc accttcatca aagagcacgt cgggagggac ggctgcgctt ggatgtttag ttaaggacta tttcccagag ccggtcacag ttagctggaa ctcaggagca cttacctcgg gcgttcacac ctttcctgca gtgcttcaat catcaggact ttactcactt tcatcagtgg tgacagtgcc ttcatcatca cttggaacac aaacatacat ctgcaacgtg aaccacaaac cttcaaacac aaaggtagac aagcgagtag aacctaaatc atgcgataag acccatacat gccctccttg ccctgcacct gaacttcttg gaggtccatc ggtattctta tttccgccaa agccgaagga tacacttatg atctcaagaa cacctgaagt gacatgcgtg gtggtggatg tgtcacacga agatcctgaa gtgaaattta actggtacgt ggatggagtg gaagtgcaca acgcaaagac gaagcctaga gaagaacaat acaactcaac atacagagtg gtgtcagtgc ttacagtgct tcaccaagat tggcttaacg gaaaggagta taaatgcaaa gtgtcaaaca aagcacttcc tgcacctatc gagaagacga tatcaaaagc aaaaggacaa cctagagaac ctcaagtgta cacacttcct ccttcaagag atgaacttac aaagaatcag gtgtcactta catgtttagt caagggcttc tacccttcag atatcgcagt ggaatgggaa tcaaacggac aacctgagaa taattataag actacaccac cggtgttgga cagtgacggg agcttcttcc tgtattcaaa gctcactgtg gataaatcaa gatggcaaca aggaaacgtg ttctcgtgtt cagtgatgca cgaagcactt cacaaccact acacacagaa gtcgctgtca ctttcacctg gtggtggaag tcaagttcag ttggtacaga gcggagcaga agtgaagaag cccggtgcga gtgtgaaagt gtcatgcaaa gcatcaggat acacatttac aggatactac atgcactggg tacgacaggc tccgggtcaa ggtttagagt ggatgggcag aatcaaccct aactctggag gcaccaacta cgcacagaag ttccagggaa gagtgacaat gacaagagat acatcaatct caacagcata catggaactt tcaagactta gatcagatga cactgcggtc tattattgtg cacgggtacc ttactgctca tcaacatcat gccacagaga ttggtacttt gatctttggg gaagaggaac acttgtcact gtgtcgtcag gaggcggagg atcagggggt gggggcagcg gcggtggcgg ttctggtgga ggtggcagcg acatccaaat gacacaatca cctctttcac ttcctgtgac acctggagaa cctgcatcaa tctcatgcag atcatcacaa tcacttctgg actcggacga cggcaacaca taccttgatt ggtaccttca gaagccgggt caatcacctc aacttcttat ctacacactt tcatacagag cgtccggagt cccggacaga ttcagcggtt caggatcagg aacagatttc acgttgaaga tttctagagt ggaagcagaa gatgtgggag tgtactactg catgcaaaga atcgaatttc ctcttacatt tggaggtggc acgaaagtgg agatcaaatg a , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/5) the light and heavy chain dna sequences (shown in seq id no:7 and seq id no:5, respectively) were cloned into expression vectors pcaggs (available from addgene), respectively, to yield recombinant expression vectors encoding the antibody heavy and light chains, respectively"
https://patents.google.com/patent/CN113563475A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/4) preferably, the bispecific antibody bs-mab-1 has the amino acid sequence of the light chain as shown in seq id no:4 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids, and has the amino acid sequence of the heavy chain as shown in seq id no:2 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids."
https://patents.google.com/patent/CN113563475A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(34/35)  the amino acid sequence of the heavy chain variable region of the monoclonal antibody h4 is shown as seq id no:34, and the amino acid sequence of the light chain variable region of the monoclonal antibody h4 is shown as seq id no:35."
https://patents.google.com/patent/CN113563475A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Pro Tyr Cys Ser Ser Thr Ser Cys His Arg Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu Asp Ser Asp Asp Gly Asn Thr Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Thr Leu Ser Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Arg Ile Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys, Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(6/8)  further preferably, the bispecific antibody bs-mab-2 has the amino acid sequence of the light chain as shown in seq id no:8 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids, and has the amino acid sequence of the heavy chain as shown in seq id no:6 or the amino acid sequence of a protein with the same function obtained by substitution, deletion or insertion of one or more amino acids."
https://patents.google.com/patent/CN113563475A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(32/33) preferably, the amino acid sequence of the heavy chain variable region of monoclonal antibody b38 is shown in seq id no:32, and the amino acid sequence of the light chain variable region of monoclonal antibody b38 is shown in seq id no:33"
https://patents.google.com/patent/CN113563475A/en, gatatccaaa tgacccagag cccattgagc cttcctgtga cacctggaga acctgcatca atctcatgca gatcatcaca atcacttctt gattcagatg atggaaacac ataccttgat tggtaccttc agaagcccgg tcagtctcct cagctactaa tttatactct atcatacaga gcatcgggcg taccggaccg cttctccgga tcagggtcag ggactgattt caccctaaag atatccagag tggaagcaga agatgtggga gtgtactact gcatgcaaag aatcgaattt cctcttacat ttggaggagg aacaaaggta gagatcaaag gtggaggagg atccggagga ggtggatccg atatcgtgat gacgcagagc cctagctttc tttctgctag tgtaggcgac agagtgacaa tcacatgcag agcatcacaa ggaatctcat cataccttgc atggtaccaa cagaagccgg gaaaggcgcc caagctgctc atatatgctg cctcaactct gcagagtggc gtgccgtctc gcttcagcgg tagcggatcg ggaacagagt ttacacttac aatctcatca cttcaacctg aagatttcgc cacgtactac tgccaacaac ttaactcata ccctccttac acatttggac aaggaacaaa gttagagatc aagcgaaccg tggcagcacc ttcagtgttt atctttcctc cttcagatga acaacttaaa tcaggaactg cgtctgtagt ttgtcttctt aacaacttct atccaagaga agcaaaggta cagtggaaag tggataacgc cctgcagtct ggtaatagcc aagaatcagt gacagaacaa gattcaaagg acagtacata ctcactttca tcaacactta cactttcaaa ggcggactac gagaagcata aggtgtacgc atgcgaagtg acacaccaag gactttcatc acctgtgaca aagtccttca acagaggaga atgctga , caggttcagt tagttcagag tggagcagaa gtgaagaagc ccggtgcctc tgtgaaagtg tcatgcaaag catcaggata cacatttaca ggatactaca tgcactgggt taggcaggcg cccggtcaag gcctggagtg gatgggcaga atcaacccta actctggcgg gacgaattat gcacagaagt tccagggaag agtgacaatg acaagagata catcaatctc aacagcatac atggaacttt caagacttag atcagatgac actgctgtct actactgcgc acgagtcccg tactgctcat caacatcatg ccacagagat tggtactttg atctttgggg gagaggtaca cttgtgacag tctcatcggg tggaggcgga tcagggggtg gtggctccga agtccagctc gtcgagagtg gtggaggact ggttcaacct ggaggatcac ttagactttc atgcgcagca tcaggattta tcgtgtcatc aaactacatg tcatgggtac gccaggctcc cgggaagggt ctggagtggg tctcggtgat ctactcagga ggatcaacat actacgcaga ttcagtgaaa ggaagattta caatctcaag acacaactca aagaatactc tttaccttca aatgaactca cttagagcag aagacactgc ggtttactac tgcgcaagag aagcgtacgg aatggatgtg tggggccagg gtacaacagt tactgtttcg tctgcgtcca ctaaaggccc ttccgtcttc ccgctggcac cttcatcaaa gtctacttct ggtggaacgg cggctcttgg atgtctggtt aaggactatt tcccggagcc tgtaactgta tcgtggaact caggagcact tacatcagga gtgcacacat ttcctgcagt gcttcaatca tcaggacttt actcactttc atcagtggtg acagtgcctt catcatcact tggaacacaa acatacatct gcaacgtgaa ccacaaacct tcaaacacaa aggttgacaa gaaggtcgag cctaaatcat gcgataagac tcatacatgc cctccttgcc ctgcacctga acttcttgga ggcccgtcgg tgtttttatt cccgccaaaa ccgaaggata cacttatgat ctcaagaaca cctgaagtga catgcgtggt ggtggatgtg tcacacgaag atcctgaagt gaaatttaac tggtacgtgg atggagtgga agtgcacaac gcaaagacta agcctagaga agaacaatac aactcaacat acagagtggt gtcagtgctt acagtgcttc accaagattg gcttaacgga aaggagtata aatgcaaagt gtcaaacaaa gcacttcctg cacctatcga gaagactata tcaaaagcaa aaggacaacc tagagaacct caagtgtaca cacttcctcc ttcaagagat gaacttacaa agaatcaggt gtcacttaca tgtttagtaa agggcttcta cccatctgac atcgcagtgg aatgggaatc aaacggacaa cctgagaata attataagac cactcctcct gtacttgatt cagatggatc attcttcctc tattcaaagt taaccgtgga taaatcaaga tggcaacaag gaaacgtgtt ctcctgttca gtgatgcacg aagcacttca caaccactac acacagaaga gtctatcact ttcacctgga tga , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(3/1) the light and heavy chain dna sequences (shown in seq id no:3 and seq id no:1, respectively) were cloned into expression vectors pcaggs (available from addgene), respectively, to yield recombinant expression vectors encoding the antibody heavy and light chains, respectively"
https://patents.google.com/patent/CN113563475A/en, gaggtccagc tcgttgagtc cggtggggga ttggtgcaac ctggaggatc acttagactt tcatgcgcag catcaggatt tatcgtgtca tcaaactaca tgtcatgggt acggcaggcg ccagggaaag gcctagagtg ggtttcggtg atctactcag gaggatcaac atactacgca gattcagtga aaggaagatt tacaatctca agacacaact caaagaatac tctttacctt caaatgaact cacttagagc agaagacact gcggtgtact actgcgcacg ggaggcgtac ggaatggatg tgtgggggca gggaacaaca gtcacggtct ctagcgccag caccaaaggc ccgtctgtct ttccactcgc accttcatca aagagcacgt cgggagggac ggctgcgctt ggatgtttag ttaaggacta tttcccagag ccggtcacag ttagctggaa ctcaggagca cttacctcgg gcgttcacac ctttcctgca gtgcttcaat catcaggact ttactcactt tcatcagtgg tgacagtgcc ttcatcatca cttggaacac aaacatacat ctgcaacgtg aaccacaaac cttcaaacac aaaggtagac aagcgagtag aacctaaatc atgcgataag acccatacat gccctccttg ccctgcacct gaacttcttg gaggtccatc ggtattctta tttccgccaa agccgaagga tacacttatg atctcaagaa cacctgaagt gacatgcgtg gtggtggatg tgtcacacga agatcctgaa gtgaaattta actggtacgt ggatggagtg gaagtgcaca acgcaaagac gaagcctaga gaagaacaat acaactcaac atacagagtg gtgtcagtgc ttacagtgct tcaccaagat tggcttaacg gaaaggagta taaatgcaaa gtgtcaaaca aagcacttcc tgcacctatc gagaagacga tatcaaaagc aaaaggacaa cctagagaac ctcaagtgta cacacttcct ccttcaagag atgaacttac aaagaatcag gtgtcactta catgtttagt caagggcttc tacccttcag atatcgcagt ggaatgggaa tcaaacggac aacctgagaa taattataag actacaccac cggtgttgga cagtgacggg agcttcttcc tgtattcaaa gctcactgtg gataaatcaa gatggcaaca aggaaacgtg ttctcgtgtt cagtgatgca cgaagcactt cacaaccact acacacagaa gtcgctgtca ctttcacctg gtggtggaag tcaagttcag ttggtacaga gcggagcaga agtgaagaag cccggtgcga gtgtgaaagt gtcatgcaaa gcatcaggat acacatttac aggatactac atgcactggg tacgacaggc tccgggtcaa ggtttagagt ggatgggcag aatcaaccct aactctggag gcaccaacta cgcacagaag ttccagggaa gagtgacaat gacaagagat acatcaatct caacagcata catggaactt tcaagactta gatcagatga cactgcggtc tattattgtg cacgggtacc ttactgctca tcaacatcat gccacagaga ttggtacttt gatctttggg gaagaggaac acttgtcact gtgtcgtcag gaggcggagg atcagggggt gggggcagcg gcggtggcgg ttctggtgga ggtggcagcg acatccaaat gacacaatca cctctttcac ttcctgtgac acctggagaa cctgcatcaa tctcatgcag atcatcacaa tcacttctgg actcggacga cggcaacaca taccttgatt ggtaccttca gaagccgggt caatcacctc aacttcttat ctacacactt tcatacagag cgtccggagt cccggacaga ttcagcggtt caggatcagg aacagatttc acgttgaaga tttctagagt ggaagcagaa gatgtgggag tgtactactg catgcaaaga atcgaatttc ctcttacatt tggaggtggc acgaaagtgg agatcaaatg a , gacatcgtga tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca aggttcagcg gcagtggatc tgggacagag ttcactctca caatcagcag cctgcagcct gaagattttg caacttatta ctgtcaacag cttaatagtt accctccgta cacttttggc caggggacca agctggagat caaacgaact gtggctgcac caagcgtgtt tatcttccct cccagcgacg agcagctgaa gagcggcacc gccagcgtgg tctgtctcct gaacaacttc tatcccaggg aggccaaggt ccagtggaaa gtggacaacg ccctgcaaag cggcaatagc caggagtccg tcacagagca ggacagcaag gacagcacct acagcctgtc cagcaccctg accctcagca aggccgacta cgagaagcac aaggtgtacg cttgcgaggt gacccatcag ggcctgtcca gccccgtgac caagtccttc aacaggggcg aatgcagc , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(5/7) the light and heavy chain dna sequences (shown in seq id no:7 and seq id no:5, respectivel"
https://patents.google.com/patent/CN113563475A/en, caggttcagt tagttcagag tggagcagaa gtgaagaagc ccggtgcctc tgtgaaagtg tcatgcaaag catcaggata cacatttaca ggatactaca tgcactgggt taggcaggcg cccggtcaag gcctggagtg gatgggcaga atcaacccta actctggcgg gacgaattat gcacagaagt tccagggaag agtgacaatg acaagagata catcaatctc aacagcatac atggaacttt caagacttag atcagatgac actgctgtct actactgcgc acgagtcccg tactgctcat caacatcatg ccacagagat tggtactttg atctttgggg gagaggtaca cttgtgacag tctcatcggg tggaggcgga tcagggggtg gtggctccga agtccagctc gtcgagagtg gtggaggact ggttcaacct ggaggatcac ttagactttc atgcgcagca tcaggattta tcgtgtcatc aaactacatg tcatgggtac gccaggctcc cgggaagggt ctggagtggg tctcggtgat ctactcagga ggatcaacat actacgcaga ttcagtgaaa ggaagattta caatctcaag acacaactca aagaatactc tttaccttca aatgaactca cttagagcag aagacactgc ggtttactac tgcgcaagag aagcgtacgg aatggatgtg tggggccagg gtacaacagt tactgtttcg tctgcgtcca ctaaaggccc ttccgtcttc ccgctggcac cttcatcaaa gtctacttct ggtggaacgg cggctcttgg atgtctggtt aaggactatt tcccggagcc tgtaactgta tcgtggaact caggagcact tacatcagga gtgcacacat ttcctgcagt gcttcaatca tcaggacttt actcactttc atcagtggtg acagtgcctt catcatcact tggaacacaa acatacatct gcaacgtgaa ccacaaacct tcaaacacaa aggttgacaa gaaggtcgag cctaaatcat gcgataagac tcatacatgc cctccttgcc ctgcacctga acttcttgga ggcccgtcgg tgtttttatt cccgccaaaa ccgaaggata cacttatgat ctcaagaaca cctgaagtga catgcgtggt ggtggatgtg tcacacgaag atcctgaagt gaaatttaac tggtacgtgg atggagtgga agtgcacaac gcaaagacta agcctagaga agaacaatac aactcaacat acagagtggt gtcagtgctt acagtgcttc accaagattg gcttaacgga aaggagtata aatgcaaagt gtcaaacaaa gcacttcctg cacctatcga gaagactata tcaaaagcaa aaggacaacc tagagaacct caagtgtaca cacttcctcc ttcaagagat gaacttacaa agaatcaggt gtcacttaca tgtttagtaa agggcttcta cccatctgac atcgcagtgg aatgggaatc aaacggacaa cctgagaata attataagac cactcctcct gtacttgatt cagatggatc attcttcctc tattcaaagt taaccgtgga taaatcaaga tggcaacaag gaaacgtgtt ctcctgttca gtgatgcacg aagcacttca caaccactac acacagaaga gtctatcact ttcacctgga tga , gatatccaaa tgacccagag cccattgagc cttcctgtga cacctggaga acctgcatca atctcatgca gatcatcaca atcacttctt gattcagatg atggaaacac ataccttgat tggtaccttc agaagcccgg tcagtctcct cagctactaa tttatactct atcatacaga gcatcgggcg taccggaccg cttctccgga tcagggtcag ggactgattt caccctaaag atatccagag tggaagcaga agatgtggga gtgtactact gcatgcaaag aatcgaattt cctcttacat ttggaggagg aacaaaggta gagatcaaag gtggaggagg atccggagga ggtggatccg atatcgtgat gacgcagagc cctagctttc tttctgctag tgtaggcgac agagtgacaa tcacatgcag agcatcacaa ggaatctcat cataccttgc atggtaccaa cagaagccgg gaaaggcgcc caagctgctc atatatgctg cctcaactct gcagagtggc gtgccgtctc gcttcagcgg tagcggatcg ggaacagagt ttacacttac aatctcatca cttcaacctg aagatttcgc cacgtactac tgccaacaac ttaactcata ccctccttac acatttggac aaggaacaaa gttagagatc aagcgaaccg tggcagcacc ttcagtgttt atctttcctc cttcagatga acaacttaaa tcaggaactg cgtctgtagt ttgtcttctt aacaacttct atccaagaga agcaaaggta cagtggaaag tggataacgc cctgcagtct ggtaatagcc aagaatcagt gacagaacaa gattcaaagg acagtacata ctcactttca tcaacactta cactttcaaa ggcggactac gagaagcata aggtgtacgc atgcgaagtg acacaccaag gactttcatc acctgtgaca aagtccttca acagaggaga atgctga , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(1/3) the light and heavy chain dna sequences (shown in seq id no:3 and seq id no:1, respectivel"
https://patents.google.com/patent/US20210300999A1/en,,,,,(29/30) a heavy chain variable sequence comprising the amino acid sequence of seq id no:29 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:30
https://patents.google.com/patent/US20210300999A1/en,,,,,(37/38)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:37 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:38.
https://patents.google.com/patent/US20210300999A1/en,,,,,(23/24)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:23 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:24
https://patents.google.com/patent/US20210300999A1/en,,,,,(33/34)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:33 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:34;
https://patents.google.com/patent/US20210300999A1/en,,,,,(25/26)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:25 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:26
https://patents.google.com/patent/US20210300999A1/en,,,,,(39/40)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:39 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:40
https://patents.google.com/patent/US20210300999A1/en,,,,,(31/32)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:31 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:32
https://patents.google.com/patent/US20210300999A1/en,,,,,(35/36)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:35 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:36
https://patents.google.com/patent/US20210300999A1/en,,,,,(27/28)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:27 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:28
https://patents.google.com/patent/US20210300999A1/en,,,,,(21/22)  a heavy chain variable sequence comprising the amino acid sequence of seq id no:21 and/or a light chain variable sequence comprising the amino acid sequence of seq id no:22
https://patents.google.com/patent/CN114002427A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Tyr Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Asp Lys Ser Met Gly Phe Gly Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Asn Tyr Leu His Trp Tyr Gln Gln Arg Pro Gly Phe Ser Pro Lys Leu Leu Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly His Ser Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , VH, VL,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18."
https://patents.google.com/patent/CN114002427A/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Pro Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asn Ile Glu Asp Tyr Ala Tyr Tyr Ala Pro Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Val Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Gly Gly Tyr Ala Ala Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser, Asp Val Val Met Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Glu Ser Val Tyr Thr Asn Asn Arg Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr Arg Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Ile Ile Ser Asp Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Val Gly Ser Gly Gly Thr Asp Ile Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , VH, VL,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8."
https://patents.google.com/patent/CN113527471A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Phe Gly Ser Ser Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Glu Ser Pro Leu Gly Gly Gly Ser Gly Tyr Ser Val Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Ser Asn Trp Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Homo sapiens, Homo sapiens,(6/5) vh is seq id no:6 and vl is seq id no:5
https://patents.google.com/patent/CN113527471A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys Cys Ala Lys Gly Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Phe Arg Glu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ala Met Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Val Pro Lys Arg Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens, Homo sapiens,(8/7) vh is seq id no:8 and vl is seq id no:7.
https://patents.google.com/patent/CN113527471A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Gly Asp Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Leu Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , Homo sapiens, Homo sapiens,"(2/1) vh is seq id no:2, vl is seq id no:1"
https://patents.google.com/patent/CN113527471A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Val Ala Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Val Asn Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Homo sapiens, Homo sapiens,(4/3) vh is seq id no:4 and vl is seq id no:3
https://patents.google.com/patent/KR20220010402A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising "
https://patents.google.com/patent/CN112239501B/en, Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Val Thr Phe Ser Thr Phe Ala Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val Ala Tyr Leu Asn Ser Ala Ser Asn Leu Ile Tyr Tyr Ala Asp Thr Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Thr Arg His Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys , Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Ile Asp Tyr Asp Gly Asp Ser Phe Met Asn Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Val Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Asn Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg Asn Glu Cys , Artificial sequence, Artificial sequence,"(14/13) mu.g of an external control antibody was used as a control, and the electrophoretogram showed two bands, 1 of which mr was 50kd (heavy chain, seq id no:14) and the other mr was 28kd (light chain, seq id no:13), as shown in fig"
https://patents.google.com/patent/CN112239501B/en,,,,,"(5/1) in alternative embodiments, the antibody comprises the light chain framework regions fr1-l, fr2-l, fr3-l and fr4-l in sequence as set forth in seq id no:1-4, and/or the heavy chain framework regions fr1-h, fr2-h, fr3-h and fr4-h in sequence as set forth in seq id no:5-8."
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(62/44) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:44, and vl is seq id no:62"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(40/58) , wherein: 15 vh is seq id no:40, and vl is seq id no:58. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(53/71) , wherein: vh is seq id no:53, and vl is seq id no:71. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(66/48) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: 15 vh is seq id no:48, and vl is seq id no:66"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(70/52) 10 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:52, and vl is seq id no:70"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(60/42) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:42, and vl is seq id no:60"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(44/62) , wherein: vh is seq id no:44, and vl is seq id no:62.  in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(38/56) , wherein: vh is seq id no:38, and vl is seq id no:56. in some embodiments, the antibody or antigen binding fragment thereof comprises a light 10 chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(55/37) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:37, and vl is seq id no:55"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(69/51) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:51, and vl is seq id no:69"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(61/43) 25 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:43, and vl is seq id no:61"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(64/46) 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:46, and vl is seq id no:64"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(56/38) 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:38, and vl is seq id no:56"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(67/49) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:49, and  vl is seq id no:67"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(68/50) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:50, and vl is seq id no:68"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(59/41) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein:  vh is seq id no:41, and vl is seq id no:59"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(39/57) , wherein: vh is seq id no:39, and vl is seq id no:57. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(48/66) , wherein: vh is seq id no:48, and 30 vl is seq id no:66. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(52/70) , wherein: vh is seq id no:52, and vl is seq id no:70.  in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(41/59) , wherein:  vh is seq id no:41, and vl is seq id no:59. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(47/65) , wherein: vh is seq id no:47, and vl is seq id no:65. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(65/47) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: 25 vh is seq id no:47, and vl is seq id no:65"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(49/67) , wherein: vh is seq id no:49, and  vl is seq id no:67. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(63/45)  in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:45, and vl is seq id no:63"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(46/64) , wherein: vh is seq id no:46, and vl is seq id no:64. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(57/39) in some embodiments, the antibody or antigen binding fragment thereof comprises a light 10 chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:39, and vl is seq id no:57"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(43/61) , wherein: vh is seq id no:43, and 10 vl is seq id no:61. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(58/40) in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: 15 vh is seq id no:40, and vl is seq id no:58"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(42/60) , wherein: 5 vh is seq id no:42, and vl is seq id no:60. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(45/63) , wherein: vh is seq id no:45, and vl is seq id no:63. 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(50/68) , wherein: vh is seq id no:50, and 5 vl is seq id no:68. in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(51/69) , wherein: vh is seq id no:51, and vl is seq id no:69. in some embodiments, the antibody or antigen binding fragment thereof comprises a light 30 chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(72/54) 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:54, and vl is seq id no:72"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(37/55) , wherein: vh is seq id no:37, and vl is seq id no:55. 5 in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (v"
https://patents.google.com/patent/WO2021207152A1/en,,,,,"(71/53)  in some embodiments, the antibody or antigen binding fragment thereof comprises a light chain variable region (vl) and/or a heavy chain variable region (vh), wherein: vh is seq id no:53, and vl is seq id no:71"
https://patents.google.com/patent/US20210332110A1/en,,,,,"(57/1) in some embodiments, the first antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of seq id no:57-58 and the second antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region comprising the respective amino acid sequences of seq id no:1-2, 55-56, 57-58, 65-66, 81-82, or 85-86."
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(8/28) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:8; and a vl comprising the amino acid sequence of seq id no:28"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(83/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:83; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(83/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:83; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(11/32) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:11; and a vl comprising the amino acid sequence of seq id no:32"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(6/29) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:6; and a vl comprising the amino acid sequence of seq id no:29"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(82/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:82; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(8/42) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:8; and a vl comprising the amino acid sequence of seq id no:42"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(3/26) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:3; and a vl comprising the amino acid sequence of seq id no:26"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(86/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:86; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(2/27) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:2; and a vl comprising the amino acid sequence of seq id no:27"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(7/28) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:7; and a vl comprising the amino acid sequence of seq id no:28"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(85/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:85; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(83/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:83; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(15/32) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:15; and a vl comprising the amino acid sequence of seq id no:32"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(5/42) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:5; and a vl comprising the amino acid sequence of seq id no:42"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(7/42) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:7; and a vl comprising the amino acid sequence of seq id no:42"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(6/28) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:6; and a vl comprising the amino acid sequence of seq id no:28"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(12/31) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:12; and a vl comprising the amino acid sequence of seq id no:31"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(81/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:81; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(85/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:85; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(79/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:79; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(80/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:80; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(82/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:82; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(2/26) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:2; and a vl comprising the amino acid sequence of seq id no:26"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(79/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:79; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(84/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:84; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(85/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:85; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(78/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:78; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(84/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:84; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/34)  and a vl comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of seq id no:34. in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(6/42) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:6; and a vl comprising the amino acid sequence of seq id no:42"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(1/26) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:1; and a vl comprising the amino acid sequence of seq id no:26"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(10/31) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:10; and a vl comprising the amino acid sequence of seq id no:31"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(85/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:85; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(4/26) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:4; and a vl comprising the amino acid sequence of seq id no:26"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(12/32) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:12; and a vl comprising the amino acid sequence of seq id no:32"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(83/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:83; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(82/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:82; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(79/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:79; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(81/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:81; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(81/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:81; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(3/27) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:3; and a vl comprising the amino acid sequence of seq id no:27"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(78/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:78; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(78/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:78; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(84/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:84; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(81/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:81; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(4/27) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:4; and a vl comprising the amino acid sequence of seq id no:27"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(83/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:83; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(81/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:81; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(8/29) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:8; and a vl comprising the amino acid sequence of seq id no:29"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(86/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:86; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(5/29) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:5; and a vl comprising the amino acid sequence of seq id no:29"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(14/32) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:14; and a vl comprising the amino acid sequence of seq id no:32"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(79/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:79; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(13/31) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:13; and a vl comprising the amino acid sequence of seq id no:31"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/33) in an embodiment, the antibody molecule comprises a vh comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of seq id no:22; and a vl comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/30) in an embodiment, the antibody molecule having the consensus sequences above does not comprise both of the following at the same time: the vh of seq id no:9 and the vl of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(82/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:82; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(79/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:79; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(19/34) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:19; and a vl comprising the amino acid sequence of seq id no:34"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(14/31) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:14; and a vl comprising the amino acid sequence of seq id no:31"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(84/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:84; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(80/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:80; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(1/27) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:1; and a vl comprising the amino acid sequence of seq id no:27"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(11/31) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:11; and a vl comprising the amino acid sequence of seq id no:31"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(80/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:80; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(5/28) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:5; and a vl comprising the amino acid sequence of seq id no:28"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(78/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:78; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(13/32) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:13; and a vl comprising the amino acid sequence of seq id no:32"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(80/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:80; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(15/31) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:15; and a vl comprising the amino acid sequence of seq id no:31"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(7/29) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:7; and a vl comprising the amino acid sequence of seq id no:29"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(24/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:24; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(84/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:84; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(85/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:85; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(78/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:78; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(23/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:23; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(22/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:22; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(16/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:16; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/37) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:37"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(82/89) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:82; and a vl comprising the amino acid sequence of seq id no:89"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(80/90) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:80; and a vl comprising the amino acid sequence of seq id no:90"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(86/91) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:86; and a vl comprising the amino acid sequence of seq id no:91"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(18/38) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:18; and a vl comprising the amino acid sequence of seq id no:38"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(10/32) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:10; and a vl comprising the amino acid sequence of seq id no:32"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(25/33) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:25; and a vl comprising the amino acid sequence of seq id no:33"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(86/87) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:86; and a vl comprising the amino acid sequence of seq id no:87"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/30) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:30"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/35) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:35"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(1/91)  and a vl comprising the amino acid sequence of seq id no:91. in an embodiment, the antibody molecule comprises one or both of (a) a vh comprising an amino acid sequence of any of seq id no:1-25, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(86/88) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:86; and a vl comprising the amino acid sequence of seq id no:88"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(17/41) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:17; and a vl comprising the amino acid sequence of seq id no:41"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(20/39) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:20; and a vl comprising the amino acid sequence of seq id no:39"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(9/36) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:9; and a vl comprising the amino acid sequence of seq id no:36"
https://patents.google.com/patent/WO2022026592A2/en,,,,,"(21/40) in an embodiment, the antibody molecule comprises a vh comprising the amino acid sequence of seq id no:21; and a vl comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/CN106414496B/en,,,,,(66/74)  the heavy chain variable region amino acid sequence of seq id no:66 and the light chain variable region amino acid sequence of seq id no:74.
https://patents.google.com/patent/CN106414496B/en,,,,,(218/226)  the heavy chain variable region amino acid sequence of seq id no:218 and the light chain variable region amino acid sequence of seq id no:226; and
https://patents.google.com/patent/WO2021190500A1/en,,,,,(65/66)  sars-2-mh202 antibody heavy chain variable region amino acid sequence (seq id no:65) and light chain variable region amino acid sequence (seq id no:66)
https://patents.google.com/patent/WO2021190500A1/en,,,,,"(22/23) the 4 humanized antibodies the amino acid sequence of the variable region of the heavy chain is seq id no:22/51/74/94, and the amino acid sequence of the variable region of the light chain is seq id no:23/52/75/95"
https://patents.google.com/patent/WO2021190500A1/en,,,,,(43/44)  sars-2-mh157 antibody heavy chain variable region amino acid sequence (seq id no:43) and light chain variable region amino acid sequence ( seq id no:44)
https://patents.google.com/patent/WO2021190500A1/en,,,,,"(26/27)  extract sars-2-h014 heavy chain (seq id no:26) expression vector, sars-2-h014 light chain (seq id no:27) expression vector plasmids, transfect hek-293 (fut8 gene knockou"
https://patents.google.com/patent/WO2021190500A1/en,,,,,(88/89)  sars-2-mh697 antibody the amino acid sequence of the heavy chain variable region (seq id no:88) and the amino acid sequence of the light chain variable region (seq id no:89).
https://patents.google.com/patent/CN113912710A/en, Val Lys Leu Gln Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Asp Tyr Ser Ile His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Val Glu Pro Thr Tyr Thr Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Ser Thr Gly Thr Glu Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ile Thr Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8) the amino acid sequence of the heavy chain variable region is shown as seq id no:7, and the amino acid sequence of the light chain variable region is shown as seq id no:8."
https://patents.google.com/patent/EP1812067B1/en,,,,,"(4/8) a composition comprising at least two immunoglobulins that are capable of specifically binding to a sars-cov and have sars-cov neutralizing activity,wherein the first immunoglobulin comprises a heavy chain variable region comprising the amino acid sequence of seq id no:4 and a light chain variable region comprising the amino acid sequence of seq id no:8 or a heavy and light chain variable region having at least 97% sequence homology thereto and still having sars-cov binding and neutralizing activity and"
https://patents.google.com/patent/EP1812067B1/en,,,,,(6/10) wherein the second immunoglobulin comprises a heavy chain variable region comprising the amino acid sequence of seq id no:6 and a light chain variable region comprising the amino acid sequence of seq id no:10 or a heavy and light chain variable region having at least 97% sequence homology thereto and still having sars-cov binding and neutralizing activity
https://patents.google.com/patent/WO2021228904A1/en,,,,,"(161/89) in another preferred embodiment said first anti-sars-cov-2-s antibody or antigen-binding fragment thereof comprises at least the hcvr/lcvr amino acid sequence pair is seq id no:161/165, 169/173, 193/197, 501/505 and said anti-sars-cov-2-s antibody or antigen binding fragment thereof comprises at least the hcvr/lcvr amino acid sequence pair is seq id no:89/93, 121/125, 137/141, 225/229, 241/245, 249/253, 265/269, 297/301, 313/317, 329/333, 345/349, 369/373, 517/521"
https://patents.google.com/patent/WO2021228904A1/en,,,,,"(329/333) in a preferred embodiment, said antibody according to the invention comprises a hcvr having the amino acid sequence of seq id no:329 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity and a lcvr having the amino acid sequence of seq id no:333 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity"
https://patents.google.com/patent/WO2021228904A1/en,,,,,"(329/17) in preferred embodiments, the hcvr/lcvr amino acid sequence pair is selected from seq id no:329/333 and 137/141. in another preferred embodiment, said hcvr/lcvr amino acid sequence pair is selected from one of seq id no:17/21, 121/125, 137/141, 161/165, 169/173, 193/197, 241/245, 265/269, 329/333, 345/349, 437/441, 517/521 (e.g., 001_p1d6, 17/"
https://patents.google.com/patent/WO2021228904A1/en,,,,,"(17/89) in another preferred embodiment said first anti-sars-cov-2-s antibody or antigen-binding fragment thereof comprises at least the hcvr/lcvr amino acid sequence pair of seq id no:17/21 , 161/165, 169/173, 501/505 and said anti-sars-cov- 2-s antibody or antigen-binding fragment thereof comprises at least the hcvr/lcvr amino acid sequence pair selected from seq id no:89/93, 121/125, 137/141 , 225/229, 241/245, 249/253, 265/269, 297/301, 313/317, 329/333, 345/349, 369/373 and 517/521"
https://patents.google.com/patent/WO2021228904A1/en,,,,,"(137/141) in a preferred embodiment, said antibody according to the invention comprises a hcvr having the amino acid sequence of seq id no:137 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity and a lcvr having the amino acid sequence of seq id no:141 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity"
https://patents.google.com/patent/CN111909261A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 092). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111909261A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 097). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111909261A/en,,,,,(29/28)  the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 106). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111909261A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (monoclonal antibody 7-cqts 099). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111909261A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (monoclonal antibody 3-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(37/36)  the light chain amino acid sequence can also be shown as seq id no:36 (mab 18-cqts 110). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111909261A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence can also be shown as seq id no:40 (mab 20-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(13/12)  the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 098). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111909261A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence can also be shown as seq id no:36 (mab 18-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence can also be shown as seq id no:38 (mab 19-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(39/38)  the light chain amino acid sequence can also be shown as seq id no:38 (mab 19-cqts 111). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111909261A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 101). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111909261A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (monoclonal antibody 4-cqts 094). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111909261A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (monoclonal antibody 7-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(23/22)  the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 103). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111909261A/en,,,,,(25/24)  the light chain amino acid sequence can also be shown as seq id no:24 (monoclonal antibody 12-cqts 104). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111909261A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to the novel coronavirus rbd, the heavy chain amino acid sequence is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111909261A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (monoclonal antibody 3-cqts 093). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111909261A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence can also be shown as seq id no:24 (monoclonal antibody 12-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(3/2)  the light chain amino acid sequence is shown as seq id no:2 (monoclonal antibody 1-cqts 091). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111909261A/en,,,,,(31/30)  the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 107). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111909261A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibodies 16-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(27/26)  the light chain amino acid sequence can also be shown as seq id no:26 (monoclonal antibody 13-cqts 105). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111909261A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence can also be shown as seq id no:34 (monoclonal antibody 17-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 102). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111909261A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence can also be shown as seq id no:26 (monoclonal antibody 13-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 100). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111909261A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (monoclonal antibody 4-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(33/32)  the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibodies 16-cqts 108). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111909261A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 
https://patents.google.com/patent/CN111909261A/en,,,,,(35/34)  the light chain amino acid sequence can also be shown as seq id no:34 (monoclonal antibody 17-cqts 109). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111909261A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 
https://patents.google.com/patent/CN113493506A/en, gaagtgcagc tggtggagtc tgggggagac ttggtacagc ctggcaggtc cctgagactc tcctgcgcag cctctggatt cgcctttgat gattatgcca tgcactgggt ccggcaagct ccagggaagg gcctggagtg ggtctcaggt agtacttgga atagtgggac catagcctat gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagaa gtccctgtat ctgcaaatga acagtctgag aactgaggac acggccttat attactgtgc aaagttgggg ggctacagtg actacgatta cccgaggccg ggagaccact attacggttt ggacgtctgg ggccaaggga ccacggtcac cgtctcctca gcgtcgacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaacccgt gacggtgtcg tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa , cagtctgccc tgactcagcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc tcctgcactg gaaccagcag tgatgttggg agttataacc ttgtctcctg gtaccaacag cacccaggca aagtccccaa actcttgatt tatgatgtca ataagcggcc ctcagggatt tccaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc caggctgagg acgaggctga ttattactgc agatcatata cagacagcaa cacttatgtc ttcggaactg ggaccaaggt caccgtccta ggtcagccca aggctgcccc ctcggtcact ctgttcccac cctcgagtga ggagcttcaa gccaacaagg ccacactggt gtgtctcata agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag gcgggagtgg agaccaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc tacctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca , Artificial sequence, Artificial sequence,"(2/4) the heavy chain coding region is seq id no:2 and the light chain coding region is seq id no:4, the above steps are carried out to obtain an antibody solution of p2a-1a 8."
https://patents.google.com/patent/CN113493506A/en, gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagtt ccagggaagg gcctggagtg ggtctcaggt attagttgga atggtggtat cataggctac gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagac ttccctgtat ctgcaaatga acagtctgag agctgaggac acggccttgt attactgtgc aaaagtcgcg ggaagggggg attacgacta ttactatggt atggacgtct ggggccaagg gaccacggtc accgtctcct cagcgtcgac caagggccca tcggtcttcc ccctggcacc ctcctccaag agcacctctg ggggcacagc ggccctgggc tgcctggtca aggactactt ccccgaaccc gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc ctacagtcct caggactcta ctccctcagc agcgtggtga ccgtgccctc cagcagcttg ggcacccaga cctacatctg caacgtgaat cacaagccca gcaacaccaa ggtggacaag aaagttgagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggtc agcctgacct gcctggtcaa aggcttctat cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc ttcttcctct acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg tctccgggta aa , cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc tcctgcactg ggagcagctc caacatcggg gcaggttatg atgtacactg gtaccagcaa cttccaggaa cagcccccaa actcctcatc tatggtaaca acaatcgccc ctcaggggtc cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc caggctgagg atgaggctga ttattactgc cagtcctatg acagcagcct gagtggttcg gtattcggcg gagggaccaa gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc actctgttcc caccctcgag tgaggagctt caagccaaca aggccacact ggtgtgtctc ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc agctacctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc a , Artificial sequence, Artificial sequence,"(6/8) the heavy chain coding region is seq id no:6 and the light chain coding region is seq id no:8, the above procedure was carried out to obtain an antibody solution of p2a-1a 9."
https://patents.google.com/patent/CN113493506A/en, gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctcagactc tcctgtgtcg cctctggatt ctccttcaat cgatatagta tgaattggct ccgccagact ccacggaagg ggctggagtg gctttcatac atcagtgcca gtggaaacac catatactac gctgactctg tgaggggccg attcaccacc tccagagaca atgccaagaa cacactgtat ctgcaaatga acagcctgcg agacgacgac acggctgtct atttctgtgc gcgacccgct atggttcggg aggggaccta caactggttc gacccctggg gccagggaac cctggtcacc gtctcctcag cgtcgaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaacccgtg acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtct ccgggtaaa , gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc ctctcctgca gggccagtca gagtgttagc aacgactact tagcctggta ccagcagaaa cctggccagg ctcccaggct cctcatctac tatgcatcca gcagggccac tggcatccca gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag cctggagatt ctgcagtgta ttactgtcag cagtatggtg actcacctcc gatcaccttc ggccaaggga cacgactgga gattaaacgt acggtggctg caccatctgt cttcatcttc ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac ttctacccca gagaagccaa agtgcagtgg aaggtggaca acgccctgca gagcggaaac agccaggaaa gcgtgacaga gcaggattcc aaggattcca catacagcct gagcagcaca ctgacactgt ccaaggccga ctacgagaag cacaaggtgt acgcctgcga agtgacacac cagggactgt cctcccctgt gacaaagagc ttcaacagag gagaatgc , Artificial sequence, Artificial sequence,"(14/16) the heavy chain coding region is seq id no:14 and the light chain coding region is the dna molecule shown in seq id no:16, the above procedure was carried out to obtain an antibody solution of p2a-1b 3."
https://patents.google.com/patent/CN113493506A/en, gaggtgcagc tggtggagtc tgggggaggc ttggtccagc ctggggggtc cctgagactc tcctgtgcag cctctggaat caccgtcagt agcaactaca tgaactgggt ccgccaggct ccagggaagg ggctggagtg ggtctcactt atttatagcg gtggtagcac atactacgca gactccgtga agggcagatt caccatctcc agagacaatt ccaagaacac gttgtatctt caaatgaaca gcctgagagc cgaggacacg gctgtgtatc actgtgcgag agatctggtg gtatacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc agcgtcgacc aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg gccctgggct gcctggtcaa ggactacttc cccgaacccg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa a , gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc ctctcctgca gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaaa cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag cagactggag cctgaagatt ttgcagtgta ttactgtcag cagtatggta gctcacccac ttttggccag gggaccaagc tggagatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctac cccagagaag ccaaagtgca gtggaaggtg gacaacgccc tgcagagcgg aaacagccag gaaagcgtga cagagcagga ttccaaggat tccacataca gcctgagcag cacactgaca ctgtccaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac acaccaggga ctgtcctccc ctgtgacaaa gagcttcaac agaggagaat gc , Artificial sequence, Artificial sequence,"(46/48) the heavy chain coding region is seq id no:46 and the light chain coding region is seq id no:48, the above steps are carried out to obtain an antibody solution of p2c-1f 11."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtggagtc tgggggaggc ttggtcaagc ctggagggtc cctgagactc tcctgtgcag cctctggatt caccttcagt gactactaca tgagctggat ccgccaggct ccagggaagg ggctggagtg ggtttcatac attagtagta gtggtagtac catatactac gcagactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatttt tctcatcagc agctggtacc ttcctggggc cagggaaccc tggtcaccgt ctcctcagcg tcgaccaagg gcccatcggt cttccccctg gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac tacttccccg aacccgtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa gcccagcaac accaaggtgg acaagaaagt tgagcccaaa tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtctcc gggtaaa , gacatccagt tgacccagtc tccatccttc ctgtctgcat ctgtaggaga cagagtcacc atcacttgcc gggccagtca gggcattagc agttatttag cctggtatca gcaaaaacca gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaaagtgg ggtcccatca aggttcagcg gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct gaagattttg caacttatta ctgtcaacag cttaatagtt acccgctcac tttcggcgga gggaccaagg tggagatcaa acgtacggtg gctgcaccat ctgtcttcat cttcccgcca tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctac cccagagaag ccaaagtgca gtggaaggtg gacaacgccc tgcagagcgg aaacagccag gaaagcgtga cagagcagga ttccaaggat tccacataca gcctgagcag cacactgaca ctgtccaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac acaccaggga ctgtcctccc ctgtgacaaa gagcttcaac agaggagaat gc , Artificial sequence, Artificial sequence,"(30/32) the heavy chain coding region is seq id no:30 and the light chain coding region is seq id no:32, the above procedure was carried out to obtain an antibody solution of p2c-1a 3."
https://patents.google.com/patent/CN113493506A/en, gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc tcctgtgcag cctctggatt cacctttagc agctttgcca tgagctgggt ccgccaggct ccagggaagg ggctggagtg ggtctcagct attagtggta gtggtggtag cacatactac gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat ttgcaaatga acagcctgag agccgaggac acggccgtat attactgtgc gaaagatccg gatggttcgg ggagttggta ctttgactac tggggccagg gaaccctggt caccgtctcc tcagcgtcga ccaagggccc atcggtcttc cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc aaggactact tccccgaacc cgtgacggtg tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacccag acctacatct gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gaaagttgag cccaaatctt gtgacaaaac tcacacatgc ccaccgtgcc cagcacctga actcctgggg ggaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca caggtgtaca ccctgccccc atcccgggat gagctgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct gtctccgggt aaa , tcctatgtgc tgactcagcc accctcagtg tcagtggccc caggaaagac ggccaggatt acctgtgggg gaaacaacat tggaagtaaa agtgtgcact ggtaccagca gaagccaggc caggcccctg tgctggtcat ctattatgat agcgaccggc cctcagggat ccctgagcga ttctctggct ccaactctgg gaacaccgcc accctgacca tcagcagggt cgaagccggg gatgaggccg actattactg tcaggtgtgg gatagtagta gtgatcatca tgtcttcgga actgggacca aggtcaccgt cctaggtcag cccaaggctg ccccctcggt cactctgttc ccaccctcga gtgaggagct tcaagccaac aaggccacac tggtgtgtct cataagtgac ttctacccgg gagccgtgac agtggcctgg aaggcagata gcagccccgt caaggcggga gtggagacca ccacaccctc caaacaaagc aacaacaagt acgcggccag cagctacctg agcctgacgc ctgagcagtg gaagtcccac agaagctaca gctgccaggt cacgcatgaa gggagcaccg tggagaagac agtggcccct acagaatgtt ca , Artificial sequence, Artificial sequence,"(42/44) the heavy chain coding region is seq id no:42 and the light chain coding region is seq id no:44, the above steps are carried out to obtain an antibody solution of p2c-1d 5."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc tcctgcaagg cttctggagg caccttcagc agctatgcta tcatctgggt gcgacaggcc cctggacaag ggcttgagtg gatgggaggg atcatcccta tctttggtac agcaaactac gcacagaagt tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagagtggta acggggtact actttgacta ctggggccag ggaaccctgg tcaccgtctc ctcagcgtcg accaagggcc catcggtctt ccccctggca ccctcctcca agagcacctc tgggggcaca gcggccctgg gctgcctggt caaggactac ttccccgaac ccgtgacggt gtcgtggaac tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcaccca gacctacatc tgcaacgtga atcacaagcc cagcaacacc aaggtggaca agaaagttga gcccaaatct tgtgacaaaa ctcacacatg cccaccgtgc ccagcacctg aactcctggg gggaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc acatgcgtgg tggtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg taaa , gaaattgtgt tgacacagtc tccagccacc ctgtctttgt ctccagggga aagagccacc ctctcctgca gggccagtca gagtgttagc agctacttag cctggtacca acagaaacct ggccaggctc ccaggctcct catctatgat gcatccaaca gggccactgg catcccagcc aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag cctagagcct gaagattttg cagtttatta ctgtcagcag cgtagcaact ggccttcttt tggccagggg accaagctgg agatcaaacg tacggtggct gcaccatctg tcttcatctt cccgccatct gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctacccc agagaagcca aagtgcagtg gaaggtggac aacgccctgc agagcggaaa cagccaggaa agcgtgacag agcaggattc caaggattcc acatacagcc tgagcagcac actgacactg tccaaggccg actacgagaa gcacaaggtg tacgcctgcg aagtgacaca ccagggactg tcctcccctg tgacaaagag cttcaacaga ggagaatgc , Artificial sequence, Artificial sequence,"(38/40) the heavy chain coding region is seq id no:38 and the light chain coding region is seq id no:40, the above steps are carried out to obtain an antibody solution which is a p2c-1c10 antibody solution."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc tcctgtgcag cgtctggatt caccttcagg agctatggca tgcactgggt ccgccaggct ccaggcaagg ggctggagtg ggtggcagtt atctggtatg atggaagtaa taaatactat gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagagatata gagatagtag tggtaaatat tgactactgg ggccagggaa ccctggtcac cgtctcctca gcgtcgacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaacccgt gacggtgtcg tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa , gatgttgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca gccggcctcc atctcctgca ggtctagtca aagcctcgta tacagtgatg gaaacaccta cttgaattgg tttcagcaga ggccaggcca atctccaagg cgcctaattt ataaggtttc tatctgggac tctggggtcc cagacagatt cagcggcagt gggtcaggca ctgatttcac actgaaaatc agcagggtgg aggctgagga tgttggggtt tattactgca tgcaaggtac acactggccg tacacttttg gccaggggac caagctggag atcaaacgta cggtggctgc accatctgtc ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgcctctgt tgtgtgcctg ctgaataact tctaccccag agaagccaaa gtgcagtgga aggtggacaa cgccctgcag agcggaaaca gccaggaaag cgtgacagag caggattcca aggattccac atacagcctg agcagcacac tgacactgtc caaggccgac tacgagaagc acaaggtgta cgcctgcgaa gtgacacacc agggactgtc ctcccctgtg acaaagagct tcaacagagg agaatgc , Artificial sequence, Artificial sequence,"(34/36) the heavy chain coding region is seq id no:34 and the light chain coding region is the dna molecule shown in seq id no:36, the above procedure was carried out to obtain an antibody solution of p2c-1c 8."
https://patents.google.com/patent/CN113493506A/en, gaagtgcagc tggtggagtc tgggggaggc ttggtacagc ctggcaggtc cctgagactc tcctgtgcag cctctggatt cacctttgat gattatgcca tgcactgggt ccggcaagct ccagggaagg gcctggagtg ggtctcaggt attagttgga atggtggtat cataggctat gcggactctg tgaagggccg attcaccatc tccagagaca acgccaagac ttccctgtat ctgcaaatga acagtctgaa acctgaggac acggccttgt attactgtgc aaaagtcgcg ggaagggggg attacgacta ctactacggt atggacgtct ggggccaagg gaccacggtc accgtctcct cagcgtcgac caagggccca tcggtcttcc ccctggcacc ctcctccaag agcacctctg ggggcacagc ggccctgggc tgcctggtca aggactactt ccccgaaccc gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc ctacagtcct caggactcta ctccctcagc agcgtggtga ccgtgccctc cagcagcttg ggcacccaga cctacatctg caacgtgaat cacaagccca gcaacaccaa ggtggacaag aaagttgagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc ccccatcgag aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggtc agcctgacct gcctggtcaa aggcttctat cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc ttcttcctct acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg tctccgggta aa , cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc tcctgcactg ggagcagctc caacatcggg gcaggttatg atgtacactg gtaccagcaa cttccaggaa cagcccccaa actcctcatc tatgggaaca acaatcggcc ctcaggggtc cctgaccgat tctctggctc caagtctggc acctcagcct ccctggccat cactgggctc caggctgagg atgaggctga ttattactgc cagtcctatg acagcagcct gagtggttcg gtattcggcg gagggaccaa gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc actctgttcc caccctcgag tgaggagctt caagccaaca aggccacact ggtgtgtctc ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc agctacctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc a , Artificial sequence, Artificial sequence,"(26/28) the heavy chain coding region is seq id no:26 and the light chain coding region is the dna molecule shown in seq id no:28, the above procedure was carried out to obtain an antibody solution of p2b-2g 11."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc acctgcactg tctctggtta ctccatcagc agtggttact actggggctg gatccggcag cccccaggga aggggctgga gtggattggg agtatctatc atagtgggag cacctactac aacccgtccc tcaagactcg agtcaccata tcagtagaca cgtccaagaa ccagttctcc ctgaagctga gctctgtgac cgccgcagac acggccgtct attactgtgc gagagcggtg gtagggattg tagtagtacc agctgccggt cgtcgggctt ttgatatctg gggccaaggg acaatggtca ccgtctcctc agcgtcgacc aagggcccat cggtcttccc cctggcaccc tcctccaaga gcacctctgg gggcacagcg gccctgggct gcctggtcaa ggactacttc cccgaacccg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc ctctccctgt ctccgggtaa a , cagtctgccc tgactcagcc tccctccgcg tccgggtctc ctggacagtc agtcaccatc tcctgcactg gaaccagcag tgacgttggt ggttataact atgtctcctg gtaccaacag cacccaggca aagcccccaa actcatgatt tatgaggtca gtaagcggcc ctcaggggtc cctgatcgct tctctggctc caagtctggc aacacggcct ccctgaccgt ctctgggctc caggctgagg atgaggctga ttattactgc agctcatatg caggcagcaa caatttggtg ttcggcggag ggaccaagct gaccgtccta ggtcagccca aggctgcccc ctcggtcact ctgttcccac cctcgagtga ggagcttcaa gccaacaagg ccacactggt gtgtctcata agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag gcgggagtgg agaccaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc tacctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttca , Artificial sequence, Artificial sequence,"(18/20) the heavy chain coding region is seq id no:18 and the light chain coding region is seq id no:20, the above procedure was carried out to obtain an antibody solution of p2b-2f 6."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc tcctgcaagg cttctggata caccttcacc ggctactata tgcactgggt gcgacaggcc cctggacaag ggcttgagtg gatgggacgg atcaacccta acagtggtgg cacaaactat gcacagaagt ttcagggcag ggtcaccatg accagggaca cgtccatcag cacagcctac atggagctga gcaggctgag atctgacgac acggccgtgt attactgtgc gagagtcccc tattgtagta gtaccagctg ccatcgggac tggtacttcg atctctgggg ccgtggcacc ctggtcactg tctcctcagc gtcgaccaag ggcccatcgg tcttccccct ggcaccctcc tccaagagca cctctggggg cacagcggcc ctgggctgcc tggtcaagga ctacttcccc gaacccgtga cggtgtcgtg gaactcaggc gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt gccctccagc agcttgggca cccagaccta catctgcaac gtgaatcaca agcccagcaa caccaaggtg gacaagaaag ttgagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca cctgaactcc tggggggacc gtcagtcttc ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag gactggctga atggcaagga gtacaagtgc aaggtctcca acaaagccct cccagccccc atcgagaaaa ccatctccaa agccaaaggg cagccccgag aaccacaggt gtacaccctg cccccatccc gggatgagct gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctacag caagctcacc gtggacaaga gcaggtggca gcaggggaac gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacgca gaagagcctc tccctgtctc cgggtaaa , gatattgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gccggcctcc atctcctgca ggtctagtca gagcctcttg gatagtgatg atggaaacac ctatttggac tggtacctgc agaagccagg gcagtctcca cagctcctga tctatacgct ttcctatcgg gcctctggag tcccagacag gttcagtggc agtgggtcag gcactgattt cacactgaaa atcagcaggg tggaggctga ggatgttgga gtttattact gcatgcaacg tatagagttt ccgctcactt tcggcggagg gaccaaggtg gagatcaaac gtacggtggc tgcaccatct gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc ctgctgaata acttctaccc cagagaagcc aaagtgcagt ggaaggtgga caacgccctg cagagcggaa acagccagga aagcgtgaca gagcaggatt ccaaggattc cacatacagc ctgagcagca cactgacact gtccaaggcc gactacgaga agcacaaggt gtacgcctgc gaagtgacac accagggact gtcctcccct gtgacaaaga gcttcaacag aggagaatgc , Artificial sequence, Artificial sequence,"(10/12) the heavy chain coding region is seq id no:10 and the light chain coding region is seq id no:12, the above procedure was carried out to obtain an antibody solution of p2a-1a 10."
https://patents.google.com/patent/CN113493506A/en, caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc tcctgtgcag cgtctggatt caccttcagt agctatggca tgcactgggt ccgccaggct ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaagtaa taaatactat gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat ctgcaaatga acagcctgag agccgaggac acggctgtgt attactgtgc gagaggggca gctatggttt ggcttgacta ctggggccag ggaaccctgg tcaccgtctc ctcagcgtcg accaagggcc catcggtctt ccccctggca ccctcctcca agagcacctc tgggggcaca gcggccctgg gctgcctggt caaggactac ttccccgaac ccgtgacggt gtcgtggaac tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcaccca gacctacatc tgcaacgtga atcacaagcc cagcaacacc aaggtggaca agaaagttga gcccaaatct tgtgacaaaa ctcacacatg cccaccgtgc ccagcacctg aactcctggg gggaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc acatgcgtgg tggtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg taaa , cagtctgccc tgactcagcc tcgctcagtg tccgggtctc ctggacagtc agtcaccatc tcctgcactg gaaccagcag tgatgttggt ggttataact atgtctcctg gtaccaacag cacccaggca aagcccccaa actcatgatt tatgatgtca gtaagcggcc ctcaggggtc cctgatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc caggctgagg atgaggctga ttattactgc tgctcatatg caggcagcta cactttcgtg gtattcggcg gagggaccaa gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc actctgttcc caccctcgag tgaggagctt caagccaaca aggccacact ggtgtgtctc ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc agctacctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc a , Artificial sequence, Artificial sequence,"(22/24) the heavy chain coding region is seq id no:22 and the light chain coding region is seq id no:24, the above steps are carried out to obtain an antibody solution of p2b-2g 4."
https://patents.google.com/patent/CN113336844A/en,,,,,"(1) a shark single domain antibody targeting a novel coronavirus n protein, characterized in that: the amino acid sequence of the shark single-domain antibody is shown as seq id no:1 or seq id no:2."
https://patents.google.com/patent/CN113336844A/en,,,,,"(3) a shark single domain antibody targeting a novel coronavirus n protein, characterized in that: the nucleotide sequence of the shark single domain antibody is shown as seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN113336844A/en,,,,,"(4) a shark single domain antibody targeting a novel coronavirus n protein, characterized in that: the nucleotide sequence of the shark single domain antibody is shown as seq id no:3 or seq id no:4."
https://patents.google.com/patent/CN113336844A/en,,,,,"(2) a shark single domain antibody targeting a novel coronavirus n protein, characterized in that: the amino acid sequence of the shark single-domain antibody is shown as seq id no:1 or seq id no:2."
https://patents.google.com/patent/CN111925444A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 165). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111925444A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 168). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111925444A/en,,,,,(29/28)  the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 178). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111925444A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqts 170). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111925444A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (monoclonal antibody 3-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(37/36)  the light chain amino acid sequence can also be shown as seq id no:36 (mab 18-cqts 186). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111925444A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence can also be shown as seq id no:40 (monoclonal antibody 20-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(13/12)  the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 169). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111925444A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence can also be shown as seq id no:36 (mab 18-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence can also be shown as seq id no:38 (monoclonal antibody 19-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (mab 9-cqts 172). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111925444A/en,,,,,(39/38)  the light chain amino acid sequence can also be shown as seq id no:38 (monoclonal antibody 19-cqts 187). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111925444A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (monoclonal antibody 4-cqts 167). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111925444A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(23/22)  the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 174). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111925444A/en,,,,,(25/24)  the light chain amino acid sequence can also be shown as seq id no:24 (mab 12-cqts 175). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111925444A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to a novel coronavirus rbd, the heavy chain amino acid sequence of which is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111925444A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (monoclonal antibody 3-cqts 166). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111925444A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence can also be shown as seq id no:24 (mab 12-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(3/2)  the light chain amino acid sequence is shown as seq id no:2 (monoclonal antibody 1-cqts 147). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111925444A/en,,,,,(31/30)  the light chain amino acid sequence can also be shown as seq id no:30 (mab 15-cqts 179). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111925444A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence can also be shown as seq id no:30 (mab 15-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(27/26)  the light chain amino acid sequence can also be shown as seq id no:26 (mab 13-cqts 177). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111925444A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence can also be shown as seq id no:34 (monoclonal antibody 17-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (mab 10-cqts 173). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111925444A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (mab 9-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence can also be shown as seq id no:26 (mab 13-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 171). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111925444A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (monoclonal antibody 4-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(33/32)  the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 180). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111925444A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 
https://patents.google.com/patent/CN111925444A/en,,,,,(35/34)  the light chain amino acid sequence can also be shown as seq id no:34 (monoclonal antibody 17-cqts 185). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111925444A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (mab 10-cqts 
https://patents.google.com/patent/WO2021060837A1/en,,,,,"(62/44) a light chain variable region comprising or consisting essentially of seq id no:44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 76; and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:62;"
https://patents.google.com/patent/WO2021060837A1/en,,,,,(59/48)  a light chain variable region comprising or consisting essentially of seq id no:48 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:59;
https://patents.google.com/patent/WO2021060837A1/en,,,,,"(58/44) a light chain variable region comprising or consisting essentially of seq id no:44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 76; and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:58;"
https://patents.google.com/patent/WO2021060837A1/en,,,,,"(63/44) a light chain variable region comprising or consisting essentially of seq id no:44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 76; and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:63; or"
https://patents.google.com/patent/WO2021060837A1/en,,,,,(77/76)  a light chain variable region comprising or consisting essentially of seq id no:76 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:77.
https://patents.google.com/patent/WO2021060837A1/en,,,,,(56/44)  a light chain variable region comprising or consisting essentially of seq id no:44 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:56;
https://patents.google.com/patent/WO2021060837A1/en,,,,,(57/44)  a light chain variable region comprising or consisting essentially of seq id no:44 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:57;
https://patents.google.com/patent/WO2021060837A1/en,,,,,(58/47)  a light chain variable region comprising or consisting essentially of seq id no:47 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:58;
https://patents.google.com/patent/WO2021060837A1/en,,,,,(62/53)  a light chain variable region comprising or consisting essentially of seq id no:53 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:62;
https://patents.google.com/patent/WO2021060837A1/en,,,,,"(59/44) a light chain variable region comprising or consisting essentially of seq id no:44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 76; and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:59;"
https://patents.google.com/patent/WO2021060837A1/en,,,,,(56/45)  a light chain variable region comprising or consisting essentially of seq id no:45 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:56;
https://patents.google.com/patent/WO2021060837A1/en,,,,,(55/46)  a light chain variable region comprising or consisting essentially of seq id no:46 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:55;
https://patents.google.com/patent/WO2021060837A1/en,,,,,"(61/44) a light chain variable region comprising or consisting essentially of seq id no:44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 76; and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:61;"
https://patents.google.com/patent/WO2021060837A1/en,,,,,(55/44)  a light chain variable region comprising or consisting essentially of seq id no:44 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:55;
https://patents.google.com/patent/WO2021060837A1/en,,,,,(62/52)  a light chain variable region comprising or consisting essentially of seq id no:52 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:62;
https://patents.google.com/patent/WO2021060837A1/en,,,,,(61/50)  a light chain variable region comprising or consisting essentially of seq id no:50 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:61;
https://patents.google.com/patent/WO2021060837A1/en,,,,,"(60/44) a light chain variable region comprising or consisting essentially of seq id no:44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 76; and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:60;"
https://patents.google.com/patent/WO2021060837A1/en,,,,,"(77/44) a light chain variable region comprising or consisting essentially of seq id no:44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 76; and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:77."
https://patents.google.com/patent/WO2021060837A1/en,,,,,(63/54)  a light chain variable region comprising or consisting essentially of seq id no:54 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:63; or
https://patents.google.com/patent/WO2021060837A1/en,,,,,(62/51)  a light chain variable region comprising or consisting essentially of seq id no:51 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:62;
https://patents.google.com/patent/WO2021060837A1/en,,,,,(60/49)  a light chain variable region comprising or consisting essentially of seq id no:49 and a heavy chain variable region comprising or consisting essentially of an amino acid sequence of seq id no:60;
https://patents.google.com/patent/CN112980885A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Arg Ser Ala Tyr Gly Asp Lys Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Gln Glu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , (1)..(122), (1)..(109),(17/18)  b) a heavy chain variable region comprising the sequence of seq id no:17 and a light chain variable region comprising the sequence of seq id no:18
https://patents.google.com/patent/CN112980885A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Ser Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Ala Asn Pro Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Val Thr Ile His Tyr Asp Ile Leu Thr Gly Tyr Tyr Ser Asn Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Ala Val Ser Ser, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Thr Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ala Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Thr Thr Phe Met Tyr Thr Phe Gly Gln Gly Thr Met Leu Glu Ile Lys , (1)..(129), (1)..(108),(7/8)  a heavy chain variable region comprising the sequence of seq id no:7 and a light chain variable region comprising seq id no:8; 
https://patents.google.com/patent/CN112980885A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Leu Gly Gly Phe Ala Asp Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Val Leu Ile Tyr Asp Ala Phe Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , (1)..(119), (1)..(109),(27/28)  a heavy chain variable region comprising the sequence of seq id no:27 and a light chain variable region comprising the sequence of seq id no:28.
https://patents.google.com/patent/US7728110B2/en,,,,,"(58/60)  domains that are at least 99% identical in amino acid sequence to the vl domain shown as seq id no:60 and the vh domain shown as seq id no:58, respectively, of the monoclonal antibody 3c7."
https://patents.google.com/patent/CN111909263A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 002). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111909263A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 005). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111909263A/en,,,,,(29/28)  the light chain amino acid sequence can also be shown as seq id no:28 (mab 14-cqts 014). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111909263A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqts 007). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111909263A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(37/36)  the light chain amino acid sequence can also be shown as seq id no:36 (monoclonal antibodies 18-cqts 018). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111909263A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence can also be shown as seq id no:40 (monoclonal antibody 20-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(13/12)  the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 006). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111909263A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence can also be shown as seq id no:36 (monoclonal antibodies 18-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence may also be as shown in seq id no:38 (mab 19-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (mab 9-cqts 009). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111909263A/en,,,,,(39/38)  the light chain amino acid sequence may also be as shown in seq id no:38 (mab 19-cqts 019). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111909263A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqts 004). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111909263A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (monoclonal antibody 8-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(23/22)  the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 011). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111909263A/en,,,,,(25/24)  the light chain amino acid sequence can also be shown as seq id no:24 (monoclonal antibody 12-cqts 012). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111909263A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to a novel coronavirus rbd, the heavy chain amino acid sequence of which is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111909263A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqts 003). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111909263A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence can also be shown as seq id no:24 (monoclonal antibody 12-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(3/2)  the light chain amino acid sequence is shown as seq id no:2 (monoclonal antibody 1-cqts 001). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111909263A/en,,,,,(31/30)  the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 015). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111909263A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(27/26)  the light chain amino acid sequence can also be shown as seq id no:26 (monoclonal antibody 13-cqts 013). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111909263A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence can also be shown as seq id no:34 (monoclonal antibody 17-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 010). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111909263A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (mab 9-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence can also be shown as seq id no:26 (monoclonal antibody 13-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (monoclonal antibody 8-cqts 008). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111909263A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(33/32)  the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 016). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111909263A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence can also be shown as seq id no:28 (mab 14-cqts 
https://patents.google.com/patent/CN111909263A/en,,,,,(35/34)  the light chain amino acid sequence can also be shown as seq id no:34 (monoclonal antibody 17-cqts 017). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111909263A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 
https://patents.google.com/patent/KR20220010411A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising "
https://patents.google.com/patent/KR20220012771A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018."
https://patents.google.com/patent/CN112062838B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ala Ser Ser Gly Tyr Tyr Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ala Asp Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Tyr Ser Ala Pro Ser Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys ,, Artificial Sequence (Artificial Sequence),,"(3) a pharmaceutical composition comprising a pharmaceutically active ingredient, wherein the pharmaceutically active ingredient comprises the neutralizing single domain antibody against sars-cov-2 of the novel coronavirus of any one of claims 1 to 3 and the sars-cov-2 neutralizing antibody 4a3 having the amino acid sequence shown in seq id no:3."
https://patents.google.com/patent/CN112062838B/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Asp Phe Tyr Asp Tyr Glu Met Ser Trp Val Arg Gln Ala Pro Gly Lys Ala Leu Glu Trp Ile Gly Glu Ile His His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Val Lys Asp Phe Val Gly Ala Asp Gly Pro Phe Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,"(2) preferably, the amino acid sequence of the single domain antibody is shown as seq id no:2."
https://patents.google.com/patent/CN112979794B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Gly Ser Tyr Tyr Trp Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the antibody of claim 1, wherein said antibody comprises the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/CN112979794B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/US20210371503A1/en,,,,,(51/52)  wherein the heavy chain variable region comprises seq id no:51 and the light chain variable region comprises seq id no:52;
https://patents.google.com/patent/US20210371503A1/en,,,,,(41/42)  wherein the heavy chain variable region comprises seq id no:41 and the light chain variable region comprises seq id no:42;
https://patents.google.com/patent/US20210371503A1/en,,,,,(5/6)  wherein the heavy chain variable region comprises seq id no:5 and the light chain variable region comprises seq id no:6;
https://patents.google.com/patent/US20210371503A1/en,,,,,(49/50)  wherein the heavy chain variable region comprises seq id no:49 and the light chain variable region comprises seq id no:50;
https://patents.google.com/patent/US20210371503A1/en,,,,,(39/40)  wherein the heavy chain variable region comprises seq id no:39 and the light chain variable region comprises seq id no:40;
https://patents.google.com/patent/US20210371503A1/en,,,,,(35/36)  wherein the heavy chain variable region comprises seq id no:35 and the light chain variable region comprises seq id no:36;
https://patents.google.com/patent/US20210371503A1/en,,,,,(47/48)  wherein the heavy chain variable region comprises seq id no:47 and the light chain variable region comprises seq id no:48;
https://patents.google.com/patent/US20210371503A1/en,,,,,(37/38)  wherein the heavy chain variable region comprises seq id no:37 and the light chain variable region comprises seq id no:38;
https://patents.google.com/patent/US20210371503A1/en,,,,,(53/54) (aa) wherein the heavy chain variable region comprises seq id no:53 and the light chain variable region comprises seq id no:54
https://patents.google.com/patent/US20210371503A1/en,,,,,(13/14)  wherein the heavy chain variable region comprises seq id no:13 and the light chain variable region comprises seq id no:14;
https://patents.google.com/patent/US20210371503A1/en,,,,,(15/16)  wherein the heavy chain variable region comprises seq id no:15 and the light chain variable region comprises seq id no:16;
https://patents.google.com/patent/US20210371503A1/en,,,,,(43/44)  wherein the heavy chain variable region comprises seq id no:43 and the light chain variable region comprises seq id no:44;
https://patents.google.com/patent/US20210371503A1/en,,,,,(55/56)  wherein the heavy chain variable region comprises seq id no:55 and the light chain variable region comprises seq id no:56.
https://patents.google.com/patent/US20210371503A1/en,,,,,(229/230) ; heavy chain sequence of seq id no:229 and light chain sequence of seq id no:230
https://patents.google.com/patent/US20210371503A1/en,,,,,(11/12)  wherein the heavy chain variable region comprises seq id no:11 and the light chain variable region comprises seq id no:12;
https://patents.google.com/patent/US20210371503A1/en,,,,,(1/2)  wherein the heavy chain variable region comprises seq id no:1 and the light chain variable region comprises seq id no:2;
https://patents.google.com/patent/US20210371503A1/en,,,,,(23/24)  wherein the heavy chain variable region comprises seq id no:23 and the light chain variable region comprises seq id no:24;
https://patents.google.com/patent/US20210371503A1/en,,,,,(31/32)  wherein the heavy chain variable region comprises seq id no:31 and the light chain variable region comprises seq id no:32;
https://patents.google.com/patent/US20210371503A1/en,,,,,(9/10)  wherein the heavy chain variable region comprises seq id no:9 and the light chain variable region comprises seq id no:10
https://patents.google.com/patent/US20210371503A1/en,,,,,(21/22)  wherein the heavy chain variable region comprises seq id no:21 and the light chain variable region comprises seq id no:22;
https://patents.google.com/patent/US20210371503A1/en,,,,,(29/30)  wherein the heavy chain variable region comprises seq id no:29 and the light chain variable region comprises seq id no:30;
https://patents.google.com/patent/US20210371503A1/en,,,,,(33/34)  wherein the heavy chain variable region comprises seq id no:33 and the light chain variable region comprises seq id no:34;
https://patents.google.com/patent/US20210371503A1/en,,,,,(3/4)  wherein the heavy chain variable region comprises seq id no:3 and the light chain variable region comprises seq id no:4;
https://patents.google.com/patent/US20210371503A1/en,,,,,(17/18)  wherein the heavy chain variable region comprises seq id no:17 and the light chain variable region comprises seq id no:18;
https://patents.google.com/patent/US20210371503A1/en,,,,,(25/26)  wherein the heavy chain variable region comprises seq id no:25 and the light chain variable region comprises seq id no:26;
https://patents.google.com/patent/US20210371503A1/en,,,,,(7/8)  wherein the heavy chain variable region comprises seq id no:7 and the light chain variable region comprises seq id no:8;
https://patents.google.com/patent/US20210371503A1/en,,,,,(45/46)  wherein the heavy chain variable region comprises seq id no:45 and the light chain variable region comprises seq id no:46;
https://patents.google.com/patent/US20210371503A1/en,,,,,(27/28)  wherein the heavy chain variable region comprises seq id no:27 and the light chain variable region comprises seq id no:28;
https://patents.google.com/patent/US20210371503A1/en,,,,,(19/20)  wherein the heavy chain variable region comprises seq id no:19 and the light chain variable region comprises seq id no:20;
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Ile Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Ala Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Gly Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Ser Ser Gly Thr Leu Asn Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 101 HC variable region , No. 101 LC variable region ,(1342/1341)  a) a light chain variable region of seq id no:1341; and b) a binding molecule comprising a heavy chain variable region of seq id no:1342; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Pro Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Ala Leu Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Thr Tyr Gly Ser Tyr Tyr Tyr Gly Met Asp Ala Trp Gly Leu Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Thr Thr Gln Asn Ile Asn Thr Tyr Leu Asn Trp Tyr Gln Gln Gln Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Ser Val Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Arg Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No. 109 HC variable region , No. 109 LC variable region ,(1358/1357)  a) a light chain variable region of seq id no:1357; and b) a binding molecule comprising a heavy chain variable region of seq id no:1358; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Glu Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 38 HC variable region , No. 38 LC variable region ,(1216/1215)  a) a light chain variable region of seq id no:1215; and b) a binding molecule comprising the heavy chain variable region of seq id no:1216; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Pro Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Gly Val Thr Ile Ser Cys Ser Gly Leu Thr Ser Asn Ile Gly Ser Asn Phe Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Gly Glu Tyr Phe Cys Ala Ala Trp Asp Asp Thr Leu Val Gly Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 171 HC variable region , No. 171 LC variable region ,(1482/1481)  a) a light chain variable region of seq id no:1481; and b) a binding molecule comprising the heavy chain variable region of seq id no:1482; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 176 HC variable region , No. 176 LC variable region ,(1492/1491)  a) a light chain variable region of seq id no:1491; and b) a binding molecule comprising a heavy chain variable region of seq id no:1492; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Ala Asp Asp Ser Thr Ser Thr Ala Phe Met Glu Leu Ser Thr Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Thr Trp Gly Gln Gly Thr Leu Val Leu Val Ser Ala , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 9 HC variable region , No.9 LC variable region ,(1158/1157)  a) a light chain variable region of seq id no:1157; and b) a binding molecule comprising the heavy chain variable region of seq id no:1158; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 86 HC variable region , No. 86 LC variable region ,(1312/1311)  a) a light chain variable region of seq id no:1311; and b) a binding molecule comprising a heavy chain variable region of seq id no:1312; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Tyr Ser Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr His Thr Ser Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 161 HC variable region , No. 161 LC variable region ,(1462/1461)  a) a light chain variable region of seq id no:1461; and b) a binding molecule comprising a heavy chain variable region of seq id no:1462; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 4 HC variable region , No.4 LC variable region ,(1148/1147)  a) a light chain variable region of seq id no:1147; and b) a binding molecule comprising a heavy chain variable region of seq id no:1148; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No. 53 HC variable region , No. 53 LC variable region ,(1246/1245)  a) a light chain variable region of seq id no:1245; and b) a binding molecule comprising a heavy chain variable region of seq id no:1246; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Asp Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 150 HC variable region , No. 150 LC variable region ,(1440/1439)  a) a light chain variable region of seq id no:1439; and b) a binding molecule comprising a heavy chain variable region of seq id no:1440; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Val Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 33 HC variable region , No. 33 LC variable region ,(1206/1205)  a) a light chain variable region of seq id no:1205; and b) a binding molecule comprising the heavy chain variable region of seq id no:1206; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 104 HC variable region , No. 104 LC variable region ,(1348/1347)  a) a light chain variable region of seq id no:1347; and b) a binding molecule comprising a heavy chain variable region of seq id no:1348; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Tyr Ser Ser Trp Tyr Gly Pro Arg Thr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 125 HC variable region , No. 125 LC variable region ,(1390/1389)  a) a light chain variable region of seq id no:1389; and b) a binding molecule comprising the heavy chain variable region of seq id no:1390; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Thr Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 122 HC variable region , No. 122 LC variable region ,(1384/1383)  a) a light chain variable region of seq id no:1383; and b) a binding molecule comprising the heavy chain variable region of seq id no:1384; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln His Gly Ser Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 168 HC variable region , No. 168 LC variable region ,(1476/1475)  a) a light chain variable region of seq id no:1475; and b) a binding molecule comprising a heavy chain variable region of seq id no:1476; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Pro Ala Val Thr Thr Ala Gly Trp Phe Asp Pro Cys Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Lys Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 132 HC variable region , No. 132 LC variable region ,(1404/1403)  a) a light chain variable region of seq id no:1403; and b) a binding molecule comprising the heavy chain variable region of seq id no:1404; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Ser Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 118 HC variable region , No. 118 LC variable region ,(1376/1375)  a) a light chain variable region of seq id no:1375; and b) a binding molecule comprising the heavy chain variable region of seq id no:1376; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Thr His Ala Leu Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Pro Ala Asp Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Leu Ser Leu Gly Phe Cys Ser Ala Gly Ser Cys Tyr Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 187 HC variable region , No. 187 LC variable region ,(1514/1513)  a) a light chain variable region of seq id no:1513; and b) a binding molecule comprising a heavy chain variable region of seq id no:1514; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 165 HC variable region , No. 165 LC variable region ,(1470/1469)  a) a light chain variable region of seq id no:1469; and b) a binding molecule comprising a heavy chain variable region of seq id no:1470; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Leu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ser Cys Ser Gly Gly Ser Cys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Glu Pro Ser Leu Thr Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Ser Ser Ser Thr Gly Ala Val Thr Arg Gly His Phe Pro Asn Trp Leu Gln Gln Lys Pro Gly Gln Thr Pro Arg Ala Leu Ile His Ser Thr Ser Asn Lys His Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly Asp Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Glu Asp Glu Ala Glu Tyr Tyr Cys Leu Leu Tyr Asp Ala Gly Ala Pro Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 75 HC variable region , No. 75 LC variable region ,(1290/1289)  a) a light chain variable region of seq id no:1289; and b) a binding molecule comprising a heavy chain variable region of seq id no:1290; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Pro Asp Asp Ser Ser Gly Tyr Tyr Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 131 HC variable region , No. 131 LC variable region ,(1402/1401)  a) a light chain variable region of seq id no:1401; and b) a binding molecule comprising a heavy chain variable region of seq id no:1402; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Arg Gly Gly Asn Tyr Arg Gly Ala Leu Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asp Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Asp Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ala Pro Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 129 HC variable region , No. 129 LC variable region ,(1398/1397)  a) a light chain variable region of seq id no:1397; and b) a binding molecule comprising a heavy chain variable region of seq id no:1398; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Asp Ser Ile Thr Ile Ser Cys Thr Gly Thr Arg Gly Asp Ile Gly Ala Tyr Asp Gly Val Ser Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Ala Val Thr Gln Arg Pro Ser Gly Ile Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 134 HC variable region , No. 134 LC variable region ,(1408/1407)  a) a light chain variable region of seq id no:1407; and b) a binding molecule comprising a heavy chain variable region of seq id no:1408; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Ser Ser Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Val Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Phe Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asp His Ile Val Ser Pro Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 55 HC variable region , No. 55 LC variable region ,(1250/1249)  a) a light chain variable region of seq id no:1249; and b) a binding molecule comprising a heavy chain variable region of seq id no:1250; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Asp Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr Gly Thr Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Gly Tyr Asn Glu Asn Ser Thr His Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ala Leu Arg Tyr Asp Ile Leu Thr Gly Phe Thr Gly Phe Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Ser Gln Arg Pro Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Val Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Met Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 149 HC variable region , No. 149 LC variable region ,(1438/1437)  a) a light chain variable region of seq id no:1437; and b) a binding molecule comprising a heavy chain variable region of seq id no:1438; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Asn Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Tyr Pro Gly Tyr Tyr Asp Ile Leu Thr Gly Gln Ile Gly Thr Gly Glu Arg Asn Ala Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asp Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 188 HC variable region , No. 188 LC variable region ,(1516/1515)  a) a light chain variable region of seq id no:1515; and b) a binding molecule comprising a heavy chain variable region of seq id no:1516; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Arg Asp Asp Ser Leu Asn Gly Ala Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 19 HC variable region , No.19 LC variable region ,(1178/1177)  a) a light chain variable region of seq id no:1177; and b) a binding molecule comprising a heavy chain variable region of seq id no:1178; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Asp Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 95 HC variable region , No. 95 LC variable region ,(1330/1329)  a) a light chain variable region of seq id no:1329; and b) a binding molecule comprising the heavy chain variable region of seq id no:1330; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Pro Val Leu Gly Leu Ser Lys Trp Leu Glu Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 139 HC variable region , No. 139 LC variable region ,(1418/1417)  a) a light chain variable region of seq id no:1417; and b) a binding molecule comprising a heavy chain variable region of seq id no:1418; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Gly Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No. 63 HC variable region , No. 63 LC variable region ,(1266/1265)  a) a light chain variable region of seq id no:1265; and b) a binding molecule comprising a heavy chain variable region of seq id no:1266; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Met Tyr Thr Phe Gly Gin Gly Thr Lys Leu Glu Ile Lys , No. 99 HC variable region , No. 99 LC variable region ,(1338/1337)  a) a light chain variable region of seq id no:1337; and b) a binding molecule comprising the heavy chain variable region of seq id no:1338; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Phe Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala Arg Gln Glu Trp Leu Arg Gly Gly Phe Asp Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 42 HC variable region , No. 42 LC variable region ,(1224/1223)  a) a light chain variable region of seq id no:1223; and b) a binding molecule comprising a heavy chain variable region of seq id no:1224; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 51 HC variable region , No. 51 LC variable region ,(1242/1241)  a) a light chain variable region of seq id no:1241; and b) a binding molecule comprising a heavy chain variable region of seq id no:1242; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Tyr Asp Ser Asp Thr Lys Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Val Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Asn Pro Thr Val Thr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Ile Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 185 HC variable region , No. 185 LC variable region ,(1510/1509)  a) a light chain variable region of seq id no:1509; and b) a binding molecule comprising a heavy chain variable region of seq id no:1510; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Asn Arg Ser Asp Ile Gly Gly Tyr Asn Ser Leu Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Asp Val Asn Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Ala Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Lys Asn Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 64 HC variable region , No. 64 LC variable region ,(1268/1267)  a) a light chain variable region of seq id no:1267; and b) a binding molecule comprising a heavy chain variable region of seq id no:1268; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Val Ala Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Gly Pro Val Leu Gly Leu Ser Lys Trp Leu Glu Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Thr Asp Ile Gly Arg Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Tyr Ala Phe Gly Thr Gly Thr Lys Val Asp Ile Lys , No. 138 HC variable region , No. 138 LC variable region ,(1416/1415)  a) a light chain variable region of seq id no:1415; and b) a binding molecule comprising a heavy chain variable region of seq id no:1416; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Lys Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Pro Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 136 HC variable region , No. 136 LC variable region ,(1412/1411)  a) a light chain variable region of seq id no:1411; and b) a binding molecule comprising a heavy chain variable region of seq id no:1412; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 164 HC variable region , No. 164 LC variable region ,(1468/1467)  a) a light chain variable region of seq id no:1467; and b) a binding molecule comprising a heavy chain variable region of seq id no:1468; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr His Cys Val Arg Val Gly Thr Tyr Asp Ser Ser Gly Tyr Ser Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Ser Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 127 HC variable region , No. 127 LC variable region ,(1394/1393)  a) a light chain variable region of seq id no:1393; and b) a binding molecule comprising the heavy chain variable region of seq id no:1394; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn Tyr Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Tyr Asp Ser Asp Thr Arg Lys Ser Pro Ser Phe Gln Gly Gln Val Thr Met Ser Ala Asp Lys Ser Ile Thr Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Thr Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gln Asp Ser Gly Thr Tyr Gly Trp Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Met Gln Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 183 HC variable region , No. 183 LC variable region ,(1506/1505)  a) a light chain variable region of seq id no:1505; and b) a binding molecule comprising a heavy chain variable region of seq id no:1506; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Thr Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asn Asp Ser Lys Asn Met Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr His Ser Arg Pro Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Ala Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , No. 8 HC variable region , No.8 LC variable region ,(1156/1155)  a) a light chain variable region of seq id no:1155; and b) a binding molecule comprising the heavy chain variable region of seq id no:1156; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Leu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ser Cys Ser Gly Gly Ser Cys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Ala Trp Asp Ser Ser Leu Ser Thr Pro Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 77 HC variable region , No. 77 LC variable region ,(1294/1293)  a) a light chain variable region of seq id no:1293; and b) a binding molecule comprising a heavy chain variable region of seq id no:1294; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Asn Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Thr Tyr Gly Ser Gly Ser Tyr Ser Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 180 HC variable region , No. 180 LC variable region ,(1500/1499)  a) a light chain variable region of seq id no:1499; and b) a binding molecule comprising a heavy chain variable region of seq id no:1500; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asn Gly Glu Thr Ile His Ala Gln Arg Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Thr Pro Met Ile Arg Ala Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Asp Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Gly Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 154 HC variable region , No. 154 LC variable region ,(1448/1447)  a) a light chain variable region of seq id no:1447; and b) a binding molecule comprising the heavy chain variable region of seq id no:1448; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Asn Ile Lys Glu Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Ser Gly Asn Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Phe Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Gln Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 155 HC variable region , No. 155 LC variable region ,(1450/1449)  a) a light chain variable region of seq id no:1449; and b) a binding molecule comprising the heavy chain variable region of seq id no:1450; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Val Ile Ser Trp Val Arg Gln Ala Pro Gly Gin Gly Leu Glu Trp Val Gly Arg Ile Ile Pro Ile Phe Gly Thr Val Lys Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Pro Gly Asp Ser Arg Asp Gly Tyr Asn Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Leu , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 80 HC variable region , No. 80 LC variable region ,(1300/1299)  a) a light chain variable region of seq id no:1299; and b) a binding molecule comprising the heavy chain variable region of seq id no:1300; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Arg Ala Ser Gly Tyr Ala Phe Thr Arg Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Leu Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Gly Ile Ala Val Ala Gly Thr Pro Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Pro , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 46 HC variable region , No. 46 LC variable region ,(1232/1231)  a) a light chain variable region of seq id no:1231; and b) a binding molecule comprising a heavy chain variable region of seq id no:1232; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Ala Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Gly Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Thr Thr Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Glu Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Ile Gly Ser Gly Asp Arg Pro Asp Ala Phe His Leu Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Arg Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 61 HC variable region , No. 61 LC variable region ,(1262/1261)  a) a light chain variable region of seq id no:1261; and b) a binding molecule comprising the heavy chain variable region of seq id no:1262; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 162 HC variable region , No. 162 LC variable region ,(1464/1463)  a) a light chain variable region of seq id no:1463; and b) a binding molecule comprising the heavy chain variable region of seq id no:1464; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Tyr Ser Ser Trp Tyr Gly Pro Arg Thr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 41 HC variable region , No. 41 LC variable region ,(1222/1221)  a) a light chain variable region of seq id no:1221; and b) a binding molecule comprising a heavy chain variable region of seq id no:1222; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro Arg Gly Tyr Ser Gly Tyr Gly Ser Asn Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 107 HC variable region , No. 107 LC variable region ,(1354/1353)  a) a light chain variable region of seq id no:1353; and b) a binding molecule comprising the heavy chain variable region of seq id no:1354; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Glu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn Ala Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Lys Thr Lys Thr Asp Gly Gly Thr Thr Asp Tyr Ala Ala Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Thr Thr Phe Ser Thr Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Leu Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Ala Ala Val Tyr Tyr Cys Leu Gln Tyr Phe Thr Ile Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 10 HC variable region , No.10 LC variable region ,(1160/1159)  a) a light chain variable region of seq id no:1159; and b) a binding molecule comprising the heavy chain variable region of seq id no:1160; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asp Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Thr Tyr Asp Ser Ser Gly Arg Pro Thr Gly Asp Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala Arg Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Val Glu Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Ala Ala Asp Asn Asn Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 12 HC variable region , No.12 LC variable region ,(1164/1163)  a) a light chain variable region of seq id no:1163; and b) a binding molecule comprising the heavy chain variable region of seq id no:1164; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Ser Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Ala Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Ser Pro Ala Val Thr Thr Ala Gly Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 24 HC variable region , No. 24 LC variable region ,(1188/1187)  a) a light chain variable region of seq id no:1187; and b) a binding molecule comprising a heavy chain variable region of seq id no:1188; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Ser Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 91 HC variable region , No. 91 LC variable region ,(1322/1321)  a) a light chain variable region of seq id no:1321; and b) a binding molecule comprising a heavy chain variable region of seq id no:1322; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 76 HC variable region , No. 76 LC variable region ,(1292/1291)  a) a light chain variable region of seq id no:1291; and b) a binding molecule comprising the heavy chain variable region of seq id no:1292; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 81 HC variable region , No. 81 LC variable region ,(1302/1301)  a) a light chain variable region of seq id no:1301; and b) a binding molecule comprising a heavy chain variable region of seq id no:1302; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Gly Ser Asn Ile Gly Ser Asn Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Ser Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 147 HC variable region , No. 147 LC variable region ,(1434/1433)  a) a light chain variable region of seq id no:1433; and b) a binding molecule comprising the heavy chain variable region of seq id no:1434; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Pro Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Gly Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 59 HC variable region , No. 59 LC variable region ,(1258/1257)  a) a light chain variable region of seq id no:1257; and b) a binding molecule comprising a heavy chain variable region of seq id no:1258; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 13 HC variable region , No.13 LC variable region ,(1166/1165)  a) a light chain variable region of seq id no:1165; and b) a binding molecule comprising the heavy chain variable region of seq id no:1166; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Ser Ser Gly Tyr Ser Phe Ile Ser Tyr Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr Leu Gln Trp Ser Ser Leu Glu Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Ser Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 174 HC variable region , No. 174 LC variable region ,(1488/1487)  a) a light chain variable region of seq id no:1487; and b) a binding molecule comprising a heavy chain variable region of seq id no:1488; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Glu Ala Trp Asp Ser Ser Leu Ser Ala Val Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 141 HC variable region , No. 141 LC variable region ,(1422/1421)  a) a light chain variable region of seq id no:1421; and b) a binding molecule comprising the heavy chain variable region of seq id no:1422; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Glu Gly Tyr Asp Ser Ser Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Arg Asn Trp Pro Pro Val Leu Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys , No. 84 HC variable region , No. 84 LC variable region ,(1308/1307)  a) a light chain variable region of seq id no:1307; and b) a binding molecule comprising a heavy chain variable region of seq id no:1308; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Glu Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Phe Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 98 HC variable region , No. 98 LC variable region ,(1336/1335)  a) a light chain variable region of seq id no:1335; and b) a binding molecule comprising a heavy chain variable region of seq id no:1336; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Val Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Thr Ser Leu Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 102 HC variable region , No. 102 LC variable region ,(1344/1343)  a) a light chain variable region of seq id no:1343; and b) a binding molecule comprising a heavy chain variable region of seq id no:1344; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Phe Ile Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Arg Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Pro Leu Thr Gly Thr Thr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 32 HC variable region , No. 32 LC variable region ,(1204/1203)  a) a light chain variable region of seq id no:1203; and b) a binding molecule comprising the heavy chain variable region of seq id no:1204; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Thr Asn Thr Val Asn Trp Tyr Gln His Leu Pro Gly Met Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 25 HC variable region , No. 25 LC variable region ,(1190/1189)  a) a light chain variable region of seq id no:1189; and b) a binding molecule comprising the heavy chain variable region of seq id no:1190; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Glu Asn Asn Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 62 HC variable region , No. 62 LC variable region ,(1264/1263)  a) a light chain variable region of seq id no:1263; and b) a binding molecule comprising a heavy chain variable region of seq id no:1264; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Thr Asp Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 17 HC variable region , No.17 LC variable region ,(1174/1173)  a) a light chain variable region of seq id no:1173; and b) a binding molecule comprising the heavy chain variable region of seq id no:1174; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Asp Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Thr Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Val Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Thr Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 47 HC variable region , No. 47 LC variable region ,(1234/1233)  a) a light chain variable region of seq id no:1233; and b) a binding molecule comprising a heavy chain variable region of seq id no:1234; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Thr Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Met Tyr Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 105 HC variable region , No. 105 LC variable region ,(1350/1349)  a) a light chain variable region of seq id no:1349; and b) a binding molecule comprising the heavy chain variable region of seq id no:1350; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Gly Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Arg Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 124 HC variable region , No. 124 LC variable region ,(1388/1387)  a) a light chain variable region of seq id no:1387; and b) a binding molecule comprising a heavy chain variable region of seq id no:1388; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 170 HC variable region , No. 170 LC variable region ,(1480/1479)  a) a light chain variable region of seq id no:1479; and b) a binding molecule comprising the heavy chain variable region of seq id no:1480; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Val Val Thr Ala Asp Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Ala Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Pro Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 49 HC variable region , No. 49 LC variable region ,(1238/1237)  a) a light chain variable region of seq id no:1237; and b) a binding molecule comprising a heavy chain variable region of seq id no:1238; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Pro , Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Lys Tyr Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys , No. 88 HC variable region , No. 88 LC variable region ,(1316/1315)  a) a light chain variable region of seq id no:1315; and b) a binding molecule comprising a heavy chain variable region of seq id no:1316; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 29 HC variable region , No. 29 LC variable region ,(1198/1197)  a) a light chain variable region of seq id no:1197; and b) a binding molecule comprising a heavy chain variable region of seq id no:1198; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 114 HC variable region , No. 114 LC variable region ,(1368/1367)  a) a light chain variable region of seq id no:1367; and b) a binding molecule comprising a heavy chain variable region of seq id no:1368; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 166 HC variable region , No. 166 LC variable region ,(1472/1471)  a) a light chain variable region of seq id no:1471; and b) a binding molecule comprising the heavy chain variable region of seq id no:1472; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Pro Glu Leu Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Gly Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ile Ser Pro Ala Ile Ile Arg Val Asp Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Asp Ser Ile Thr Ile Ser Cys Thr Gly Thr Arg Gly Asp Ile Gly Ala Tyr Asp Gly Val Ser Trp Tyr Gln Gln Leu Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Ala Val Thr Gln Arg Pro Ser Gly Ile Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 133 HC variable region , No. 133 LC variable region ,(1406/1405)  a) a light chain variable region of seq id no:1405; and b) a binding molecule comprising a heavy chain variable region of seq id no:1406; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 44 HC variable region , No. 44 LC variable region ,(1228/1227)  a) a light chain variable region of seq id no:1227; and b) a binding molecule comprising a heavy chain variable region of seq id no:1228; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Glu Gly Tyr Asp Ser Ser Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Arg Asn Trp Pro Pro Arg Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 90 HC variable region , No. 90 LC variable region ,(1320/1319)  a) a light chain variable region of seq id no:1319; and b) a binding molecule comprising the heavy chain variable region of seq id no:1320; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , No. 65 HC variable region , No. 65 LC variable region ,(1270/1269)  a) a light chain variable region of seq id no:1269; and b) a binding molecule comprising a heavy chain variable region of seq id no:1270; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 57 HC variable region , No. 57 LC variable region ,(1254/1253)  a) a light chain variable region of seq id no:1253; and b) a binding molecule comprising the heavy chain variable region of seq id no:1254; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Ser Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Gly Gly Ser Tyr Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 89 HC variable region , No. 89 LC variable region ,(1318/1317)  a) a light chain variable region of seq id no:1317; and b) a binding molecule comprising the heavy chain variable region of seq id no:1318; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Gly Ser Tyr Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 73 HC variable region , No. 73 LC variable region ,(1286/1285)  a) a light chain variable region of seq id no:1285; and b) a binding molecule comprising a heavy chain variable region of seq id no:1286; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 173 HC variable region , No. 173 LC variable region ,(1486/1485)  a) a light chain variable region of seq id no:1485; and b) a binding molecule comprising a heavy chain variable region of seq id no:1486; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Ser Arg Gly Asp Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr His Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Ala Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ala Tyr Tyr Cys Ala Arg His Gly Thr Ser Gly Tyr Tyr Tyr Pro Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 15 HC variable region , No.15 LC variable region ,(1170/1169)  a) a light chain variable region of seq id no:1169; and b) a binding molecule comprising the heavy chain variable region of seq id no:1170; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Glu Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 2 HC variable region , No.2 LC variable region ,(1144/1143)  a) a light chain variable region of seq id no:1143; and b) a binding molecule comprising the heavy chain variable region of seq id no:1144; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 156 HC variable region , No. 156 LC variable region ,(1452/1451)  a) a light chain variable region of seq id no:1451; and b) a binding molecule comprising the heavy chain variable region of seq id no:1452; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Met Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 115 HC variable region , No. 115 LC variable region ,(1370/1369)  a) a light chain variable region of seq id no:1369; and b) a binding molecule comprising a heavy chain variable region of seq id no:1370; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 5 HC variable region , No.5 LC variable region ,(1150/1149)  a) a light chain variable region of seq id no:1149; and b) a binding molecule comprising a heavy chain variable region of seq id no:1150; 
https://patents.google.com/patent/KR20220013344A/en, Gln Ile Thr Leu Lys Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Gly Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Arg Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 106 HC variable region , No. 106 LC variable region ,(1352/1351)  a) a light chain variable region of seq id no:1351; and b) a binding molecule comprising a heavy chain variable region of seq id no:1352; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Phe Ile Asn Pro Ser Asp Val Thr Thr Tyr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys Ala Arg Ser Arg Ile Ala Pro Thr Glu Asp Phe Phe Asp Tyr Trp Gly Gln Gly Ser Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 190 HC variable region , No. 190 LC variable region ,(1520/1519)  a) a light chain variable region of seq id no:1519; and b) a binding molecule comprising the heavy chain variable region of seq id no:1520. 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Pro Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Ser His Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile Leu Tyr Glu Val Ser Asp Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 58 HC variable region , No. 58 LC variable region ,(1256/1255)  a) a light chain variable region of seq id no:1255; and b) a binding molecule comprising a heavy chain variable region of seq id no:1256; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Leu Thr Glu Leu Pro Ile His Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Met Gly Arg Phe Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Gln Asn Phe Gln Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Leu Thr Thr Val Thr Asn Pro Leu Asn Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Arg Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 148 HC variable region , No. 148 LC variable region ,(1436/1435)  a) a light chain variable region of seq id no:1435; and b) a binding molecule comprising the heavy chain variable region of seq id no:1436; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ile Ser Tyr Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Val Asp Lys Ser Ile Thr Thr Ala Tyr Leu Gln Trp Ser Ser Leu Glu Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly His Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 175 HC variable region , No. 175 LC variable region ,(1490/1489)  a) a light chain variable region of seq id no:1489; and b) a binding molecule comprising a heavy chain variable region of seq id no:1490; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 23 HC variable region , No. 23 LC variable region ,(1186/1185)  a) a light chain variable region of seq id no:1185; and b) a binding molecule comprising a heavy chain variable region of seq id no:1186; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Gln , No. 48 HC variable region , No. 48 LC variable region ,(1236/1235)  a) a light chain variable region of seq id no:1235; and b) a binding molecule comprising a heavy chain variable region of seq id no:1236; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Arg Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Pro Asp Asp Ser Ser Gly Tyr Tyr Pro Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Thr Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Ser Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 70 HC variable region , No. 70 LC variable region ,(1280/1279)  a) a light chain variable region of seq id no:1279; and b) a binding molecule comprising a heavy chain variable region of seq id no:1280; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Arg Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 181 HC variable region , No. 181 LC variable region ,(1502/1501)  a) a light chain variable region of seq id no:1501; and b) a binding molecule comprising the heavy chain variable region of seq id no:1502; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 169 HC variable region , No. 169 LC variable region ,(1478/1477)  a) a light chain variable region of seq id no:1477; and b) a binding molecule comprising the heavy chain variable region of seq id no:1478; 
https://patents.google.com/patent/KR20220013344A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Arg Asn Tyr Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 157 HC variable region , No. 157 LC variable region ,(1454/1453)  a) a light chain variable region of seq id no:1453; and b) a binding molecule comprising the heavy chain variable region of seq id no:1454; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Ser Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Lys Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 93 HC variable region , No. 93 LC variable region ,(1326/1325)  a) a light chain variable region of seq id no:1325; and b) a binding molecule comprising the heavy chain variable region of seq id no:1326; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Ser Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 116 HC variable region , No. 116 LC variable region ,(1372/1371)  a) a light chain variable region of seq id no:1371; and b) a binding molecule comprising a heavy chain variable region of seq id no:1372; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Leu Lys Lys Pro Gly Ser Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Ala Asp Asp Ser Thr Ala Thr Ala Phe Met Glu Leu Ser Ser Leu Gly Tyr Gly Asp Thr Gly Val Tyr Tyr Cys Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Phe Val Ser Thr , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 7 HC variable region , No.7 LC variable region ,(1154/1153)  a) a light chain variable region of seq id no:1153; and b) a binding molecule comprising the heavy chain variable region of seq id no:1154; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ile Ser Tyr Trp Ile Val Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Thr Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Pro Asn Ile Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 31 HC variable region , No. 31 LC variable region ,(1202/1201)  a) a light chain variable region of seq id no:1201; and b) a binding molecule comprising a heavy chain variable region of seq id no:1202; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 146 HC variable region , No. 146 LC variable region ,(1432/1431)  a) a light chain variable region of seq id no:1431; and b) a binding molecule comprising a heavy chain variable region of seq id no:1432; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ala Ser Leu Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 16 HC variable region , No.16 LC variable region ,(1172/1171)  a) a light chain variable region of seq id no:1171; and b) a binding molecule comprising a heavy chain variable region of seq id no:1172; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Phe Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Thr Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 137 HC variable region , No. 137 LC variable region ,(1414/1413)  a) a light chain variable region of seq id no:1413; and b) a binding molecule comprising the heavy chain variable region of seq id no:1414; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Phe Ala Asp Ser Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Asp Phe Leu Thr Asp Tyr Thr Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 56 HC variable region , No. 56 LC variable region ,(1252/1251)  a) a light chain variable region of seq id no:1251; and b) a binding molecule comprising the heavy chain variable region of seq id no:1252; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 128 HC variable region , No. 128 LC variable region ,(1396/1395)  a) a light chain variable region of seq id no:1395; and b) a binding molecule comprising a heavy chain variable region of seq id no:1396; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Asn Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Thr Tyr Gly Ser Gly Ser Tyr Ser Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Ser Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 179 HC variable region , No. 179 LC variable region ,(1498/1497)  a) a light chain variable region of seq id no:1497; and b) a binding molecule comprising the heavy chain variable region of seq id no:1498; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Arg Ser Asn Ile Gly Ile Asn Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Leu Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Glu Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 100 HC variable region , No. 100 LC variable region ,(1340/1339)  a) a light chain variable region of seq id no:1339; and b) a binding molecule comprising a heavy chain variable region of seq id no:1340; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Leu Ser Cys Lys Ala Ser Gly Gly Pro Phe Glu Arg Lys Val Ile Ala Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Gly His Ala Pro Phe Val Arg Lys Pro Thr Tyr Ala Arg Lys Phe Gln Gly Arg Val Thr Leu Thr Ala Asp Asp Ser Thr Ser Thr Ala Phe Met Glu Phe Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Phe Cys Ala Thr Lys Ala Val Thr Thr Tyr Ser Gly Phe Asp Asn Trp Gly Gln Gly Thr Leu Val Phe Val Ser Ala , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 68 HC variable region , No. 68 LC variable region ,(1276/1275)  a) a light chain variable region of seq id no:1275; and b) a binding molecule comprising a heavy chain variable region of seq id no:1276; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Thr Tyr Tyr Tyr Asp Ser Ser Gly Pro Leu Asn Trp Phe Asp Pro Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 151 HC variable region , No. 151 LC variable region ,(1442/1441)  a) a light chain variable region of seq id no:1441; and b) a binding molecule comprising a heavy chain variable region of seq id no:1442; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Phe Phe Gly Thr Ser Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Val Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gln Phe Ser Asp Ser Ser Gly Tyr Gln His Pro Tyr Tyr Asp Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 186 HC variable region , No. 186 LC variable region ,(1512/1511)  a) a light chain variable region of seq id no:1511; and b) a binding molecule comprising a heavy chain variable region of seq id no:1512; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Gly Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 92 HC variable region , No. 92 LC variable region ,(1324/1323)  a) a light chain variable region of seq id no:1323; and b) a binding molecule comprising the heavy chain variable region of seq id no:1324; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Asp Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Asp Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 3 HC variable region , No.3 LC variable region ,(1146/1145)  a) a light chain variable region of seq id no:1145; and b) a binding molecule comprising a heavy chain variable region of seq id no:1146; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Phe Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 108 HC variable region , No. 108 LC variable region ,(1356/1355)  a) a light chain variable region of seq id no:1355; and b) a binding molecule comprising the heavy chain variable region of seq id no:1356; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Arg Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 71 HC variable region , No. 71 LC variable region ,(1282/1281)  a) a light chain variable region of seq id no:1281; and b) a binding molecule comprising the heavy chain variable region of seq id no:1282; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 66 HC variable region , No. 66 LC variable region ,(1272/1271)  a) a light chain variable region of seq id no:1271; and b) a binding molecule comprising a heavy chain variable region of seq id no:1272; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Thr Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 142 HC variable region , No. 142 LC variable region ,(1424/1423)  a) a light chain variable region of seq id no:1423; and b) a binding molecule comprising a heavy chain variable region of seq id no:1424; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Glu Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Pro Val Phe Gly Gly Thr Gln Leu Thr Val Leu , No. 172 HC variable region , No. 172 LC variable region ,(1484/1483)  a) a light chain variable region of seq id no:1483; and b) a binding molecule comprising a heavy chain variable region of seq id no:1484; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Thr Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Asn Asn Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ser Ser His Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Gly Tyr Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Arg Phe Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Leu Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 27 HC variable region , No. 27 LC variable region ,(1194/1193)  a) a light chain variable region of seq id no:1193; and b) a binding molecule comprising a heavy chain variable region of seq id no:1194; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ile Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Ser Arg Ser Thr Tyr Tyr Tyr Tyr Ser Gly Ser Tyr Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Asn Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Pro Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 69 HC variable region , No. 69 LC variable region ,(1278/1277)  a) a light chain variable region of seq id no:1277; and b) a binding molecule comprising a heavy chain variable region of seq id no:1278; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Ala Met Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Pro Thr Gly Trp Tyr Ser Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Val Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Ile Thr Phe Gly Gin Gly Thr Lys Val Glu Ile Lys , No. 130 HC variable region , No. 130 LC variable region ,(1400/1399)  a) a light chain variable region of seq id no:1399; and b) a binding molecule comprising a heavy chain variable region of seq id no:1400; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 160 HC variable region , No. 160 LC variable region ,(1460/1459)  a) a light chain variable region of seq id no:1459; and b) a binding molecule comprising a heavy chain variable region of seq id no:1460; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Thr Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Ala Leu Asn Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 110 HC variable region , No. 110 LC variable region ,(1360/1359)  a) a light chain variable region of seq id no:1359; and b) a binding molecule comprising the heavy chain variable region of seq id no:1360; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Gly Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Ala Thr Thr Lys Phe Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Trp Gly Leu Arg Leu Phe Gly Glu Phe Ser Val Trp Phe Asp Pro Trp Gly Leu Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Ala Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Ser Tyr Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Arg Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ala Leu Arg Gly Pro Leu Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 72 HC variable region , No. 72 LC variable region ,(1284/1283)  a) a light chain variable region of seq id no:1283; and b) a binding molecule comprising a heavy chain variable region of seq id no:1284; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Ser Gly Gly Ser Thr Ser Asn Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Tyr Cys Gly Asp Asp Cys Tyr Pro Val Val Gly Thr Pro Gly Asp Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 182 HC variable region , No. 182 LC variable region ,(1504/1503)  a) a light chain variable region of seq id no:1503; and b) a binding molecule comprising the heavy chain variable region of seq id no:1504; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys His Gln Tyr Gly Thr Ser Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 158 HC variable region , No. 158 LC variable region ,(1456/1455)  a) a light chain variable region of seq id no:1455; and b) a binding molecule comprising the heavy chain variable region of seq id no:1456; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 52 HC variable region , No. 52 LC variable region ,(1244/1243)  a) a light chain variable region of seq id no:1243; and b) a binding molecule comprising a heavy chain variable region of seq id no:1244; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , No. 153 HC variable region , No. 153 LC variable region ,(1446/1445)  a) a light chain variable region of seq id no:1445; and b) a binding molecule comprising a heavy chain variable region of seq id no:1446; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 112 HC variable region , No. 112 LC variable region ,(1364/1363)  a) a light chain variable region of seq id no:1363; and b) a binding molecule comprising the heavy chain variable region of seq id no:1364; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Ser Ser Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Asn Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala His Lys Leu Met Met Tyr Asp Val Ser Asn Arg Pro Ser Gly Ala Tyr Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Ala Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Ser His Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 14 HC variable region , No.14 LC variable region ,(1168/1167)  a) a light chain variable region of seq id no:1167; and b) a binding molecule comprising a heavy chain variable region of seq id no:1168; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Asp Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Pro Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Arg Gly Tyr Ser Gly Tyr Gly Ala Asn Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Glu Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 45 HC variable region , No. 45 LC variable region ,(1230/1229)  a) a light chain variable region of seq id no:1229; and b) a binding molecule comprising a heavy chain variable region of seq id no:1230; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Ala Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys , No. 36 HC variable region , No. 36 LC variable region ,(1212/1211)  a) a light chain variable region of seq id no:1211; and b) a binding molecule comprising a heavy chain variable region of seq id no:1212; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Gly Thr Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Gly Val Ile Ser Tyr Asp Gly Phe Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 94 HC variable region , No. 94 LC variable region ,(1328/1327)  a) a light chain variable region of seq id no:1327; and b) a binding molecule comprising a heavy chain variable region of seq id no:1328; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 111 HC variable region , No. 111 LC variable region ,(1362/1361)  a) a light chain variable region of seq id no:1361; and b) a binding molecule comprising the heavy chain variable region of seq id no:1362; 
https://patents.google.com/patent/KR20220013344A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 20 HC variable region , No.20 LC variable region ,(1180/1179)  a) a light chain variable region of seq id no:1179; and b) a binding molecule comprising the heavy chain variable region of seq id no:1180; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Gly Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Leu Tyr Tyr Tyr Asp Arg Ser Gly Tyr Pro Ile Ser Glu Asp Tyr Phe Asp Tyr Trp Gly Gly Gly Thr Leu Val Thr Val Ser Ala , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 35 HC variable region , No. 35 LC variable region ,(1210/1209)  a) a light chain variable region of seq id no:1209; and b) a binding molecule comprising the heavy chain variable region of seq id no:1210; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Asn Tyr Pro Leu Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Gly Ile Ile Pro Ile Ile Gly Ala Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 34 HC variable region , No. 34 LC variable region ,(1208/1207)  a) a light chain variable region of seq id no:1207; and b) a binding molecule comprising a heavy chain variable region of seq id no:1208; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Ser Gly Tyr Asp Ser Ser Gly Tyr Tyr Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 126 HC variable region , No. 126 LC variable region ,(1392/1391)  a) a light chain variable region of seq id no:1391; and b) a binding molecule comprising a heavy chain variable region of seq id no:1392; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Arg Phe Ser Ser Asn Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Asn Ser Pro Ser Phe Gln Gly Gln Val Thr Met Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Ser Ala Met Tyr Tyr Cys Ala Arg Leu Ala Tyr Phe His Pro Gln Arg Asn Gly Gly Tyr Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Pro , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 78 HC variable region , No. 78 LC variable region ,(1296/1295)  a) a light chain variable region of seq id no:1295; and b) a binding molecule comprising the heavy chain variable region of seq id no:1296; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ser Ser Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Ala Leu Asn Asn Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 67 HC variable region , No. 67 LC variable region ,(1274/1273)  a) a light chain variable region of seq id no:1273; and b) a binding molecule comprising a heavy chain variable region of seq id no:1274; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Arg Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Val Arg Tyr Tyr Asp Phe Trp Ser Gly Trp Asp Val Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 117 HC variable region , No. 117 LC variable region ,(1374/1373)  a) a light chain variable region of seq id no:1373; and b) a binding molecule comprising the heavy chain variable region of seq id no:1374; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Arg Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Glu Glu Leu Gly Pro Tyr Ser Asn Arg Trp Tyr Ser Ser Ser Ser Asp Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 54 HC variable region , No. 54 LC variable region ,(1248/1247)  a) a light chain variable region of seq id no:1247; and b) a binding molecule comprising a heavy chain variable region of seq id no:1248; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Phe Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Phe Cys Ala Arg Gln Glu Trp Leu Arg Gly Gly Phe Asp Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 184 HC variable region , No. 184 LC variable region ,(1508/1507)  a) a light chain variable region of seq id no:1507; and b) a binding molecule comprising a heavy chain variable region of seq id no:1508; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Asn Tyr Val Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Phe Ile Pro Val Phe Gly Ile Ala Asp Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Gly Leu Phe Asp Trp Leu Leu Pro Arg Ser Arg His Arg Asp Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 145 HC variable region , No. 145 LC variable region ,(1430/1429)  a) a light chain variable region of seq id no:1429; and b) a binding molecule comprising the heavy chain variable region of seq id no:1430; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys , No. 159 HC variable region , No. 159 LC variable region ,(1458/1457)  a) a light chain variable region of seq id no:1457; and b) a binding molecule comprising a heavy chain variable region of seq id no:1458; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Phe Tyr Ala Ile Ser Trp Met Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Phe Gly Thr Ala Lys Tyr Ala Gln Arg Phe Gln Asp Arg Val Thr Phe Ile Ala Asp Asp Thr Ser Thr Ala Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Ile Tyr Arg Gly Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Gly Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 26 HC variable region , No. 26 LC variable region ,(1192/1191)  a) a light chain variable region of seq id no:1191; and b) a binding molecule comprising a heavy chain variable region of seq id no:1192; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 40 HC variable region , No. 40 LC variable region ,(1220/1219)  a) a light chain variable region of seq id no:1219; and b) a binding molecule comprising the heavy chain variable region of seq id no:1220; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Asp Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ala Thr Tyr Asp Ser Ser Gly Arg Pro Thr Gly Asp Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Arg Ile Thr Cys Ser Gly Asp Val Leu Ala Lys Lys Tyr Ala Arg Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Lys Asp Ser Glu Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Ser Ser Gly Thr Thr Val Thr Leu Thr Ile Ser Gly Ala Gln Val Glu Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Ala Ala Asp Asn Asn Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 123 HC variable region , No. 123 LC variable region ,(1386/1385)  a) a light chain variable region of seq id no:1385; and b) a binding molecule comprising the heavy chain variable region of seq id no:1386; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 74 HC variable region , No. 74 LC variable region ,(1288/1287)  a) a light chain variable region of seq id no:1287; and b) a binding molecule comprising a heavy chain variable region of seq id no:1288; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Ser Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 113 HC variable region , No. 113 LC variable region ,(1366/1365)  a) a light chain variable region of seq id no:1365; and b) a binding molecule comprising a heavy chain variable region of seq id no:1366; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Gly Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 39 HC variable region , No. 39 LC variable region ,(1218/1217)  a) a light chain variable region of seq id no:1217; and b) a binding molecule comprising a heavy chain variable region of seq id no:1218; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gly Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Met Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 167 HC variable region , No. 167 LC variable region ,(1474/1473)  a) a light chain variable region of seq id no:1473; and b) a binding molecule comprising a heavy chain variable region of seq id no:1474; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Gly Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Gln Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 22 HC variable region , No. 22 LC variable region ,(1184/1183)  a) a light chain variable region of seq id no:1183; and b) a binding molecule comprising the heavy chain variable region of seq id no:1184; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 140 HC variable region , No. 140 LC variable region ,(1420/1419)  a) a light chain variable region of seq id no:1419; and b) a binding molecule comprising the heavy chain variable region of seq id no:1420; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asp Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Gly Leu Tyr Gly Ser Gly Trp Ser Thr Tyr Gln Tyr Tyr Ala Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gly Gln Thr Gln Gln Leu Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 85 HC variable region , No. 85 LC variable region ,(1310/1309)  a) a light chain variable region of seq id no:1309; and b) a binding molecule comprising the heavy chain variable region of seq id no:1310; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Gln Tyr Leu His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Tyr Gly Gly Ser Thr Thr Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Pro Ser Gly Tyr Tyr Gly Asp Tyr Glu Gly Asp Ala Phe Asp Ile Trp Gly Gin Gly Thr Met Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Ala Ser Lys Asp Ala Ala Ser Ala Tyr Leu Thr Ile Thr Gly Leu Gln Ala Glu Asp Glu Gly Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Arg Leu Arg Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 79 HC variable region , No. 79 LC variable region ,(1298/1297)  a) a light chain variable region of seq id no:1297; and b) a binding molecule comprising a heavy chain variable region of seq id no:1298; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Thr Ser Gly Gly Thr Phe Ser Asn Tyr Pro Leu Thr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Gly Ile Ile Pro Ile Ile Gly Ala Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Phe Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Arg Gly Tyr Ser Gly Tyr Gly Ala Ala Tyr Tyr Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 189 HC variable region , No. 189 LC variable region ,(1518/1517)  a) a light chain variable region of seq id no:1517; and b) a binding molecule comprising a heavy chain variable region of seq id no:1518; and 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Val Thr Phe Ser Arg Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Leu Gly Thr Ala Asp Tyr Pro Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Thr Asp Glu Ser Thr Thr Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Leu Tyr Tyr Tyr Asp Arg Ser Gly Asn Ala Arg Thr Asp Asp Tyr Phe Asp His Trp Ala Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Pro Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 50 HC variable region , No. 50 LC variable region ,(1240/1239)  a) a light chain variable region of seq id no:1239; and b) a binding molecule comprising a heavy chain variable region of seq id no:1240; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Val Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 30 HC variable region , No. 30 LC variable region ,(1200/1199)  a) a light chain variable region of seq id no:1199; and b) a binding molecule comprising the heavy chain variable region of seq id no:1200; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Thr Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 120 HC variable region , No. 120 LC variable region ,(1380/1379)  a) a light chain variable region of seq id no:1379; and b) a binding molecule comprising a heavy chain variable region of seq id no:1380; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 18 HC variable region , No.18 LC variable region ,(1176/1175)  a) a light chain variable region of seq id no:1175; and b) a binding molecule comprising the heavy chain variable region of seq id no:1176; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Ser Ser Leu Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Arg Tyr Ser Ser Asn Trp Tyr Glu Ala Trp Thr Pro Arg Gly Ile Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Ser Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Arg Leu Ser Ala Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 1 HC variable region , No.1 LC variable region ,(1142/1141)  a) a light chain variable region of seq id no:1141; and b) a binding molecule comprising a heavy chain variable region of seq id no:1142; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Arg Gly Gly Ser Tyr Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 97 HC variable region , No. 97 LC variable region ,(1334/1333)  a) a light chain variable region of seq id no:1333; and b) a binding molecule comprising the heavy chain variable region of seq id no:1334; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 43 HC variable region , No. 43 LC variable region ,(1226/1225)  a) a light chain variable region of seq id no:1225; and b) a binding molecule comprising a heavy chain variable region of seq id no:1226; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Arg Gly Ser Gly Tyr Ser Phe Thr Ser His Trp Ile Ala Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Ser Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Gly Pro Asn Leu Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Thr Asn Asn Arg Arg Pro Ser Gly Ala Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 37 HC variable region , No. 37 LC variable region ,(1214/1213)  a) a light chain variable region of seq id no:1213; and b) a binding molecule comprising a heavy chain variable region of seq id no:1214; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ala Pro Ser Asp Leu Ser Phe Ile Trp Thr Gly Tyr Tyr Ser Glu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Asn Tyr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 28 HC variable region , No. 28 LC variable region ,(1196/1195)  a) a light chain variable region of seq id no:1195; and b) a binding molecule comprising the heavy chain variable region of seq id no:1196; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Ala Ala Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 178 HC variable region , No. 178 LC variable region ,(1496/1495)  a) a light chain variable region of seq id no:1495; and b) a binding molecule comprising a heavy chain variable region of seq id no:1496; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys Ala Arg Gly Pro Asn Ile Tyr Asn Trp Phe Asp Ser Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 83 HC variable region , No. 83 LC variable region ,(1306/1305)  a) a light chain variable region of seq id no:1305; and b) a binding molecule comprising the heavy chain variable region of seq id no:1306; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Phe Leu Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Arg Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Thr Gly Lys Pro Tyr Tyr Cys Thr Gly Ser Thr Cys Tyr Gln Pro Leu Gly Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Ser Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Gly Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 152 HC variable region , No. 152 LC variable region ,(1444/1443)  a) a light chain variable region of seq id no:1443; and b) a binding molecule comprising the heavy chain variable region of seq id no:1444; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 82 HC variable region , No. 82 LC variable region ,(1304/1303)  a) a light chain variable region of seq id no:1303; and b) a binding molecule comprising the heavy chain variable region of seq id no:1304; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ile Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Thr Gly Tyr Asp Ser Ser Gly Tyr Tyr Gln Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , No. 60 HC variable region , No. 60 LC variable region ,(1260/1259)  a) a light chain variable region of seq id no:1259; and b) a binding molecule comprising a heavy chain variable region of seq id no:1260; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ala Ile Trp His Asp Gly Tyr Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Lys Ala Ala Asp Tyr Trp Gly Gln Gly Thr Leu Val Ile Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Arg Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Lys Thr Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , No. 103 HC variable region , No. 103 LC variable region ,(1346/1345)  a) a light chain variable region of seq id no:1345; and b) a binding molecule comprising the heavy chain variable region of seq id no:1346; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Asn Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys , No. 87 HC variable region , No. 87 LC variable region ,(1314/1313)  a) a light chain variable region of seq id no:1313; and b) a binding molecule comprising a heavy chain variable region of seq id no:1314; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asn Val Gly Asp Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Thr Asn Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Gly Ser Thr Pro Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 163 HC variable region , No. 163 LC variable region ,(1466/1465)  a) a light chain variable region of seq id no:1465; and b) a binding molecule comprising a heavy chain variable region of seq id no:1466; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Tyr Ile Gln Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala His Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ser Tyr Tyr Asn Val Met Tyr Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , No. 177 HC variable region , No. 177 LC variable region ,(1494/1493)  a) a light chain variable region of seq id no:1493; and b) a binding molecule comprising a heavy chain variable region of seq id no:1494; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Arg Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ile Arg Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Pro Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Lys Val Asn Tyr Ala Gln Lys Phe Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Val Asn Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Gly Ser Thr Trp Tyr Gly Gly Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Leu Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 11 HC variable region , No.11 LC variable region ,(1162/1161)  a) a light chain variable region of seq id no:1161; and b) a binding molecule comprising the heavy chain variable region of seq id no:1162; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser Ser , Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro Arg Arg Val Thr Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , No. 21 HC variable region , No. 21 LC variable region ,(1182/1181)  a) a light chain variable region of seq id no:1181; and b) a binding molecule comprising a heavy chain variable region of seq id no:1182; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Val Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 144 HC variable region , No. 144 LC variable region ,(1428/1427)  a) a light chain variable region of seq id no:1427; and b) a binding molecule comprising the heavy chain variable region of seq id no:1428; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Glu Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ile Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Leu Gly Gly Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , No. 96 HC variable region , No. 96 LC variable region ,(1332/1331)  a) a light chain variable region of seq id no:1331; and b) a binding molecule comprising a heavy chain variable region of seq id no:1332; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Asp His Gly Met Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Arg Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 121 HC variable region , No. 121 LC variable region ,(1382/1381)  a) a light chain variable region of seq id no:1381; and b) a binding molecule comprising a heavy chain variable region of seq id no:1382; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Pro Leu Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Pro Arg Gly Gln Asp Tyr Gly Asp Tyr Gly Phe Leu Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 143 HC variable region , No. 143 LC variable region ,(1426/1425)  a) a light chain variable region of seq id no:1425; and b) a binding molecule comprising a heavy chain variable region of seq id no:1426; 
https://patents.google.com/patent/KR20220013344A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser His Lys Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Asn Cys Gly Gly Asp Cys Gly Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Ser Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 135 HC variable region , No. 135 LC variable region ,(1410/1409)  a) a light chain variable region of seq id no:1409; and b) a binding molecule comprising the heavy chain variable region of seq id no:1410; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Ala Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 6 HC variable region , No.6 LC variable region ,(1152/1151)  a) a light chain variable region of seq id no:1151; and b) a binding molecule comprising a heavy chain variable region of seq id no:1152; 
https://patents.google.com/patent/KR20220013344A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Ser Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Leu Gly Ile Ile Asn Arg Ser Gly Gly Ser Thr Ile Tyr Ala Gln Thr Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met Glu Met Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Arg His Ser Leu Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Val Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Arg Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Thr Ser Leu Ser Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 119 HC variable region , No. 119 LC variable region ,(1378/1377)  a) a light chain variable region of seq id no:1377; and b) a binding molecule comprising a heavy chain variable region of seq id no:1378; 
https://patents.google.com/patent/CN113683686A/en, Gln Val Gln Leu Lys Gln Ser Gly Pro Ser Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Met Trp Arg Gly Gly Asn Thr Asp Tyr Asn Ala Ala Phe Met Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys Asn Gly Gly Ala His Ala Met Asp Phe Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asp Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Asn Asn Glu Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(3/9) in another preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown as seq id no:3, and the amino acid sequence of the light chain variable region of the antibody is shown as seq id no:9."
https://patents.google.com/patent/CN113683686A/en, Glu Val Gln Leu Gln Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Val Thr Gly Asp Ser Ile Thr Asn Gly Tyr Trp Asn Trp Ile Arg Lys Phe Pro Gly Asn Lys Leu Glu Tyr Met Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Tyr Tyr Ser Pro Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln His Tyr Leu Gln Leu Asn Ser Val Thr Ser Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Ser Asp Tyr His Gly Ser Lys Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly His Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Arg Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),"(15/21) in another preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:15, and the amino acid sequence of the light chain variable region of the antibody is shown in seq id no:21."
https://patents.google.com/patent/WO2022003530A1/en,,,,,(333/334) or the heavy chain of said antibody having seq id no:333 and the light chain of said antibody having seq id no:334
https://patents.google.com/patent/WO2022003530A1/en,,,,,(333/332) >seq id no:332 variable domain of light chain of mad0103j13 eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrat giparf sgsgsgtdftltis slepedf avyycqqrsnwppftfgpgtkvdikrt >seq id no:333 heavy chain of mad0103j13 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(171/170) >seq id no:170 variable domain of light chain of mad0101h20 eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnrat giparf sgsgsgtdftltis slepedf a v y y c qlrgnwpp wtf gqgtk veikrt >seq id no:171 heavy chain ofmad0101h20
https://patents.google.com/patent/WO2022003530A1/en,,,,,(61/62) vh having seq id no:61 and said vl having seq id no:62 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(151/152) vh having seq id no:151 and said vl having seq id no:152 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(45/44) >seq id no:44 variable domain of light chain of mad0102f05 aiqmtqspsslsasvgdrvtitcrasqdirnnlgwfqqkpgkapkrliyaastlqr gvpsrfsgsgsgteftltis slqpedf atyy clqhn s ylwtf gqgtkveikrt >seq id no:45 heavy chain of mad0102f05
https://patents.google.com/patent/WO2022003530A1/en,,,,,(187/188) vh having seq id no:187 and said vl having seq id no:188 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(99/98) >seq id no:98 variable domain of light chain of mad0041k22 divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllvygassra tgipgrfsgsgsgtdftltisrlepedfavyycqqyggpltfgggtkveikrt >seq id no:99 heavy chain of mad0041k22
https://patents.google.com/patent/WO2022003530A1/en,,,,,(97/98) vh having seq id no:97 and said vl having seq id no:98 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(205/206) vh having seq id no:205 and said vl having seq id no:206 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(115/116) vh having seq id no:115 and said vl having seq id no:116 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(81/80) >seq id no:80 variable domain of light chain of mad0041i21 aiqmtqspsflsasvgdrvtitcrasqgissslawyqqkpgkapklliyaastlqsg vpsrfsgsgs gtef tltis slqpedf at y y c qqln s yp s ttf gggtk veikrt >seq id no:81 heavy chain of mad0041i21 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(189/188) >seq id no:188 variable domain of light chain of mad0102f20 eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastrat glparfsgsgsgteftltisslqsedfavyycqqynnwppltfgqgtkleikrt >seq id no:189 heavy chain of mad0102f20 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(79/80) vh having seq id no:79 and said vl having seq id no:80 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(43/44) vh having seq id no:43 and said vl having seq id no:44 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(297/296) >seq id no:296 variable domain of light chain of mad0008d12 aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqs gvp srf sgsgsgt qftltis slqpedf at yy crhln s yppitf gqgtrleikrt >seq id no:297 heavy chain of mad0008d12 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(153/152) >seq id no:152 variable domain of light chain of mad0100l19 divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqt gvpsrfsgsgsgtdftftisslqpediatyycqqydhllitfgqgtrleikrt >seq id no:153 heavy chain ofmad0100l19 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(133/134) vh having seq id no:133 and said vl having seq id no:134 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(169/170) vh having seq id no:169 and said vl having seq id no:170 or 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(207/206) >seq id no:206 variable domain of light chain of mad0102f22 eivmtqspgtlslspgeratlscrasqsisssylawyqqkpgqaprlllygassrat gipdrf sgsgsgtdftltisrlepedf avyycqq ygs spqtfgqgtkleikrt >seq id no:207 heavy chain of mad0102f22
https://patents.google.com/patent/WO2022003530A1/en,,,,,"(9/10) 13. the human monoclonal antibody according to any one of the claims from 1 to 12, wherein the heavy chain of said antibody having seq id no:9 and the light chain of said antibody having seq id no:10"
https://patents.google.com/patent/WO2022003530A1/en,,,,,(27/26) >seq id no:26 variable domain of light chain of mad0100i14 eivmtqspgtlslapgeratlscrasqsvsssylgwyqqkpgqaprlliygassra tgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveikrt >seq id no:27 heavy chain of mad0100i14 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(315/314) >seq id no:314 variable domain of light chain of mad0102i15 aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqs gvp srf s gs gs gtef tltis slqpedf at y y c qqln s yprtf gqgtkleikrt >seq id no:315 heavy chain ofmad0102i15 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(243/242) >seq id no:242 variable domain of light chain of mad0008c14 aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqs gvpsrfsgsgsgteftltisslqpedfatyycqqvnsyptfgqgtrleikrt >seq id no:243 heavy chain of mad0008c14 
https://patents.google.com/patent/WO2022003530A1/en,,,,,(25/26) vh having seq id no:25 and said vl having seq id no:26
https://patents.google.com/patent/WO2022003530A1/en,,,,,(63/62) >seq id no:62 variable domain of light chain of mad0041g12 divmt q sp aals v spgeratl scrasq s v s snl aw y qqkpgq aprlli y gastrat gip arf sgsw sgteftltis slqsedlavyycqqynnwltf gggtkveikrt >seq id no:63 heavy chain of mad0041g12
https://patents.google.com/patent/WO2022003530A1/en,,,,,(7/8) vh having seq id no:7 and said vl having seq id no:8
https://patents.google.com/patent/WO2022003530A1/en,,,,,(279/278) >seq id no:278 variable domain of light chain of mad0008b07 aiqmtqspsslsasvgdrvtitcrasqginnylawfqqkpgkapksliyaasslqs gvpskfsgsgsgtdftltisslqpedfatyycqqynsypftfgqgtrleikrt >seq id no:279 heavy chain of mad0008b07
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(179/180) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:179 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:180, or a variant thereof; or c"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(149/150) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:149 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:150, or a variant thereof; or n"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(193/194) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:193 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:194, or a variant thereof; or j "
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(171/172) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:171 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:172, or a variant thereof; or y"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(151/152) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:151 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:152, or a variant thereof; or o"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(189/190) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:189 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:190, or a variant thereof; or h"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(185/186) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:185 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:186, or a variant thereof; or f"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(183/184) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:183 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:184, or a variant thereof; or e"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(187/188) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:187 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:188, or a variant thereof; or g"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(177/178) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:177 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:178, or a variant thereof; or b"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(195/196) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:195 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:196, or a variant thereof; or k"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(141/142) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:141 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:142, or a variant thereof; or j "
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(173/174) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:173 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:174, or a variant thereof; or z"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(157/158) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:157 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:158, or a variant thereof; or r"
https://patents.google.com/patent/WO2021229561A1/en,,,,,(199/200) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:199 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:200
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(191/192) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:191 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:192, or a variant thereof; or i"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(165/166) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:165 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:166, or a variant thereof; or v"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(153/154) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:153 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:154, or a variant thereof; or p"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(169/170) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:169 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:170, or a variant thereof; or x"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(23/24) (d) a heavy chain variable region of the amino acid sequence denoted by seq id no:23 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:24, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(145/146) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:145 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:146, or a variant thereof; or l"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(163/164) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:163 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:164, or a variant thereof; or u"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(147/148) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:147 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:148, or a variant thereof; or m"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(167/168) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:167 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:168, or a variant thereof; or w"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(175/176) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:175 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:176, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(31/32)  a heavy chain variable region of the amino acid sequence denoted by seq id no:31 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:32, or a variant thereof. "
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(143/144) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:143 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:144, or a variant thereof; or k"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(21/22) (c) a heavy chain variable region of the amino acid sequence denoted by seq id no:21 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:22, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(29/30) (g) a heavy chain variable region of the amino acid sequence denoted by seq id no:29 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:30, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(181/182) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:181 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:182, or a variant thereof; or d"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(17/18) (a) a heavy chain variable region of the amino acid sequence denoted by seq id no:17 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:18, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(25/26) (e) a heavy chain variable region of the amino acid sequence denoted by seq id no:25 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:26, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(155/156) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:155 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:156, or a variant thereof; or q"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(197/198) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:197 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:198, or a variant thereof; or l"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(161/162) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:161 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:162, or a variant thereof; or t"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(27/28) (f) a heavy chain variable region of the amino acid sequence denoted by seq id no:27 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:28, or a variant thereof"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(159/160) a heavy chain variable region comprising the amino acid sequence denoted by seq id no:159 or a variant thereof and a light chain variable region comprising the amino acid sequence denoted by seq id no:160, or a variant thereof; or s"
https://patents.google.com/patent/WO2021229561A1/en,,,,,"(19/20) (b) a heavy chain variable region of the amino acid sequence denoted by seq id no:19 or a variant thereof and a light chain variable region of the amino acid sequence denoted by seq id no:20, or a variant thereof"
https://patents.google.com/patent/CN113766928A/en,,,,,"(640/646) the isolated antibody of claim 26, comprising an hcvr comprising the amino acid sequence set forth in seq id no:640 and an lcvr comprising the amino acid sequence set forth in seq id no:646."
https://patents.google.com/patent/CN113766928A/en,,,,,"(202/210) the isolated antibody of claim 6, comprising an hcvr comprising the amino acid sequence set forth in seq id no:202 and an lcvr comprising the amino acid sequence set forth in seq id no:210."
https://patents.google.com/patent/CN113766928A/en,,,,,"(216/218) in some embodiments, the isolated antibody comprises: a heavy chain comprising the amino acid sequence set forth in seq id no:216 and a light chain comprising the amino acid sequence set forth in seq id no:218"
https://patents.google.com/patent/CN113766928A/en,,,,,"(654/656) in some embodiments, the isolated antibody comprises: a heavy chain comprising the amino acid sequence set forth in seq id no:654 and a light chain comprising the amino acid sequence set forth in seq id no:656"
https://patents.google.com/patent/US7622112B2/en,,,,,(5/14)  monoclonal antibody f26g18 having a light chain amino acid sequence as set forth in seq id no:14 and a heavy chain amino acid sequence as set forth in seq id no:5.
https://patents.google.com/patent/CN111995674A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr Ala Met Asn Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Lys Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Thr Pro Tyr Tyr Gly Asn Tyr Ala Asp Trp Phe Thr Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Artificial sequence,  Artificial sequence,"(7/8) the heavy chain amino acid sequence of the human-mouse chimeric whole antibody mhc3 is shown as seq id no:7, and the light chain amino acid sequence is shown as seq id no:8."
https://patents.google.com/patent/CN111995674A/en, gaggtgcagc ttgttgagtc tgggggagac ttagtgaagc ctggagggtc cctgaaactc tcctgtgcag cctctggatt caccttcaat acctacgcca tgaactgggt ccgccagact ccaggaaagg gtttggaatg ggttgctcgc ataagaagta aaagtaataa ttatgcaaca tattatgccg attcagtgaa agacaggttc accatctcca gagatgattc gcaaagcatg ctctatctgc aaatgaacaa cttgaaaact gaggacacag ccatgtatta ctgtgtgaca ccctactatg gtaattacgc agactggttt acttactggg gccaaggaac ctcagtcacc gtgtcctcag ctagcaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc acctctgggg gcacagcggc cctgggctgc ctggtcaagg actacttccc cgaaccggtg acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc cgggaggaga tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc ttcctctata gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtcc ccgggtaaat ga , gatgttgtga tgacccagac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc atctcttgca gatctagtca gagccttgta cacagtaatg gaaacaccta tttacattgg tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc agcagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac acatgttccg tacacgttcg gaggggggac caagttggaa ataaaacgta cggtggcggc gccatctgtc ttcatcttcc cgccatctga tgagcagttg aaatctggta ccgctagcgt tgtgtgcctg ctgaataact tctatcccag agaggccaaa gtacagtgga aggtggataa cgccctccaa tcgggtaact cccaggagag tgtcacagag caggacagca aggacagcac ctacagcctc agcagcaccc tgacgctgag caaagcagac tacgagaaac acaaagtcta cgcctgcgaa gtcacccatc agggcctgag ctcgcccgtc acaaagagct tcaacagggg agagtgttag ,  Artificial sequence,  Artificial sequence,"(11/12) in one embodiment of the invention, the recombinant expression vector for expressing the heavy chain of the antibody is obtained by cloning seq id no:11 (encoding gene of the heavy chain of the antibody) between enzyme cutting sites hind iii and bamh i of pcdna3.1(+) vector; cloning seq id no:12 (coding gene of antibody light chain) between enzyme cutting site hind iii and bamh i of pcdna3.1(+) vector to obtain recombinant expression vector for expressing the light chain of the antibody"
https://patents.google.com/patent/CN114044821A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Asn Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Met Thr Gly Ser Ser Ile Asp Ser Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Gly Glu Leu Leu Trp Phe Gly Asp Leu Leu His Asn Trp Phe Asp Pro Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile His Gly Ala Ser Thr Arg Ala Thr Gly Leu Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Asp Ser Trp Pro Gly Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys Arg , Homo sapiens, Homo sapiens,"(1/5) in a preferred embodiment, the amino acid sequence of the heavy chain variable region of the antibody is shown in seq id no:1, and the amino acid sequence of the light chain variable region is shown in seq id no:5."
https://patents.google.com/patent/WO2021218879A1/en,,,,,(50/27)  the cov2-hb27-fe4-igg1 heavy chain (seq id no:50) expression vector and cov2-hb27 light chain (seq id no:27) expression vector plasmids were extracted and transfected into hek-293 (fut8 gene knockou
https://patents.google.com/patent/WO2021218879A1/en,,,,,"(18/20)  its heavy chain containing signal peptide the amino acid sequence of the light chain and the light chain are shown in seq id no:18/19, respectively, which respectively include the heavy chain/light chain signal peptide amino acid sequence (seq id no:20/21) connected in sequence"
https://patents.google.com/patent/WO2021218879A1/en,,,,,"(26/27)  the cov2-hb27 heavy chain (seq id no:26) expression vector and cov2-hb27 light chain (seq id no:27) expression vector plasmids were extracted, transfected into hek-293 (fut8 gene knockou"
https://patents.google.com/patent/CN112521494B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Met Glu Val Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Leu Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Glu Asn Asp Asn Val Asn Trp Phe Gln Gln Gln Val Pro Gly Ser Thr Pro Lys Leu Val Ile Tyr Asn Asp Arg Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Tyr Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Val Ala Trp Asp Ala Ser Leu Gln Ser Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Artificial sequence, Artificial sequence,"(7/8) specifically, the sequences of the light chain variable region and the heavy chain variable region are respectively the same as seq id no:8 and seq id no:7."
https://patents.google.com/patent/WO2021194896A1/en,,,,,(78/85) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:78 a vl having an amino acid sequence of seq id no:85
https://patents.google.com/patent/WO2021194896A1/en,,,,,(71/80) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:71 a vl having an amino acid sequence of seq id no:80
https://patents.google.com/patent/WO2021194896A1/en,,,,,(69/80) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:69 a vl having an amino acid sequence of seq id no:80
https://patents.google.com/patent/WO2021194896A1/en,,,,,"(77/84) . [0070] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:77 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:84 (covid19_r01_a"
https://patents.google.com/patent/WO2021194896A1/en,,,,,"(73/81) . [0066] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:73 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:81 (covid19_p04_d"
https://patents.google.com/patent/WO2021194896A1/en,,,,,(76/87) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:76 a vl having an amino acid sequence of seq id no:87
https://patents.google.com/patent/WO2021194896A1/en,,,,,"(72/80) . [0065] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:72 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:80 (covid19_r01_b"
https://patents.google.com/patent/WO2021194896A1/en,,,,,"(74/82) . [0067] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:74 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:82 (covid19_p04_b"
https://patents.google.com/patent/WO2021194896A1/en,,,,,"(70/80) . [0063] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:70 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:80 (covid19_p04_g"
https://patents.google.com/patent/WO2021194896A1/en,,,,,(75/83) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:75 a vl having an amino acid sequence of seq id no:83
https://patents.google.com/patent/WO2021194896A1/en,,,,,"(79/86) . [0072] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:79 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:86 (covid19_r01_b"
https://patents.google.com/patent/WO2021194896A1/en,,,,,"(76/83) . [0069] in one instance, an antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:76 a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:83 (covid19_p04_e"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(278/334) [0163] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:278 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:334"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(231/285) [0112] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:231 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:285"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(250/305) [0132] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:250 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:305"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(264/318) [0146] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:264 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:318"
https://patents.google.com/patent/WO2021194985A1/en,,,,,(244/298) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:244 and a vl having an amino acid sequence of seq id no:298
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(245/299) [0126] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:245 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:299"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(262/316) [0144] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:262 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:316"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(228/282) [0109] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:228 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:282"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(247/301) [0128] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:247 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:301"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(271/327) [0155] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:271 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:327"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(262/335) [0164] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:262 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:335"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(279/336) [0165] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:279 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:336"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(275/331) [0159] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:275 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:331"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(235/289) [0116] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:235 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:289"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(276/332) [0160] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:276 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:332"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(248/303) [0130] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:248 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:303"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(256/311) [0138] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:256 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:311"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(273/329) [0157] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:273 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:329"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(246/300) [0127] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:246 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:300"
https://patents.google.com/patent/WO2021194985A1/en,,,,,(241/295) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:241 and a vl having an amino acid sequence of seq id no:295
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(238/292) [0119] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:238 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:292"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(229/283) [0110] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:229 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:283"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(234/288) [0115] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:234 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:288"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(233/287) [0114] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:233 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:287"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(269/325) [0153] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:269 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:325"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(261/315) [0143] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:261 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:315"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(252/307) [0134] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:252 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:307"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(280/337) [0166] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:280 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:337"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(240/319) [0147] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:319"
https://patents.google.com/patent/WO2021194985A1/en,,,,,(240/324) [0009] the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:240 and a vl having an amino acid sequence of seq id no:324
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(281/338) [0167] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:281 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:338"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(268/323) [0151] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:268 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:323"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(243/297) [0124] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:243 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:297"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(230/284) [0111] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:230 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:284"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(232/286) [0113] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:232 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:286"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(237/291) the antibody or antigen-binding fragment of 1 or 5, that comprises a vh having an amino acid sequence of seq id no:237 and a vl having an amino acid sequence of seq id no:291"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(253/308) [0135] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:253 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:308"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(240/294) [0121] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:294"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(267/322) [0150] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:267 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:322"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(258/313) [0140] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:258 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:313"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(277/324) [0162] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:277 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:324"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(236/333) [0161] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:333"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(259/309) [0141] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:259 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:309"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(254/309) [0136] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:254 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:309"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(242/296) [0123] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:242 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:296"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(270/326) [0154] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:270 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:326"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(240/302) . [0129] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:240 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:302 (covid19_p08_g"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(236/290) [0117] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:236 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:290"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(249/304) [0131] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:249 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:304"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(251/306) [0133] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:251 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:306"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(265/320) [0148] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:265 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:320"
https://patents.google.com/patent/WO2021194985A1/en,,,,,(272/328) the antibody or the antigen-binding fragment can comprise a vh having an amino acid sequence of seq id no:272 and a vl having an amino acid sequence of seq id no:328
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(260/314) [0142] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:260 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:314"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(255/310) [0137] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:255 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:310"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(266/321) [0149] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:266 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:321"
https://patents.google.com/patent/WO2021194985A1/en,,,,,"(263/317) [0145] in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:263 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:317"
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Thr Ser Val Lys Val Ser Cys Arg Ala Ser Gly Gly Thr Val Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Phe Gly Thr Val Asn Tyr Thr Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Ala Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Thr Ser Gly Trp Tyr Gly Gly Arg Asn Trp Leu Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Asp Ile Val Met Thr Gln Ser Pro Phe Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ala Ile Tyr Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Gly Ala Ser Gly Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr His Ser Thr Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg , MERS-CoV Spike S1 KNIH-90, Mers-cov spike S1 KNIH-90,(48/55)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:48 and a light chain variable region having an amino acid sequence represented by seq id no:55
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Glu Asp Thr Phe Arg Arg Phe Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Ala Phe Phe Gly Ser Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Val Tyr Met Glu Leu Gly Ser Leu Arg Phe Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Gly Phe Gly Val Val Thr Pro Pro Asn Ile Tyr Ser Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Thr Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Gly Ser Ser Pro Gln Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys arg , MERS-CoV Spike S1 KNIH-95, Mers-cov spike S1 KNIH-95,(49/56)  and  an antibody comprising a heavy chain variable region having the amino acid sequence represented by seq id no:49 and a light chain variable region having the amino acid sequence represented by seq id no:56  an antibody or antigen-binding fragment thereof selected from the group consisting of:  
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ile Asp Tyr Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ala Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Tyr Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Asp Tyr Leu Ala Ala Gly Gly Leu Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser , Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Glu Leu Leu Ile Tyr Gly Ala Ser Asn Leu Lys Pro Gly Val Pro Ser Arg Phe Ser Gly Ser Ala Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Met Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys Tyr Asp Ser Ala Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg , MERS-CoV Spike S1 KNIH-88, Mers-cov spike S1 KNIH-88,(47/54)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:47 and a light chain variable region having an amino acid sequence represented by seq id no:54
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Phe Ser Thr Tyr Glu Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Leu Gly Trp Met Asn Pro Lys Ser Gly Ile Thr Gly Tyr Ala Pro Lys Phe Gln Gly Arg Val Thr Met Thr Gly Asn Thr Ser Ile Asn Thr Thr Tyr Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Phe Leu Gly Ala Asp Tyr Tyr Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Arg Leu Leu Gln Leu , Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Arg Val Ile Ser Thr Tyr Leu Asn Trp Tyr Gln Gln Ser Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Arg Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Gly Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asn Thr Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , MERS-CoV Spike S1 KNIH-72, MERS-CoV Spike S1 KNIH-72,(45/52)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:45 and a light chain variable region having an amino acid sequence represented by seq id no:52
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Leu Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Lys Ile Ser Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val Gly Gly Ile Ile Pro Ile Phe Gly Thr Pro His Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Ile Thr Ala Asp Asp Ser Thr Ala Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Asp Leu Gly Gly Thr Thr Gly Phe Trp Gln Leu Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Ser Tyr Glu Leu Thr Gln Pro Leu Ser Val Ser Val Ala Leu Gly Gln Thr Ala Thr Leu Thr Cys Gly Gly Asp Asn Ile Gly Ser Lys Asn Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr Ile Asn Asp Asn Arg Pro Ser Ala Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Arg Arg Ala Gln Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Leu Trp Asp Gly Ser Thr Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu Leu , MERS-CoV Spike S1 KNIH-58, MERS-CoV Spike S1 KNIH-58,(43/50)  an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:43 and a light chain variable region having an amino acid sequence represented by seq id no:50
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Ala Phe Asn Thr Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Leu Phe Arg Ser Ser Ser Tyr Ala Gln Arg Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Glu Ser Thr Asn Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Arg Gly Asp Gly Ser Gly Arg Leu Gly Tyr Ile His Tyr Asp Thr Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Gln Pro Val Leu Thr Gln Leu Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val Tyr Trp Tyr Gln Gln Leu Ala Gly Ala Ala Pro Lys Leu Leu Ile Tyr Lys Asn Asn Glu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Asp Asp Glu Gly Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Leu , MERS-CoV Spike S1 KNIH-68, MERS-CoV Spike S1 KNIH-68,(44/51)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:44 and a light chain variable region having an amino acid sequence represented by seq id no:51
https://patents.google.com/patent/KR102007161B1/en, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Met Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Ser Gly Ile Ile Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Phe Phe Gly Thr Thr Thr Tyr Ala Gln Arg Phe Gln Gly Arg Phe Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr Met Glu Leu Asn Asn Leu Arg Phe Glu Asp Thr Ala Ile Tyr Phe Cys Ala Arg Asp Gly Gly Ile Pro Ser Ala Arg Leu Asn Asn His Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser, Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Cys Thr Ile Cys Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Ser Gly Ala Ser Ser Arg Ala Ala Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ile Ile Asp Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Gly Ser Ala Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , MERS-CoV Spike S1 KNIH-78, Mers-cov spike S1 KNIH-78,(46/53)   an antibody comprising a heavy chain variable region having an amino acid sequence represented by seq id no:46 and a light chain variable region having an amino acid sequence represented by seq id no:53
https://patents.google.com/patent/US11021531B1/en,,,,,"(83/95) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:83 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:95."
https://patents.google.com/patent/US11021531B1/en,,,,,"(75/87) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:75 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:87."
https://patents.google.com/patent/US11021531B1/en,,,,,"(72/84) in further embodiments, the 2ghw-derived antibody or antigen-binding fragment comprises a vl having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:84-95, and a vh having an amino acid sequence that is at least 90%, 95%, 98%, 99%, or 100% identical to any one of seq id no:72-83"
https://patents.google.com/patent/US11021531B1/en,,,,,"(80/92) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:80 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:92."
https://patents.google.com/patent/US11021531B1/en,,,,,"(78/90) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:78 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:90."
https://patents.google.com/patent/US11021531B1/en,,,,,"(77/89) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:77 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:89."
https://patents.google.com/patent/US11021531B1/en,,,,,"(76/88) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:76 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:88."
https://patents.google.com/patent/US11021531B1/en,,,,,"(74/86) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:74 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:86."
https://patents.google.com/patent/US11021531B1/en,,,,,"(79/91) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:79 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:91."
https://patents.google.com/patent/US11021531B1/en,,,,,"(73/85) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:73 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:85."
https://patents.google.com/patent/US11021531B1/en,,,,,"(82/94) in one instance, a 2ghw-derived antibody or antigen-binding fragment, described herein that selectively binds to sars-cov-2 can comprise an vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:82 an vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:94."
https://patents.google.com/patent/US11021531B1/en,,,,,"(81/93) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh having an amino acid sequence of seq id no:81 and a vl having an amino acid sequence of seq id no:93."
https://patents.google.com/patent/CN113999302A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Ile Thr Phe Ser Asp Tyr Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Asn Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Asp Lys Ser Met Gly Phe Gly Ala Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Asn Tyr Leu His Trp Tyr Gln Gln Arg Pro Gly Phe Ser Pro Lys Leu Leu Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly His Ser Ile Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , VH, VL,"(17/18) one of the antibodies was mab #9, whose heavy chain variable region sequence is shown in seq id no:17 and light chain variable region sequence is shown in seq id no:18."
https://patents.google.com/patent/CN113999302A/en, Gln Ser Val Glu Glu Ser Gly Gly Arg Leu Val Thr Pro Gly Thr Pro Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Pro Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asn Ile Glu Asp Tyr Ala Tyr Tyr Ala Pro Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Asp Leu Lys Val Thr Ser Pro Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Gly Arg Gly Gly Tyr Ala Ala Asp Ile Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser, Asp Val Val Met Thr Gln Thr Ala Ser Pro Val Ser Ala Ala Val Gly Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Glu Ser Val Tyr Thr Asn Asn Arg Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr Arg Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Ile Ile Ser Asp Val Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Val Gly Ser Gly Gly Thr Asp Ile Ala Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , VH, VL,"(7/8) the heavy chain variable region sequence is shown as seq id no:7, and the light chain variable region sequence is shown as seq id no:8."
https://patents.google.com/patent/WO2021170090A1/en,,,,,(6/5)  the sequence of the cr3022 antibody light chain variable region is shown in seq id no:5. the cr3022 antibody heavy chain sequence is shown in seq id no:6
https://patents.google.com/patent/WO2021170090A1/en,,,,,"(64/5)  in some embodiments, the first antibody and the second antibody are respectively selected from the following antibody sequences: the heavy chain variable region of the first/second antibody comprises the amino acid sequence shown in seq id no:64, the the light chain variable region of the first/second antibody comprises the amino acid sequence shown in seq id no:5."
https://patents.google.com/patent/WO2021170090A1/en,,,,,"(6/7) in some embodiments, the heavy chain of the first antibody is shown in seq id no:6, and the light chain is shown in seq id no:7"
https://patents.google.com/patent/WO2021170090A1/en,,,,,"(4/5) in some embodiments, the variable region of the antibody heavy chain is shown in seq id no:4, and the variable region of the antibody light chain is shown in seq id no:5."
https://patents.google.com/patent/CN111925441A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 022). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111925441A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 026). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111925441A/en,,,,,(29/28)  the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 036). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111925441A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (monoclonal antibody 7-cqts 029). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111925441A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(37/36)  the light chain amino acid sequence can also be shown as seq id no:36 (monoclonal antibody 18-cqts 042). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111925441A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence can also be shown as seq id no:40 (monoclonal antibody 20-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(13/12)  the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 028). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111925441A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence can also be shown as seq id no:36 (monoclonal antibody 18-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence can also be shown as seq id no:38 (monoclonal antibody 19-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 031). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111925441A/en,,,,,(39/38)  the light chain amino acid sequence can also be shown as seq id no:38 (monoclonal antibody 19-cqts 043). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111925441A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqts 025). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111925441A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (monoclonal antibody 7-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (monoclonal antibodies 8-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(23/22)  the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 033). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111925441A/en,,,,,(25/24)  the light chain amino acid sequence can also be shown as seq id no:24 (monoclonal antibody 12-cqts 034). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111925441A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to a novel coronavirus rbd, the heavy chain amino acid sequence of which is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111925441A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqts 023). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111925441A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence can also be shown as seq id no:24 (monoclonal antibody 12-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(3/2)  the light chain amino acid sequence is shown in seq id no:2 (monoclonal antibody 1-cqts 021). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111925441A/en,,,,,(31/30)  the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 038). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111925441A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(27/26)  the light chain amino acid sequence can also be shown as seq id no:26 (mab 13-cqts 035). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111925441A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence may also be as shown in seq id no:34 (monoclonal antibody 17-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 032). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111925441A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence can also be shown as seq id no:26 (mab 13-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (monoclonal antibodies 8-cqts 030). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111925441A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(33/32)  the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 040). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111925441A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 
https://patents.google.com/patent/CN111925441A/en,,,,,(35/34)  the light chain amino acid sequence may also be as shown in seq id no:34 (monoclonal antibody 17-cqts 041). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111925441A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 
https://patents.google.com/patent/KR20220010456A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  according to claim 1, the antibody or antigen-binding fragment thereof light chain variable region of the polypeptide sequence of seq id no:2017; and heavy chain variable region of the polypeptide sequence of seq id no:2018 a method comprising "
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(127/134) [0263] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:127 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/140) [0276] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:140"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(124/143) [0298] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:124 and an immunoglobulin light chain variable region comprising seq id no:143
https://patents.google.com/patent/WO2021212049A2/en,,,,,(1/58) an antibody or antigen-binding fragment thereof comprising: (a) an immunoglobulin heavy chain variable region comprising an amino acid sequence having at least 70% identity to any one of seq id no:1–57 and 115–133; or (b) an immunoglobulin light chain variable region comprising an amino acid sequence having at least 70% identity to any one of seq id no:58–114 and 134–152
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/134) [0251] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:115 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(123/142) [0297] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:123 and an immunoglobulin light chain variable region comprising seq id no:142
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/142) [0278] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:142"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/139) [0275] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:139"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/136) [0272] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:136"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(126/134) [0262] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:126 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(132/151) [0306] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:132 and an immunoglobulin light chain variable region comprising seq id no:151
https://patents.google.com/patent/WO2021212049A2/en,,,,,(131/150) [0305] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:131 and an immunoglobulin light chain variable region comprising seq id no:150
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(128/134) [0264] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:128 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(124/134)  [0260] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:124 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(120/139) [0294] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:120 and an immunoglobulin light chain variable region comprising seq id no:139
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/152) [0288] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(122/134) [0258] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:122 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(118/137) [0292] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:118 and an immunoglobulin light chain variable region comprising seq id no:137
https://patents.google.com/patent/WO2021212049A2/en,,,,,(127/146) [0301] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:127 and an immunoglobulin light chain variable region comprising seq id no:146
https://patents.google.com/patent/WO2021212049A2/en,,,,,(128/147) [0302] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:128 and an immunoglobulin light chain variable region comprising seq id no:147
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(121/134) [0257] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:121 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/151) [0287] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:151"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/143) [0279] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:143"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(131/134) [0267] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:131 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/138) [0274] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:138"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(125/144) [0299] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:125 and an immunoglobulin light chain variable region comprising seq id no:144
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/150) [0286] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:150"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/145) [0281] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:145"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(133/134) [0269] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:133 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(116/134) [0252] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:116 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(120/134) [0256] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:120 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(118/134) [0254] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:118 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(129/134) [0265] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:129 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/137) [0273] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:137"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(132/134) [0268] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:132 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(117/136) [0291] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:117 and an immunoglobulin light chain variable region comprising seq id no:136
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(119/134) [0255] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:119 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(126/145) [0300] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:126 and an immunoglobulin light chain variable region comprising seq id no:145
https://patents.google.com/patent/WO2021212049A2/en,,,,,(122/141) [0296] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:122 and an immunoglobulin light chain variable region comprising seq id no:141
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/144) [0280] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:144"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/146)  [0282] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:146"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(123/134) [0259] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:123 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/147) [0283] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:147"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(130/149)  [0304] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:130 and an immunoglobulin light chain variable region comprising seq id no:149
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/141) [0277] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:141"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(116/135) [0290] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:116 and an immunoglobulin light chain variable region comprising seq id no:135
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(125/134) [0261] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:125 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/149) [0285] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:149"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(117/134) [0253] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:117 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(121/140) [0295] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:121 and an immunoglobulin light chain variable region comprising seq id no:140
https://patents.google.com/patent/WO2021212049A2/en,,,,,(129/148) [0303] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:129 and an immunoglobulin light chain variable region comprising seq id no:148
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/135)  [0271] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:135"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(115/148) [0284] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising any one of seq id no:115–133 and an immunoglobulin light chain variable region comprising seq id no:148"
https://patents.google.com/patent/WO2021212049A2/en,,,,,"(130/134) [0266] for example, the antibody or antibody-binding fragment can comprise an immunoglobulin heavy chain variable region comprising seq id no:130 and an immunoglobulin light chain variable region comprising any one of seq id no:134–152"
https://patents.google.com/patent/WO2021212049A2/en,,,,,(133/152) [0307] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:133 and an immunoglobulin light chain variable region comprising seq id no:152
https://patents.google.com/patent/WO2021212049A2/en,,,,,(119/138)  [0293] another illustrative antibody or antibody binding fragment provided herein can comprise an immunoglobulin heavy chain variable region comprising seq id no:119 and an immunoglobulin light chain variable region comprising seq id no:138
https://patents.google.com/patent/CN113045647A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Tyr Ser Ser Tyr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ser Ile Ser Pro Ser Tyr Ser Tyr Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Ser Tyr Tyr Gly Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Val Ser Ser Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Ser Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Pro Pro Trp His Gly Leu Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(18/22) in some embodiments, the antibody is a fab, wherein the vl amino acid sequence of the fab is set forth in seq id no:22, and the vh amino acid sequence of the fab is set forth in seq id no:18."
https://patents.google.com/patent/CN111995676B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile Thr Asn Asn Gly Ala Asn Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Tyr Ala Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asn Ala Ser Gly Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Ala Tyr Tyr Pro Thr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(1/5) the monoclonal antibody against non-rbd region of the spinous protein of a neocoronavirus according to claim 1, wherein: the amino acid sequence of the heavy chain variable region of the monoclonal antibody is seq id no:1, the amino acid sequence of the light chain variable region of the monoclonal antibody is seq id no:5."
https://patents.google.com/patent/CN112062840A/en, atgggcagca gccatcatca tcatcatcac agcagcggcc tggtgccgcg cggcagccat atggctagca tgtcggactc agaagtcaat caagaagcta agccagaggt caagccagaa gtcaagcctg agactcacat caatttaaag gtgtccgatg gatcttcaga gatcttcttc aagatcaaaa agaccactcc tttaagaagg ctgatggaag cgttcgctaa aagacagggt aaggaaatgg actccttaag attcttgtac gacggtatta gaatccaagc tgatcagacc cctgaagatt tggacatgga ggataacgat attattgagg ctcacagaga acagattggt ggatcccagg tgcagctgca ggagtctgga ggaggcttgg tgcaggctgg agggtctctg agactctctt gtgccgccag cggacgtact ttctcttcta acgctatggg ctggttccgc caggctccag ggaaggagcg tgagttcgta gcagcgattt cttctggttc tggttctact aactatgcag actccgtgaa gggccgattc accatctcca gagacaacgc caagaacacg gtgtatcttc aaatgaacag cctgaaacct gaggacacgg ccgtttatta ctgtgcagcc gcttaccgtt acaacggtcg tgactactac gaccgttacg actactgggg tcagggtact caggtcaccg tctcctcagc ggccgcatac ccgtacgacg ttccggacta cggttcctga ctcgag ,, Artificial Sequence (Artificial Sequence),,"(1) the nanobody based on the s protein of coronavirus of claim 1, characterized in that: the nucleotide sequence of the expression cassette sequence of the nano antibody is shown in seq id no:1."
https://patents.google.com/patent/CN112062840A/en, Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro Arg Gly Ser His Met Ala Ser Met Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu Val Lys Pro Glu Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser Asp Gly Ser Ser Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu Arg Arg Leu Met Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp Ser Leu Arg Phe Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Thr Pro Glu Asp Leu Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg Glu Gln Ile Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Asn Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ser Gly Ser Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ala Tyr Arg Tyr Asn Gly Arg Asp Tyr Tyr Asp Arg Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Ala Ala Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Gly Ser,, Artificial Sequence (Artificial Sequence),,"(2) a nanobody based on the s protein of a novel coronavirus, characterized in that: the amino acid sequence of the expression cassette sequence of the nano antibody is shown in seq id no:2."
https://patents.google.com/patent/CN113173995A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Arg Phe Asp Asp His Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asp Ser Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Arg Ser Tyr Gly Pro Pro Asp Val Phe Asn Tyr Glu Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence, Artificial Sequence,"(2/1) wherein the sequence of the variable region vl-1 of the light chain of the scfv-1 is shown in seq id no:1, and the sequence of the variable region vh-1 of the heavy chain of the scfv-1 is shown in seq id no:2"
https://patents.google.com/patent/CN113173995A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Leu Thr Arg Asp Thr Ser Ile Thr Thr Val Tyr Met Glu Leu Ser Arg Leu Arg Phe Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ser Arg Tyr Asp Trp Asn Gln Asn Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Phe Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Phe Thr Thr Ser Ser Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence, Artificial Sequence,(4/3) the sequence of the variable region vl-2 of the light chain of the scfv-2 is shown as seq id no:3; the sequence of the heavy chain variable region vh-2 of the scfv-2 is shown as seq id no:4.
https://patents.google.com/patent/WO2021190980A1/en,,,,,"(307) optionally, the antigen is a viral antigen (eg, a coronavirus or sars-cov or sars-cov-2 antigen, such as rbd or spike antigen) and each single variable domain is an anti-viral antigen variable domain (eg, nanobody or vh or vhh) disclosed herein, such as a variable domain that comprises the amino acid sequence of qb-gb (seq id no:307), qb-dd, qb-bg or qb-fe)"
https://patents.google.com/patent/WO2021190980A1/en,,,,,"(17/18)  cr3022/3013 or cr3022/3014). [00335] in a configuration, the polypeptide of the invention comprises one or more binding sites for human tmprss2 protein, for example, the polypeptide comprises a binding site for tmprss2 protein as disclosed in us20190300625, eg, the vh/vl pair of any anti-tmprss2 antibody disclosed in us20190300625, eg wherein the binding site comprises seq id no:17 and 18 disclosed in us20190300625"
https://patents.google.com/patent/WO2021190980A1/en,,,,,"(262/263)  or (d) wherein the multimer comprises 4 copies of an antigen binding site, wherein the binding site comprises a vh/vl pair, wherein the vh and vl respectively comprise the amino acid sequences of seq id no:262 and 263, 264 and 265, or 266 and 267"
https://patents.google.com/patent/WO2021190980A1/en,,,,,"(289)   table 34: amino acid sequences of a binding domain (nb-112, seq id no:288) and polypeptides (seq id no:289 & 290) for use in the present invention.   table 35: amino acid sequences of nb-112 based quad polypeptides with an intact hinge region.  table 36: antibody single variable domains (a) the amino acid sequence of an anti-hrsv protein f nanobody for use as a binding domain in the present invention)"
https://patents.google.com/patent/WO2021190980A1/en,,,,,"(288) [00437] optionally, the bd is a single variable domain (also referred to as a domain antibody or dab, eg, a nanobody or vhh, eg, a single variable domain comprising seq id no:288, preferably nb-112)"
https://patents.google.com/patent/WO2021158521A1/en,,,,,(197/205) antibody ncov-5 comprises the vh sequence of seq id no:197 and the vl sequence of seq id no:205
https://patents.google.com/patent/WO2021158521A1/en,,,,,(181/189) antibody ncov-12 comprises the vh sequence of seq id no:181 and the vl sequence of seq id no:189
https://patents.google.com/patent/WO2021158521A1/en,,,,,(293/301) antibody ncov-2 comprises the vh sequence of seq id no:293 and the vl sequence of seq id no:301
https://patents.google.com/patent/WO2021158521A1/en,,,,,(117/125) (figure ib.) antibody ncov-4 comprises the vh sequence of seq id no:117 and the vl sequence of seq id no:125
https://patents.google.com/patent/WO2021158521A1/en,,,,,(85/93) (figure 1 a.) antibody ncov-16 comprises the vh sequence of seq id no:85 and the vl sequence of seq id no:93
https://patents.google.com/patent/WO2021158521A1/en,,,,,(101/109) antibody ncov-20 comprises the vh sequence of seq id no:101 and the vl sequence of seq id no:109
https://patents.google.com/patent/WO2021158521A1/en,,,,,(165/173) antibody ncov-15 comprises the vh sequence of seq id no:165 and the vl sequence of seq id no:173
https://patents.google.com/patent/WO2021158521A1/en,,,,,(277/285) antibody ncov-7 comprises the vh sequence of seq id no:277 and the vl sequence of seq id no:285
https://patents.google.com/patent/WO2021158521A1/en,,,,,(69/77) antibody ncov-6 comprises the vh sequence of seq id no:69 and the vl sequence of seq id no:77
https://patents.google.com/patent/WO2021158521A1/en,,,,,(213/221) antibody ncov-14 comprises the vh sequence of seq id no:213 and the vl sequence of seq id no:221
https://patents.google.com/patent/WO2021158521A1/en,,,,,(325/333) antibody ncov-1 comprises the vh sequence of seq id no:325 and the vl sequence of seq id no:333
https://patents.google.com/patent/WO2021158521A1/en,,,,,(245/253) antibody ncov-18 comprises the vh sequence of seq id no:245 and the vl sequence of seq id no:253
https://patents.google.com/patent/WO2021158521A1/en,,,,,(5/13) antibody ncov-3 comprises the vh sequence of seq id no:5 and the vl sequence of seq id no:13
https://patents.google.com/patent/WO2021158521A1/en,,,,,(309/317) antibody ncov-19 comprises the vh sequence of seq id no:309 and the vl sequence of seq id no:317
https://patents.google.com/patent/WO2021158521A1/en,,,,,(21/29) antibody ncov- 10 comprises the vh sequence of seq id no:21 and the vl sequence of seq id no:29
https://patents.google.com/patent/WO2021158521A1/en,,,,,(261/269) (figure 1c.) antibody ncov-8 comprises the vh sequence of seq id no:261 and the vl sequence of seq id no:269
https://patents.google.com/patent/WO2021158521A1/en,,,,,(341/349) antibody ncov-11 comprises the vh sequence of seq id no:341 and the vl sequence of seq id no:349
https://patents.google.com/patent/WO2021158521A1/en,,,,,(357/365) antibody ncov-13 comprises the vh sequence of seq id no:357 and the vl sequence of seq id no:365
https://patents.google.com/patent/WO2021158521A1/en,,,,,(229/237) antibody ncov-9 comprises the vh sequence of seq id no:229 and the vl sequence of seq id no:237
https://patents.google.com/patent/CN113501872A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Thr Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Leu Asn Arg Leu Gly Val Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Ile Tyr Tyr Arg Asp Arg Asn Leu Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly Asp Thr Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Asp Asn Tyr Leu His Trp Tyr Gln Lys Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile Ser Ala Thr Ser Thr Leu Glu Asn Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ile Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly His Ser Val Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Val Arg , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(8/7) preferably, the amino acid sequence of the light chain variable region of the antibody sk1 is shown as seq id no:7, and the amino acid sequence of the heavy chain variable region is shown as seq id no:8."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Gly Tyr Ser Ser Ser Gly Ser Asn Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Arg Thr Ala Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , R14 heavy chain full length-IgG1(Artificial Sequence), R14 light chain full length(Artificial Sequence),"(29/31) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:29, and the amino acid sequence of the light chain is identical to that of seq id no:31 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ser Gly Gly Ser Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Val Leu Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Leu Ser Thr Tyr Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , R44 heavy chain full length-IgG1(Artificial Sequence), R44 light chain full length(Artificial Sequence),"(33/35) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:33, and the amino acid sequence of the light chain is identical to that of seq id no:35 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Val Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Pro Arg, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Gly Tyr Ser Gly Ser Gly Ala Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , R157 light chain variable(Artificial Sequence), R157 heavy chain variable(Artificial Sequence),"(27/25) in another preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:25, the amino acid sequence of the light chain variable region is identical to seq id no:27 shown as consistent."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Gly Tyr Ser Gly Ser Gly Ala Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Val Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Pro Arg Thr Ala Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , R157 heavy chain full length-IgG1(Artificial Sequence), R157 light chain full length(Artificial Sequence),"(37/39) the monoclonal antibody of claim 17, wherein the amino acid sequence of the heavy chain thereof is identical to the amino acid sequence of seq id no:37, and the amino acid sequence of the light chain is identical to that of seq id no:39 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Gly Tyr Ser Ser Ser Gly Ser Asn Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Arg, R14 heavy chain variable(Artificial Sequence), R14 light chain variable(Artificial Sequence),"(17/19) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:17, the amino acid sequence of the light chain variable region is identical to seq id no:19 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Gly Tyr Ser Gly Ser Gly Ala Asn Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Val Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Thr Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Asp Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Pro Arg, R157 heavy chain variable(Artificial Sequence), R157 light chain variable(Artificial Sequence),"(25/27) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:25, the amino acid sequence of the light chain variable region is identical to seq id no:27 shown as consistent."
https://patents.google.com/patent/CN113956352A/en, Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Pro Arg, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Ile Gly Tyr Ser Ser Ser Gly Ser Asn Tyr Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , R14 light chain variable(Artificial Sequence), R14 heavy chain variable(Artificial Sequence),"(19/17) in a preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:17, the amino acid sequence of the light chain variable region is identical to seq id no:19 are shown as being identical."
https://patents.google.com/patent/CN113956352A/en, Asp Ile Val Leu Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Leu Ser Thr Tyr Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ser Gly Gly Ser Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , R44 light chain variable(Artificial Sequence), R44 heavy chain variable(Artificial Sequence),"(23/21) in another preferred embodiment, the present invention provides a monoclonal antibody, or antigen-binding portion thereof, targeting the receptor binding domain of the novel coronavirus sars-cov-2 spike protein, comprising heavy and light chain variable region sequences, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:21, the amino acid sequence of the variable region of the light chain is identical to that of seq id no:23, shown in agreement."
https://patents.google.com/patent/CN113956352A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Leu Tyr Ser Gly Gly Ser Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Leu Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Glu Leu Ser Thr Tyr Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , R44 heavy chain variable(Artificial Sequence), R44 light chain variable(Artificial Sequence),"(21/23) the monoclonal antibody or antigen-binding portion thereof according to claim 6, wherein the amino acid sequence of the heavy chain variable region is identical to the amino acid sequence of seq id no:21, the amino acid sequence of the variable region of the light chain is identical to that of seq id no:23, shown in agreement."
https://patents.google.com/patent/CN113683692A/en, Gln Val Gln Leu Gln Gln Pro Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Gly Ser Gly Tyr Thr Phe Thr Asp Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Trp Ile Gln Thr Glu Thr Gly Asp Pro Thr Tyr Phe Lys Gly Arg Phe Ala Phe Thr Leu Glu Thr Ser Ala Thr Ala Tyr Met Gln Leu Ser Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Gly Ser Asp Tyr Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Gln Arg Ala Thr Ile Ser Cys Lys Thr Ser Ala Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Trp Tyr Trp Glu Ser Thr Gln His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Thr Val Gln Ser Glu Asp Tyr Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr , artificial sequence, artificial sequence,"(13/14) in some embodiments, the heavy chain variable region of a is as set forth in seq id no:13 and the light chain variable region is as set forth in seq id no:14."
https://patents.google.com/patent/CN113683692A/en, Gln Val Gln Leu Gln Gln Pro Glu Ala Glu Leu Met Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Glu Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Val Ile Ser Thr Gly Asn Gly Ser Asn Asp Lys Phe Lys Gly Lys Ala Thr Met Thr Val Thr Ser Ser Asn Thr Ala Tyr Met Gln Leu Ala Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Ile His Tyr Phe Gly Phe Tyr Ala Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser , Asp Ile Val Leu Ser Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Glu Lys Val Thr Met Ser Cys Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ile Tyr Ser Thr Arg Glu Ser Gln Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Glu Ala Ser Asp Tyr Ala Val Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr , artificial sequence, artificial sequence,"(15/16) the heavy chain variable region of b is shown as seq id no:15, and the light chain variable region is shown as seq id no:16."
https://patents.google.com/patent/WO2021237534A1/en,,,,,"(60/64)  furthermore, a monoclonal antibody or an antigen binding portion thereof in the combination comprises a heavy chain variable region shown in seq id no:60 and a light chain variable region shown in seq id no:64."
https://patents.google.com/patent/CN112940087A/en, Glu Val Lys Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr Ser Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Asn Gly Gly Gly Tyr Ile Tyr Tyr Leu Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Gly Arg Pro Arg Pro Glu Lys Glu Phe Ile Ser Thr Ser Thr Ala Met Asp His Trp Gly Gln Gly Thr Thr Val Thr , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Glu Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Tyr Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(27/28) the sequencing results were as follows: the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody are respectively shown in seq id no:27 and seq id no:28
https://patents.google.com/patent/CN111518202B/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Gly Ser Gly Ser Tyr Tyr Trp Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the monoclonal antibody of claim 1, comprising the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/CN111518202B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN111978399A/en,,,,,"(19/5) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: comprises the amino acid sequence shown in seq id no:5 in the light chain variable region; and a polypeptide comprising seq id no:19 in a heavy chain variable region of the amino acid sequence of seq id no."
https://patents.google.com/patent/CN111978399A/en,,,,,"(1/18) in particular, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of seq id no:1-17 (see table 1) and a light chain variable region comprising an amino acid sequence selected from seq id no:18-26 (see table 2)"
https://patents.google.com/patent/CN111978399A/en,,,,,"(18/1) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: a light chain variable region comprising a sequence selected from seq id no:1-4; and a heavy chain variable region comprising seq id no:18."
https://patents.google.com/patent/CN111978399A/en,,,,,"(78/80)  and seq id no:78, and a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the heavy chain set forth in seq id no:80, or a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto."
https://patents.google.com/patent/CN113583114A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Leu Val Ala Ser Tyr Arg Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Ile Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Thr Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys His Gln Tyr Asp Asn Leu Pro Val Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , amino acid sequence of 3C11 heavy chain variable region (VH), 3C11 light chain variable region (VL) amino acid sequence,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2."
https://patents.google.com/patent/CN113583114A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Leu Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Ile Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Thr Thr Val Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Pro Pro Tyr Asn Trp Asn Gly Pro Leu Arg Ser Gln Arg Phe Asp Cys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Tyr Asp Asn Leu Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , 6G9 amino acid sequence of heavy chain variable region (VH), 6G9 light chain variable region (VL) amino acid sequence,"(17/18) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:18."
https://patents.google.com/patent/CN113583114A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Thr Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Met Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Val Ala Ala Ala Gly Ser Ser Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Asn Phe Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Tyr Ser Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , amino acid sequence of heavy chain variable region (VH) of 5C6, 5C6 light chain variable region (VL) amino acid sequence,"(9/10) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:9 and a vl comprising the sequence shown as seq id no:10."
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(122/127)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:122 and 127, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(127/122)  the vl comprises the amino acid sequence depicted in seq id no:127, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:122 and 127, respectively; or (xx"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(17/12)  the vl comprises the amino acid sequence depicted in seq id no:17, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:12 and 17, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(142/147)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:142 and 147, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(112/117)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:112 and 117, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(177/172)  the vl comprises the amino acid sequence depicted in seq id no:177, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:172 and 177, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(47/42)  the vl comprises the amino acid sequence depicted in seq id no:47, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:42 and 47, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(77/72)  the vl comprises the amino acid sequence depicted in seq id no:77, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:72 and 77, respectively; or (x"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(297/292)  the vl comprises the amino acid sequence depicted in seq id no:297, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:292 and 297, respectively. "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(82/87)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:82 and 87, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(152/157)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:152 and 157, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(272/277)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:272 and 277, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(62/67)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:62 and 67, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(132/137)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:132 and 137, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(222/227)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:222 and 227, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(27/22)  the vl comprises the amino acid sequence depicted in seq id no:27, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:22 and 27, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(52/57)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:52 and 57, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(192/197)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:192 and 197, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(157/152)  the vl comprises the amino acid sequence depicted in seq id no:157, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:152 and 157, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(252/257)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:252 and 257, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(202/207)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:202 and 207, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(97/92)  the vl comprises the amino acid sequence depicted in seq id no:97, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:92 and 97, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(247/242)  the vl comprises the amino acid sequence depicted in seq id no:247, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:242 and 247, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(207/202)  the vl comprises the amino acid sequence depicted in seq id no:207, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:202 and 207, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(292/297)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:292 and 297, respectively. "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(237/232)  the vl comprises the amino acid sequence depicted in seq id no:237, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:232 and 237, respectively; or (xl"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(12/17)   preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:12 and 17, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(162/167)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:162 and 167, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(187/182)  the vl comprises the amino acid sequence depicted in seq id no:187, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:182 and 187, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(267/262)  the vl comprises the amino acid sequence depicted in seq id no:267, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:262 and 267, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(102/107)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:102 and 107, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(107/102)  the vl comprises the amino acid sequence depicted in seq id no:107, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:102 and 107, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(37/32)  the vl comprises the amino acid sequence depicted in seq id no:37, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:32 and 37, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(277/272)  the vl comprises the amino acid sequence depicted in seq id no:277, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:272 and 277, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(22/27)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:22 and 27, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(172/177)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:172 and 177, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(2/7)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:2 and 7, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(67/62)  the vl comprises the amino acid sequence depicted in seq id no:67, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:62 and 67, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(232/237)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:232 and 237, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(287/282)  the vl comprises the amino acid sequence depicted in seq id no:287, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:282 and 287, respectively; or (l"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(72/77)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:72 and 77, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(137/132)  the vl comprises the amino acid sequence depicted in seq id no:137, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:132 and 137, respectively; or (xx"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(32/37)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:32 and 37, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(7/2)  the vl comprises the amino acid sequence depicted in seq id no:7, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:2 and 7, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(87/82)  the vl comprises the amino acid sequence depicted in seq id no:87, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:82 and 87, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(92/97)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:92 and 97, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(117/112)  the vl comprises the amino acid sequence depicted in seq id no:117, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:112 and 117, respectively; or (xx"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(282/287)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:282 and 287, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(42/47)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:42 and 47, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(227/222)  the vl comprises the amino acid sequence depicted in seq id no:227, or a variant thereof, wherein the variant comprises one or more amino acid substitutions;  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:222 and 227, respectively; or (xl"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(167/162)  the vl comprises the amino acid sequence depicted in seq id no:167, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:162 and 167, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(182/187)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:182 and 187, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(242/247)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:242 and 247, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(217/212)  the vl comprises the amino acid sequence depicted in seq id no:217, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:212 and 217, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(257/252)  the vl comprises the amino acid sequence depicted in seq id no:257, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:252 and 257, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(212/217)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:212 and 217, respectively"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(147/142)  the vl comprises the amino acid sequence depicted in seq id no:147, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:142 and 147, respectively; or (xxx"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(197/192)  the vl comprises the amino acid sequence depicted in seq id no:197, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:192 and 197, respectively; or (xl"
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(57/52)  the vl comprises the amino acid sequence depicted in seq id no:57, or a variant thereof, wherein the variant comprises one or more amino acid substitutions; preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:52 and 57, respectively; or "
https://patents.google.com/patent/WO2021245184A1/en,,,,,"(262/267)  preferably wherein the vh and vl chain amino acid sequence is at least 90% identical to seq id no:262 and 267, respectively"
https://patents.google.com/patent/EP3878862A2/en,,,,,(1243/1244) (v) the vh set forth as seq id no:1243 and the vl set forth as seq id no:1244
https://patents.google.com/patent/EP3878862A2/en,,,,,(873/874) (d) the vh set forth as seq id no:873 and the vl set forth as seq id no:874
https://patents.google.com/patent/EP3878862A2/en,,,,,"(5322/5323) in some embodiments, provided herein is an antibody comprising a heavy chain comprising seq id no:5322 and a light chain comprising seq id no:5323"
https://patents.google.com/patent/EP3878862A2/en,,,,,(1103/1104) (o) the vh set forth as seq id no:1103 and the vl set forth as seq id no:1104
https://patents.google.com/patent/EP3878862A2/en,,,,,(979/980) (i) the vh set forth as seq id no:979 and the vl set forth as seq id no:980
https://patents.google.com/patent/EP3878862A2/en,,,,,(5347/5348)  a heavy chain comprising seq id no:5347 and a light chain comprising seq id no:5348;
https://patents.google.com/patent/EP3878862A2/en,,,,,(5333/5334) (i) a heavy chain comprising seq id no:5333 and a light chain comprising seq id no:5334
https://patents.google.com/patent/EP3878862A2/en,,,,,(1157/1158) (t) the vh set forth as seq id no:1157 and the vl set forth as seq id no:1158
https://patents.google.com/patent/EP3878862A2/en,,,,,(5365/5366)  a heavy chain comprising seq id no:5365 and a light chain comprising seq id no:5366.
https://patents.google.com/patent/EP3878862A2/en,,,,,(5323/5324) (d) a heavy chain comprising seq id no:5323 and a light chain comprising seq id no:5324
https://patents.google.com/patent/EP3878862A2/en,,,,,(1035/1036) (l) the vh set forth as seq id no:1035 and the vl set forth as seq id no:1036
https://patents.google.com/patent/EP3878862A2/en,,,,,(1143/1144)  the vh set forth as seq id no:1143 and the vl set forth as seq id no:1144; (x
https://patents.google.com/patent/EP3878862A2/en,,,,,(867/868)  a vh set forth as seq id no:867 and a vl set forth as seq id no:868; (
https://patents.google.com/patent/EP3878862A2/en,,,,,(5327/5328) (f) a heavy chain comprising seq id no:5327 and a light chain comprising seq id no:5328
https://patents.google.com/patent/EP3878862A2/en,,,,,(5337/5338) (k) a heavy chain comprising seq id no:5337 and a light chain comprising seq id no:5338
https://patents.google.com/patent/EP3878862A2/en,,,,,(1133/1134) (s) the vh set forth as seq id no:1133 and the vl set forth as seq id no:1134
https://patents.google.com/patent/EP3878862A2/en,,,,,(1267/1268)  (vii) a vh set forth as seq id no:1267 and a vl set forth as seq id no:1268
https://patents.google.com/patent/EP3878862A2/en,,,,,(661/662) (b) a heavy chain variable region set forth as seq id no:661 and a light chain variable region set forth as seq id no:662
https://patents.google.com/patent/EP3878862A2/en,,,,,(5359/5360) (v) a heavy chain comprising seq id no:5359 and a light chain comprising seq id no:5360
https://patents.google.com/patent/EP3878862A2/en,,,,,(727/728)  a vh set forth as seq id no:727 and a vl set forth as seq id no:728; (
https://patents.google.com/patent/EP3878862A2/en,,,,,(1039/1040) (m) the vh set forth as seq id no:1039 and the vl set forth as seq id no:1040
https://patents.google.com/patent/EP3878862A2/en,,,,,(1071/1072) (s) a heavy chain variable region set forth as seq id no:1071 and a light chain variable region set forth as seq id no:1072
https://patents.google.com/patent/EP3878862A2/en,,,,,(1111/1112) (q) the vh set forth as seq id no:1111 and the vl set forth as seq id no:1112
https://patents.google.com/patent/EP3878862A2/en,,,,,(5353/5354) (s) a heavy chain comprising seq id no:5353 and a light chain comprising seq id no:5354
https://patents.google.com/patent/EP3878862A2/en,,,,,(961/962) (g) the vh set forth as seq id no:961 and the vl set forth as seq id no:962
https://patents.google.com/patent/EP3878862A2/en,,,,,(1107/1108) (p) the vh set forth as seq id no:1107 and the vl set forth as seq id no:1108
https://patents.google.com/patent/EP3878862A2/en,,,,,(983/984) (j) the vh set forth as seq id no:983 and the vl set forth as seq id no:984
https://patents.google.com/patent/EP3878862A2/en,,,,,(5345/5346) (o) a heavy chain comprising seq id no:5345 and a light chain comprising seq id no:5346
https://patents.google.com/patent/EP3878862A2/en,,,,,(1029/1030) (k) the vh set forth as seq id no:1029 and the vl set forth as seq id no:1030
https://patents.google.com/patent/EP3878862A2/en,,,,,(5351/5352) (r) a heavy chain comprising seq id no:5351 and a light chain comprising seq id no:5352
https://patents.google.com/patent/EP3878862A2/en,,,,,(891/892) (e) the vh set forth as seq id no:891 and the vl set forth as seq id no:892
https://patents.google.com/patent/EP3878862A2/en,,,,,(5335/5336) (j) a heavy chain comprising seq id no:5335 and a light chain comprising seq id no:5336
https://patents.google.com/patent/EP3878862A2/en,,,,,(1069/1070) (n) the vh set forth as seq id no:1069 and the vl set forth as seq id no:1070
https://patents.google.com/patent/EP3878862A2/en,,,,,(1255/1256)  the vh set forth as seq id no:1255 and the vl set forth as seq id no:1256.
https://patents.google.com/patent/EP3878862A2/en,,,,,(5349/5350) (q) a heavy chain comprising seq id no:5349 and a light chain comprising seq id no:5350
https://patents.google.com/patent/EP3878862A2/en,,,,,(1167/1168)  a vh set forth as seq id no:1167 and a vl set forth as seq id no:1168; (
https://patents.google.com/patent/EP3878862A2/en,,,,,(725/726) (c) a heavy chain variable region set forth as seq id no:725 and a light chain variable region set forth as seq id no:726
https://patents.google.com/patent/EP3878862A2/en,,,,,(5331/5332) (h) a heavy chain comprising seq id no:5331 and a light chain comprising seq id no:5332
https://patents.google.com/patent/EP3878862A2/en,,,,,(779/780)  the vh set forth as seq id no:779 and the vl set forth as seq id no:780; (
https://patents.google.com/patent/EP3878862A2/en,,,,,(729/730) (b) the vh set forth as seq id no:729 and the vl set forth as seq id no:730
https://patents.google.com/patent/EP3878862A2/en,,,,,(1225/1226) (u) the vh set forth as seq id no:1225 and the vl set forth as seq id no:1226
https://patents.google.com/patent/EP3878862A2/en,,,,,(5361/5362) (w) a heavy chain comprising seq id no:5361 and a light chain comprising seq id no:5362
https://patents.google.com/patent/EP3878862A2/en,,,,,(5329/5330) (g) a heavy chain comprising seq id no:5329 and a light chain comprising seq id no:5330
https://patents.google.com/patent/EP3878862A2/en,,,,,(5325/5326) (e) a heavy chain comprising seq id no:5325 and a light chain comprising seq id no:5326
https://patents.google.com/patent/EP3878862A2/en,,,,,(921/922) (f) the vh set forth as seq id no:921 and the vl set forth as seq id no:922
https://patents.google.com/patent/EP3878862A2/en,,,,,(1123/1124)  a vh set forth as seq id no:1123 and a vl set forth as seq id no:1124; (
https://patents.google.com/patent/EP3878862A2/en,,,,,(763/764) (c) the vh set forth as seq id no:763 and the vl set forth as seq id no:764
https://patents.google.com/patent/EP3878862A2/en,,,,,(5319/5320) (b) a heavy chain comprising seq id no:5319 and a light chain comprising seq id no:5320
https://patents.google.com/patent/EP3878862A2/en,,,,,(1121/1122) (r) the vh set forth as seq id no:1121 and the vl set forth as seq id no:1122
https://patents.google.com/patent/EP3878862A2/en,,,,,(5357/5358) (u) a heavy chain comprising seq id no:5357 and a light chain comprising seq id no:5358
https://patents.google.com/patent/EP3878862A2/en,,,,,(5343/5344) (n) a heavy chain comprising seq id no:5343 and a light chain comprising seq id no:5344
https://patents.google.com/patent/EP3878862A2/en,,,,,(1269/1270)  the vh set forth as seq id no:1269 and the vl set forth as seq id no:1270.
https://patents.google.com/patent/EP3878862A2/en,,,,,(5363/5364) (a) a heavy chain comprising seq id no:5363 and a light chain comprising seq id no:5364
https://patents.google.com/patent/EP3878862A2/en,,,,,(5341/5342) (m) a heavy chain comprising seq id no:5341 and a light chain comprising seq id no:5342
https://patents.google.com/patent/EP3878862A2/en,,,,,(973/974) (h) the vh set forth as seq id no:973 and the vl set forth as seq id no:974
https://patents.google.com/patent/EP3878862A2/en,,,,,(1251/1252) (w) the vh set forth as seq id no:1251 and the vl set forth as seq id no:1252
https://patents.google.com/patent/EP3878862A2/en,,,,,(761/762)  a vh set forth as seq id no:761 and a vl set forth as seq id no:762; (
https://patents.google.com/patent/EP3878862A2/en,,,,,(5339/5340) (l) a heavy chain comprising seq id no:5339 and a light chain comprising seq id no:5340
https://patents.google.com/patent/EP3878862A2/en,,,,,(5355/5356) (t) a heavy chain comprising seq id no:5355 and a light chain comprising seq id no:5356
https://patents.google.com/patent/EP3878862A2/en,,,,,(5321/5322) (c) a heavy chain comprising seq id no:5321 and a light chain comprising seq id no:5322
https://patents.google.com/patent/EP3878862A2/en,,,,,(1313/1314)  a vh set forth as seq id no:1313 and a vl set forth as seq id no:1314.
https://patents.google.com/patent/CN112979792B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN112538111A/en, Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser Ile Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Ser Met His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Gly Ser Asp Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Met Asp Ser Gln Ala Gln Val Leu Met Leu Leu Leu Leu Trp Val Ser Gly Thr Cys Gly Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) a new coronavirus single-chain antibody sequentially comprises a light chain variable region and a heavy chain variable region from an n section to a c end, wherein the amino acid sequence of the light chain variable region is shown as seq id no:1, and the amino acid sequence of the heavy chain variable region is shown as seq id no:2."
https://patents.google.com/patent/CN113527472A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Ala Ser Glu Lys Tyr Tyr Leu Asp Ser Leu Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gly Ile Leu Trp Phe Gly Asp Tyr Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Leu Tyr Ala Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , MW07-HL, MW07-VL,"(10/9) antibody or fragment thereof specific for the sars-cov-2s protein according to claim 6 or 7, wherein the heavy chain variable region of the antibody or fragment thereof is identical to the heavy chain variable region of seq id no:10 has a sequence homology of 70% or more; the light chain variable region is identical to seq id no:9 has a sequence homology of 70% or more."
https://patents.google.com/patent/CN111925443A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 134). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111925443A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (mab 5-cqts 138). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111925443A/en,,,,,(29/28)  the light chain amino acid sequence can also be shown as seq id no:28 (mab 14-cqts 155). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111925443A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqts 144). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111925443A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(37/36)  the light chain amino acid sequence can also be shown as seq id no:36 (mab 18-cqts 161). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111925443A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence can also be shown as seq id no:40 (mab 20-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(13/12)  the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 143). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111925443A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence can also be shown as seq id no:36 (mab 18-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence can also be shown as seq id no:38 (mab 19-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(39/38)  the light chain amino acid sequence can also be shown as seq id no:38 (mab 19-cqts 163). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111925443A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 146). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111925443A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqts 136). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111925443A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(23/22)  the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 151). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111925443A/en,,,,,(25/24)  the light chain amino acid sequence can also be shown as seq id no:24 (mab 12-cqts 152). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111925443A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to a novel coronavirus rbd, the heavy chain amino acid sequence of which is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111925443A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqts 135). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111925443A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence can also be shown as seq id no:24 (mab 12-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(3/2)  the light chain amino acid sequence is shown in seq id no:2 (monoclonal antibody 1-cqts 133). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111925443A/en,,,,,(31/30)  the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 157). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111925443A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (mab 5-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(27/26)  the light chain amino acid sequence can also be shown as seq id no:26 (monoclonal antibody 13-cqts 154). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111925443A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence can also be shown as seq id no:34 (monoclonal antibody 17-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 148). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111925443A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence can also be shown as seq id no:26 (monoclonal antibody 13-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 145). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111925443A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(33/32)  the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 159). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111925443A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence can also be shown as seq id no:28 (mab 14-cqts 
https://patents.google.com/patent/CN111925443A/en,,,,,(35/34)  the light chain amino acid sequence can also be shown as seq id no:34 (monoclonal antibody 17-cqts 160). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111925443A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 
https://patents.google.com/patent/CN111978397A/en,,,,,"(19/5) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: comprises the amino acid sequence shown in seq id no:5 in the light chain variable region; and a polypeptide comprising seq id no:19 in a heavy chain variable region of the amino acid sequence of seq id no."
https://patents.google.com/patent/CN111978397A/en,,,,,"(1/18) in particular, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of seq id no:1-17 (see table 1) and a light chain variable region comprising an amino acid sequence selected from seq id no:18-26 (see table 2)"
https://patents.google.com/patent/CN111978397A/en,,,,,"(18/1) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: a light chain variable region comprising a sequence selected from seq id no:1-4; and a heavy chain variable region comprising seq id no:18."
https://patents.google.com/patent/CN111978397A/en,,,,,"(78/80)  and seq id no:78, and a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the heavy chain set forth in seq id no:80, or a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto."
https://patents.google.com/patent/CN112409479A/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Thr Leu Ser Cys Gly Ala Ser Gly Phe Thr Phe Glu Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Val Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu His Met Arg Ser Leu Thr Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Asp Val Tyr Ser Glu Ser Gly Ser Gly Ser Tyr Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Gln Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) the amino acid sequences of the variable regions of the light chain and the heavy chain of antibody ncov-121 are shown as seq id no:1 and 2, respectively."
https://patents.google.com/patent/KR101828794B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr Ser Met Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Pro Ile Asp Ala Val Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Asn Ile Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Ala Val Thr Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asn Asn Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Glu Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu Gly , Heavy chain variable region, Light chain variable region,"(7/8)  in one embodiment of the invention, the antibody comprises the heavy chain variable region of seq id no:7 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/EP3872091A1/en,,,,,"(105/168) ""s309-11"" comprises the wild-type vh sequence (seq id no:105) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/EP3872091A1/en,,,,,"(119/168) ""s309-14"" comprises a w105f vh variant sequence (seq id no:119) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/EP3872091A1/en,,,,,"(79/83) in still further embodiments, an antigen or an antigen-binding fragment of the present disclosure comprises a vh comprising or consisting of the amino acid sequence according to seq id no:79 and a vl comprising or consisting of the amino acid sequence according to seq id no:83 and is capable of neutralizing a sars-cov-2 infection, or a virus pseudotyped with sars-cov-2, with an ic50 of about 16 to about 20 µg/ml."
https://patents.google.com/patent/EP3872091A1/en,,,,,"(168/105)  vl seq id no.:243), s308-v1, s309 (comprising the s309-v1 vh sequence set forth in seq id no:105 and the s309-v13 vl sequence set forth in seq id no:168), and s310 were tested for neutralization function (table 4, figure 2a). antibodies sars-cov-2 s300-v1 and sars-cov-2 s309 neutralized sars-cov-2 infection (figures 2a and 2b).  table 4. percent neutralization of infection by antibodies (titration series)     dilution   s300   s301   s302   s303   s304   s306   s307   s308   s309   s310      2  93 -31 -47 6 -21 -19 36 -46 65 -4    6  94 10 6 5 25 15 5 19 11 -15    18  75 21 -16 2 -22 -9 2 32 -29 -15    54  -41 7 -60 12 7 6 32 16 14 -6     "
https://patents.google.com/patent/EP3872091A1/en,,,,,"(172/168) ""s309-15"" comprises a w50f/g56a/w105f vh variant (seq id no:172) and the wild-type vl sequence of s309 (seq id no:168)"
https://patents.google.com/patent/EP3872091A1/en,,,,,"(129/168) ""s309-13"" comprises a w50f mutation in vh (seq id no:129) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/CN111690058B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr Ser Ser Ser Trp Leu Leu Gln Ser Phe Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asn Ile Gln Leu Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Gly Tyr Ser Leu Val Trp Tyr Gln Lys Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Val Ile His Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , antibody P16-A3 VH sequence, antibody P16-A3 VL sequence,(1/2) (a) a heavy chain variable region comprising the sequence of seq id no:1 and a light chain variable region comprising the sequence of seq id no:2
https://patents.google.com/patent/CN111690058B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ala Tyr Ser Ser Ser Trp Leu Leu Gln Ser Phe Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asn Ile Gln Leu Thr Gln Ser Pro Val Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Gly Ile Gly Tyr Ser Leu Val Trp Tyr Gln Lys Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile Phe Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ser Ala Thr Tyr Tyr Cys Gln Gln Val Ile His Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , antibody P16-A3 HC, antibody P16-A3 LC,"(17/18) (a) the heavy chain sequence of seq id no:17, and the light chain sequence of seq id no:18"
https://patents.google.com/patent/CN111690058B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Ala Thr Leu Met Asn Asn Lys Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , antibody P17-A11 HC, antibody P17-A11 LC,"(19/20)  the heavy chain sequence of seq id no:19, and the light chain sequence of seq id no:20."
https://patents.google.com/patent/CN111690058B/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg His Ala Thr Leu Met Asn Asn Lys Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , antibody P17-A11 VH sequence, antibody P17-A11 VL sequence,(3/4)  a heavy chain variable region comprising the sequence of seq id no:3 and a light chain variable region comprising the sequence of seq id no:4.
https://patents.google.com/patent/WO2021222128A1/en,,,,,"(1/2) in some embodiments, the monoclonal antibody or derivative thereof comprises a heavy chain variable domain (vh) comprising amino acid sequence seq id no:1 and a light chain variable domain (vl) comprising amino acid sequence seq id no:2"
https://patents.google.com/patent/WO2021222128A1/en,,,,,(223/224)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:223 and a light chain variable domain (vl) comprising amino acid sequence seq id no:224
https://patents.google.com/patent/WO2021222128A1/en,,,,,(221/222)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:221 and a light chain variable domain (vl) comprising amino acid sequence seq id no:222
https://patents.google.com/patent/WO2021222128A1/en,,,,,(233/234)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:233 and a light chain variable domain (vl) comprising amino acid sequence seq id no:234
https://patents.google.com/patent/WO2021222128A1/en,,,,,(135/136)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:135 and a light chain variable domain (vl) comprising amino acid sequence seq id no:136
https://patents.google.com/patent/WO2021222128A1/en,,,,,(109/110)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:109 and a light chain variable domain (vl) comprising amino acid sequence seq id no:110
https://patents.google.com/patent/WO2021222128A1/en,,,,,(55/56)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:55 and a light chain variable domain (vl) comprising amino acid sequence seq id no:56
https://patents.google.com/patent/WO2021222128A1/en,,,,,(175/176)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:175 and a light chain variable domain (vl) comprising amino acid sequence seq id no:176
https://patents.google.com/patent/WO2021222128A1/en,,,,,(81/82)  a heavy chain variable domain (vh) comprising amino acid sequence seq id no:81 and a light chain variable domain (vl) comprising amino acid sequence seq id no:82
https://patents.google.com/patent/WO2021222128A1/en,,,,,"(9/10) in some embodiments, the antibody or derivative thereof comprises: a heavy chain variable domain (vh) comprising amino acid sequence seq id no:9 and a light chain variable domain (vl) comprising amino acid sequence seq id no:10"
https://patents.google.com/patent/WO2021222128A1/en,,,,,(241/242)  or a heavy chain variable domain (vh) comprising amino acid sequence seq id no:241 and a light chain variable domain (vl) comprising amino acid sequence seq id no:242. 
https://patents.google.com/patent/KR102051052B1/en, Leu Pro Glu Phe Gln Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Gln Pro Lys Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ile Tyr Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Thr Tyr Cys Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Met Leu Tyr Leu Gln Met Asn Asn Leu Asn Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Arg Tyr Tyr Gly Gly Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Arg Ser Ser , Glu Leu Asp Ile Val Met Thr Gln Ser Thr Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Asn Asn Phe Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Leu Ala Thr Tyr Tyr Cys His Gln Asn Tyr Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ala Cys Thr , VH, VL,"(7/8)  the monoclonal antibody according to claim 1, wherein the monoclonal antibody is a heavy chain comprising a polypeptide sequence of seq id no:7 and a light chain comprising a polypeptide sequence of seq id no:8."
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ser Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Asn Leu Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , No. 9 HC variable region, No. 9 LC variable region,(126/125)  a) the light chain variable region set forth in seq id no:125; and b) an antibody comprising the heavy chain variable region set forth in seq id no:126; 
https://patents.google.com/patent/KR102229225B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Ser Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 12 HC variable region, No. 12 LC variable region,(132/131)  a) the light chain variable region set forth in seq id no:131; and b) an antibody comprising the heavy chain variable region set forth in seq id no:132; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Arg Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 3 HC variable region, No. 3 LC variable region,(114/113)  a) the light chain variable region set forth in seq id no:113; and b) an antibody comprising the heavy chain variable region set forth in seq id no:114; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No. 1 HC variable region, No. 1 LC variable region,(110/109)  a) the light chain variable region set forth in seq id no:109; and b) an antibody comprising the heavy chain variable region set forth in seq id no:110; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 4 HC variable region, No. 4 LC variable region,(116/115)  a) the light chain variable region set forth in seq id no:115; and b) an antibody comprising the heavy chain variable region set forth in seq id no:116; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Val Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Arg Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 5 HC variable region, No. 5 LC variable region,(118/117)  a) the light chain variable region set forth in seq id no:117; and b) an antibody comprising the heavy chain variable region set forth in seq id no:118; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No. 6 HC variable region, No. 6 LC variable region,(120/119)  a) the light chain variable region set forth in seq id no:119; and b) an antibody comprising the heavy chain variable region set forth in seq id no:120; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn Phe Val Ser Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 8 HC variable region, No. 8 LC variable region,(124/123)  a) the light chain variable region set forth in seq id no:123; and b) an antibody comprising the heavy chain variable region set forth in seq id no:124; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Ala Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 14 HC variable region, No. 14 LC variable region,(136/135)  a) the light chain variable region set forth in seq id no:135; and b) an antibody comprising the heavy chain variable region set forth in seq id no:136; 
https://patents.google.com/patent/KR102229225B1/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 7 HC variable region, No. 7 LC variable region,(122/121)  a) the light chain variable region set forth in seq id no:121; and b) an antibody comprising the heavy chain variable region set forth in seq id no:122; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 13 HC variable region, No. 13 LC variable region,(134/133)  a) the light chain variable region set forth in seq id no:133; and b) an antibody comprising the heavy chain variable region set forth in seq id no:134; 
https://patents.google.com/patent/KR102229225B1/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Glu Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , No. 11 HC variable region, No. 11 LC variable region,(130/129)  a) the light chain variable region set forth in seq id no:129; and b) an antibody comprising a heavy chain variable region set forth in seq id no:130; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asp Leu Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , No. 2 HC variable region, No. 2 LC variable region,(112/111)  a) the light chain variable region set forth in seq id no:111; and b) an antibody comprising the heavy chain variable region set forth in seq id no:112; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Pro Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu , No. 17 HC variable region, No. 17 LC variable region,(142/141)  a) the light chain variable region set forth in seq id no:141; and b) an antibody comprising the heavy chain variable region set forth in seq id no:142; and 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 18 HC variable region, No. 18 LC variable region,(144/143)  a) the light chain variable region set forth in seq id no:143; and b) an antibody comprising a heavy chain variable region set forth in seq id no:144. 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Met Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , No. 16 HC variable region, No. 16 LC variable region,(140/139)  a) the light chain variable region set forth in seq id no:139; and b) an antibody comprising a heavy chain variable region set forth in seq id no:140; 
https://patents.google.com/patent/KR102229225B1/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Val Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 10 HC variable region, No. 10 LC variable region,(128/127)  a) the light chain variable region set forth in seq id no:127; and b) an antibody comprising the heavy chain variable region set forth in seq id no:128; 
https://patents.google.com/patent/KR102229225B1/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Leu Glu Leu Thr Gln Pro Pro Ser Val Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu , No. 15 HC variable region, No. 15 LC variable region,(138/137)  a) the light chain variable region set forth in seq id no:137; and b) an antibody comprising the heavy chain variable region set forth in seq id no:138; 
https://patents.google.com/patent/CN113429476A/en, Glu Val Gln Leu Val Gln Ser Gly Thr Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Gly Phe Ile Thr Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Glu Thr Arg Tyr Ser Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Asn Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys Ala Gly Gly Ser Gly Ile Ser Thr Pro Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Ile Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial sequence (Artificial sequence), Artificial sequence (Artificial sequence),"(6/2) the coronavirus-binding bifunctional fusion protein of claim 1, which has the amino acid sequence of seq id no:6 and the amino acid sequence of the heavy chain shown in seq id no:2, or a light chain amino acid sequence set forth in seq id no."
https://patents.google.com/patent/CN112979793A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Gly Pro Thr Gly Trp Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Asp Ser Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Arg Ser Asn Trp Lys Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) preferably, the antibody comprises the heavy chain variable region shown in seq id no:4 and the light chain variable region shown in seq id no:8."
https://patents.google.com/patent/CN112979793A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/US10851155B2/en,,,,,"(14/16) , and neutralizes mers-cov, and wherein the monoclonal antibody or scfv antibody comprises a vh amino acid sequence having seq id no:14, and a vl amino acid sequence having seq id no:16."
https://patents.google.com/patent/WO2021174595A1/en,,,,,"(7/8)  preferably, it includes: vh shown in seq id no:7 and/or vl shown in seq id no:8."
https://patents.google.com/patent/WO2021227687A1/en,,,,,"(11/16)  in one embodiment, the antibody is 89c8, the amino acid sequence of its heavy chain is shown in seq id no:11, and the amino acid sequence of its light chain is shown in seq id no:16."
https://patents.google.com/patent/WO2021227687A1/en,,,,,"(21/22)  in one embodiment, the antibody is cr3022, the amino acid sequence of its heavy chain is shown in seq id no:21, and the amino acid sequence of its light chain is shown in seq id no:22."
https://patents.google.com/patent/US11175293B1/en,,,,,"(1)  fig. 4 shows two mutations in the ih4 nanobody permit efficient secretion of spike-rbd fusion proteins. fusion constructs with modified forms of ih4 (ih4vs2) (seq id no:21-22), i.e., ih4vs2-spike (i.e., “nanospike”; seq id no:1-2) and a similar construct containing an igk-leader sequence (instead of the lfnb leader sequence of nanospik"
https://patents.google.com/patent/US11175293B1/en,,,,,(32)  one or more anti-sars co-v-2 nanobody domains comprising 90-99% identity to seq id no:32 and one or more multimerization domains comprising 90-99% identity to seq id no:34 o4 36.
https://patents.google.com/patent/US11175293B1/en,,,,,"(12) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,,,,,"(2) one embodiment described herein is the “nanospike,” (seq id no:2) which refers to the respective nanobody and sars-cov-2 surface glycoprotein receptor “spike” domains of the fusion protein (fig"
https://patents.google.com/patent/US11175293B1/en,,,,,(18) the nanobody region of the nanolink (seq id no:16) and nanotrim (seq id no:18) constructs binds to the sars-cov-2 surface glycoprotein receptor biding domain (rb
https://patents.google.com/patent/US11175293B1/en,,,,,"(8) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,,,,,(65)  fig. 3 shows a fusion protein of the ih4 nanobody and the spike rbd is not efficiently secreted. a fusion construct of the ih4 nanobody (seq id no:65-
https://patents.google.com/patent/US11175293B1/en,,,,,"(14) also described herein are fusion proteins that can serve as negative or positive controls for the method or assay described herein. in one embodiment, the fusion protein “nanocontrol” (seq id no:14) can be used as a negative control. nanocontrol comprises the glycophorin a nanobody domain, but no covid domain. this polypeptide will not react with sars-cov-2-specific antibodies of subjects infected with or convalescing from sars-cov-2 when added to a sample of the subject's blood. this construct serves as a negative control."
https://patents.google.com/patent/US11175293B1/en,,,,,"(24) . in one aspect, the rbd comprises a glycophorin a-binding nanobody comprising 90-99% identity to seq id no:22. in another aspect, the cvd comprises one or more of a spike protein, a nucleocapsid protein, orf8 protein, orf3b protein, or envelope protein comprising 90-99% identity to all or a portion of seq id no:24, 26, 28, or 30."
https://patents.google.com/patent/US11175293B1/en,,,,,(22)  a glycophorin a-binding nanobody domain comprising 90-99% identity to seq id no:22; (
https://patents.google.com/patent/US11175293B1/en,,,,,"(10) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,,,,,(16) the nanobody region of the nanolink (seq id no:16
https://patents.google.com/patent/US11175293B1/en,,,,,(34)  one or more anti-sars co-v-2 nanobody domains comprising 90-99% identity to seq id no:32 and one or more multimerization domains comprising 90-99% identity to seq id no:34 o4 36.
https://patents.google.com/patent/US11175293B1/en,,,,,(66)  fig. 3 shows a fusion protein of the ih4 nanobody and the spike rbd is not efficiently secreted. a fusion construct of the ih4 nanobody (seq id no:65-66
https://patents.google.com/patent/US11175293B1/en,,,,,"(4) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,,,,,"(6) other embodiments useful in the assay include “nanonuc” (seq id no:4), “nanoorf8” (seq id no:6), “nanospikeorf8” (seq id no:8), “nanoorf3b” (seq id no:10), and “nanospikeorf3b” (seq id no:12), which refer to the nanobody and sars-cov-2 nucleocapsid, orf 8, surface glycoprotein receptor binding domain and orf 8, orf 3b, and orf 3b and surface glycoprotein receptor binding domains, respectively"
https://patents.google.com/patent/US11175293B1/en,,,,,"(21)  fig. 4 shows two mutations in the ih4 nanobody permit efficient secretion of spike-rbd fusion proteins. fusion constructs with modified forms of ih4 (ih4vs2) (seq id no:21-22), i.e., ih4vs2-spike (i.e., “nanospike”"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Glu Val Gln Pro Gly Thr Ser Leu Arg Leu Ser Cys Val Thr Ser Gly Phe Thr Phe Ala His Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Thr Trp Ser Asp Gly Ile Arg Arg Tyr Tyr Gly Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Lys Asp Thr Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp His Ser Ile Gly Leu Phe Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser , Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Leu Asn Ser Asp Ser Val Ser Thr Asn Tyr Tyr Pro Ser Trp His Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Asn Thr Asn Ile Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser Gly Ile Trp Val Phe Gly Gly Gly Thr Arg Leu Thr Val Leu , Artificial sequence, Artificial sequence,"(37/38) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:37 and the light chain variable region shown in seq id no:38"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Asn Tyr Phe Trp Ser Trp Ile Arg Gln Pro Ala Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Thr Thr Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Ala Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Val Arg Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr Cys Ala Arg Glu Ser Arg Thr Tyr Asp Gly Ser Gly Tyr Tyr Ile Asp Ser Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Leu Asn Cys Glu Ser Ser His Thr Leu Leu Tyr Ser Leu Asn Asn Lys Ser Ser Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Val Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Val Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys, Artificial sequence, Artificial sequence,"(46/47) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:46 and the light chain variable region shown in seq id no:47"
https://patents.google.com/patent/CN112940110A/en, Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Phe Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ile Tyr Ala Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Gly Gly Leu Gly Arg Gly Tyr Asp Ile Leu Thr Gly Thr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Ser Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys , Artificial sequence, Artificial sequence,"(56/57) preferably, the monoclonal antibody c10897p3s comprises the heavy chain variable region of seq id no:56 and the light chain variable region of seq id no:57"
https://patents.google.com/patent/CN112940110A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Ser His Gly Met His Trp Val Arg Gln Ala Thr Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Gly Ala Ala Gly Asp Pro Tyr Tyr Pro Gly Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Val Ala Gly Gly Leu Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Cys Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Ile Tyr Tyr Cys Gln Gln Tyr Tyr Ser Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys, Artificial sequence, Artificial sequence,"(17/18) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:17 and the light chain variable region shown in seq id no:18"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Phe Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp Ala Thr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Val Gly Trp Ile Asn Ala Gly Ser Gly Asn Thr Glu Phe Pro Gln Lys Phe Arg Gly Arg Val Thr Val Thr Arg Asp Thr Ser Ala Ser Val Leu Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly Gly Val His Thr Asp Gly Val Arg Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Thr Tyr Asn Tyr Val Ser Trp Tyr Gln His His Pro Gly Gln Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly His Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Thr Ser His Ala Gly Phe Asn Asn Phe Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial sequence, Artificial sequence,"(85/86) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:85 and the light chain variable region shown in seq id no:86."
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asp Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Leu Glu Trp Met Gly Trp Met Asn Pro Asn Ser Gly Asn Thr Gly Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Asn Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Arg Glu Gly Pro Asp Leu Arg Trp Leu Gln Glu Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Asn Asn Gly Asn Thr Tyr Leu Cys Trp Phe Gln Gln Arg Pro Gly Gln Ser Pro Arg Arg Leu Ile Tyr Asn Val Ser Asn Arg Asp Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Leu Gln Ala Thr His Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial sequence, Artificial sequence,"(75/76) preferably, the monoclonal antibody c10543o1s comprises the heavy chain variable region of seq id no:75 and the light chain variable region of seq id no:76"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Lys Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Ser Arg His Glu Gly Tyr Gly Ser Gly Ser Tyr Tyr Ile Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Tyr Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(65/66) preferably, the monoclonal antibody comprises the heavy chain variable region shown as seq id no:65 and the light chain variable region shown as seq id no:66"
https://patents.google.com/patent/CN112940110A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Ser Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Val Arg Asp Arg Gly Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Ser Thr Ser Tyr Tyr Pro Ser Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr Leu Ile Tyr Ser Thr Asn Thr Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser Gly Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial sequence, Artificial sequence,"(7/8) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:7 and the light chain variable region shown in seq id no:8"
https://patents.google.com/patent/CN112940110A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Ser Met Ala Gln Asp Gly Ser Asp Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu His Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Ser Cys Ala Ile His Gly Gly Asn Leu Ala Phe Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial sequence, Artificial sequence,"(27/28) preferably, the monoclonal antibody comprises the heavy chain variable region shown in seq id no:27 and the light chain variable region shown in seq id no:28."
https://patents.google.com/patent/CN111647079B/en, Gln Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Thr Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Ser Ser Ser Ala Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Ile Glu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Thr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys ,  Homo sapiens,  Homo sapiens,"(2/1) the neutralizing antibody for resisting the novel coronavirus n protein consists of a light chain and a heavy chain, wherein the amino acid sequence of a variable region of the light chain is shown as seq id no:1, the amino acid sequence of the heavy chain variable region is shown as seq id no:2, respectively."
https://patents.google.com/patent/CN111647079B/en, Gln Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Thr Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Ser Ser Ser Ala Gly Gly Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His His His His His His , Glu Ile Glu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala Leu Gln Thr Pro Thr Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys ,  Homo sapiens,  Homo sapiens,"(4/3) the amino acid sequence of the light chain of the neutralizing antibody of the anti-novel coronavirus n protein is shown as seq id no:3, the amino acid sequence of the heavy chain is shown as seq id no:4, respectively"
https://patents.google.com/patent/CN113402602A/en, Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys , VL(Artificial Sequence), VL(Artificial Sequence),"(34/44) still further, the amino acid sequence of vh of the antibody is selected from one of seq id no:2-seq id number 4, seq id no:14; and/or the amino acid sequence of the vl of the antibody is selected from one of seq id no:32-seq id no:34 and seq id no:44."
https://patents.google.com/patent/CN113402602A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Glu Asp Ala Gly Tyr Tyr Tyr Asp Ser Ser Gly Tyr Tyr Tyr Pro Lys Ala His Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Ala Ile Arg Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Ser Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Gln Glu Arg Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Gly Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Arg Leu Leu Ile Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys, VH_VL(Artificial Sequence), VH_VL(Artificial Sequence),"(218/228) further, the amino acid sequence of the scfv single-chain antibody is one of seq id no:216-seq id no:218 and seq id no:228. more specifically, the scfv single-chain antibodies are hts0422, hts0433, hts0446 and hts0483 in table 1 below, and the sequences of their heavy chains, light chains and their variable regions are also shown in table 1."
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(20/6) the antibody of claim 1, comprising (a) a light chain variable region comprising an amino acid sequence selected from the group consisting of seq id no:6-8 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:20"
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(21/9) the antibody of claim 1, comprising (a) a light chain variable region comprising the amino acid sequence of seq id no:9 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:21"
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(22/10) the antibody of claim 1, comprising (a) a light chain variable region comprising the amino acid sequence of seq id no:10 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:22"
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(24/13) the antibody of claim 1, comprising (a) a light chain variable region comprising the amino acid sequence of seq id no:13 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:24"
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(26/15) the antibody of claim 1, comprising (a) a light chain variable region comprising an amino acid sequence selected from the group consisting of seq id no:15-17 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:26"
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(19/5) the antibody of claim 1, comprising (a) a light chain variable region comprising the amino acid sequence of seq id no:5 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:19"
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(25/14) the antibody of claim 1, comprising (a) a light chain variable region comprising the amino acid sequence of seq id no:14 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:25"
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(18/1) the antibody of claim 1, comprising (a) a light chain variable region comprising an amino acid sequence selected from the group consisting of seq id no:1-4 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:18"
https://patents.google.com/patent/WO2021221668A1/en,,,,,"(23/11) the antibody of claim 1, comprising (a) a light chain variable region comprising an amino acid sequence selected from the group consisting of seq id no:11-12 and (b) a heavy chain variable region comprising the amino acid sequence of seq id no:23"
https://patents.google.com/patent/CN113444169B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(22/23) (i) a heavy chain having an amino acid sequence shown in seq id no:22 and a light chain having an amino acid sequence shown in seq id no:23
https://patents.google.com/patent/CN113444169B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Ala Gly Trp Val Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(33/34)  a heavy chain with an amino acid sequence shown as seq id no:33 and a light chain with an amino acid sequence shown as seq id no:34.
https://patents.google.com/patent/CN113444169B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(7/8)  a heavy chain variable region having an amino acid sequence shown in seq id no:7 and a light chain variable region having an amino acid sequence shown in seq id no:8;
https://patents.google.com/patent/CN113444169B/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg Ala Gly Trp Val Arg Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Asn Phe Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys Thr Val Thr Ile Ser Cys Thr Gly Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Asn Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys , Artificial sequence (artificial sequence), Artificial sequence (artificial sequence),(31/32)  heavy chain variable region whose amino acid sequence is shown as seq id no:31 and light chain variable region whose amino acid sequence is shown as seq id no:32.
https://patents.google.com/patent/CN113583116A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Asn Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Phe Tyr Cys Ala Arg Glu Gly Asp Tyr Tyr Val Ser Ser Tyr Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, 36H6 VH, 36H6 VL,"(1/2) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:1 and a vl comprising the sequence shown as seq id no:2."
https://patents.google.com/patent/CN113583116A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Asp Tyr Tyr Val Ser Ser Tyr Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys, h36H6-10/h36H6-12 VH, h36H6-10 VL,(17/18) (1) a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:18
https://patents.google.com/patent/CN113583116A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gly Asp Tyr Tyr Val Ser Ser Tyr Gly Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Phe Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys, h36H6-10/h36H6-12 VH, h36H6-12 VL,(17/19)  a vh comprising the sequence shown as seq id no:17 and a vl comprising the sequence shown as seq id no:19.
https://patents.google.com/patent/CN113583116A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Asn Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly Arg Ile Asp Pro Tyr Asp Ser Glu Thr His Tyr Asn Gln Lys Phe Lys Asp Lys Ala Ile Leu Thr Val Asp Lys Ser Ser Thr Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Trp Gly Thr Val Glu Trp Phe Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Gln , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Met Ser Val Gly Gln Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Tyr Asn Gln Glu Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln His Tyr Ser Thr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys, 2B4 VH, 2B4 VL,"(3/4) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:3 and a vl comprising the sequence shown as seq id no:4."
https://patents.google.com/patent/CN112010963A/en,,,,,"(21/9) (a) comprises the amino acid sequence shown in seq id no:9 and (b) a light chain variable region comprising the amino acid sequence of seq id no:21, a heavy chain variable region of the amino acid sequence of seq id no"
https://patents.google.com/patent/CN112010963A/en,,,,,"(1/18) in particular, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of seq id no:1-17 (see table 1) and a light chain variable region comprising an amino acid sequence selected from seq id no:18-26 (see table 2)"
https://patents.google.com/patent/CN112010963A/en,,,,,"(78/80)  and seq id no:78, and a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the heavy chain set forth in seq id no:80, or a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto."
https://patents.google.com/patent/CN112010963A/en,,,,,"(19/5) (a) comprises the amino acid sequence shown in seq id no:5 and (b) a light chain variable region comprising the amino acid sequence of seq id no:19, the heavy chain variable region of the amino acid sequence of seq id no"
https://patents.google.com/patent/CN112010963A/en,,,,,"(18/1) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: a light chain variable region comprising a sequence selected from seq id no:1-4; and a heavy chain variable region comprising seq id no:18."
https://patents.google.com/patent/CN112979790A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN111925440A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 046). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111925440A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 049). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111925440A/en,,,,,(29/28)  the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 058). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111925440A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqts 051). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111925440A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (monoclonal antibody 3-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(37/36)  the light chain amino acid sequence may also be shown as seq id no:36 (mab 18-cqts 063). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111925440A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence can also be shown as seq id no:40 (monoclonal antibody 20-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(13/12)  the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 050). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111925440A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence may also be shown as seq id no:36 (mab 18-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence can also be shown as seq id no:38 (monoclonal antibody 19-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (mab 9-cqts 053). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111925440A/en,,,,,(39/38)  the light chain amino acid sequence can also be shown as seq id no:38 (monoclonal antibody 19-cqts 064). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111925440A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (monoclonal antibody 4-cqts 048). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111925440A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(23/22)  the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 055). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111925440A/en,,,,,(25/24)  the light chain amino acid sequence can also be shown as seq id no:24 (mab 12-cqts 056). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111925440A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to the novel coronavirus rbd, the heavy chain amino acid sequence is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111925440A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (monoclonal antibody 3-cqts 047). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111925440A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence can also be shown as seq id no:24 (mab 12-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(3/2)  the light chain amino acid sequence is shown in seq id no:2 (monoclonal antibody 1-cqts 045). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111925440A/en,,,,,(31/30)  the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 059). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111925440A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(27/26)  the light chain amino acid sequence can also be shown as seq id no:26 (mab 13-cqts 057). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111925440A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence may also be as shown in seq id no:34 (mab 17-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (monoclonal antibody 2-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (mab 10-cqts 054). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111925440A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (mab 9-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence can also be shown as seq id no:26 (mab 13-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 052). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111925440A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (monoclonal antibody 4-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(33/32)  the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibody 16-cqts 061). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111925440A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 
https://patents.google.com/patent/CN111925440A/en,,,,,(35/34)  the light chain amino acid sequence may also be as shown in seq id no:34 (mab 17-cqts 062). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111925440A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (mab 10-cqts 
https://patents.google.com/patent/WO2021238854A1/en,,,,,"(12/13)  the amino acid sequence of the heavy chain variable region is shown in seq id no:12, and the amino acid sequence of the light chain variable region is shown in seq id no:13."
https://patents.google.com/patent/WO2021238854A1/en,,,,,"(6/7)  the amino acid sequence of the heavy chain variable region is shown in seq id no:6, and the amino acid sequence of the light chain variable region is shown in seq id no:7;"
https://patents.google.com/patent/WO2021238854A1/en,,,,,"(8/9)  the amino acid sequence of the heavy chain variable region is shown in seq id no:8, and the amino acid sequence of the light chain variable region is shown in seq id no:9;"
https://patents.google.com/patent/WO2021238854A1/en,,,,,"(2/3)  the amino acid sequence of the heavy chain variable region is shown in seq id no:2, and the amino acid sequence of the light chain variable region is shown in seq id no:3;"
https://patents.google.com/patent/WO2021238854A1/en,,,,,"(4/5)  the amino acid sequence of the heavy chain variable region is shown in seq id no:4, and the amino acid sequence of the light chain variable region is shown in seq id no:5;"
https://patents.google.com/patent/WO2021238854A1/en,,,,,"(10/11)  (e) the amino acid sequence of the heavy chain variable region is shown in seq id no:10, and the amino acid sequence of the light chain variable region is shown in seq id no:11"
https://patents.google.com/patent/WO2006095180A2/en,,,,,"(24/25) the preparation of claim 20, wherein said vh chain comprises a sequence of seq id no:24 and said vl chain comprises a sequence of seq id no:25"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Ala Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Ser Ala Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(29/30) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:29, and the light chain amino acid sequence is shown as seq id no:30"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Phe Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Cys Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Arg Gly Met Leu His Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln His Tyr Asp Asn Leu Pro Gly Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(59/60) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:59, and the light chain amino acid sequence is shown as seq id no:60"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Glu Ile Gln Pro Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Phe Gly Gly Tyr Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Asn Asn Phe Asp Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(49/50) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:49, and the light chain amino acid sequence is shown as seq id no:50"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Leu Leu Val Ala Thr Ile Arg Asp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(39/40) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:39, and the light chain amino acid sequence is shown as seq id no:40"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Gly Asp Tyr Glu Asn Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Gly Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(69/70) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:69, and the light chain amino acid sequence is shown as seq id no:70."
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Leu Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ile Thr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(9/10) in a preferred embodiment of the invention, the heavy chain amino acid sequence of the antibody or antigen binding fragment thereof is set forth in seq id no:9, and the light chain amino acid sequence is set forth in seq id no:10"
https://patents.google.com/patent/CN112159469A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ile Asp Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence, Artificial Sequence,"(19/20) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:19, and the light chain amino acid sequence is shown as seq id no:20"
https://patents.google.com/patent/CN111925442A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (mab 2-cqt 190). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111925442A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (mab 5-cqt 197). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111925442A/en,,,,,(29/28)  the light chain amino acid sequence may also be shown as seq id no:28 (mab 14-cqt 209). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111925442A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqt 199). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111925442A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(37/36)  the light chain amino acid sequence may also be shown as seq id no:36 (mab 18-cqt 216). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111925442A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence may also be shown as seq id no:40 (mab 20-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(13/12)  the light chain amino acid sequence may also be shown as seq id no:12 (mab 6-cqt 198). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111925442A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence may also be shown as seq id no:36 (mab 18-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence may also be shown as seq id no:38 (mab 19-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(39/38)  the light chain amino acid sequence may also be shown as seq id no:38 (mab 19-cqt 217). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111925442A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (mab 9-cqt 201). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111925442A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqt 195). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111925442A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (mab 7-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(23/22)  the light chain amino acid sequence may also be shown as seq id no:22 (mab 11-cqt 202). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111925442A/en,,,,,(25/24)  the light chain amino acid sequence may also be shown as seq id no:24 (mab 12-cqt 203). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111925442A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence may also be shown as seq id no:12 (mab 6-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to a novel coronavirus rbd, the heavy chain amino acid sequence of which is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111925442A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqt 191). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111925442A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence may also be shown as seq id no:24 (mab 12-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(3/2)  the light chain amino acid sequence is shown in seq id no:2 (monoclonal antibody 1-cqt 149). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111925442A/en,,,,,(31/30)  the light chain amino acid sequence may also be shown as seq id no:30 (mab 15-cqt 210). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111925442A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence may also be shown as seq id no:32 (mab 16-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (mab 5-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence may also be shown as seq id no:22 (mab 11-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence may also be shown as seq id no:30 (mab 15-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(27/26)  the light chain amino acid sequence may also be shown as seq id no:26 (mab 13-cqt 206). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111925442A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence can also be shown as seq id no:34 (mab 17-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (mab 2-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (mab 10-cqt 201). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111925442A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (mab 9-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence may also be shown as seq id no:26 (mab 13-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqt 200). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111925442A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(33/32)  the light chain amino acid sequence may also be shown as seq id no:32 (mab 16-cqt 212). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111925442A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence may also be shown as seq id no:28 (mab 14-cqt 
https://patents.google.com/patent/CN111925442A/en,,,,,(35/34)  the light chain amino acid sequence can also be shown as seq id no:34 (mab 17-cqt 215). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111925442A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (mab 10-cqt 
https://patents.google.com/patent/KR20220012826A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017) the method according to any one of claims 1 to 6, the binding molecule is light chain variable region of the polypeptide sequence of seq id no:2017; and seq id no:2018 heavy chain variable region of the polypeptide sequence a binding molecule comprising a."
https://patents.google.com/patent/CN113956353A/en, gaggtccagc tgcagcagtc tggacctgag ctggtgaagc ctggggcttc agtgaaggta tcctgcaagg cttctggtta ttcattcact gactacaaca tgttctgggt gaagcagagc catggaaaga gccttgagtg gattggatat tttgatcctt acaatggtgg tactaactac aaccagaagt tcaagggcaa ggccacattg actgttgaca agtcctccag cacagccttc atgcatctca acaacctgac atctgaggac tctgcagtct attactgtgc aagagagaac gatatgacta cgacggttta ctatgctatg gactactggg gtcaaggaac cacggtcact gtctc , attgttctca cccagtctcc agcactcatg tctgcatctc caggggagaa ggtcaccatg acctgcagtg ccagctcaag tgtgaattac atttactggt accagcagag gccaagatcc tcccccaaac cctggattta tctcacatcc aacctggctt ctggagtccc tgctcgcttc agtggcagtg ggtctgggac ctcttactct ctcacaatta gcagcatgga ggctgaagat gctgccactt attactgcca gcagtggaat agtaacccgc tcacgttcgg tgctgggacc aagctggagc tgaaa , Artificial Sequence, Artificial Sequence,"(15/19) specifically, the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:15; the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown in seq id no:19"
https://patents.google.com/patent/CN113956353A/en, caggtgcaac tgaagcagtc tggggctgag ctggtgaggc ctggggtctc agtgaagatt tcctgcaagg gttctggcta cacattcact gattatgctg tgcactgggt gaagcagagt catgcaaaga gtctagagtg gattggagtt tttagtactt actatggtaa tgctaactac aaccagaact tcaagggcaa ggccacaatg accgtagaca aatcctccaa cacagcctat atggaacttg ccagactgac atctgaggat tctgccatct attactgtgc aagaggaggg gattactacg gtagtagcaa cgtagactat gctatggact actggggtca aggaacctca , gaaaatgtgc tcacccagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc atctcataca gggccagcaa aagtgtcagt acatctggct atagttatat gcactggaac caacagaaac caggacagcc acccagactc ctcatctatc ttgtatccaa cctagaatct ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat cctgtggagg aggaggatgc tgcaacctat tactgtcagc acattaggga gcttacacgt tcggaggggg gaccaagctg gagctga , Artificial Sequence, Artificial Sequence,(16/20) the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:16; the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 6e8 is shown in seq id no:20.
https://patents.google.com/patent/CN113956353A/en, caggtgcaac tgaagcagtc tggggctgag ctggtgaggc ctggggtctc agtgaagatt tcctgcaagg gttctggcta cacattcact gattatgctg tgcactgggt gaagcagagt catgcaaaga gtctagagtg gattggagtt tttagtactt actatggtaa tgctaactac aaccagaact tcaagggcaa ggccacaatg accgtagaca aatcctccaa cacagcctat atggaacttg ccagactgac atctgaggat tctgccatct attactgtgc aagaggaggg gattactacg gtagtagcaa cgtagactat gctatggact actggggtca aggaacctca , attgttctca cccagtctcc agcactcatg tctgcatctc caggggagaa ggtcaccatg acctgcagtg ccagctcaag tgtgaattac atttactggt accagcagag gccaagatcc tcccccaaac cctggattta tctcacatcc aacctggctt ctggagtccc tgctcgcttc agtggcagtg ggtctgggac ctcttactct ctcacaatta gcagcatgga ggctgaagat gctgccactt attactgcca gcagtggaat agtaacccgc tcacgttcgg tgctgggacc aagctggagc tgaaa , Artificial Sequence, Artificial Sequence,(16/19)  the dna sequence of the light chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown in seq id no:19. the dna sequence of the heavy chain variable region of the mouse anti-sads-cov n protein monoclonal antibody 4b10 is shown as seq id no:16
https://patents.google.com/patent/CN113956353A/en, gaggtccagc tgcagcagtc tggacctgag ctggtgaagc ctggggcttc agtgaaggta tcctgcaagg cttctggtta ttcattcact gactacaaca tgttctgggt gaagcagagc catggaaaga gccttgagtg gattggatat tttgatcctt acaatggtgg tactaactac aaccagaagt tcaagggcaa ggccacattg actgttgaca agtcctccag cacagccttc atgcatctca acaacctgac atctgaggac tctgcagtct attactgtgc aagagagaac gatatgacta cgacggttta ctatgctatg gactactggg gtcaaggaac cacggtcact gtctc , caggtgcaac tgaagcagtc tggggctgag ctggtgaggc ctggggtctc agtgaagatt tcctgcaagg gttctggcta cacattcact gattatgctg tgcactgggt gaagcagagt catgcaaaga gtctagagtg gattggagtt tttagtactt actatggtaa tgctaactac aaccagaact tcaagggcaa ggccacaatg accgtagaca aatcctccaa cacagcctat atggaacttg ccagactgac atctgaggat tctgccatct attactgtgc aagaggaggg gattactacg gtagtagcaa cgtagactat gctatggact actggggtca aggaacctca , Artificial Sequence, Artificial Sequence,"(15/16) 3. the dna sequence of the heavy chain variable region and the light chain variable region of the monoclonal antibody for resisting the porcine acute diarrhea syndrome coronavirus n protein of claim 2, wherein the dna sequence of the heavy chain variable region of the monoclonal antibody for resisting the porcine acute diarrhea syndrome coronavirus n protein is shown as seq id no:15 or seq id no:16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(15) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(5) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(1) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(3) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(12) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(2) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(8) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(13) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(14) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(9) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(10) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(16) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(11) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(4) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(7) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/WO2021231803A2/en,,,,,"(6) the coding sequence which encodes a single domain antibody may be identical to one of the nucleotide sequences provided in the appendices, or it may also be a different coding sequence which, as a result of the redundancy or degeneracy of the genetic code, encodes a polypeptide provided in the appendices, including those listed in seq id no:1-16"
https://patents.google.com/patent/CN112430265A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Glu Ile Ile Val Asn Arg Asn Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ile Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Met Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Tyr Gly Asp Phe Tyr Val Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(2/1) the amino acid sequences of the variable regions of the light and heavy chains of antibody ncov-61 are shown in seq id no:1 and 2, respectively."
https://patents.google.com/patent/CN112125973B/en, Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Arg Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Met Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Gln Gly Asn Gln Thr Leu Arg Tyr Phe Asp Trp Ser Ala Pro Leu Val Thr Phe Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Ser Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Met Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser , Artificial Sequence, Artificial Sequence,"(9/10) the heavy chain amino acid sequence of the antibody or the antigen binding fragment thereof is shown as seq id no:9, and the light chain amino acid sequence is shown as seq id no:10."
https://patents.google.com/patent/US11034762B1/en,,,,,"(345/405) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:345 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:405."
https://patents.google.com/patent/US11034762B1/en,,,,,"(347/407) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:347 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:407."
https://patents.google.com/patent/US11034762B1/en,,,,,"(324/384) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:324 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:384."
https://patents.google.com/patent/US11034762B1/en,,,,,"(342/402) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:342 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:402."
https://patents.google.com/patent/US11034762B1/en,,,,,"(348/408) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:348 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:408."
https://patents.google.com/patent/US11034762B1/en,,,,,"(331/391) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:331 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:391."
https://patents.google.com/patent/US11034762B1/en,,,,,"(377/437) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:377 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:437."
https://patents.google.com/patent/US11034762B1/en,,,,,"(344/404) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:344 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:404."
https://patents.google.com/patent/US11034762B1/en,,,,,"(363/423) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:363 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:423."
https://patents.google.com/patent/US11034762B1/en,,,,,"(369/429) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:369 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:429."
https://patents.google.com/patent/US11034762B1/en,,,,,"(327/387) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:327 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:387."
https://patents.google.com/patent/US11034762B1/en,,,,,"(353/413) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:353 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:413."
https://patents.google.com/patent/US11034762B1/en,,,,,"(335/395) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:335 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:395."
https://patents.google.com/patent/US11034762B1/en,,,,,"(376/436) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:376 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:436."
https://patents.google.com/patent/US11034762B1/en,,,,,"(360/420) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:360 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:420."
https://patents.google.com/patent/US11034762B1/en,,,,,"(343/403) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:343 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:403."
https://patents.google.com/patent/US11034762B1/en,,,,,"(362/422) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:362 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:422."
https://patents.google.com/patent/US11034762B1/en,,,,,"(320/380) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:320 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:380."
https://patents.google.com/patent/US11034762B1/en,,,,,"(322/382) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:322 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:382."
https://patents.google.com/patent/US11034762B1/en,,,,,"(332/392) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:332 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:392."
https://patents.google.com/patent/US11034762B1/en,,,,,"(357/417) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:357 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:417."
https://patents.google.com/patent/US11034762B1/en,,,,,"(367/427) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:367 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:427."
https://patents.google.com/patent/US11034762B1/en,,,,,"(338/398) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:338 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:398."
https://patents.google.com/patent/US11034762B1/en,,,,,"(352/412) an antibody or an antigen-binding fragment that selectively binds to a sars-cov-2, that comprises a vh having an amino acid sequence of seq id no:352 and a vl having an amino acid sequence of seq id no:412."
https://patents.google.com/patent/US11034762B1/en,,,,,"(321/381) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:321 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:381."
https://patents.google.com/patent/US11034762B1/en,,,,,"(364/424) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:364 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:424."
https://patents.google.com/patent/US11034762B1/en,,,,,"(375/435) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:375 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:435."
https://patents.google.com/patent/US11034762B1/en,,,,,"(339/399) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:339 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:399."
https://patents.google.com/patent/US11034762B1/en,,,,,"(370/430) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:370 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:430."
https://patents.google.com/patent/US11034762B1/en,,,,,"(346/406) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:346 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:406."
https://patents.google.com/patent/US11034762B1/en,,,,,"(354/414) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:354 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:414."
https://patents.google.com/patent/US11034762B1/en,,,,,"(356/416) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:356 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:416."
https://patents.google.com/patent/US11034762B1/en,,,,,"(374/434) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:374 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:434."
https://patents.google.com/patent/US11034762B1/en,,,,,"(372/432) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:372 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:432."
https://patents.google.com/patent/US11034762B1/en,,,,,"(329/389) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:329 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:389."
https://patents.google.com/patent/US11034762B1/en,,,,,"(325/385) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:325 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:385."
https://patents.google.com/patent/US11034762B1/en,,,,,"(340/400) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:340 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:400."
https://patents.google.com/patent/US11034762B1/en,,,,,"(359/419) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:359 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:419."
https://patents.google.com/patent/US11034762B1/en,,,,,"(337/397) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:337 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:397."
https://patents.google.com/patent/US11034762B1/en,,,,,"(349/409) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:349 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:409."
https://patents.google.com/patent/US11034762B1/en,,,,,"(323/383) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:323 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:383."
https://patents.google.com/patent/US11034762B1/en,,,,,"(373/433) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:373 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:433."
https://patents.google.com/patent/US11034762B1/en,,,,,"(333/393) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:333 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:393."
https://patents.google.com/patent/US11034762B1/en,,,,,"(330/390) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:330 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:390."
https://patents.google.com/patent/US11034762B1/en,,,,,"(336/396) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:336 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:396."
https://patents.google.com/patent/US11034762B1/en,,,,,"(358/418) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:358 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:418."
https://patents.google.com/patent/US11034762B1/en,,,,,"(355/415) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:355 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:415."
https://patents.google.com/patent/US11034762B1/en,,,,,"(366/426) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:366 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:426."
https://patents.google.com/patent/US11034762B1/en,,,,,"(361/421) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:361 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:421."
https://patents.google.com/patent/US11034762B1/en,,,,,"(319/379) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:319 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:379."
https://patents.google.com/patent/US11034762B1/en,,,,,"(326/386) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:326 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:386."
https://patents.google.com/patent/US11034762B1/en,,,,,"(341/401) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:341 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:401."
https://patents.google.com/patent/US11034762B1/en,,,,,"(334/394) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:334 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:394."
https://patents.google.com/patent/US11034762B1/en,,,,,"(328/388) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:328 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:388."
https://patents.google.com/patent/US11034762B1/en,,,,,"(351/411) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:351 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:411."
https://patents.google.com/patent/US11034762B1/en,,,,,"(368/428) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:368 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:428."
https://patents.google.com/patent/US11034762B1/en,,,,,"(371/431) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:371 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:431."
https://patents.google.com/patent/US11034762B1/en,,,,,"(350/410) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:350 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:410."
https://patents.google.com/patent/US11034762B1/en,,,,,"(318/378) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:318 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:378."
https://patents.google.com/patent/US11034762B1/en,,,,,"(365/425) in one instance, the antibody or antigen-binding fragment that selectively binds to sars-cov-2 can comprise a vh having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:365 and a vl having an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identical to seq id no:425."
https://patents.google.com/patent/CN113563464A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Thr Tyr Glu Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Tyr Ile His Asn Ser Gly Asn Pro Val Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Glu Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Ala Leu Arg Tyr Ser Thr Ser Trp Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Glu Ile Val Leu Thr Gln Ser Pro Val Ser Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Phe Ile Tyr Asp Ala Ser Lys Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(9/11)  seq id no:9 and seq id no:11, the antibody having the amino acid sequences of the variable region of the heavy chain and the variable region of the light chain in one embodiment of the present invention is named ""wjq-c11""."
https://patents.google.com/patent/CN113563464A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Glu Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ala Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Ile Tyr Tyr Cys Ala Arg Asp Leu Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser , Asp Ile Gln Leu Thr Gln Phe Pro Phe Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Leu Leu Asn Ser Tyr Pro Val His Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(5/7)  seq id no:5 and seq id no:7; in the present invention, an antibody having the amino acid sequences of the variable regions of the heavy chain and the variable regions of the light chain is named ""wjq-g10"", or"
https://patents.google.com/patent/CN113563464A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Phe Ile Val Ser Arg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Thr Gly Leu Glu Trp Val Ser Val Ile Tyr Pro Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asp Ser Leu Arg Val Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Tyr Gly Asp Phe Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser , Glu Ile Val Met Thr Gln Ser Pro Val Ser Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Gly Val Ala Ser Asn Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Thr Leu Gln Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asp Arg Pro Arg Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr ,  Homo sapiens,  Homo sapiens,"(1/3)  seq id no:1 and seq id no:3; in the present invention, an antibody having the amino acid sequences of the variable regions of the heavy chain and the variable regions of the light chain is designated as ""sw-c11"", or"
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Ala Thr Phe Arg His Tyr Ile Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Ala Ala Asn Gly Glu His Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Ile Val Asp Gly Trp Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(1)  a neutralizing nanobody shown in seq id no:1 or a functionally active variant thereof;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Asp Phe Ser Trp Ser Tyr Ile Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Asp His Trp Thr Gln Asp Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Met Ser Ile Gly Trp Pro Glu Leu Phe Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(3)  a neutralizing nanobody shown in seq id no:3 or a functionally active variant thereof;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Ala Thr Phe Gly His Tyr Ala Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Gly Ala Gly Asp Arg Arg Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Ile Asp Thr Glu Tyr Gly Gln Asn Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(5)  a neutralizing nanobody shown in seq id no:5 or a functionally active variant thereof;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Arg Tyr Ser Asp Trp Thr Ser Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Gly Tyr Asp Asn Thr Pro Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Trp Tyr Ile Lys Met Asn Ser Asp Met His Val Gln Arg Glu Trp Glu Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(2)  a neutralizing nanobody shown in seq id no:2 or a functionally active variant thereof;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Ser Thr Trp Arg His Tyr Val Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Ser Leu Asp Ser Ser Val Ala Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Ile Glu Thr Val His Gly His Met Ile Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(4)  a neutralizing nanobody or a functionally active variant thereof represented by seq id no:4;
https://patents.google.com/patent/CN113563463A/en, Gln Val Gln Leu Val Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Glu Tyr Thr Tyr Ser Tyr Ile Tyr Ala Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Ala Val Ser Ala Ile Ala Gly Glu Asn Tyr Ser Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Thr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Ala Trp Pro Thr Gln Asp Gly Tyr Ala Ala Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial Sequence (Artificial Sequence),,(6)  a neutralizing nanobody shown in seq id no:6 or a functionally active variant thereof.
https://patents.google.com/patent/KR20220012800A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018."
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Gly Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , Artificial Sequence, Artificial Sequence,"(27/29)  vh comprises the amino acid sequence as set forth in seq id no:27, and vl comprises the amino acid sequence set forth in seq id no:29;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Asn Ser Tyr Pro Arg Phe Gly Pro Gly Thr Lys Val Glu Ile Lys , Artificial Sequence, Artificial Sequence,"(31/33)  vh comprises the amino acid sequence as set forth in seq id no:31, and vl comprises the amino acid sequence set forth in seq id no:33;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Ser Val Leu Pro Leu Phe Pro Gly Glu Ser Gly Ser Leu Ser Cys Arg Ala Ser Gln Asn Val Gly Asp Phe Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Lys Leu Leu Ile Tyr Gly Ala Thr Asn Arg Pro Thr Gly Ile Pro Asp Arg Phe Ser Gly Thr Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Met Glu Pro Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Gly Thr Ser Pro Pro Ile Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence, Artificial Sequence,"(19/21)  vh comprises the amino acid sequence as set forth in seq id no:19, and vl comprises the amino acid sequence set forth in seq id no:21;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , Artificial Sequence, Artificial Sequence,"(15/17)  vh comprises the amino acid sequence as set forth in seq id no:15, and vl comprises the amino acid sequence set forth in seq id no:17;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Val Thr Leu Ser Cys Arg Thr Ser Gln Ser Val Ser Arg Phe Phe Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile His Thr Ala Ser Thr Arg Ala Thr Asp Ile Pro Asp Arg Phe Ser Ala Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Ser Ala Met Tyr Tyr Cys Gln His Tyr Gly Ala Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys , Artificial Sequence, Artificial Sequence,"(23/25)  vh comprises the amino acid sequence as set forth in seq id no:23, and vl comprises the amino acid sequence set forth in seq id no:25;"
https://patents.google.com/patent/CN112574299A/en, Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val Ser Leu Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Arg Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Ser Glu Lys Gly Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ala Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Arg Ile Thr Cys Gly Gly Asn His Ile Gly Ser Lys Ser Val Asn Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Val Leu Val Ile Tyr Ser Asp Ser Asp Arg Pro Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Asn Ser Gly Asp Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Arg Ser Asp His Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu , Artificial Sequence, Artificial Sequence,"(35/37)  vh comprises the amino acid sequence as set forth in seq id no:35, and vl comprises the amino acid sequence set forth in seq id no:37;"
https://patents.google.com/patent/US20210347860A1/en,,,,,"(99/101)  also include variable regions having amino acid sequences that have 99%, 95%, 90%, 80% or 70% sequence identity with one of the heavy chains from variable region seq id no:99, 109, 119, 129, 139, or 149, and a light chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one light chains from variable region seq id no:101, 11, 121, 131, 141, or 151."
https://patents.google.com/patent/US20210347860A1/en,,,,,"(1/3)  also include variable regions having amino acid sequences that have 99%, 95%, 90%, 80% or 70% sequence identity with one of the heavy chains from variable region seq id no:1, 5, 11, 15, 19, 23, 27, 31 or 35, and a light chain that has 99%, 95%, 90%, 80% or 70% sequence identity with one light chains from variable region seq id no:3, 7, 13, 17, 21, 25, 29, 33, or 37."
https://patents.google.com/patent/CN113512114A/en, Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu Ser Leu Lys Ile Ser Cys Gln Phe Ser Glu Tyr Lys Leu Ile Ser Phe Trp Ile Ala Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Met Gly Ile Ile Tyr Pro Asp Asp Ser Asp Thr Lys Tyr Ser Pro Ser Ser Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Arg Thr Ala Tyr Leu Gln Trp Ser Ser Leu Met Ala Ser Asp Thr Ala Met Tyr Tyr Cys Thr Ser Gly Ser Tyr Tyr Gly Thr Leu Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Glu Ile Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Thr Tyr Val Ala Trp Tyr Gln Gln Arg Pro Gly Lys Val Pro Arg Leu Leu Ile Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Arg Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Ala Pro Leu Thr Phe Gly Gly Gly Ala Lys Val Glu Ile Lys , BD812 VH, BD812 VL,"(7/8) preferably, the antibody or antigen-binding fragment thereof comprises: a vh comprising the sequence shown as seq id no:7and a vl comprising the sequence shown as seq id no:8"
https://patents.google.com/patent/CN113512114A/en, Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Thr Ser Val Arg Val Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Thr Ser Ala Val Gln Trp Val Arg Gln Ala Arg Gly Gln Arg Leu Glu Trp Ile Gly Trp Ile Ala Val Gly Ser Gly Lys Thr Asp Tyr Leu Gln Lys Phe Gln Glu Arg Val Thr Met Thr Arg Asp Glu Ser Thr Asn Thr Ala Tyr Met Gln Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Pro His Cys Ser Gly Gly Thr Cys Tyr Asp Gly Phe Asp Ile Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Gly Tyr Phe Ala Trp Tyr Gln Gln Arg Pro Gly Arg Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Ala Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Thr Ser Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , BD836 VH, BD836 VL,"(27/28) (b) a heavy chain variable region (vh) comprising seq id no:27 or a variant thereof; and/or, a light chain variable region (vl) comprising seq id no:28 or a variant thereof;"
https://patents.google.com/patent/WO2021196268A1/en,,,,,"(1/2)  (a) heavy chain variable region and light chain variable region, wherein the heavy chain variable region comprises the sequence of seq id no:1 or has at least 90%, 91%, 92%, 93%, 94%, 95% therewith , 96%, 97%, 98%, or 99% identity sequence, and the light chain variable region includes the sequence of seq id no:2 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequences"
https://patents.google.com/patent/WO2021196268A1/en,,,,,"(17/18)  seq id no:17 or a heavy chain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to it, and seq id no:18 or a light chain sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with it; or"
https://patents.google.com/patent/WO2021196268A1/en,,,,,"(19/20)  seq id no:19 or a heavy chain sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to it, and seq id no:20 or a light chain sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with it;"
https://patents.google.com/patent/WO2021196268A1/en,,,,,"(3/4)  heavy chain variable region and light chain variable region, wherein the heavy chain variable region comprises the sequence of seq id no:3 or has at least 90%, 91%, 92%, 93%, 94%, 95% therewith , 96%, 97%, 98%, or 99% identity sequence, and the light chain variable region includes the sequence of seq id no:4 or has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical sequences;"
https://patents.google.com/patent/CN113150135A/en, Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Ile Val Ser Gly Gly Ser Ile Ser Ser Ser Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Phe Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Ser Ser Gly Ser Tyr His Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Val Leu Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu , Artificial sequence, Artificial sequence,"(17/18) preferably, the neutralizing antibody c2767p3s comprises the heavy chain variable region shown in seq id no:17 and the light chain variable region shown in seq id no:18"
https://patents.google.com/patent/CN113150135A/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Phe Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Thr Pro Leu His Met Ala Thr Glu Glu Gly Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial sequence, Artificial sequence,"(7/8) preferably, the neutralizing antibody c14646p3s comprises the heavy chain variable region of seq id no:7 and the light chain variable region of seq id no:8"
https://patents.google.com/patent/CN113004397B/en, Gln Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Arg Ser Ser Gly Tyr His Asp Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Glu Asn Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Arg Gly Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8)  wherein, the amino acid sequence of vh is shown as seq id no:4, and the amino acid sequence of vl is shown as seq id no:8."
https://patents.google.com/patent/CN113004397B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(12/16)  wherein the amino acid sequence of vh is shown as seq id no:12, and the amino acid sequence of vl is shown as seq id no:16."
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(399/403)  a second antibody or antigen-binding fragment comprising a vh comprising or consisting of the amino acid sequence as set forth in seq id no:399, 748, 749, 750, 752, 754, 756, 758, 759, or 761, and a vl comprising or consisting of the amino acid sequence as set forth in seq id no:403, 744, or 746. "
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(36/32) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:32 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:36.  embodiment 31. an antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain (v"
https://patents.google.com/patent/WO2021226560A1/en,,,,,(228/238) s2h58-v2 comprises the vh amino acid sequence set forth in seq id no:228 and the vl amino acid sequence (kappa light chain) set forth in seq id no:238
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(139/143)  a second antibody or antigen-binding fragment comprising, a vh comprising or consisting of the amino acid sequence as set forth in seq id no:139 and a vl comprising of consisting of the amino acid sequence as set forth in seq id no:143. "
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(32/36) , wherein the vh comprises or consists of the amino acid sequence as set forth in seq id no:32 and the vl comprises or consists of the amino acid sequence as set forth in seq id no:36. "
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(399/746) , wherein the vh comprises or consists of the amino acid sequence set forth in any one of seq id no:399, 748, 749, 750, 752, 754, 756, 758, 759, and 761, the vl comprises or consists of the amino acid sequence set forth in seq id no:746, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion. "
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(524/528) , wherein the vh comprises or consists of the amino acid sequence set forth in seq id no:524 and the vl comprises or consists of the amino acid sequence set forth in seq id no:528, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion. "
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(738/399) , wherein the vh comprises or consists of the amino acid sequence set forth in any one of seq id no:399, 748, 749, 750, 752, 754, 756, 758, 759, and 761, the vl comprises or consists of the amino acid sequence set forth in seq id no:738, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion.  embodiment 24. an antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable domain (v"
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(399/738) , wherein the vh comprises or consists of the amino acid sequence set forth in seq id no:399 and the vl comprises or consists of the amino acid sequence set forth in seq id no:738, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion. "
https://patents.google.com/patent/WO2021226560A1/en,,,,,"(399/744) , wherein the vh comprises or consists of the amino acid sequence set forth in any one of seq id no:399, 748, 749, 750, 752, 754, 756, 758, 759, and 761, the vl comprises or consists of the amino acid sequence set forth in seq id no:744, wherein the antibody or antigen-binding fragment is capable of binding to a surface glycoprotein of sars-cov-2 expressed on a cell surface of a host cell and/or on a virion. "
https://patents.google.com/patent/WO2022018040A2/en,,,,,"(55/64) [0011] in some aspects, the antibody or antigen-binding fragment thereof provided herein comprises the variable heavy chain (vh) amino acid sequence and the variable light chain (vl) amino acid sequence selected from the group consisting of: (a) seq id no:55 and seq id no:64, respectively"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ser Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Pro Leu Ile Tyr Ser Thr Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Asn Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A3、A20、A21 VH, A20 VH,"(1/22) or, the heavy chain variable region comprises an amino acid sequence as shown in seq id no:1, and the light chain variable region comprises an amino acid sequence as shown in seq id no:22"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ser Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , A3、A20、A21 VH, A3 VH,"(1/17) the anti-drug antibody of claim 4, wherein the heavy chain variable region comprises the amino acid sequence set forth in seq id no:1 and the light chain variable region comprises the amino acid sequence set forth in seq id no:17;"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Glu Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Ser Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Arg Gly Leu Leu Leu Leu Thr Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Lys Ser Leu Ser Met Ser Val Gly Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Asp Thr Tyr Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Ala Thr Tyr Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Thr Tyr Ser Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , A24 VH, A24 VH,"(6/24) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:6 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:24"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Gln Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Ser Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Arg Gly Ile Thr Thr Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Asp Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A8、A50、A81 VH, A50 VH,"(3/27) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:3 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:27"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Gly Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , A96 VH, A96 VH,"(15/33) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:15 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:33"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Phe Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A14 VH, A14 VH,"(5/21) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:5 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:21"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Ile Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ile Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A48 VH, A48 VH,"(8/26) or, the heavy chain variable region comprises the amino acid sequence shown as seq id no:8, and the light chain variable region comprises the amino acid sequence shown as seq id no:26"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ser Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Asp Ser Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Thr Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A105 VH, A105 VH,"(16/34) alternatively, the heavy chain variable region comprises the amino acid sequence shown as seq id no:16 and the light chain variable region comprises the amino acid sequence shown as seq id no:34."
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Tyr Tyr Gly Tyr Gln Asp Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Ser Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A45 VH, A45 vh,"(7/25) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:7 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:25"
https://patents.google.com/patent/CN113980135A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Thr Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp His Tyr Ile His Trp Gly Lys Gln Ser His Gly Glu Asn Leu Glu Trp Ile Gly Arg Val Ser Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Ile Phe Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Trp Ile Tyr Tyr Asp Tyr Asp Gly Arg Ala Gly Phe Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , A5, A5、A57 VH,"(2/18) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:2 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:18"
https://patents.google.com/patent/CN113980135A/en, Gln Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp His Tyr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Arg Ile Ser Pro Asn Asn Gly Ile Thr Ile Tyr Asn Gln Lys Phe Lys Asp Lys Ala Leu Leu Thr Val Asp Gln Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Leu Ile Tyr Tyr Asp Asn Asp Ser Phe Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Leu Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A82 VH, A82 VH,"(14/32) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:14 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:32"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ser Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , A3、A20、A21 VH, A21 VH,"(1/23) or, the heavy chain variable region comprises an amino acid sequence as shown in seq id no:1, and the light chain variable region comprises an amino acid sequence as shown in seq id no:23"
https://patents.google.com/patent/CN113980135A/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys , VH, VL,"(94/95)  preferably, the first binding epitope comprises the heavy chain variable region of seq id no:94 and the light chain variable region of seq id no:95"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Lys Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Lys Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Leu Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Tyr Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile Tyr Ser Ala Ala Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A58 VH, A58 VH,"(11/29) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:11 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:29"
https://patents.google.com/patent/CN113980135A/en, Gln Met Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Phe Tyr Tyr Gly Ser Gly Ser Tyr Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys , Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asp Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Arg Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , HC, LC,"(96/97) more preferably, the first binding epitope comprises a heavy chain having the sequence shown in seq id no:96 and a light chain having the sequence shown in seq id no:97."
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Lys Arg Gly Leu Leu Arg Phe Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A9 VH, A9、A74 VH,"(4/20) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:4 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:20"
https://patents.google.com/patent/CN113980135A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Val Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Ser Tyr Thr Pro Ser Leu Lys Asp Glu Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala His Tyr Tyr Cys Ala Arg Arg Gly Leu Leu Leu Leu Thr Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Gln Met Asn Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Asp Thr Ile Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp Leu Ser Trp Tyr Gln Gln Lys Pro Gly Asn Ile Pro Lys Leu Leu Ile Tyr Lys Ala Ser Lys Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Leu Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , A55 VH, A55 VH,"(9/28) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:9 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:28"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile His Pro Asp Ser Ser Thr Ile Asn Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Pro Asp Tyr Tyr Gly Ser Arg Tyr Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Pro Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Arg Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A77 VH, A77 VH,"(13/30) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:13 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:30"
https://patents.google.com/patent/CN113980135A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Thr Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp His Tyr Ile His Trp Gly Lys Gln Ser His Gly Glu Ser Leu Glu Trp Ile Gly Arg Val Ser Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Ile Phe Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Trp Ile Tyr Phe Asp Tyr Asp Gly Arg Ala Gly Phe Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys , A57 VH, A5、A57 VH,"(10/18) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:10 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:18"
https://patents.google.com/patent/CN113980135A/en, Glu Val Lys Val Ile Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Gln Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser Ser Thr Ile Ser Tyr Thr Pro Ser Leu Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Arg Gly Ile Thr Thr Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Ile Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , A8、A50、A81 VH, A81 VH,"(3/31) or, the heavy chain variable region comprises an amino acid sequence as set forth in seq id no:3 and the light chain variable region comprises an amino acid sequence as set forth in seq id no:31"
https://patents.google.com/patent/CN113980135A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Asp Leu Val Thr Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp His Tyr Ile His Trp Gly Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Arg Val Ser Pro Asn Asn Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys Gly Lys Ala Ile Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Gly Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Trp Ile Tyr Tyr Asp Tyr Asp Gly Arg Ala Gly Phe Thr Tyr Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , A74 VH, A9、A74 VH,"(12/20) or, the heavy chain variable region comprises the amino acid sequence shown as seq id no:12 and the light chain variable region comprises the amino acid sequence shown as seq id no:20"
https://patents.google.com/patent/CN112898416B/en, Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Gly Trp Val Ile Cys Ser Ser Thr Ser Cys Tyr Thr Lys Tyr Ser Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ile Ser Asn Ile Gly Ser Ala His Val Ser Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Ser Glu Arg Pro Ser Gly Ile Pro Ala Arg Phe Ser Ala Phe Lys Tyr Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Asp Ile Ser Leu Ser Ala Gly Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(4/8) the binding protein of claim 1, comprising the heavy chain variable region of seq id no:4 and the light chain variable region of seq id no:8."
https://patents.google.com/patent/CN112898416B/en, Gln Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asp Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Glu Gln Phe Ser Gly Gly Asp Tyr Glu Gly Phe Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Gln Ser Val Leu Thr Gln Glu Pro Ser Val Ser Gly Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),(12/16) the amino acid sequence of the heavy chain variable region is shown as seq id no:12; the amino acid sequence of the light chain variable region is shown in seq id no:16.
https://patents.google.com/patent/CN111909260A/en,,,,,(5/4)  the light chain amino acid sequence can also be shown as seq id no:4 (mab 2-cqts 114). the heavy chain amino acid sequence can also be shown as seq id no:5
https://patents.google.com/patent/CN111909260A/en,,,,,(11/10)  the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 117). the heavy chain amino acid sequence can also be shown as seq id no:11
https://patents.google.com/patent/CN111909260A/en,,,,,(29/28)  the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 126). the heavy chain amino acid sequence can also be shown as seq id no:29
https://patents.google.com/patent/CN111909260A/en,,,,,(15/14)  the light chain amino acid sequence can also be shown as seq id no:14 (monoclonal antibody 7-cqts 119). the heavy chain amino acid sequence can also be shown as seq id no:15
https://patents.google.com/patent/CN111909260A/en,,,,,(5/6) . the heavy chain amino acid sequence can also be shown as seq id no:5; the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(37/36)  the light chain amino acid sequence can also be shown as seq id no:36 (monoclonal antibody 18-cqts 130). the heavy chain amino acid sequence can also be shown as seq id no:37
https://patents.google.com/patent/CN111909260A/en,,,,,(39/40) . the heavy chain amino acid sequence can also be shown as seq id no:39; the light chain amino acid sequence can also be shown as seq id no:40 (monoclonal antibody 20-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(13/12)  the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 118). the heavy chain amino acid sequence can also be shown as seq id no:13
https://patents.google.com/patent/CN111909260A/en,,,,,(35/36) . the heavy chain amino acid sequence can also be shown as seq id no:35; the light chain amino acid sequence can also be shown as seq id no:36 (monoclonal antibody 18-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(37/38) . the heavy chain amino acid sequence can also be shown as seq id no:37; the light chain amino acid sequence can also be shown as seq id no:38 (mab 19-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(19/18)  the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 121). the heavy chain amino acid sequence can also be shown as seq id no:19
https://patents.google.com/patent/CN111909260A/en,,,,,(39/38)  the light chain amino acid sequence can also be shown as seq id no:38 (mab 19-cqts 131). the heavy chain amino acid sequence can also be shown as seq id no:39
https://patents.google.com/patent/CN111909260A/en,,,,,(9/8)  the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqts 116). the heavy chain amino acid sequence can also be shown as seq id no:9
https://patents.google.com/patent/CN111909260A/en,,,,,(13/14) . the heavy chain amino acid sequence can also be shown as seq id no:13; the light chain amino acid sequence can also be shown as seq id no:14 (monoclonal antibody 7-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(15/16) . the heavy chain amino acid sequence can also be shown as seq id no:15; the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(23/22)  the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 123). the heavy chain amino acid sequence can also be shown as seq id no:23
https://patents.google.com/patent/CN111909260A/en,,,,,(25/24)  the light chain amino acid sequence can also be shown as seq id no:24 (mab 12-cqts 124). the heavy chain amino acid sequence can also be shown as seq id no:25
https://patents.google.com/patent/CN111909260A/en,,,,,(11/12) . the heavy chain amino acid sequence can also be shown as seq id no:11; the light chain amino acid sequence can also be shown as seq id no:12 (monoclonal antibody 6-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,"(1/2) this example provides a monoclonal antibody specific to a novel coronavirus rbd, the heavy chain amino acid sequence of which is shown in seq id no:1; the light chain amino acid sequence is shown as seq id no:2."
https://patents.google.com/patent/CN111909260A/en,,,,,(7/6)  the light chain amino acid sequence can also be shown as seq id no:6 (mab 3-cqts 115). the heavy chain amino acid sequence can also be shown as seq id no:7
https://patents.google.com/patent/CN111909260A/en,,,,,(23/24) . the heavy chain amino acid sequence can also be shown as seq id no:23; the light chain amino acid sequence can also be shown as seq id no:24 (mab 12-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(3/2)  the light chain amino acid sequence is shown in seq id no:2 (monoclonal antibody 1-cqts 113). the heavy chain amino acid sequence can also be shown as seq id no:3
https://patents.google.com/patent/CN111909260A/en,,,,,(31/30)  the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 127). the heavy chain amino acid sequence can also be shown as seq id no:31
https://patents.google.com/patent/CN111909260A/en,,,,,(31/32) . the heavy chain amino acid sequence can also be shown as seq id no:31; the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibodies 16-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(9/10) . the heavy chain amino acid sequence can also be shown as seq id no:9; the light chain amino acid sequence can also be shown as seq id no:10 (monoclonal antibody 5-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(21/22) . the heavy chain amino acid sequence can also be shown as seq id no:21; the light chain amino acid sequence can also be shown as seq id no:22 (monoclonal antibody 11-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(29/30) . the heavy chain amino acid sequence can also be shown as seq id no:29; the light chain amino acid sequence can also be shown as seq id no:30 (monoclonal antibody 15-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(27/26)  the light chain amino acid sequence can also be shown as seq id no:26 (monoclonal antibody 13-cqts 125). the heavy chain amino acid sequence can also be shown as seq id no:27
https://patents.google.com/patent/CN111909260A/en,,,,,(33/34) . the heavy chain amino acid sequence can also be shown as seq id no:33; the light chain amino acid sequence can also be shown as seq id no:34 (mab 17-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(3/4) . the heavy chain amino acid sequence can also be shown as seq id no:3; the light chain amino acid sequence can also be shown as seq id no:4 (mab 2-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(21/20)  the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 122). the heavy chain amino acid sequence can also be shown as seq id no:21
https://patents.google.com/patent/CN111909260A/en,,,,,(17/18) . the heavy chain amino acid sequence can also be shown as seq id no:17; the light chain amino acid sequence can also be shown as seq id no:18 (monoclonal antibody 9-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(25/26) . the heavy chain amino acid sequence can also be shown as seq id no:25; the light chain amino acid sequence can also be shown as seq id no:26 (monoclonal antibody 13-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(17/16)  the light chain amino acid sequence can also be shown as seq id no:16 (mab 8-cqts 120). the heavy chain amino acid sequence can also be shown as seq id no:17
https://patents.google.com/patent/CN111909260A/en,,,,,(7/8) . the heavy chain amino acid sequence can also be shown as seq id no:7; the light chain amino acid sequence can also be shown as seq id no:8 (mab 4-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(33/32)  the light chain amino acid sequence can also be shown as seq id no:32 (monoclonal antibodies 16-cqts 128). the heavy chain amino acid sequence can also be shown as seq id no:33
https://patents.google.com/patent/CN111909260A/en,,,,,(27/28) . the heavy chain amino acid sequence can also be shown as seq id no:27; the light chain amino acid sequence can also be shown as seq id no:28 (monoclonal antibody 14-cqts 
https://patents.google.com/patent/CN111909260A/en,,,,,(35/34)  the light chain amino acid sequence can also be shown as seq id no:34 (mab 17-cqts 129). the heavy chain amino acid sequence can also be shown as seq id no:35
https://patents.google.com/patent/CN111909260A/en,,,,,(19/20) . the heavy chain amino acid sequence can also be shown as seq id no:19; the light chain amino acid sequence can also be shown as seq id no:20 (monoclonal antibody 10-cqts 
https://patents.google.com/patent/CN111995672A/en,,,,,"(19/5) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: comprises the amino acid sequence shown in seq id no:5 in the light chain variable region; and a polypeptide comprising seq id no:19 in a heavy chain variable region of the amino acid sequence of seq id no."
https://patents.google.com/patent/CN111995672A/en,,,,,"(1/18) in particular, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of seq id no:1-17 (see table 1) and a light chain variable region comprising an amino acid sequence selected from seq id no:18-26 (see table 2)"
https://patents.google.com/patent/CN111995672A/en,,,,,"(18/1) in some embodiments, the invention relates to an isolated or non-naturally occurring monoclonal antibody comprising: a light chain variable region comprising a sequence selected from seq id no:1-4; and a heavy chain variable region comprising seq id no:18."
https://patents.google.com/patent/CN111995672A/en,,,,,"(78/80)  and seq id no:78, and a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the heavy chain set forth in seq id no:80, or a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto."
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(93/97)  comprises a vh comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:93 and a vl comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:97.  embodiment 52. a composition comprising: "
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(31/35) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:31 and a vl amino acid sequence according to seq id no:35 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(64/58) in some embodiments, an antibody, or an antigen-binding fragment thereof, is provided that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:64 and a vl amino acid sequence according to seq id no:58 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(64/68) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:64 and a vl amino acid sequence according to seq id no:68 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(150/154) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:150 and a vl amino acid sequence according to seq id no:154 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(101/105)  comprises a vh comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:101 and a vl comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:105; and/or"
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(16/26) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:16 and a vl amino acid sequence according to seq id no:26 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en,,,,,(142/146)  a sars-cov-2 s polypeptide or multimer thereof capable of being bound by an antibody or antigen-binding fragment thereof comprising a vh comprising the sequence set forth in seq id no:142 and a vl comprising the sequence set forth in seq id no:146; 
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(47/51) an antibody, or an antigen-binding fragment thereof, that competes with an antibody or antigen-binding fragment comprising a vh amino acid sequence according to seq id no:47 and a vl amino acid sequence according to seq id no:51 for binding to a sars-cov-2 s glycoprotein of a s glycoprotein trimer"
https://patents.google.com/patent/WO2021247925A1/en,,,,,(123/138) (b) a sars-cov-2 s polypeptide or multimer thereof capable of being bound by an antibody or antigen-binding fragment thereof comprising a vh comprising the sequence set forth in seq id no:123 and a vl comprising the sequence set forth in seq id no:138
https://patents.google.com/patent/WO2021247925A1/en,,,,,"(138/123) 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the amino acid sequence set forth in seq id no:123 and a vl comprising or consisting of an amino acid sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96,%, 97%, 98%, or 99% identity to the sequence set forth in seq id no:138;  (3) the an antibody or antigen-binding fragment thereof of (c)(i) comprises a vh comprising or consisting of an amino acid sequence having at least 80%, 85%,"
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Asp Ser Ser Leu Ala Gly Leu Arg Gly Arg Leu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(15) c7 nanobody: has the sequence shown in seq id no:15
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Ser Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ser Gly Gly Ser Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Leu Ala Ser Ser Gly Tyr Ser Arg Asp Tyr Gly Ala Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(12) a1 nanobody: has the sequence shown in seq id no:12
https://patents.google.com/patent/CN111825762A/en,Asp Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Gly Gly Gly Ser Leu Arg Val Ser Cys Thr Tyr Ser Gly Arg Thr Phe Ser Arg Asn Ile Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Thr Arg Glu Phe Val Ala Ala Ile Gly Trp Ser Arg Val Thr Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Gly Ala Val Pro Ala His Gln Ile Gly Phe Arg Ser Thr Thr Leu Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(2) b6 nanobody: has the sequence shown in seq id no:2
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ser Thr Gly Ser Ile Phe Ser Gly Asp Val Asp Gly Val Gly Trp Phe Arg Arg Ala Pro Gly Lys Glu Arg Glu Leu Leu Ala Arg Ile Arg Asp Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Gly Asp Asp Ala Met Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Phe Gly His Thr His Met Val Arg Pro Gly Ser Thr Val Met Ile Met Tyr Trp Asp Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,"(9) f8 nanobody: has the sequence shown in seq id no:9, and ("
https://patents.google.com/patent/CN111825762A/en,Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Ala Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val Ser Val Ile Glu Ser Ser Gly Ser Thr Tyr Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Tyr Val Val Pro Tyr Ala Ile Ala Ala Gly Ala Pro Asp Gln Ile Gly Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(10) g2 nanobody: has the sequence shown in seq id no:10
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ser Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Trp Gly Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Tyr Gly Tyr Leu Asp Leu Asp Leu Pro Ala Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(16) d4 nanobody: has the sequence shown in seq id no:16
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Ser Ser Gln Thr Val Ser Leu Thr Cys Ser Asp Ser Gly Gly Ser Ile Thr Thr Thr His Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Ala Tyr Ile Gly Asp Thr Phe Tyr Asn Ser Ser Leu Lys Ser Arg Thr Ala Ile Ser Trp Asp Thr Ser Lys Asn Gln Phe Thr Leu His Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Asp Arg Asn Arg Val Arg Gly Tyr Asp Pro Cys Leu His Gly Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(18) h4 nanobody: has the sequence shown in seq id no:18
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Tyr Asp Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Thr Ala Asn Gly Gly Ser Thr Phe Tyr Ala Gly Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Val Val Ser Leu Gln Met Ser Ser Leu Thr Leu Glu AspThr Ala Val Tyr Tyr Cys Ala Arg Thr Ser Glu Ala Arg Tyr Arg Gly Tyr Pro Arg Phe Arg Val Met Phe Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(17) h3 nanobody: has the sequence shown in seq id no:17
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Ala Ile Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Asp Arg Leu Ser Gly Leu Arg Ser Tyr Gly Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(14) g3 nanobody: has the sequence shown in seq id no:14
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Ala Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Ser Ser Asn Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Thr Leu Ile Arg Pro Thr Asn Gly Asn Lys Asp Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Arg Val Arg Leu Lys Val Arg Phe Gln Asp Arg Val Met Val Thr Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(11) g5 nanobody: has the sequence shown in seq id no:11
https://patents.google.com/patent/CN111825762A/en,Asp Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Thr Phe Ser Thr Tyr Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly Phe Asn Ile Gly Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Phe Gly Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Leu Leu Ala Ser Ala Phe Val Leu Met Tyr Gly Ser Arg His Leu Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(6) e7 nanobody: has the sequence shown in seq id no:6
https://patents.google.com/patent/CN111825762A/en,Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Pro Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Asp Asn Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Lys Leu His Thr Gly Val Leu Asn Thr Tyr Tyr Ala Asn Ser Val Lys Gly Arg Phe Thr Ile Ser Thr Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Gln Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Phe Gly Pro Ala Pro Lys Pro Gln Asn Val Leu Thr Thr Ala Leu Pro Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(5) e6 nanobody: has the sequence shown in seq id no:5
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Thr Phe Ser Ser Asn Ala Met Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Asn Trp Gly Ser Ser Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Tyr Leu Ser Ser Ser Arg Ser Gly Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(13) f1 nanobody: has the sequence shown in seq id no:13
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Thr Thr Asp Val Ala Tyr Trp Ser Trp Leu Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Met Gly Ala Ile Ala Ser Ser Gly Ser Thr Tyr Asn Ser Pro Phe Phe Gly Ser Arg Thr Phe Ile Ser Arg Asp Thr Ser Lys Ser Gln Phe Thr Leu Gln Leu Ser Ser Val Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ile Ala Val Arg Asp Pro His Tyr Val Gly Val Gly Gly Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(19) h6 nanobody: has the sequence shown in seq id no:19.
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Ala Ser Gly Gly Gly Trp Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Thr Trp Val Arg Gln Ala Leu Gly Lys Gly Leu Glu Trp Val Ser Asp Ile Asn Tyr Gly Gly His Thr Ser Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Ala Met Leu Pro Phe Leu Thr Ala Val Thr Pro Arg Pro Gly Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(4) e3 nanobody: has the sequence shown in seq id no:4
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Thr Gly Gly Ser Leu Arg Leu Ser Cys Ala Ser Ser Gly Arg Ala Phe Thr Leu Asn Glu Val Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr Ile Thr Arg Gly Gly Asp Ile Asn Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Thr Arg Asp Asn Ala Arg Asn Thr Leu Tyr Leu Gln Met Thr Asn Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Arg Asn Gly Ser Pro Ser Val Phe Glu Ile Leu Leu Val Ser Val Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(1) b4 nanobody: has the sequence shown in seq id no:1
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Ile Phe Ser Leu Asn Tyr Met Gly Trp Tyr Arg Gln Ala Ala Gly Lys Gly Arg Glu Leu Val Ala Thr Ile Asn Arg Ser Gly Gly Ala Ser Tyr Gly Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asp Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr AlaVal Tyr Tyr Cys Ala Asn Val Ile Gly Thr Val Asn Ala Tyr Gly Ala Ala Ser Lys Pro Ala Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(3) b9 nanobody: has the sequence shown in seq id no:3
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Tyr Ser Tyr Ile Ser Asn Ser Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Gly Ser Thr Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala His Arg Phe Gln Thr Arg Val Arg Thr Thr Asn Pro Ile Glu Ser Glu Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(8) f5 nanobody: has the sequence shown in seq id no:8
https://patents.google.com/patent/CN111825762A/en,Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile His Ser Gly Gly Asp Asn Thr Asn Tyr Ala Glu Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Pro Gly Pro Gly Phe Thr Thr Met Asp Arg Ser Gln Ala Arg Ile Ala Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser ,, human (Homo sapiens),,(7) f4 nanobody: has the sequence shown in seq id no:7
https://patents.google.com/patent/CN113797333A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(7/8)  preferably, antibody cb6 has the amino acid sequence shown in seq id no:7 for the heavy chain variable region and seq id no:8 for the light chain variable region"
https://patents.google.com/patent/CN113797333A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Met Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Val Leu Pro Met Tyr Gly Asp Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys, Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro Glu Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),"(9/10)  preferably, antibody cb6 has the heavy chain amino acid sequence shown as seq id no:9 and the light chain amino acid sequence shown as seq id no:10."
https://patents.google.com/patent/US20210355196A1/en,,,,,(23/24)  or (ii) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:23 and a variable light chain (vl) comprising the amino acid sequence of seq id no:24.
https://patents.google.com/patent/US20210355196A1/en,,,,,"(15/16)  7. the antibody or antigen-binding fragment thereof of claim 1, wherein the antibody the antibody or antigen-binding fragment thereof (a) competitively inhibits binding to the spike protein of sars-cov-2 of an antibody comprising (i) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:15 and a variable light chain (vl) comprising the amino acid sequence of seq id no:16"
https://patents.google.com/patent/US20210355196A1/en,,,,,(61/62)  or (iv) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:61 and a variable light chain (vl) comprising the amino acid sequence of seq id no:62.
https://patents.google.com/patent/US20210355196A1/en,,,,,"(39/40)  2. the antibody or antigen-binding fragment thereof of claim 1, wherein (a) the antibody or antigen-binding fragment thereof competitively inhibits binding to the spike protein of sars-cov-2 of an antibody comprising (i) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:39 and a variable light chain (vl) comprising the amino acid sequence of seq id no:40"
https://patents.google.com/patent/US20210355196A1/en,,,,,(31/32)  (ii) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:31 and a variable light chain (vl) comprising the amino acid sequence of seq id no:32
https://patents.google.com/patent/US20210355196A1/en,,,,,(47/48)  (iii) a variable heavy chain (vh) comprising the amino acid sequence of seq id no:47 and a variable light chain (vl) comprising the amino acid sequence of seq id no:48
https://patents.google.com/patent/CN113234151A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Met Ile Gly Arg Thr Tyr Asp Ala Asp Ser Val Lys Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ala Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala Gly Ser Ser Arg Ser Ser Leu Leu Arg Tyr Gly Tyr Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(1) the nanobody of claim 1, wherein the nanobody has an amino acid sequence shown in seq id no:1."
https://patents.google.com/patent/CN113234151A/en,,,,,"(12) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is one of the types shown in fig"
https://patents.google.com/patent/CN113234151A/en,,,,,"(8) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is one of the types shown in fig"
https://patents.google.com/patent/CN113234151A/en, Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Met Ile Gly Arg Thr Tyr Asp Ala Asp Ser Val Lys Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ala Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala Gly Ser Ser Arg Ser Ser Leu Leu Arg Tyr Gly Tyr Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Met Ile Gly Arg Thr Tyr Asp Ala Asp Ser Val Lys Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ala Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala Gly Ser Ser Arg Ser Ser Leu Leu Arg Tyr Gly Tyr Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Asn Ser Arg Tyr Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala Ala Ile Ser Met Ile Gly Arg Thr Tyr Asp Ala Asp Ser Val Lys Asn Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ala Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Ala Ala Gly Ser Ser Arg Ser Ser Leu Leu Arg Tyr Gly Tyr Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser ,, Artificial sequence,,"(13)  further, the trimeric nanobody is shown in seq id no:13."
https://patents.google.com/patent/CN113234151A/en,,,,,"(9) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is one of the types shown in fig"
https://patents.google.com/patent/CN113234151A/en,,,,,"(10) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is one of the types shown in fig"
https://patents.google.com/patent/CN113234151A/en,,,,,"(11) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is one of the types shown in fig"
https://patents.google.com/patent/CN113234151A/en,,,,,"(7) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is one of the types shown in fig"
https://patents.google.com/patent/CN113234151A/en,,,,,"(6) a trimeric nanobody targeting sars-cov2 virus s protein, which is characterized in that the trimeric nanobody is the nanobody of claim 1 linked to a linker selected from the group consisting of: seq id no:6, seq id no:7, seq id no:8, seq id no:9, seq id no:10, seq id no:11, seq id no:12 is one of the types shown in fig"
https://patents.google.com/patent/WO2021189245A1/en,,,,,(6/2)  the bifunctional fusion protein that specifically binds to the coronavirus as described above has the heavy chain amino acid sequence shown in seq id no:6 that binds to the spike protein of the coronavirus and the heavy chain amino acid sequence shown in seq id no:2 the amino acid sequence of the light chain is shown.
https://patents.google.com/patent/CN111420048A/en,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFWMNWVRQAPGKGLEWVSEIRLKSNNYATHYAESVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTSYDYEYWGQGTLVTVSA,DIQMTQSPSTLSASVGDRVTLSCKASENVGTYVSWYQQKPGKAPKLLIYGASNRYTGVPSRFTGSGSGTDFTLTISSLQPEDFATYYCGQSYSYPFTFGSGTKLEIK, heavy chain variable region (VH) amino acid sequence of humanized antibody against BASIGIN, anti-BASIGIN humanized antibody light chain variable region (V L) amino acid sequence,"(3/1) the invention also provides a light chain variable region amino acid sequence of the antihuman basigin humanized antibody as shown in seq id no:1, and a heavy chain amino acid sequence as shown in seq id no:3"
https://patents.google.com/patent/WO2021183947A1/en,,,,,"(40/48) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:40 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:48"
https://patents.google.com/patent/WO2021183947A1/en,,,,,"(24/32) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:24 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:32"
https://patents.google.com/patent/WO2021183947A1/en,,,,,"(49/64) , provided that the heavy chain variable domain includes the amino acid sequences set forth in seq id no:49, 50, and 51, and can include a light chain variable domain having the amino acid sequence set forth in seq id no:64 with one, two, three, four, five, six, seven, eight, nine, or 10 amino acid modifications (e.g., amino acid substitutions, amino acid deletions, and/or amino acid addition"
https://patents.google.com/patent/WO2021183947A1/en,,,,,"(33/48) , provided that the heavy chain variable domain includes the amino acid sequences set forth in seq id no:33, 34, and 35, and can include a light chain variable domain having the amino acid sequence set forth in seq id no:48 with one, two, three, four, five, six, seven, eight, nine, or 10 amino acid modifications (e.g., amino acid substitutions, amino acid deletions, and/or amino acid addition"
https://patents.google.com/patent/WO2021183947A1/en,,,,,"(56/64) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:56 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:64"
https://patents.google.com/patent/WO2021183947A1/en,,,,,"(17/32) , provided that the heavy chain variable domain includes the amino acid sequences set forth in seq id no:17, 18, and 19, and can include a light chain variable domain having the amino acid sequence set forth in seq id no:32 with one, two, three, four, five, six, seven, eight, nine, or 10 amino acid modifications (e.g., amino acid substitutions, amino acid deletions, and/or amino acid addition"
https://patents.google.com/patent/WO2021183947A1/en,,,,,"(8/16) in some cases, a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) provided herein can include (a) a heavy chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:8 and/or (b) a light chain variable domain that includes an amino acid sequence having 100 percent identity to the amino acid sequence set forth in seq id no:16"
https://patents.google.com/patent/KR20220012810A/en, Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser , Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu , No.139 HC variable region , No.139 LC variable region ,"(2018/2017)  in one embodiment of the present invention, the binding molecule comprises a light chain variable region of the polypeptide sequence of seq id no:2017; and a heavy chain variable region of the polypeptide sequence of seq id no:2018."
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Tyr Asn Asp Asp Thr Asn Tyr Ile Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Asp Tyr Asp Tyr Ala Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Val Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr Ser Met His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Thr Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp His Gly Asn Tyr Val Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Asp Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Asp Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Gly Tyr Asp Val Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Arg Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Met His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr His Tyr Asp Gly Tyr Tyr Val Thr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Ile His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr His Tyr Asp Gly Tyr Tyr Val Thr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Met Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg His Asp Gly Asn Tyr Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Leu Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Thr Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Cys Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Gly Ile Asn Pro Asn Asn Gly Asp Thr Ile Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Cys Cys Ala Arg Glu Asp Tyr Gly Ser Ser Tyr Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala , Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Val Gly Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Asn Ser Asn Gln Lys Lys Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Ile Tyr Tyr Cys Gln Gln Tyr Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys, Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Ser Met His Trp Val Lys Gln Thr Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Thr Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Asp Tyr His Tyr Asp Gly Tyr Tyr Val Thr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly Ser Arg Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Ala Ser Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Phe Met Asn Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Arg Ile Asn Pro Tyr Asn Gly Asp Thr Phe Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala His Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gly Arg Gly Tyr Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser, Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Phe Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Glu His Tyr Ser Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Met Phe Ser Arg Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Met Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Asn Cys Ala Arg His Asp Gly Asn Tyr Val Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser His Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Leu Leu Ile Tyr Ser Thr Phe Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp Ser Ser Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser Tyr Gly Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly Asn Thr Asp Tyr Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Phe Lys Met Asn Ser Leu Gln Ala Asn Asp Thr Ala Ile Tyr Tyr Cys Ala Arg Asn Arg Tyr Gly Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Val Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Asn Ile Gly Asp Gln Ala Ser Ile Ser Cys Lys Ser Thr Lys Arg Leu Leu Asn Ser Asp Gly Phe Thr Phe Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Leu Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Ser His Tyr Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asp Pro Ser Asp Ser Tyr Thr Asn Ser Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Glu Leu Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser His Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Arg , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Phe Val Met Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile Asp Thr Ser Asp Thr Tyr Thr Arg Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Val Asp Glu Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Phe Leu Tyr Tyr Tyr Gly Asn Pro Thr Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser , Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Lys Leu Leu Ile Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln His Asn Glu Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asp Tyr Ser Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Gly Gly Ser Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala Lys His Pro Leu Tyr Tyr Gly Ser Asn Ser Asp Gly Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Ile Val Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN111978395A/en, Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Ser Tyr Trp Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Glu Ile Asp Pro Ser Asp Ser Tyr Ser Asn Tyr Asn Gln Asn Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Ser Glu Leu Trp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser , Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn Pro Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser His Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile , Artificial Sequence (Artificial Sequence), Artificial Sequence (Artificial Sequence),
https://patents.google.com/patent/CN113527444A/en,,,,,"(9/8)  (the amino acid sequences of the light and heavy chains of the cb6 antibody are shown in seq id no:8 and seq id no:9, respectively"
https://patents.google.com/patent/WO2021226179A2/en,,,,,"(16/17) an isolated antibody that binds sars-cov-2 s protein, wherein the antibody comprises a vh domain comprising the amino acid of seq id no:16 and a vl domain comprising the amino acid sequence of seq id no:17"
https://patents.google.com/patent/WO2021203053A1/en,,,,,"(105/168) ""s309-11"" comprises the wild-type vh sequence (seq id no:105) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/WO2021203053A1/en,,,,,"(172/168) ""s309-15"" comprises a w50f/g56a/w105f vh variant (seq id no:172) and the wild-type vl sequence of s309 (seq id no:168)"
https://patents.google.com/patent/WO2021203053A1/en,,,,,"(129/168) ""s309-13"" comprises a w50f mutation in vh (seq id no:129) and the wild-type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/WO2021203053A1/en,,,,,"(119/168) ""s309-14"" comprises a w105f vh variant sequence (seq id no:119) and the wild- type vl sequence (seq id no:168) of s309"
https://patents.google.com/patent/CN113735969A/en, Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Thr Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Ser Phe Ser Asn Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asn Ile Lys Gln Asp Gly Ser Glu Thr His Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Phe Cys Val Lys Asp Arg Thr Asp Trp Glu Leu Ile Arg Gly Tyr Phe Gly His Trp Gly Gln Gly Thr Gln Ile Thr Val Ser Ser , Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ser Leu Ser Pro Gly Asp Arg Ala Thr Leu Ser Cys Arg Ala Ser Glu Asn Ile Ile Asn Tyr Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ile Ile Trp Pro Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg ,  Homo sapiens,  Homo sapiens,"(1/5) in a preferred embodiment, the heavy chain variable region of the monoclonal antibody has the amino acid sequence shown in seq id no:1, and the light chain variable region has the amino acid sequence shown in seq id no:5."
